{
  "cells": [
    {
      "cell_type": "markdown",
      "id": "5cff1e02",
      "metadata": {
        "id": "5cff1e02"
      },
      "source": [
        "# <span style=\"color:blue\">Week 6 Class Demo: Building Knowledge Base</span>"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "57877f04",
      "metadata": {
        "id": "57877f04"
      },
      "source": [
        "**Install Vector Database pinecone-client if you have not yet**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 66,
      "id": "8b53e5d5",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8b53e5d5",
        "outputId": "ea5fbefc-655b-4eb2-9969-bbea4863653a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: pinecone-client in /usr/local/lib/python3.10/dist-packages (5.0.1)\n",
            "Requirement already satisfied: certifi>=2019.11.17 in /usr/local/lib/python3.10/dist-packages (from pinecone-client) (2024.8.30)\n",
            "Requirement already satisfied: pinecone-plugin-inference<2.0.0,>=1.0.3 in /usr/local/lib/python3.10/dist-packages (from pinecone-client) (1.1.0)\n",
            "Requirement already satisfied: pinecone-plugin-interface<0.0.8,>=0.0.7 in /usr/local/lib/python3.10/dist-packages (from pinecone-client) (0.0.7)\n",
            "Requirement already satisfied: tqdm>=4.64.1 in /usr/local/lib/python3.10/dist-packages (from pinecone-client) (4.66.5)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4 in /usr/local/lib/python3.10/dist-packages (from pinecone-client) (4.12.2)\n",
            "Requirement already satisfied: urllib3>=1.26.0 in /usr/local/lib/python3.10/dist-packages (from pinecone-client) (2.2.3)\n"
          ]
        }
      ],
      "source": [
        "!pip3 install pinecone-client"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "6a0dea78",
      "metadata": {
        "id": "6a0dea78"
      },
      "source": [
        "**You could use .env file to store both your OPENAI_API_KEY as well as the new PINECONE_API_KEY**\n",
        "To get the PINECONE_API_KEY, you could visit website https://www.pinecone.io/      \n"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "16fcd4d3",
      "metadata": {
        "id": "16fcd4d3"
      },
      "source": [
        "Create a (modify the) **.env** file in your **working directory**. **Please replace the key with your own keys** The following keys are just place holder keys.\n",
        "```\n",
        "    # environment variables defined inside a .env file\n",
        "    OPENAI_API_KEY=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\n",
        "    PINECONE_API_KEY = 12ddd430-8b02-40f9-9177-f8422853d98e\n",
        "\n",
        "```\n",
        "If **.env** file is in a different directory, you could use the following `load_dotenv()` function:\n",
        "```\n",
        "    dotenv_path = '/path/to/your/directory/.env'  # Specify the path to the .env file\n",
        "    load_dotenv(dotenv_path)\n",
        "```"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install python-dotenv\n",
        "!pip install openai"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JJI2TSmDeUyQ",
        "outputId": "75e858be-f633-48a9-f5e5-db0a417dec25"
      },
      "id": "JJI2TSmDeUyQ",
      "execution_count": 67,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: python-dotenv in /usr/local/lib/python3.10/dist-packages (1.0.1)\n",
            "Requirement already satisfied: openai in /usr/local/lib/python3.10/dist-packages (1.52.2)\n",
            "Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.10/dist-packages (from openai) (3.7.1)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai) (1.7.0)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from openai) (0.27.2)\n",
            "Requirement already satisfied: jiter<1,>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from openai) (0.6.1)\n",
            "Requirement already satisfied: pydantic<3,>=1.9.0 in /usr/local/lib/python3.10/dist-packages (from openai) (2.9.2)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from openai) (1.3.1)\n",
            "Requirement already satisfied: tqdm>4 in /usr/local/lib/python3.10/dist-packages (from openai) (4.66.5)\n",
            "Requirement already satisfied: typing-extensions<5,>=4.11 in /usr/local/lib/python3.10/dist-packages (from openai) (4.12.2)\n",
            "Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (3.10)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (1.2.2)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->openai) (2024.8.30)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->openai) (1.0.6)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.14.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (2.23.4)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 68,
      "id": "a24aaea3",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "a24aaea3",
        "outputId": "428c9cc3-d164-48ab-8d14-dfca1613176a"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 68
        }
      ],
      "source": [
        "import os\n",
        "import time\n",
        "from math import exp\n",
        "import numpy as np\n",
        "from IPython.display import display, HTML\n",
        "\n",
        "from dotenv import load_dotenv\n",
        "load_dotenv()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 69,
      "id": "69a2c382",
      "metadata": {
        "id": "69a2c382"
      },
      "outputs": [],
      "source": [
        "import openai\n",
        "from openai import OpenAI\n",
        "import json\n",
        "import pinecone # We now will use PineCone\n",
        "\n",
        "# Assign pinecone PINECONE_API_KEY\n",
        "pinecone_api_key = os.getenv(\"PINECONE_API_KEY\")\n",
        "\n",
        "client = OpenAI()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 70,
      "id": "30dedd2a-6413-40e4-b16d-e700acaa4e8e",
      "metadata": {
        "id": "30dedd2a-6413-40e4-b16d-e700acaa4e8e"
      },
      "outputs": [],
      "source": [
        "def chat_complete_messages(messages, temperature):\n",
        "    # query against the model \"gpt-3.5-turbo-1106\"\n",
        "    completion = client.chat.completions.create(\n",
        "        model=\"gpt-4o\",\n",
        "        messages= messages,\n",
        "        temperature=temperature, # this is the degree of randomness of the model's output\n",
        "    )\n",
        "    return completion.choices[0].message.content"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "1cab7389-d2cf-4d02-aebc-ec71cfa8ea6b",
      "metadata": {
        "id": "1cab7389-d2cf-4d02-aebc-ec71cfa8ea6b"
      },
      "source": [
        "# 1 Model Parameters"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "d5df622e",
      "metadata": {
        "id": "d5df622e"
      },
      "source": [
        "## 1.1 Model Parameter: logit_bias\n",
        "\n",
        "**Once upon a \"time\", the \"time\" token id is \"1712\" and \"892\" in the tokenizaer for \"gpt-3.5-turbo-1106\"**"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install tiktoken"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eOTV9GIvS2Bi",
        "outputId": "7356ce7d-1191-4691-9e93-1eed341af718"
      },
      "id": "eOTV9GIvS2Bi",
      "execution_count": 71,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: tiktoken in /usr/local/lib/python3.10/dist-packages (0.8.0)\n",
            "Requirement already satisfied: regex>=2022.1.18 in /usr/local/lib/python3.10/dist-packages (from tiktoken) (2024.9.11)\n",
            "Requirement already satisfied: requests>=2.26.0 in /usr/local/lib/python3.10/dist-packages (from tiktoken) (2.32.3)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (2024.8.30)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 74,
      "id": "de0db9a9",
      "metadata": {
        "id": "de0db9a9"
      },
      "outputs": [],
      "source": [
        "import tiktoken"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 77,
      "id": "026fea3b",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "026fea3b",
        "outputId": "38035940-2d24-4ac2-cc2f-c1eb7c2b8881"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "The encoded words1 result is:  [21152, 561, 9572]\n"
          ]
        }
      ],
      "source": [
        "encoding = tiktoken.encoding_for_model(\"gpt-3.5-turbo-1106\")\n",
        "\n",
        "words1 = \"breast cancer\"\n",
        "encoded1 = encoding.encode(words1)\n",
        "\n",
        "print(\"The encoded words1 result is: \", encoded1)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "d07dfcf8-dbc7-45b4-8834-e0ae6a29addd",
      "metadata": {
        "id": "d07dfcf8-dbc7-45b4-8834-e0ae6a29addd"
      },
      "source": [
        "**Define a helper function to accept a prompt as before**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 78,
      "id": "145ab07e-e8eb-457b-946b-13b43cb8dbdc",
      "metadata": {
        "id": "145ab07e-e8eb-457b-946b-13b43cb8dbdc"
      },
      "outputs": [],
      "source": [
        "def chat_complete_prompt(text):\n",
        "    # query against the model \"gpt-3.5-turbo-1106\"\n",
        "    completion = client.chat.completions.create(\n",
        "        model=\"gpt-3.5-turbo-1106\",\n",
        "        messages= [{\"role\": \"user\", \"content\": text}],\n",
        "        temperature=0, # this is the degree of randomness of the model's output\n",
        "\n",
        "        max_tokens = 40, #This is new added in this class, we want to just show 40 tokens.\n",
        "\n",
        "    )\n",
        "    return completion.choices[0].message.content"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 79,
      "id": "8a7b4f2a",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "id": "8a7b4f2a",
        "outputId": "2748ef71-898b-40d5-e6aa-b8c257033c6c"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Breast cancer is a type of cancer that forms in the cells of the breasts. It can occur in both men and women, but it is much more common in women. The exact cause of breast'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 79
        }
      ],
      "source": [
        "words = \"Breast cancer\"\n",
        "res = chat_complete_prompt(words)\n",
        "res"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "0f03a911-5f98-4e1e-adb7-ffc5d7f8c811",
      "metadata": {
        "id": "0f03a911-5f98-4e1e-adb7-ffc5d7f8c811"
      },
      "source": [
        "**We really like the word \"time\". So, we give some bias on \"time\" and \" time\"(with space). So we add the following `logit_bias` by using \"time\" and \" time\" token id [1712, 892]**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 80,
      "id": "96d58186-99a6-4c73-9022-c5514407623f",
      "metadata": {
        "id": "96d58186-99a6-4c73-9022-c5514407623f"
      },
      "outputs": [],
      "source": [
        "def chat_complete_prompt(text):\n",
        "    # query against the model \"gpt-3.5-turbo-1106\"\n",
        "    completion = client.chat.completions.create(\n",
        "        model=\"gpt-3.5-turbo-1106\",\n",
        "        messages= [{\"role\": \"user\", \"content\": text}],\n",
        "        temperature=0, # this is the degree of randomness of the model's output\n",
        "\n",
        "        max_tokens = 40, #This is new added in this class, we want to just show 40 tokens.\n",
        "\n",
        "        logit_bias={1712:18, 892:18}, #set logit_bias to be 18, range [-100, 100]\n",
        "\n",
        "    )\n",
        "    return completion.choices[0].message.content"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "93d17119-5016-46b9-9006-79e70738a3c0",
      "metadata": {
        "id": "93d17119-5016-46b9-9006-79e70738a3c0"
      },
      "source": [
        "**Now let's see what is the response from GPT now**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 83,
      "id": "37717151-5bb3-4005-ad0b-767451888172",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "id": "37717151-5bb3-4005-ad0b-767451888172",
        "outputId": "6567817b-1c7f-4da9-ea52-96fa324d44a9"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Breast cancer is a type of cancer that forms in the cells of the breasts. It can occur in both men and women, but it is much more common in women. The exact cause of breast'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 83
        }
      ],
      "source": [
        "words = \"Breast Cancer\"\n",
        "res = chat_complete_prompt(words)\n",
        "res"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "6a60b103-3412-4999-b5c2-22e88aee2a00",
      "metadata": {
        "id": "6a60b103-3412-4999-b5c2-22e88aee2a00"
      },
      "source": [
        "**We need to add frequency_penalty**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 84,
      "id": "a9ed8a0a-fdb9-4a73-b79a-5a3be1b6d982",
      "metadata": {
        "id": "a9ed8a0a-fdb9-4a73-b79a-5a3be1b6d982"
      },
      "outputs": [],
      "source": [
        "def chat_complete_prompt(text):\n",
        "    # query against the model \"gpt-3.5-turbo-1106\"\n",
        "    completion = client.chat.completions.create(\n",
        "        model=\"gpt-3.5-turbo-1106\",\n",
        "        messages= [{\"role\": \"user\", \"content\": text}],\n",
        "        temperature=0, # this is the degree of randomness of the model's output\n",
        "\n",
        "        max_tokens = 40, #This is new added in this class, we want to just show 40 tokens.\n",
        "\n",
        "        logit_bias={1712:18, 892:18},\n",
        "\n",
        "        frequency_penalty = 2,     #set to be 2, range [-2, 2]\n",
        "    )\n",
        "    return completion.choices[0].message.content"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 85,
      "id": "f25b5298",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "id": "f25b5298",
        "outputId": "04fd831b-f591-4084-e153-f44e937169d9"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'1. A lump or thickening in the breast or underarm area\\n2. Changes in the size, shape, or appearance of the breast\\n3. Nipple discharge other than breast milk\\n'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 85
        }
      ],
      "source": [
        "words = \"Breast cancer signs\"\n",
        "res = chat_complete_prompt(words)\n",
        "res"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "e8d4be25-844d-4378-bdde-7580acbd7103",
      "metadata": {
        "id": "e8d4be25-844d-4378-bdde-7580acbd7103"
      },
      "source": [
        "## 1.2 Model Parameter: logprobs"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 86,
      "id": "2121a40d-3214-4279-b054-16eee2f51a01",
      "metadata": {
        "id": "2121a40d-3214-4279-b054-16eee2f51a01"
      },
      "outputs": [],
      "source": [
        "def get_completion(\n",
        "    messages: list[dict[str, str]],\n",
        "    model: str = \"gpt-3.5-turbo-1106\",\n",
        "    max_tokens=500,\n",
        "    temperature=0,\n",
        "    stop=None,\n",
        "    seed=123,\n",
        "    tools=None,\n",
        "    logprobs=None,  # whether to return log probabilities of the output tokens or not. If true, returns the log probabilities of each output token returned in the content of message..\n",
        "    top_logprobs=None,\n",
        ") -> str:\n",
        "    params = {\n",
        "        \"model\": model,\n",
        "        \"messages\": messages,\n",
        "        \"max_tokens\": max_tokens,\n",
        "        \"temperature\": temperature,\n",
        "        \"stop\": stop,\n",
        "        \"seed\": seed,\n",
        "        \"logprobs\": logprobs,\n",
        "        \"top_logprobs\": top_logprobs,\n",
        "    }\n",
        "    if tools:\n",
        "        params[\"tools\"] = tools\n",
        "\n",
        "    completion = client.chat.completions.create(**params)\n",
        "    return completion"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 87,
      "id": "0a1b5f4a-4db5-41f6-84b6-9181effb6763",
      "metadata": {
        "id": "0a1b5f4a-4db5-41f6-84b6-9181effb6763"
      },
      "outputs": [],
      "source": [
        "CLASSIFICATION_PROMPT = \"\"\"You will be given a headline of a news article.\n",
        "Classify the article into one of the following categories: Technology, politics , Sports, and Art.\n",
        "Return only the name of the category, and nothing else.\n",
        "MAKE SURE your output is one of the four categories stated.\n",
        "Article headline: {headline}\"\"\""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 88,
      "id": "fbe0ba75-6b93-4bd6-8512-d43cf1cc571f",
      "metadata": {
        "id": "fbe0ba75-6b93-4bd6-8512-d43cf1cc571f"
      },
      "outputs": [],
      "source": [
        "headlines = [\n",
        "    \"Tech Giant Unveils Latest Smartphone Model with Advanced Photo-Editing Features.\",\n",
        "    \"Local Mayor Launches Initiative to Enhance Urban Public Transport.\",\n",
        "    \"Tennis Champion Showcases Hidden Talents in Symphony Orchestra Debut\",\n",
        "]\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 89,
      "id": "1b2f20ab-713b-4ca5-af18-357d3b01b4b5",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "1b2f20ab-713b-4ca5-af18-357d3b01b4b5",
        "outputId": "a4472b48-5ae1-47e6-b184-edd7ae442bde"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Headline: Tech Giant Unveils Latest Smartphone Model with Advanced Photo-Editing Features.\n",
            "Category: Technology\n",
            "\n",
            "\n",
            "Headline: Local Mayor Launches Initiative to Enhance Urban Public Transport.\n",
            "Category: Politics\n",
            "\n",
            "\n",
            "Headline: Tennis Champion Showcases Hidden Talents in Symphony Orchestra Debut\n",
            "Category: Art\n",
            "\n"
          ]
        }
      ],
      "source": [
        "for headline in headlines:\n",
        "    print(f\"\\nHeadline: {headline}\")\n",
        "    API_RESPONSE = get_completion(\n",
        "        [{\"role\": \"user\", \"content\": CLASSIFICATION_PROMPT.format(headline=headline)}],\n",
        "        model=\"gpt-3.5-turbo-1106\",\n",
        "    )\n",
        "\n",
        "    print(f\"Category: {API_RESPONSE.choices[0].message.content}\\n\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 90,
      "id": "6114a333-2944-4286-ad02-c5bdd44d3b37",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 454
        },
        "id": "6114a333-2944-4286-ad02-c5bdd44d3b37",
        "outputId": "2c253d46-c82c-40ec-87d6-dc43288ac0e8"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Headline: Tech Giant Unveils Latest Smartphone Model with Advanced Photo-Editing Features.\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "<span style='color: cyan'>Output token 1:</span> Technology, <span style='color: darkorange'>logprobs:</span> -1.8624639e-06, <span style='color: magenta'>linear probability:</span> 100.0%<br><span style='color: cyan'>Output token 2:</span> Techn, <span style='color: darkorange'>logprobs:</span> -14.063936, <span style='color: magenta'>linear probability:</span> 0.0%<br>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "********************************************************************************\n",
            "API_RESPONSE:  ChatCompletion(id='chatcmpl-ANZseOUcWIQsy16qbApHLYN4EOuw5', choices=[Choice(finish_reason='stop', index=0, logprobs=ChoiceLogprobs(content=[ChatCompletionTokenLogprob(token='Technology', bytes=[84, 101, 99, 104, 110, 111, 108, 111, 103, 121], logprob=-1.8624639e-06, top_logprobs=[TopLogprob(token='Technology', bytes=[84, 101, 99, 104, 110, 111, 108, 111, 103, 121], logprob=-1.8624639e-06), TopLogprob(token='Techn', bytes=[84, 101, 99, 104, 110], logprob=-14.063936)])], refusal=None), message=ChatCompletionMessage(content='Technology', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None))], created=1730182832, model='gpt-4-0613', object='chat.completion', service_tier=None, system_fingerprint=None, usage=CompletionUsage(completion_tokens=1, prompt_tokens=81, total_tokens=82, completion_tokens_details=CompletionTokensDetails(audio_tokens=None, reasoning_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=None, cached_tokens=0)))\n",
            "\n",
            "Headline: Local Mayor Launches Initiative to Enhance Urban Public Transport.\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "<span style='color: cyan'>Output token 1:</span> Politics, <span style='color: darkorange'>logprobs:</span> -0.036514804, <span style='color: magenta'>linear probability:</span> 96.41%<br><span style='color: cyan'>Output token 2:</span> pol, <span style='color: darkorange'>logprobs:</span> -3.3283582, <span style='color: magenta'>linear probability:</span> 3.59%<br>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "********************************************************************************\n",
            "API_RESPONSE:  ChatCompletion(id='chatcmpl-ANZseWiAc4AlyBoRrUMn43pn0VpkG', choices=[Choice(finish_reason='stop', index=0, logprobs=ChoiceLogprobs(content=[ChatCompletionTokenLogprob(token='Politics', bytes=[80, 111, 108, 105, 116, 105, 99, 115], logprob=-0.036514804, top_logprobs=[TopLogprob(token='Politics', bytes=[80, 111, 108, 105, 116, 105, 99, 115], logprob=-0.036514804), TopLogprob(token='pol', bytes=[112, 111, 108], logprob=-3.3283582)])], refusal=None), message=ChatCompletionMessage(content='Politics', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None))], created=1730182832, model='gpt-4-0613', object='chat.completion', service_tier=None, system_fingerprint=None, usage=CompletionUsage(completion_tokens=1, prompt_tokens=78, total_tokens=79, completion_tokens_details=CompletionTokensDetails(audio_tokens=None, reasoning_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=None, cached_tokens=0)))\n",
            "\n",
            "Headline: Tennis Champion Showcases Hidden Talents in Symphony Orchestra Debut\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "<span style='color: cyan'>Output token 1:</span> Art, <span style='color: darkorange'>logprobs:</span> -0.019549882, <span style='color: magenta'>linear probability:</span> 98.06%<br><span style='color: cyan'>Output token 2:</span> Sports, <span style='color: darkorange'>logprobs:</span> -3.9445987, <span style='color: magenta'>linear probability:</span> 1.94%<br>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "********************************************************************************\n",
            "API_RESPONSE:  ChatCompletion(id='chatcmpl-ANZsfHoi7iHS0VFUnQeZRw5JHgvLP', choices=[Choice(finish_reason='stop', index=0, logprobs=ChoiceLogprobs(content=[ChatCompletionTokenLogprob(token='Art', bytes=[65, 114, 116], logprob=-0.019549882, top_logprobs=[TopLogprob(token='Art', bytes=[65, 114, 116], logprob=-0.019549882), TopLogprob(token='Sports', bytes=[83, 112, 111, 114, 116, 115], logprob=-3.9445987)])], refusal=None), message=ChatCompletionMessage(content='Art', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None))], created=1730182833, model='gpt-4-0613', object='chat.completion', service_tier=None, system_fingerprint=None, usage=CompletionUsage(completion_tokens=1, prompt_tokens=78, total_tokens=79, completion_tokens_details=CompletionTokensDetails(audio_tokens=None, reasoning_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=None, cached_tokens=0)))\n"
          ]
        }
      ],
      "source": [
        "for headline in headlines:\n",
        "    print(f\"\\nHeadline: {headline}\")\n",
        "    API_RESPONSE = get_completion(\n",
        "        [{\"role\": \"user\", \"content\": CLASSIFICATION_PROMPT.format(headline=headline)}],\n",
        "        model=\"gpt-4\",\n",
        "        logprobs=True,\n",
        "        top_logprobs=2,\n",
        "    )\n",
        "    top_two_logprobs = API_RESPONSE.choices[0].logprobs.content[0].top_logprobs\n",
        "    html_content = \"\"\n",
        "    for i, logprob in enumerate(top_two_logprobs, start=1):\n",
        "        html_content += (\n",
        "            f\"<span style='color: cyan'>Output token {i}:</span> {logprob.token}, \"\n",
        "            f\"<span style='color: darkorange'>logprobs:</span> {logprob.logprob}, \"\n",
        "            f\"<span style='color: magenta'>linear probability:</span> {np.round(np.exp(logprob.logprob)*100,2)}%<br>\"\n",
        "        )\n",
        "    display(HTML(html_content))\n",
        "    print(\"\\n\")\n",
        "\n",
        "    print(\"*\"*80)\n",
        "    print(\"API_RESPONSE: \", API_RESPONSE)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "b51b6909",
      "metadata": {
        "id": "b51b6909"
      },
      "source": [
        "# 2. Embedding"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 91,
      "id": "de95a5c9",
      "metadata": {
        "id": "de95a5c9"
      },
      "outputs": [],
      "source": [
        "embed_model = \"text-embedding-3-small\"\n",
        "\n",
        "res = client.embeddings.create(\n",
        "    input=[\n",
        "        \"I need to visit the bank to deposit some cash.\",\n",
        "\n",
        "        \"I have to stop by the financial institution to save money to my account.\",\n",
        "\n",
        "        \"One of my favorite pastimes is leisurely swimming along the meandering river bank.\"\n",
        "    ],\n",
        "    model=embed_model\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 92,
      "id": "66f9efdf",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "66f9efdf",
        "outputId": "2d4a39af-de92-4c8b-aa0b-6debd46ffd6c"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "CreateEmbeddingResponse(data=[Embedding(embedding=[0.028481855988502502, 0.0037790860515087843, 0.01257640402764082, -0.005234003532677889, -0.02996143326163292, -0.0006234258762560785, 0.02941892109811306, 0.05597732588648796, -0.010548150166869164, -0.04687792807817459, -0.03156430646777153, 0.005606980063021183, -0.013131245039403439, -0.022760825231671333, 0.014191608875989914, -0.0023457459174096584, -0.043746158480644226, 0.039997898042201996, 0.0029606951866298914, -0.01567118614912033, 0.007527347654104233, 0.035213932394981384, -0.03181090205907822, -0.001954274484887719, 0.03511529415845871, -0.033068545162677765, -0.0016167460707947612, -0.034128908067941666, 0.027964003384113312, -0.09479156136512756, 0.04653269425034523, -0.03375901281833649, -0.017939869314432144, -0.007558172103017569, -0.03082451969385147, 0.05153859779238701, -0.007323905825614929, 0.05725962668657303, 0.0024952448438853025, -0.02655840665102005, -0.011201630346477032, 0.01978934183716774, 0.029295623302459717, -0.06362180411815643, -0.03888821229338646, 0.038986850529909134, -0.0032304096966981888, -0.04458458349108696, -0.011546865105628967, 0.014117630198597908, -0.05992286652326584, -0.03955402225255966, -0.05306749418377876, 0.01891392469406128, 0.005141529720276594, -0.03846900165081024, 0.0017462089890614152, -0.010122772306203842, 0.022538889199495316, 0.024560976773500443, 0.018235785886645317, -0.0025152808520942926, 0.007644480559974909, -0.007792438380420208, 0.021268919110298157, 0.025966575369238853, -0.011466721072793007, 0.0366935059428215, -0.05047823116183281, 0.0023873590398579836, -0.015079354867339134, 0.024856891483068466, 0.030060071498155594, 0.007866417057812214, -0.028210600838065147, -0.02922164462506771, -0.03348775953054428, -0.05844328925013542, -0.013390171341598034, 0.014339566230773926, 0.00031787785701453686, -0.04961514472961426, -0.02712557651102543, -0.0392087884247303, 0.004580523353070021, -0.013254542835056782, -0.040910303592681885, 0.03299456462264061, -0.014203938655555248, 0.015473908744752407, 0.0025738473050296307, 0.013797054998576641, 0.02279781363904476, 0.0024012301582843065, 0.01856869086623192, 0.02213200554251671, -0.04729714244604111, -0.016460293903946877, 0.004071918781846762, 0.004623678047209978, 0.013303862884640694, -0.008347279392182827, 0.01310658548027277, -0.02459796704351902, 0.06524933874607086, 0.031441010534763336, 0.010128936730325222, -0.010992023162543774, -0.03442482277750969, -0.014154619537293911, -0.04959048703312874, -0.05247566103935242, 0.013809384778141975, 0.036471571773290634, 0.01711377315223217, 0.026977619156241417, -0.029098346829414368, -0.043746158480644226, -0.01658359169960022, -0.04522573575377464, 0.034671418368816376, -0.002569223754107952, 0.006380675360560417, -0.037186700850725174, -0.02390749752521515, -0.024708934128284454, 0.01329153310507536, 0.015831472352147102, 0.0051908488385379314, -0.010911880061030388, 0.002751088235527277, -0.02924630418419838, -0.022921113297343254, -0.010757757350802422, -0.004155145026743412, 0.003427686635404825, -0.024881551042199135, 0.035065971314907074, -0.0033413779456168413, -0.01904955320060253, -0.013254542835056782, 0.015806812793016434, 0.07136492431163788, -0.0017277143197134137, -0.03957868367433548, -0.014006661251187325, 0.02066475711762905, 0.0194071177393198, 0.0010927291586995125, -0.03834570199251175, 0.0290736872702837, 0.006929351948201656, -0.05474434792995453, -0.050034359097480774, 0.0065347980707883835, -0.005181601736694574, -0.0038993016351014376, 0.03213147819042206, 0.0110598374158144, 0.06337521225214005, -0.0224525798112154, 0.019826330244541168, -0.054990943521261215, 0.013180564157664776, 0.008612371049821377, 0.030947817489504814, -0.07141424715518951, -0.04774101451039314, -0.037704553455114365, 0.016904165968298912, 0.00141407479532063, 0.020973002538084984, -0.025448722764849663, 0.021786769852042198, -0.03829638287425041, -0.024018464609980583, -0.005156942177563906, 0.01210787147283554, 0.029369601979851723, 0.03933208808302879, -0.08300426602363586, 0.021712791174650192, 0.030923157930374146, 0.016842518001794815, 0.018038509413599968, 0.02835855819284916, 0.019481096416711807, 0.014154619537293911, -0.028284579515457153, 0.03696476295590401, 0.021441536024212837, 0.02532542496919632, 0.005286404862999916, 0.0370880626142025, -0.023438964039087296, 0.031391691416502, -0.013747735880315304, 0.03208215907216072, -0.009604920633137226, 0.0038869718555361032, 0.03834570199251175, -0.008113013580441475, 0.004084249027073383, 0.05824601277709007, -0.04275977239012718, 0.010233740322291851, -0.00234420457854867, 0.029912114143371582, 0.040910303592681885, -0.03225477784872055, 0.014820428565144539, -0.031169753521680832, -0.09030351042747498, -0.016497282311320305, -0.005754937883466482, 0.03299456462264061, 0.013797054998576641, -0.01588079147040844, -0.022711506113409996, 0.004099661018699408, 0.021145619451999664, 0.009765207767486572, 0.03528790920972824, -0.005813504569232464, -0.015991760417819023, 0.05656915903091431, 0.023451294749975204, -0.009870011359453201, 0.005539166275411844, -0.025202127173542976, 0.0288764089345932, 0.015362940728664398, -0.03851832076907158, 0.012194179929792881, -0.0190742127597332, 0.02692830003798008, -0.01139890681952238, -0.018827617168426514, -0.05578004941344261, -0.007835593074560165, -0.008717173710465431, 0.0445106066763401, 0.0042414539493620396, 0.021811429411172867, -0.0027587944641709328, -0.023660901933908463, 0.017027463763952255, -0.016460293903946877, 0.02244025096297264, 0.07082241773605347, 0.0034153566230088472, -0.023660901933908463, 0.0013701498974114656, -0.01678086817264557, -0.04100894182920456, -0.010326214134693146, -0.020208554342389107, 0.015042365528643131, 0.002862056717276573, 0.011608514003455639, 0.06258610635995865, 0.0024736677296459675, -0.03279728814959526, -0.02266218699514866, 0.03104645572602749, -0.04828352853655815, -0.015399930067360401, 0.005579237826168537, -0.055188219994306564, 0.02012224681675434, 0.006744404789060354, -0.007071144878864288, 0.04488050192594528, 0.0044541428796947, -0.06968807429075241, -0.028259919956326485, -0.05104540288448334, -0.021515514701604843, 0.02354993298649788, 0.043943434953689575, -0.05790077522397041, -0.011263279244303703, -0.007188277784734964, 0.023599252104759216, -0.028851749375462532, -0.01763162575662136, -0.014647811651229858, -0.04811090975999832, 0.014598492532968521, 0.07072377949953079, 0.015190322883427143, 0.02584327757358551, -0.03903616964817047, -0.020442821085453033, 0.025399403646588326, -0.10228808224201202, -0.022785484790802002, -0.02267451584339142, 0.0606626532971859, 0.023093730211257935, -0.009315169416368008, 0.01691649667918682, 0.06021878123283386, 0.025645999237895012, -0.029566878452897072, 0.018593350425362587, -0.012397621758282185, -0.007761613931506872, 0.0050367265939712524, -0.03671816736459732, -0.023586921393871307, -0.025892596691846848, 0.05883784219622612, -0.029270963743329048, 0.001975851599127054, 0.04283375293016434, -0.00548984669148922, 0.008174662478268147, 0.00016914955631364137, -0.0047685531899333, -0.0001601911790203303, -0.00588748324662447, 0.012773680500686169, 0.007021825294941664, 0.08058762550354004, -0.01639864407479763, 0.03760591521859169, 0.028827089816331863, 0.00557307293638587, -0.046113479882478714, -0.03223011642694473, -0.019875649362802505, 0.013032606802880764, 0.010819406248629093, -0.02569531835615635, 0.018408402800559998, 0.02493087202310562, 0.02530076541006565, 0.016189036890864372, 0.043400924652814865, 0.003062416100874543, -0.02421574294567108, 0.05494162440299988, -0.00821165181696415, 0.01017209142446518, -0.013698416762053967, 0.04779033362865448, 0.02369789034128189, -0.0022995092440396547, 0.006633436772972345, -0.027347514405846596, 0.033241160213947296, 0.0377538725733757, 0.030553262680768967, 0.006559457629919052, 0.03639759123325348, -0.008285630494356155, 0.022748494520783424, -0.024203412234783173, 0.010098112747073174, 0.01061596442013979, 0.02870379202067852, -0.020405832678079605, -0.024906212463974953, 0.04855478182435036, 0.019542744383215904, -0.015313621610403061, -0.010881055146455765, 0.02801332250237465, 0.009882341139018536, 0.0018032343359664083, -0.048579443246126175, -0.0020929849706590176, 0.01166399847716093, -0.0036003037821501493, 0.02835855819284916, 0.015572546981275082, 0.018124816939234734, 0.060169462114572525, 0.017163092270493507, 0.0221196748316288, -0.010708438232541084, 0.0125825684517622, -0.0036989422515034676, 0.024844562634825706, 0.005021314136683941, 0.01998661831021309, -0.04406673461198807, 0.05474434792995453, -0.012613393366336823, 0.07240062952041626, -0.00441098865121603, 0.02569531835615635, -0.004777800291776657, -0.006473149172961712, -0.020566118881106377, 0.03321650251746178, 0.04246385768055916, -0.05222906544804573, -0.050996083766222, 0.0031687605660408735, 0.008304125629365444, -0.05868988484144211, -0.02867913246154785, 0.029813475906848907, 0.06643300503492355, 0.0030809107702225447, -0.05114404112100601, -0.016287675127387047, -0.041625432670116425, 0.017717933282256126, -0.026336468756198883, 0.03240273520350456, -0.0033783672843128443, -0.011405072174966335, 0.0004985866253264248, 0.01114614587277174, -0.012274323962628841, 0.025399403646588326, 0.015560217201709747, -0.003979445435106754, -0.023118389770388603, -0.025892596691846848, 0.030947817489504814, 0.009518611244857311, 0.02315537817776203, -0.037334658205509186, -0.002735676011070609, -0.018654998391866684, -0.0417240709066391, -0.010215246118605137, -0.04391877353191376, -0.009715888649225235, 0.0224525798112154, -0.0044911326840519905, 0.013032606802880764, 0.01166399847716093, 0.00314564211294055, 0.001790904556401074, -0.006787559017539024, -0.05380728095769882, 0.010400192812085152, 0.010276895016431808, 0.05173587426543236, 0.0024397606030106544, 0.002133056754246354, 0.02784070558845997, -0.017680944874882698, 0.02655840665102005, 0.05217974632978439, 0.0021222680807113647, -0.05666779726743698, -0.012958628125488758, 0.008982265368103981, 0.0013462608912959695, 0.013439490459859371, 0.014117630198597908, 0.04243919998407364, -0.009722053073346615, 0.02121959999203682, 0.023599252104759216, 0.03454812243580818, 0.05104540288448334, 0.06983602792024612, -0.011010518297553062, 0.022958101704716682, 0.008772658184170723, 0.047149185091257095, 0.034326184540987015, -0.014462864026427269, 0.011793460696935654, -0.012761350721120834, 0.02195938676595688, 0.06603845208883286, -0.003529407549649477, -0.04670531302690506, 0.005415868014097214, -0.03674282878637314, -0.038616959005594254, 0.006127914413809776, -0.031145093962550163, -0.04058972746133804, -0.019308479502797127, -0.018297433853149414, -0.004078083671629429, 0.007761613931506872, 0.004694574512541294, 0.026065213605761528, -0.04917127266526222, -0.008612371049821377, 0.046976566314697266, 0.06751802563667297, -0.007083474658429623, -0.010652953758835793, 0.012712031602859497, 0.012594898231327534, -0.024659615010023117, -0.04246385768055916, 0.025004850700497627, -0.00198355782777071, -0.007293081376701593, 0.019505755975842476, -0.020430492237210274, 0.010560479946434498, -0.03940606489777565, -0.03494267538189888, -0.011737977154552937, -0.03454812243580818, 0.024462338536977768, 0.0031687605660408735, 0.009567930363118649, 0.004938087891787291, -0.03262466937303543, 0.014240927994251251, -0.01203389186412096, 0.02850651554763317, -0.004435648210346699, 0.02798866294324398, 0.0009655780741013587, 0.0035972213372588158, 0.028654472902417183, 0.03652089089155197, 0.031120434403419495, -0.0029730249661952257, -0.004016434773802757, -0.004614430479705334, -0.009629580192267895, 0.016349324956536293, 0.05065084993839264, 0.01523964200168848, 0.02244025096297264, -0.006118666846305132, -0.01622602716088295, -0.032032839953899384, 0.014906737953424454, -0.03580576181411743, -0.017015134915709496, 0.02658306621015072, 0.02514047734439373, -0.005471352022141218, 0.006621106527745724, -0.014684800989925861, -0.03050394356250763, -0.016534272581338882, -0.017693273723125458, -0.03597838059067726, -0.0045743584632873535, 0.009296675212681293, 0.008415093645453453, 0.0311944130808115, -0.001041098148562014, 0.020418161526322365, 0.0019357798155397177, -0.017409687861800194, -0.02569531835615635, 0.006423829589039087, -0.00548984669148922, -0.02475825324654579, -0.001610581181012094, -0.025424063205718994, 0.0035787266679108143, -0.045176416635513306, 0.009253520518541336, -0.001439505023881793, -0.01363676693290472, 0.015572546981275082, 0.02653374709188938, -0.023808859288692474, 4.895800520898774e-05, -0.013760065659880638, 0.006608776748180389, 0.023969145491719246, 0.0029976845253258944, -0.01290930900722742, -0.004864109214395285, 0.030627243220806122, -0.02315537817776203, 0.0015812978381291032, 0.018482381477952003, 0.04224191978573799, 0.02264985628426075, -0.053363408893346786, 0.015387600287795067, -0.02409244515001774, 0.005372713785618544, 0.020775726065039635, 0.012101706117391586, -0.014105300419032574, 0.018778298050165176, -0.04261181503534317, -0.016152048483490944, 0.01872897706925869, 0.02012224681675434, 0.01605341024696827, 0.006738239899277687, 0.002877468941733241, -0.037359315901994705, 0.04372149705886841, 0.056766435503959656, 0.025892596691846848, -0.022896453738212585, 0.011972242966294289, -0.03319184109568596, -0.016632910817861557, -0.015979431569576263, -0.011639338918030262, 0.035238590091466904, -0.03316718339920044, 0.0008376563200727105, 0.0011004353873431683, 0.006540962960571051, 0.015251971781253815, 0.02744615264236927, -0.02029486373066902, 0.002179293427616358, 0.008347279392182827, -0.030972477048635483, 0.021268919110298157, -0.005828916560858488, 0.05222906544804573, -0.004605183377861977, 0.045743588358163834, 0.006824548356235027, 0.0235129427164793, 0.004762388300150633, 0.04904797673225403, 0.02334032580256462, -0.017039794474840164, -0.02511581778526306, 0.029665516689419746, -0.030429964885115623, 0.02653374709188938, 0.033265821635723114, -0.03560848534107208, -0.03277263045310974, 0.013340852223336697, -0.004540451802313328, -0.016275346279144287, -0.007761613931506872, -0.012798340059816837, 0.030627243220806122, -0.04996038228273392, -0.0251651369035244, -0.007588996551930904, 0.03186022490262985, 0.017952200025320053, 0.015942441299557686, 0.032032839953899384, 0.032575350254774094, -0.017175422981381416, -0.00280503137037158, 0.03528790920972824, 0.034523461014032364, -0.0035047477576881647, 0.019850989803671837, -0.011873604729771614, 0.03494267538189888, -0.022230643779039383, 0.014462864026427269, 0.04988640174269676, -0.0198016706854105, 0.006559457629919052, 0.013612107373774052, 0.03400560840964317, 5.928903556196019e-05, 0.0016861011972650886, -0.025078829377889633, -0.009765207767486572, 0.022501898929476738, -0.014869747683405876, -0.050157658755779266, -0.005785762332379818, 0.024006135761737823, -0.02638578787446022, -0.000974054797552526, -0.00032808847026899457, -0.003637293353676796, -0.01293396856635809, -0.023130718618631363, -0.02049214020371437, 0.0606626532971859, 0.0037482616025954485, 0.013328522443771362, -0.005455940030515194, -0.01872897706925869, -0.008359609171748161, 0.07092105597257614, 0.010628294199705124, -0.009080903604626656, 0.033956289291381836, 0.007761613931506872, 0.013772395439445972, 0.047864314168691635, -0.017323380336165428, -0.01114614587277174, 0.022908782586455345, 0.0018356001237407327, -0.03425220400094986, -0.016657570376992226, -0.027668088674545288, -0.01691649667918682, -0.017261730507016182, -0.0010202915873378515, 0.0020035938359797, -0.007027990184724331, -0.011066002771258354, -0.004158227704465389, 0.008914451114833355, 0.02959153801202774, -0.00972821842879057, 0.03553450480103493, -0.011805790476500988, -0.006118666846305132, 0.001034933258779347, -0.003772921161726117, 0.0038931367453187704, -0.02263752743601799, -0.017964530736207962, -0.01639864407479763, -0.05079880729317665, -0.005582320503890514, 0.02047981135547161, 0.023747209459543228, -0.04293239116668701, 0.003717436920851469, -0.013131245039403439, -0.017039794474840164, 0.004099661018699408, 0.025041839107871056, 0.007650645915418863, -0.015486238524317741, 0.025399403646588326, -0.0016059573972597718, -0.008846636861562729, -0.007212937343865633, -0.019912639632821083, -0.044658564031124115, -0.010813241824507713, 0.007903406396508217, -0.0041274032555520535, -0.02673102356493473, -0.01489440817385912, -0.004543534014374018, 0.005070633254945278, -0.020960673689842224, -0.05474434792995453, 0.03615099564194679, 0.0014541466953232884, -0.0065717874094843864, -0.0014371932484209538, -0.015806812793016434, 0.009604920633137226, 0.02422807179391384, 0.008180827833712101, 0.04140349477529526, -0.02621317096054554, -0.009296675212681293, -0.024819903075695038, 0.012477765791118145, 0.020800385624170303, -0.009019254706799984, -0.013365511782467365, 0.0016922660870477557, 0.013390171341598034, -0.0160287506878376, -0.012810669839382172, -0.040367789566516876, -0.00409349612891674, 0.00548676447942853, 0.016435634344816208, 0.03585508093237877, 0.008131507784128189, 0.010492666624486446, -0.01238529197871685, 0.037852510809898376, -0.046458713710308075, -0.014068310149013996, -0.011232455261051655, -0.000767915858887136, -0.025645999237895012, -0.004762388300150633, 0.024560976773500443, 0.01061596442013979, 0.017002804204821587, 0.016793198883533478, 0.012274323962628841, 0.008341114968061447, -0.008439753204584122, 0.02029486373066902, 0.0345727801322937, -0.006343686021864414, -0.03067656233906746, 0.017261730507016182, -0.005585402715951204, 0.05780213698744774, 0.000608784263022244, 0.0005752625875174999, -0.0035263251047581434, 0.0019943465013056993, 0.0029052109457552433, 0.005807339213788509, -0.027396833524107933, -0.003680447582155466, 0.022514229640364647, 0.018235785886645317, 0.025239115580916405, 0.013094255700707436, -9.10286616999656e-05, -0.012822999618947506, -0.04229123890399933, 0.00917954184114933, 0.016263015568256378, -0.02976415492594242, 0.012638052925467491, 0.014191608875989914, 0.019579734653234482, 0.008957604877650738, -0.05188383162021637, -0.008002045564353466, -0.03696476295590401, 0.022859463468194008, -0.018987903371453285, -0.029813475906848907, -0.015658855438232422, 0.018667329102754593, -0.03587973862886429, 0.006115584634244442, 0.03918413072824478, 0.027717407792806625, -0.02191006764769554, -0.009382983669638634, -0.010431017726659775, 0.017052123323082924, -0.013365511782467365, 0.002225530333817005, -0.021170279011130333, 0.02499251998960972, -0.018075497820973396, 0.023648571223020554, -0.006707415450364351, 0.008476742543280125, 0.018839946016669273, 0.025793958455324173, 0.02316770888864994, 0.008402763865888119, 0.029098346829414368, -0.003954785875976086, 0.04779033362865448, 0.008704843930900097, 0.007952725514769554, 0.010918044485151768, -0.003193420125171542, -0.012675042264163494, -0.0301340501755476, 0.016904165968298912, 0.01133109349757433, 0.013279203325510025, 0.027742067351937294, -0.01523964200168848, -0.004142815247178078, 0.015005376189947128, 0.022329282015562057, 0.01053582038730383, -0.016176708042621613, -0.023660901933908463, 0.026163851842284203, 0.004737728741019964, -0.05188383162021637, 0.00794039573520422, 0.017557647079229355, 0.010017968714237213, -0.024696605280041695, -0.0335124172270298, -0.024560976773500443, -0.0019234500359743834, 0.03526325151324272, -0.010276895016431808, 0.03250137344002724, 0.008581546135246754, -0.04672997072339058, -0.023056739941239357, -0.015325951389968395, -0.030725881457328796, 0.0385429784655571, -0.004950417671352625, -0.04320364445447922, -0.010091947391629219, -0.0068985274992883205, -0.05030561611056328, 0.010449511930346489, 0.0118551105260849, 0.02104698121547699, 0.002714098896831274, -0.0288764089345932, -0.008279466070234776, 0.052524980157613754, 0.008711009286344051, 0.05183451250195503, -0.029862795025110245, 9.040253644343466e-05, 0.0018032343359664083, -0.017323380336165428, -0.02941892109811306, 0.033808331936597824, -0.04275977239012718, -0.0023673230316489935, 0.003016179194673896, 0.017027463763952255, 0.024844562634825706, 0.02049214020371437, 0.014758779667317867, -0.004898016341030598, 0.018605679273605347, -0.0026293315459042788, -0.006349850911647081, -0.009241190738976002, 0.014573832973837852, 0.00023022062669042498, -0.0031410185620188713, 0.022329282015562057, -0.045546308159828186, -0.02100999280810356, 0.022736165672540665, 0.000487027398776263, -0.00508912792429328, 0.04586688429117203, -0.04488050192594528, 0.008347279392182827, 0.028210600838065147, -0.02569531835615635, 0.014240927994251251, -0.009765207767486572, -0.027766726911067963, -0.015634195879101753, -0.021811429411172867, 0.01923450082540512, 0.012083211913704872, 0.0036619529128074646, -0.017964530736207962, -0.006232718005776405, 0.024474667385220528, -0.01959206536412239, -0.010689943097531796, -0.011435897089540958, 0.0006750569446012378, -0.03943072631955147, 0.01802617870271206, 0.00516927195712924, 0.02944358065724373, -0.014339566230773926, 0.003264316590502858, -0.024388359859585762, -0.03839502111077309, -0.0194687657058239, 0.03526325151324272, 0.0406637042760849, 0.02303208038210869, 0.021120959892868996, 0.035756442695856094, 0.012434611096978188, -0.04885069653391838, -0.017052123323082924, 0.013747735880315304, -0.030035411939024925, 0.009752877987921238, -0.01745900698006153, -0.011466721072793007, 0.012335972860455513, 0.038444340229034424, 0.06480547040700912, -0.02462262660264969, 0.029838135465979576, 0.031268391758203506, 0.04004721716046333, -0.02494320087134838, 0.013205223716795444, -0.0051168701611459255, -0.00810684822499752, 0.0042815255001187325, 0.03822240233421326, 0.012083211913704872, 0.00633135624229908, 0.01222500391304493, 0.053412728011608124, 0.026829661801457405, 0.03992391750216484, 0.012847659178078175, -0.03065190277993679, -0.020603109151124954, -0.01660825125873089, -0.009364488534629345, 0.007471863646060228, 0.026681704446673393, 0.012360632419586182, -0.004028764553368092, -0.048406824469566345, 0.00047007392277009785, -0.00677522923797369, 0.04419003054499626, 0.004078083671629429, 0.008957604877650738, 0.02747081220149994, -0.013118915259838104, 0.017606966197490692, 0.004580523353070021, 0.014684800989925861, -0.00046429430949501693, -0.02262519672513008, -0.013982001692056656, -0.012416115961968899, 0.02601589448750019, -0.025498041883111, -0.013451820239424706, -0.024191083386540413, -0.009574095718562603, 0.020220885053277016, 0.03513995185494423, 0.0032180799171328545, 0.0029021285008639097, -0.01870431751012802, 0.026435106992721558, 0.022711506113409996, 0.02890106849372387, -0.004947335459291935, -0.026854321360588074, -0.001826352789066732, 0.020430492237210274, 0.025374744087457657, 0.02229229174554348, 0.013747735880315304, 8.390048606088385e-05, 0.0013616731157526374, 0.003387614618986845, -0.01363676693290472, -0.0064608193933963776, 0.02156483381986618, -0.004084249027073383, 0.04226658120751381, 0.030701221898198128, 0.04599018394947052, 0.038962192833423615, -0.029270963743329048, 0.013525798916816711, -0.041477471590042114, 0.03294524550437927, 0.035731781274080276, 0.06312861293554306, -0.01692882552742958, -0.03846900165081024, 0.021885408088564873, -0.0021222680807113647, -0.014191608875989914, 0.017680944874882698, -0.010036463849246502, -0.0017739511094987392, -0.0237102210521698, -0.00544361025094986, -0.009783701971173286, 0.017397359013557434, -0.01622602716088295, 0.030355986207723618, -0.028629813343286514, -0.004947335459291935, -0.02155250310897827, 0.002885174937546253, 0.03550984710454941, 0.01363676693290472, -0.011744141578674316, -0.0036280460190027952, 0.0093706538900733, -0.02123192884027958, 0.020615437999367714, 0.03151498734951019, -0.004802460316568613, 0.0036557880230247974, -0.006929351948201656, -0.014129959978163242, -0.010930374264717102, 0.017976859584450722, -0.004882603883743286, -0.02567065879702568, 0.0009031583904288709, -0.039134807884693146, -0.002470585284754634, -0.04061438515782356, -0.03193420171737671, 0.019678372889757156, 0.01113998144865036, -0.019740022718906403, 0.01489440817385912, 0.004734646063297987, -0.023993805050849915, 0.016472622752189636, 0.04194600507616997, 0.01673154905438423, 0.0069355168379843235, 0.017150763422250748, 0.018605679273605347, -0.014018991030752659, 0.01290930900722742, -0.031268391758203506, -0.02194705791771412, 0.0012753645423799753, 0.02141687646508217, 0.01060979999601841, -0.005936802364885807, -0.023130718618631363, 0.0221196748316288, 0.007434873841702938, 0.0089082857593894, 0.030553262680768967, 0.029887454584240913, 0.03440016508102417, -0.0201345756649971, -0.018470052629709244, -0.02601589448750019, -0.0032057499047368765, -0.019887980073690414, -0.012514755129814148, -0.01838374324142933, -0.01785356178879738, -0.04458458349108696, -0.0007417150191031396, 0.01713843271136284, -0.0160287506878376, 0.00045196450082585216, -0.008421259000897408, 0.004121238365769386, -0.054793667048215866, -0.004623678047209978, -0.02369789034128189, -0.016472622752189636, 0.01749599725008011, 0.019653713330626488, 0.05045357346534729, -0.026065213605761528, -0.0311944130808115, -0.02052913047373295, 0.005949132144451141, -0.03319184109568596, 0.02515280805528164, 0.007601326331496239, 0.021984046325087547, -0.01945643685758114, 0.028777770698070526, -0.028457196429371834, -0.002892881166189909, 0.08714707940816879, -0.02356226183474064, 0.0038469000719487667, -0.005135364830493927, -0.02833389863371849, -0.017372699454426765, 0.02192239835858345, -0.03136702999472618, 0.007866417057812214, -0.019172850996255875, 0.0072314320132136345, -0.0012337514199316502, 0.0077739437110722065, 0.04167475178837776, 0.010881055146455765, -0.022847134619951248, -0.026114532724022865, -0.0020159236155450344, -0.0010788581566885114, -0.0044911326840519905, -0.007552007213234901, -0.04492982104420662, -0.02479524351656437, 0.029813475906848907, 0.01249009557068348, 0.03193420171737671, 0.03422754630446434, 0.019542744383215904, -0.029492899775505066, 0.010357038117945194, 0.023130718618631363, -0.02103465236723423, -0.012533249333500862, -0.03839502111077309, -0.011324928142130375, -0.007052650209516287, -0.01782890222966671, -0.0029730249661952257, -0.0032766463700681925, 0.013501139357686043, -0.017039794474840164, 0.010326214134693146, 0.009845351800322533, -0.01727406121790409, 0.029270963743329048, 0.026509085670113564, 0.0015859215054661036, 0.01097969338297844, 0.006682755891233683, 0.015646526589989662, -0.0003146027447655797, -0.008945275098085403, -0.020430492237210274, 0.028777770698070526, -0.04404207319021225, -0.03301922604441643, 0.03015870973467827, -0.0025245281867682934, 0.032895926386117935, 0.015523227863013744, 0.00015200341294985265, -0.0006411499925889075, -0.0015026952605694532, 0.003859229851514101, 0.007268421817570925, 0.007508852984756231, -0.0043524219654500484, 0.005240168422460556, -0.009216531179845333, 0.0381484255194664, 0.0064608193933963776, -0.0023935239296406507, -0.03301922604441643, 0.0031625956762582064, 0.0038407351821660995, -0.009481621906161308, 0.005197013728320599, -0.014808098785579205, 0.008513731881976128, 0.012077046558260918, 0.017372699454426765, 0.0024166423827409744, 0.04192134737968445, 0.003979445435106754, -0.00332288327626884, -0.022847134619951248, 0.00892678089439869, -0.0037205193657428026, 0.038074444979429245, -0.02655840665102005, -0.012342137284576893, -0.0014996128156781197, 0.027865365147590637, 0.030725881457328796, 0.0290736872702837, 0.01747133769094944, -0.050897445529699326, -0.0066149416379630566, -0.01638631522655487, -0.03459744155406952, 0.0040657538920640945, -0.00034850972588174045, 0.011294104158878326, -0.01006112340837717, 0.013538128696382046, 0.01409297063946724, -0.006094007287174463, 0.01302027702331543, 0.018494712188839912, -0.005785762332379818, 0.028037982061505318, 0.0074780285358428955, 0.003093240549787879, -0.018100157380104065, -0.0187413077801466, -0.06416431814432144, 0.019135860726237297, -0.05050289258360863, -0.0034338515251874924, 0.018482381477952003, -0.013599777594208717, 0.03437550365924835, -0.032526031136512756, -0.0278160460293293, 0.022748494520783424, -0.0034061092883348465, 0.02102232165634632, 0.03617565706372261, -0.002498327288776636, -0.05459638684988022, -0.01695348508656025, 0.010381697677075863, -0.007360895164310932, 0.02530076541006565, 0.011824285611510277, -0.007699965033680201, 0.0011343422811478376, -0.02581861801445484, 0.014401215128600597, -0.006436159834265709, 0.03190954402089119, 0.009389149025082588, -0.003495500423014164, -0.026139192283153534, -0.03891287371516228, -0.019296148791909218, -0.00717594800516963, 0.0020328769460320473, -0.01533828116953373, 0.023623911663889885, 0.018260445445775986, 0.015732834115624428, -0.031465668231248856, 0.01802617870271206, -0.033438436686992645, -0.025424063205718994, 0.02279781363904476, -0.035361889749765396, 0.029739495366811752, -0.03864161670207977, 0.04246385768055916, 0.008507567457854748, -0.025621339678764343, -0.02266218699514866, -0.012015397660434246, -0.03314252197742462, 0.013365511782467365, 0.008057529106736183, 0.01159001886844635, 0.015954772010445595, -0.0068307132460176945, 0.0034615935292094946, -0.03866627812385559, 0.0017138433177024126, 0.04258715733885765, 0.028802430257201195, 0.01891392469406128, -0.07767778635025024, -0.01891392469406128, -0.0008499860996380448, -0.0025368579663336277, 0.037729211151599884, -0.023944485932588577, 0.018852276727557182, -0.008618535473942757, 0.03763057291507721, -0.013279203325510025, -0.009050078690052032, -0.002270225901156664, 0.014450534246861935, -0.00645465450361371, -0.0030192616395652294, 0.0022024118807166815, -0.00713279377669096, -0.0030963229946792126, 0.04007187485694885, -0.0061309970915317535, 0.01426558755338192, 0.024191083386540413, -0.030799860134720802, 0.017323380336165428, -0.01745900698006153, -0.012144860811531544, 0.04391877353191376, 0.015621866099536419, 0.005197013728320599, -0.027199555188417435, -0.019690703600645065, 0.006343686021864414, 0.04063904657959938, 0.020899023860692978, -0.02653374709188938, -0.02390749752521515, 0.05247566103935242, 0.00258463597856462, 0.002378111705183983, 0.00316567812114954, 0.029986092820763588, -0.006229635328054428, 0.0004392493865452707, -0.01641097478568554, 0.016152048483490944, -0.032008182257413864, -0.02226763218641281, -0.0013701498974114656, -0.05434979125857353, 0.0320575013756752, -0.03370969370007515, -0.043228305876255035, -0.03161362558603287, -0.0047500585205852985, -0.018975574523210526, -0.0024027712643146515, 0.00818699225783348, -0.008008209988474846, -0.000750191742554307, -0.016127388924360275, 0.007471863646060228, -0.030232688412070274, -0.006695085670799017, 0.021848419681191444, -0.030060071498155594, -0.003951703198254108, 0.051291998475790024, 0.025424063205718994, -0.0007166700670495629, 0.022933442145586014, -0.031983520835638046, 0.002240942558273673, 0.011577689088881016, 0.009931660257279873, -0.004981242120265961, -0.013686086982488632, 0.00677522923797369, -0.03777853026986122, -0.03874025493860245, -0.0015566382789984345, 0.00928434543311596, 0.015042365528643131, 0.010776251554489136, -0.00970972329378128, 0.0044572255574166775, -0.007071144878864288, 0.005724113434553146, 0.016978144645690918, -0.03851832076907158, -0.019579734653234482, 0.026287149637937546, -0.026607725769281387, -0.01462315209209919, -0.03511529415845871, 0.014906737953424454, 0.023944485932588577, 0.011010518297553062, 0.0060970899648964405, 0.03459744155406952, 0.0004966600681655109, 0.023401975631713867, 0.045201074331998825, -0.007903406396508217, 0.008797317743301392, 0.016509613022208214, -0.024030795320868492, -0.018470052629709244, 0.0003325194993522018, 0.03015870973467827, -0.030035411939024925, -0.010202916339039803, 0.0021500103175640106, 0.014512184076011181, 0.03657021000981331, -0.02267451584339142, -0.022070355713367462, -0.015523227863013744, 0.018470052629709244, -0.04576824605464935, 0.005160024389624596, -0.07082241773605347, -0.009956319816410542, 0.020775726065039635, -0.012545579113066196, -0.015301291830837727, -0.02136755734682083, -0.006910857278853655, 0.0170891135931015, -0.0015681973891332746, 0.04209396243095398, 0.05203178897500038, -0.05296885222196579, 0.013686086982488632, -0.030035411939024925, -0.022773154079914093, -0.00926585029810667, -0.004796295426785946, -0.036077018827199936, -0.01871664822101593, 0.02248957008123398, 0.0024752088356763124, 0.020615437999367714, 0.023278677836060524, 0.02978881634771824, -0.002133056754246354, 0.013525798916816711, -0.03494267538189888, 0.03869093582034111, -0.0056593818590044975, -0.020233213901519775, -0.04049108922481537, -0.009296675212681293, 0.03168760612607002, -0.022686846554279327, -0.014549173414707184, 0.004121238365769386, -0.001875672023743391, 0.005406620912253857, 0.017976859584450722, -0.01489440817385912, -0.00865552481263876, -0.018149476498365402, -0.01095503382384777, 0.016805527731776237, -0.01943177729845047, -0.022773154079914093, 0.006806053686887026, -0.0056254747323691845, 0.033586397767066956, 0.014771109446883202, 0.006590282078832388, -0.017569975927472115, 0.02229229174554348, 0.011466721072793007, 0.022711506113409996, 0.0198016706854105, -0.0442393496632576, -0.024462338536977768, -0.01290930900722742, 0.04014585539698601, 0.009413808584213257, 0.02336498536169529, -0.007453368976712227, -0.02939426153898239, 0.007638315670192242, -0.0015288961585611105, 0.022353941574692726, 0.02176211029291153, 0.02729819342494011, -0.009919330477714539, 0.005779597442597151, -0.00624812999740243, -0.006738239899277687, 0.00046390900388360023, -0.008618535473942757, -0.0010595928179100156, -0.02156483381986618, 0.02462262660264969, 0.015165663324296474, -0.007120463997125626, -0.017150763422250748, -0.0023226274643093348, -0.027890024706721306, 0.006954011507332325, -0.017212411388754845, 0.004432565998286009, 0.019160520285367966, 0.04658201336860657, 0.01621369644999504, -0.002643202431499958, -0.006466984283179045, 0.030060071498155594], index=0, object='embedding'), Embedding(embedding=[0.021421415731310844, -0.011824673041701317, -0.0004573497863020748, -0.007471246644854546, -0.01836121268570423, 0.014276675879955292, 0.026837589219212532, 0.06934750825166702, -0.0076441033743321896, -0.06540381908416748, -0.007752939127385616, -0.033905502408742905, -0.010640284977853298, -0.009334256872534752, 0.010902770794928074, 0.015838786959648132, -0.028783826157450676, 0.032753124833106995, 0.005140883848071098, 0.021126918494701385, 0.007631299085915089, 0.05026926472783089, 0.010160127654671669, -0.002935361349955201, 0.010454623959958553, -0.026248596608638763, -0.0056018345057964325, -0.03692729398608208, 0.04051246866583824, -0.058950506150722504, 0.049705877900123596, -0.04642800614237785, -0.042868439108133316, -0.011357319541275501, 0.00628045666962862, 0.05905294045805931, -0.0406661182641983, 0.04117828607559204, 0.0396161749958992, -0.017183227464556694, -0.02727293223142624, 0.006478921975940466, 0.021575065329670906, -0.061613779515028, 0.007119131740182638, 0.061664994806051254, 0.03211291879415512, -0.036440733820199966, -0.004273399710655212, 0.023610932752490044, -0.05516046658158302, -0.0005641847965307534, -0.04422568529844284, 0.032420217990875244, -0.008188281208276749, 0.007868177257478237, 0.045250020921230316, -0.016965556889772415, 0.0035339572932571173, 0.0270936731249094, 0.015096143819391727, 0.014545563608407974, -0.010889966040849686, -0.009174204431474209, 0.006971883121877909, 0.023380456492304802, 0.022496968507766724, 0.03482740744948387, -0.02783631719648838, -0.011709434911608696, -0.03797723725438118, 0.010300973430275917, 0.02957768738269806, 0.0065109324641525745, -0.029372818768024445, 0.0030810090247541666, 0.026210183277726173, -0.045608535408973694, 0.033572595566511154, -0.021523848176002502, -0.004065331537276506, -0.02594129554927349, -0.056133583188056946, -0.007304792292416096, 0.0050448523834347725, -0.018591688945889473, -0.07585204392671585, 0.019782477989792824, -0.021639086306095123, 0.020205017179250717, -0.014596780762076378, 0.02504500187933445, -0.010493036359548569, 0.009743991307914257, 0.027221715077757835, 0.04614631459116936, -0.03139588236808777, -0.004340621642768383, 0.030166679993271828, 0.04448176920413971, 0.01943676546216011, -0.014980906620621681, 0.036107826977968216, -0.06151134520769119, 0.01486566849052906, 0.0528557114303112, 0.059923626482486725, -0.008681243285536766, -0.030294721946120262, -0.017439311370253563, -0.049629054963588715, -0.04553171247243881, -0.023201199248433113, 0.06847682595252991, 0.008796480484306812, 0.012189592234790325, -0.04752916470170021, 0.04737551510334015, 0.006059584673494101, -0.05469951406121254, 0.03024350479245186, -0.002346368506550789, 0.008572407066822052, -0.009244627319276333, 0.03403354436159134, -0.02066596783697605, -0.01060827448964119, 0.018950205296278, 0.02527547813951969, -0.029936203733086586, 0.04030760005116463, -0.03073006495833397, -0.012733770534396172, -0.038335755467414856, 0.017080793157219887, 0.003077808069065213, 0.005512205418199301, -0.007439236156642437, -0.01503212284296751, -0.0009763197158463299, -0.01951359026134014, -0.0012107965303584933, 0.09546806663274765, -0.020243430510163307, -0.011120442301034927, -0.013252340257167816, 0.03267630189657211, 0.006959079299122095, 0.022061625495553017, -0.04614631459116936, 0.05500681325793266, -0.03912961483001709, -0.04389277473092079, -0.05016683042049408, 0.03006424568593502, 0.01865570992231369, -0.0204739049077034, 0.07411067187786102, -0.009494309313595295, 0.09024395793676376, -0.05510924756526947, -0.0036555971018970013, -0.07728610932826996, 0.006914264522492886, -0.027170497924089432, 0.007733732927590609, -0.04322695732116699, -0.007893784902989864, -0.044942717999219894, -0.0013260343112051487, -0.0032026488333940506, -0.013341969810426235, 0.009276637807488441, -0.04135754331946373, -0.034878622740507126, -0.0002588847710285336, -0.006574953440576792, -0.000910698261577636, 0.014097416773438454, 0.01177985779941082, -0.06192107871174812, 0.020422687754034996, 0.010102508589625359, 0.0008058639359660447, 0.016082067042589188, 0.019974540919065475, 0.00726637989282608, -0.011933508329093456, -0.03959056735038757, 0.03626147657632828, 0.025954099372029305, 0.05016683042049408, -0.0070679145865142345, 0.05011561140418053, 0.01062748022377491, 0.018041107803583145, -0.04627435654401779, 0.02408468723297119, 0.00044574597268365324, 0.003812448587268591, 0.012791389599442482, -0.052445974200963974, 0.04927053675055504, 0.049961961805820465, -0.027733882889151573, 0.030448371544480324, -0.0028569356072694063, 0.0038540621753782034, 0.04340621456503868, -0.009007750079035759, 0.04448176920413971, 0.0015941220335662365, -0.05562141537666321, -0.0368504673242569, -0.02133178524672985, 0.023572519421577454, 0.037695545703172684, -0.009283040650188923, 0.027400974184274673, -0.018937401473522186, 0.034212805330753326, 0.007682516239583492, 0.030678847804665565, 0.019487982615828514, 0.019833695143461227, 0.06868169456720352, 0.07477649301290512, 0.022240884602069855, -0.013892550021409988, 0.011216473765671253, 0.03994908183813095, -0.00034711367334239185, -0.012381655164062977, -0.018220366910099983, 0.022573793306946754, 0.03910400718450546, -0.018079521134495735, -0.014020591974258423, -0.041972145438194275, -0.005758685991168022, -0.007400823757052422, 0.035134706646203995, 0.01425106730312109, 0.036287084221839905, -0.0102369524538517, 0.02096046507358551, 0.025518758222460747, -0.011267689988017082, 0.009423886425793171, 0.06586477160453796, 0.01519857719540596, -0.026479071006178856, -0.014161437749862671, -0.017938675358891487, -0.040973417460918427, 0.013444403186440468, 0.018975814804434776, 0.06658180803060532, 0.02029464580118656, -0.0014340697089210153, 0.048220593482255936, 0.019014226272702217, -0.006312467157840729, 0.006991089787334204, 0.05731156840920448, -0.004148558713495731, 0.00852759275585413, 0.01453275978565216, -0.044200073927640915, 0.0368504673242569, -0.024443205446004868, 0.020717184990644455, 0.015352227725088596, 0.020781205967068672, -0.07277903705835342, -6.907262286404148e-05, -0.020089779049158096, 0.011562186293303967, 0.009161400608718395, 0.069706030189991, -0.062484461814165115, -0.012977049686014652, 0.03065323829650879, 0.005016042850911617, 0.007951403968036175, 0.002909753005951643, -0.04965466260910034, -0.016376562416553497, 0.01326514407992363, 0.054392214864492416, -0.04440494254231453, -0.0028905465733259916, -0.019091052934527397, -0.02195919118821621, 0.028732609003782272, -0.05014122277498245, -0.015531486831605434, -0.014007787220180035, 0.03905278816819191, 0.009820816107094288, 0.014212654903531075, 0.015044927597045898, 0.01146615482866764, 0.038668662309646606, 0.04110145941376686, 0.01742650754749775, 0.010653088800609112, -0.008220291696488857, 0.004218981601297855, -0.024814527481794357, -0.044532984495162964, -0.06786222755908966, 0.07323998957872391, 0.0019830495584756136, 0.036619994789361954, -0.006485323887318373, 0.017964283004403114, -0.017324073240160942, 0.01185668259859085, -0.035313963890075684, -0.008169075474143028, 0.0010259359842166305, -0.008572407066822052, 0.021971995010972023, 0.05067899823188782, -0.0075864847749471664, 0.0365687757730484, 0.02326522022485733, -0.026735154911875725, -0.024353574961423874, -0.011395731940865517, 0.00642770528793335, 0.02035866677761078, 0.009462298825383186, -0.06535260379314423, 0.03129344806075096, 0.020986072719097137, -0.003735623322427273, -0.009154998697340488, 0.030089855194091797, -0.027119280770421028, -0.015365032479166985, 0.06565990298986435, 0.01924470253288746, -0.015352227725088596, -0.04207457974553108, 0.024033470079302788, 0.007951403968036175, -0.005848315544426441, 0.015774765983223915, -0.018105128780007362, -0.005557019729167223, 0.008668438531458378, -0.0138797452673316, 0.016210108995437622, 0.037516284734010696, -0.008649232797324657, -0.0021927182096987963, -0.013303556479513645, -0.0006662181694991887, 0.007733732927590609, 0.02768266573548317, 0.041383154690265656, -0.0017029576702043414, 0.06069187819957733, 0.018476450815796852, -0.01877094805240631, -0.05039730668067932, 0.00026088542654179037, 0.006786222569644451, 0.012759379111230373, -0.044097643345594406, -0.019462373107671738, 0.03339333459734917, 0.006264451425522566, 0.03854062035679817, -0.014929689466953278, 0.03516031429171562, 0.0765690729022026, 0.006459715776145458, 0.06243324652314186, -0.012368850409984589, 0.016453389078378677, 0.01153657864779234, 0.029142344370484352, 0.03672242537140846, 0.04412325099110603, -0.023802995681762695, 0.0033322912640869617, -0.009449495002627373, 0.03582613170146942, -0.019859304651618004, 0.03764432668685913, -0.03039715439081192, -0.028604568913578987, -0.011414938606321812, 0.022881094366312027, 0.06919386237859726, -0.045352451503276825, -0.014712017960846424, -0.012407263740897179, -0.002727293176576495, -0.06663302332162857, -0.05731156840920448, 0.021190939471125603, 0.05357274413108826, 0.006232440937310457, -0.040896594524383545, 0.013905353844165802, -0.026991238817572594, 0.021831149235367775, -0.04253552854061127, 0.0443793348968029, 0.001730166608467698, 0.012496892362833023, -0.005457787308841944, 7.487452239729464e-05, -0.05034608766436577, -0.02482733130455017, -0.03088371455669403, -0.02256098948419094, -0.010896368883550167, -0.008854099549353123, -0.010787532664835453, -0.006341276690363884, 0.010883564129471779, -0.010320180095732212, 0.008501984179019928, -0.0069974916987121105, -0.06806708872318268, -0.020269038155674934, -0.04210018739104271, -0.0382845364511013, 0.008802883327007294, -0.020755598321557045, -0.04478906840085983, 0.002541632391512394, -0.0020678772125393152, 0.01391815859824419, -0.022573793306946754, -0.060179710388183594, -0.007516061421483755, 0.014776038937270641, 0.06847682595252991, 0.014929689466953278, 0.018630102276802063, 0.03848940506577492, -0.02519865334033966, -0.016504604369401932, 0.01012811716645956, -0.05398247763514519, -0.00841875746846199, 0.010806739330291748, 0.000943508988711983, 0.015096143819391727, -0.003257066709920764, -0.009187009185552597, -0.011133246123790741, -0.005057656206190586, 0.014302284456789494, 0.019270310178399086, 0.03910400718450546, 0.008457169868052006, 0.03915522247552872, 0.027810707688331604, 0.016005242243409157, -0.007925795391201973, 0.0548531636595726, -0.015301011502742767, 0.0009491108357906342, 0.02500659041106701, 0.0006110001122578979, 0.024110296741127968, 0.027554623782634735, -0.0031850431114435196, -0.010921976529061794, -0.002311156829819083, -0.029270386323332787, -0.03252265229821205, -0.03088371455669403, -0.025173043832182884, -0.044942717999219894, -0.01746491901576519, -0.0164277795702219, -0.03690168634057045, 0.020870834589004517, 0.009500711224973202, 0.025390716269612312, -0.038771096616983414, 0.016120480373501778, 0.060333359986543655, 0.03267630189657211, 0.006434107199311256, -0.012784986756742, -0.019014226272702217, -0.015365032479166985, -0.009955259971320629, -0.026581505313515663, 0.05536533147096634, -0.02891186811029911, 0.025838863104581833, 0.030422763898968697, -0.03280434384942055, 0.018719730898737907, -0.02612055465579033, -0.031908050179481506, -0.007618495263159275, -0.06432826817035675, -0.0021575065329670906, 0.017644178122282028, -0.01051864493638277, 0.04276600480079651, -0.04417446628212929, 0.009801610372960567, -0.01615889184176922, 0.0304739810526371, 0.0341871976852417, 0.008425159379839897, 0.02508341521024704, 0.028809435665607452, 0.0249041561037302, 0.020128192380070686, 0.023534107953310013, 0.018796555697917938, 0.005793897435069084, -0.001570114167407155, 0.0012588122626766562, 0.01060827448964119, 0.03073006495833397, 0.012548109516501427, 0.04991074651479721, 0.0005997964181005955, 0.016402171924710274, -0.0164277795702219, 0.00953272171318531, -0.018450843170285225, -0.030448371544480324, 0.030269112437963486, -0.00308420998044312, -0.029449645429849625, 0.022496968507766724, -0.029884986579418182, -0.006347679067403078, -0.008277910761535168, 0.010115312412381172, -0.034724973142147064, -0.01836121268570423, -0.005749082658439875, -0.005765087902545929, -0.006869449745863676, -0.010710707865655422, -0.030115462839603424, 0.02103728987276554, -0.033726245164871216, -0.027785100042819977, -0.011882291175425053, -0.011594196781516075, 0.004350224509835243, 0.010979595594108105, -0.03088371455669403, -0.01254170760512352, -0.02816922590136528, 0.013418794609606266, 0.015108948573470116, -0.01347001176327467, 0.01802830398082733, 0.012234406545758247, -0.006136409472674131, -0.018489254638552666, -0.0017525739967823029, -0.02236892655491829, 0.04120389372110367, -0.013649269938468933, -0.028630176559090614, -0.001034738845191896, 0.00698468741029501, 0.0019030232215300202, 0.004167764913290739, 0.030115462839603424, 0.0027160895988345146, 0.020525122061371803, -0.025288281962275505, 0.026581505313515663, -0.01836121268570423, -0.02396944910287857, 0.018015500158071518, -0.0028345282189548016, 0.0077017224393785, 0.01122287567704916, -0.038668662309646606, -0.040333207696676254, -0.017490528523921967, -0.024199925363063812, -0.0030249906703829765, -0.005873923655599356, 0.0076569076627492905, -0.025762036442756653, 0.050858255475759506, 0.057721301913261414, -0.010729913599789143, 0.013316361233592033, -0.004769561812281609, -0.0037228192668408155, -0.017516136169433594, -0.004497473128139973, 0.03096053935587406, 0.008252302184700966, 0.005009640473872423, 0.03326529264450073, 0.009577536955475807, 0.013994983397424221, 0.026133358478546143, 0.019193485379219055, 0.008732459507882595, -0.021946387365460396, 0.008866904303431511, -0.03749067708849907, 0.02824605070054531, 0.008713253773748875, 0.06335514783859253, -0.011267689988017082, 0.015416248701512814, -0.018963010981678963, -0.013482815586030483, -0.011875889264047146, 0.0361846499145031, -0.027196107432246208, -0.04038442671298981, -0.023764582350850105, -0.005960351787507534, -0.011491763405501842, 0.007189554627984762, 0.016888730227947235, -0.03841257840394974, -0.017413703724741936, 0.03354698792099953, 0.018386822193861008, -0.01172223873436451, 0.0065461439080536366, -0.010525046847760677, 0.026325421407818794, -0.040896594524383545, -0.014443130232393742, 0.010083301924169064, -0.0037324223667383194, -0.008041033521294594, 0.025505952537059784, -0.0029497661162167788, 0.02355971559882164, -0.018898990005254745, -0.0073304008692502975, 0.042048972100019455, 0.04368790611624718, 0.021344590932130814, 0.012791389599442482, -0.020576339215040207, 0.01731126941740513, -0.017810633406043053, 0.028937477618455887, 0.06151134520769119, -0.03549322485923767, 0.018924597650766373, 0.008930925279855728, 0.03749067708849907, -0.00041173482895828784, 0.02492976374924183, -0.012400860898196697, -0.025595583021640778, 0.0076441033743321896, 0.004382234998047352, -0.07001332938671112, 0.0030730064027011395, 0.03846379742026329, -0.021190939471125603, -0.017400898039340973, -0.005765087902545929, 0.009263833984732628, -0.022791463881731033, 0.0010707506444305182, -0.014391913078725338, 0.015505878254771233, -0.016069263219833374, 0.003000982804223895, 0.011914301663637161, 0.00499683665111661, -0.00012384055298753083, 0.0433293916285038, 0.0013524428941309452, 0.014507151208817959, 0.027708275243639946, -0.007119131740182638, 0.018348408862948418, 0.064942866563797, -0.01734968274831772, -0.010691501200199127, -0.005291332956403494, 0.00010943583765765652, -0.023175589740276337, -0.02270183525979519, -0.03633829951286316, -0.00022027213708497584, -0.032650694251060486, 0.014891277067363262, -0.008373942226171494, -0.006133208516985178, 0.010717109777033329, -0.013162710703909397, 0.026914414018392563, -0.009327854961156845, -0.02434077113866806, 0.010000075213611126, -0.0006662181694991887, -0.009763197042047977, 0.015992438420653343, -0.008649232797324657, 0.005470591597259045, -0.021984800696372986, -0.023393262177705765, -0.0069078621454536915, -0.06345758587121964, 0.009878435172140598, 0.010397004894912243, 0.01738809421658516, -0.033162862062454224, -0.006991089787334204, -0.006895058322697878, -0.008348333649337292, 0.012189592234790325, -0.008790078572928905, -7.902588549768552e-06, -0.009551928378641605, -0.0030858106911182404, -0.029884986579418182, -0.027196107432246208, 0.015313815325498581, 0.007759341038763523, -0.04458419978618622, -0.03449449688196182, 0.0068246349692344666, -0.016210108995437622, -0.018706927075982094, -0.01969284936785698, -0.027144890278577805, -0.01724724844098091, -0.019487982615828514, -0.02875821851193905, 0.031344667077064514, 0.03403354436159134, -0.019974540919065475, 0.008188281208276749, -0.02816922590136528, 0.010454623959958553, 0.005032048095017672, 0.020128192380070686, 0.012362448498606682, -0.04985952749848366, -0.0022567391861230135, 0.019411157816648483, 0.008726057596504688, 0.010838749818503857, 0.024622464552521706, 0.01458397600799799, -0.03267630189657211, 0.03024350479245186, -0.01222800463438034, 0.020205017179250717, -0.02601812034845352, -0.010326582007110119, 0.021114114671945572, 0.03987225890159607, 0.026248596608638763, 0.026222987100481987, 0.028322875499725342, -0.0011227676877751946, 0.0368504673242569, -0.039001572877168655, -0.013956570997834206, -0.006123605649918318, 0.01976967416703701, -0.010416211560368538, 0.002427995204925537, 0.008956532925367355, 0.009379071183502674, -0.014763235114514828, 0.00953272171318531, -0.00047775646089576185, 0.03303482010960579, -0.003847660031169653, -0.012503295205533504, 0.03321407735347748, 0.008777274750173092, -0.03720898553729057, 0.003434724872931838, -0.004167764913290739, 0.03720898553729057, 0.004916810430586338, -0.012093560770154, -0.012240808457136154, 0.026914414018392563, -0.006104398984462023, 0.015160164795815945, -0.020051367580890656, 0.026735154911875725, 0.009193411096930504, -0.01001287903636694, 0.05889929085969925, 0.012791389599442482, -0.014199850149452686, -0.007112729363143444, -0.033060427755117416, -0.011907899752259254, 0.05854077264666557, -0.013034668751060963, 0.04335499927401543, -0.0157619621604681, 0.032087307423353195, 0.02058914303779602, -0.028630176559090614, -0.04417446628212929, -0.06489165127277374, 0.009558330290019512, -0.00018586087389849126, -0.02389262430369854, -0.02686319686472416, 0.05149846524000168, -0.012509697116911411, -0.026581505313515663, 0.036696817725896835, 0.010531448759138584, -0.009929652325809002, 0.0029689723160117865, 0.00015825183072593063, 0.0365687757730484, -0.018591688945889473, 0.016811905428767204, -0.028860650956630707, 0.04514758661389351, -0.020038561895489693, 0.0025608385913074017, 0.025915687903761864, 0.0026872800663113594, -0.010704305954277515, 0.028886260464787483, -0.016491800546646118, -0.0002606853668112308, 0.012631337158381939, -0.04268918186426163, 0.031908050179481506, -0.007426432333886623, 0.02412310056388378, -0.009955259971320629, -0.008258705027401447, -0.027785100042819977, -0.022957919165492058, 0.037106551229953766, -0.010845151729881763, 0.006965481210500002, 0.019423961639404297, -0.020205017179250717, -0.0067542120814323425, 0.020076975226402283, 0.019039835780858994, 0.008905316703021526, 0.018822163343429565, -0.02448161691427231, 0.029680119827389717, -0.025569973513484, -0.015249794349074364, 0.021536653861403465, -0.0016837514704093337, -0.009801610372960567, -0.009090977720916271, -0.048143766820430756, -0.03692729398608208, 0.015505878254771233, 0.018719730898737907, 0.0017157619586214423, 0.02916795201599598, 0.02686319686472416, -0.01486566849052906, -0.004244590178132057, -0.03567248210310936, -0.007035904098302126, 0.021895170211791992, 0.0277594905346632, -0.02455844357609749, -0.039923474192619324, -0.004542287439107895, -0.03428962826728821, 0.013341969810426235, -0.0038924748077988625, 0.03741385415196419, -0.0007094323518685997, 0.012829801999032497, 0.0021479034330695868, 0.0065109324641525745, 0.0014164638705551624, 0.04243309795856476, -0.010473830625414848, -0.006123605649918318, 0.005422575864940882, 0.0003389109915588051, -0.03831014782190323, 0.0017445713747292757, -0.006914264522492886, 0.027324149385094643, 0.012266417033970356, 0.013559640385210514, 0.02694002352654934, 0.04717065021395683, 0.03454571217298508, 0.02162628248333931, 0.007452040445059538, -0.009500711224973202, -0.019910519942641258, -0.02471209317445755, 0.0009347061277367175, -0.015096143819391727, 0.012688955292105675, -0.006760613992810249, -0.03902718052268028, -0.03382867947220802, 0.03106297366321087, -0.0013884546933695674, 0.006626170128583908, 0.01734968274831772, -0.017849044874310493, 0.027733882889151573, 0.02793874964118004, -0.00852759275585413, -0.007778547704219818, -0.00148688699118793, -0.01548026967793703, -0.017567353323101997, -0.04079416021704674, 0.036619994789361954, -0.0029257582500576973, 0.01839962601661682, -0.010358592495322227, -0.027221715077757835, 0.010166529566049576, -0.009609547443687916, -0.004231785889714956, -0.01992332562804222, 0.010166529566049576, 0.017260052263736725, -0.003221855266019702, 0.05628723278641701, 0.006194028537720442, -0.04225383698940277, -0.024238338693976402, -0.023649346083402634, 0.013482815586030483, -0.011382928118109703, -0.0005365757388062775, 0.01727285608649254, 0.012285623699426651, 0.01248408854007721, 0.03444328159093857, -0.035057879984378815, -0.01503212284296751, -0.020678771659731865, 0.010749120265245438, -0.02297072298824787, -0.009225421585142612, 0.0030457975808531046, -0.030192287638783455, -0.011171658523380756, 0.03615904226899147, 0.06898899376392365, -0.0024407992605119944, 0.009340658783912659, 0.0028217241633683443, 0.05454586446285248, -0.0007190355099737644, 0.026658330112695694, 0.0006522135809063911, -0.02486574277281761, 0.005861119367182255, 0.04522440955042839, 0.040973417460918427, 0.032240960747003555, 0.025429127737879753, 0.04455859214067459, 0.016786297783255577, 0.028963085263967514, 0.011709434911608696, 0.00023787790269125253, 0.002163908677175641, -0.02582605741918087, 0.013277948834002018, -0.0014996911631897092, 0.023610932752490044, 0.012292025610804558, 0.029961813241243362, -0.04440494254231453, -0.010589067824184895, -0.04622313752770424, 0.04210018739104271, 0.0091421939432621, -0.042945265769958496, 0.013290752656757832, -0.0010947585105895996, 0.017196031287312508, -0.010019280947744846, -0.011510970070958138, 0.014404717832803726, 0.008514788933098316, -0.016850318759679794, -0.00078385672532022, 0.02125496044754982, -0.031984876841306686, 0.007452040445059538, -0.009603144600987434, 0.004116548225283623, -0.005646649282425642, 0.04135754331946373, -0.01548026967793703, 0.017656981945037842, -0.01816914975643158, 0.026005316525697708, 0.01582598313689232, -0.011338112875819206, -0.0020198614802211523, -0.032343391329050064, 0.011357319541275501, 0.0023655747063457966, 0.014558367431163788, 0.03831014782190323, 0.019193485379219055, -0.0073111942037940025, 0.007304792292416096, 0.012913028709590435, 0.03021789714694023, 0.02096046507358551, 0.027810707688331604, 0.001478884369134903, 0.020499514415860176, 0.004020516760647297, 0.031242230907082558, 0.01239445898681879, 0.031421490013599396, 0.001060347305610776, -0.01750333234667778, 0.02615896798670292, 0.019078247249126434, 0.04804133251309395, -0.023098764941096306, 0.005326544400304556, 0.019705653190612793, 0.013508424162864685, -0.01976967416703701, 0.016632646322250366, 0.00038572633638978004, 0.005294533912092447, 0.00953272171318531, 0.01638936810195446, -0.00044334519770927727, 0.005912336520850658, -0.005857918411493301, 0.03861744701862335, -0.007887382991611958, -0.007663309574127197, -0.02865578420460224, 0.012368850409984589, 0.02256098948419094, 0.03131905570626259, 0.03984665125608444, 0.0024055878166109324, -0.01906544342637062, -0.0024760109372437, -0.011632610112428665, 0.04934735968708992, -0.00934706162661314, 0.023982254788279533, -0.022023212164640427, -0.009711980819702148, -0.0036555971018970013, 0.02668393962085247, -0.004833582788705826, -0.0032906776759773493, 0.01128049474209547, -0.025019394233822823, 0.01615889184176922, -0.036210257560014725, -0.042458705604076385, 0.007035904098302126, 0.007810557726770639, 0.009910445660352707, -0.0010867558885365725, -0.014622388407588005, -0.016747884452342987, 0.0019830495584756136, 0.034724973142147064, -0.009116585366427898, -0.039411306381225586, 0.014980906620621681, -0.011062823235988617, -0.01038420107215643, 0.016965556889772415, -0.023662149906158447, -0.02110131084918976, -0.011216473765671253, 0.02924477681517601, 0.007247173227369785, -0.004030120093375444, -0.03236900269985199, 0.02809240110218525, 0.0315239243209362, 0.015493074432015419, 0.027247322723269463, 0.006162018049508333, 0.029833771288394928, -0.0013452405110001564, -0.02367495372891426, -0.013994983397424221, 0.010307375341653824, 0.013598053716123104, -0.023802995681762695, -0.027196107432246208, -0.021600674837827682, -0.04432811588048935, -0.0063156685791909695, 0.012240808457136154, 0.010960389859974384, -0.017400898039340973, 0.02883504331111908, -0.014059004373848438, -0.047913290560245514, 0.019270310178399086, -0.006991089787334204, 0.00013474412844516337, 0.015544290654361248, 0.02527547813951969, 0.035877350717782974, -0.028783826157450676, -0.032753124833106995, -0.021344590932130814, 0.008930925279855728, -0.029193561524152756, 0.04240749031305313, 0.02195919118821621, 9.298045188188553e-05, -0.02973133698105812, 0.036031000316143036, -0.03498105704784393, -0.0020102583803236485, 0.08783676475286484, -0.023457283154129982, 0.009001348167657852, -0.01083234790712595, -0.025109022855758667, -0.009097379632294178, 0.017157619819045067, -0.017861850559711456, 0.013892550021409988, -0.008591613732278347, 0.010064096190035343, 0.02991059608757496, 0.030525196343660355, 0.03408476337790489, 0.02259940095245838, 0.0010795535054057837, -0.02430235967040062, 0.008495582267642021, -0.01101800799369812, -0.010864358395338058, -0.0027561027090996504, -0.01806671731173992, -0.004084537737071514, 0.024737700819969177, 0.03024350479245186, -0.00628045666962862, -0.002653669100254774, 0.025659603998064995, 0.014558367431163788, 0.021805541589856148, 0.047401122748851776, -0.028041183948516846, -0.0006210033898241818, -0.01717042364180088, -0.018041107803583145, -0.001651740982197225, -0.012477686628699303, -0.001214797841385007, -5.044151839683764e-05, -0.01720883511006832, -0.02750340662896633, 0.02106289751827717, 0.006299663335084915, 0.004094140604138374, 0.010454623959958553, 0.020012954249978065, 0.01017933338880539, 0.011658217757940292, -0.007227967027574778, 0.010435417294502258, -0.0005433779442682862, -0.017400898039340973, 0.008937327191233635, 0.0035019468050450087, -0.02508341521024704, -0.051114339381456375, -0.006799026858061552, 0.0041005429811775684, 0.03733702749013901, 0.01928311586380005, 0.01062748022377491, -0.0036107825580984354, 0.02177993208169937, 0.012362448498606682, -0.004363028798252344, -0.0001802590413717553, 0.012272818945348263, -0.022906702011823654, -0.008578809909522533, 0.031984876841306686, -0.008021826855838299, -0.003994908183813095, -0.03088371455669403, 0.0035531637258827686, 0.011619805358350277, 0.008258705027401447, -0.00017205634503625333, -0.016043653711676598, -0.020691577345132828, -0.01850206032395363, 0.01664545200765133, 0.005256121512502432, 0.031421490013599396, 0.0013692483771592379, -0.005822706967592239, 0.012388057075440884, 0.0019878509920090437, 0.0091421939432621, 0.02653028815984726, 0.013610857538878918, -0.0009419084526598454, -0.025877274572849274, 0.016082067042589188, 0.018783751875162125, -0.008591613732278347, -0.023956645280122757, -0.049961961805820465, -0.01270816195756197, -0.024033470079302788, -0.0304739810526371, 0.008271508850157261, 0.01935994066298008, 0.003716417122632265, -0.0315239243209362, 0.01846364699304104, -0.0021975196432322264, 0.03889913856983185, 0.0029385623056441545, 0.01601804606616497, -0.000455349130788818, 0.009334256872534752, 0.009814414195716381, 0.008866904303431511, 0.006469318643212318, 0.03231778368353844, -0.033162862062454224, 0.029270386323332787, -0.005534612573683262, -0.00015465065371245146, 0.0020966867450624704, 0.007637701462954283, -0.0061076004058122635, 0.0007470446289516985, -0.026402246206998825, 0.006414900999516249, 0.0073239984922111034, 0.02932160347700119, 0.030345939099788666, -0.001161980559118092, -0.04368790611624718, 0.032573867589235306, 0.02760584093630314, -0.01347001176327467, 0.034724973142147064, 0.000520170375239104, 0.001534902723506093, 0.014481542631983757, 0.004356626886874437, -0.002935361349955201, 0.00026688739308156073, 0.06048700958490372, 0.015147360973060131, 0.032983601093292236, -0.027964359149336815, -0.002615256467834115, -0.011178060434758663, -0.009340658783912659, -0.007560876198112965, -0.0017205635085701942, 0.011037214659154415, 0.007349607069045305, 0.01408461295068264, -0.047990117222070694, 0.002255138475447893, -0.04215140640735626, -0.043534256517887115, 0.022087233141064644, 0.021933583542704582, 0.003988506272435188, -0.008783676661550999, 0.022612204775214195, 0.004084537737071514, -0.02348289079964161, 0.03518592193722725, -0.011574991047382355, -0.025851666927337646, 0.0062964619137346745, 0.01839962601661682, 0.00841875746846199, -0.009058967232704163, -0.002493616659194231, 0.0024920161813497543, -0.04681213200092316, 0.005364956799894571, 0.03411037102341652, 0.014007787220180035, 0.022573793306946754, -0.046325571835041046, 0.019680045545101166, -0.011747847311198711, -0.027452191337943077, 0.019052639603614807, -0.03475058078765869, -0.005224111024290323, 0.006658180616796017, 0.041152678430080414, -0.0015212981961667538, -0.013495619408786297, 0.014519955031573772, -2.5883477974275593e-06, 0.011434144340455532, -0.02694002352654934, 0.0025784445460885763, -0.005550617817789316, 0.02768266573548317, 0.03674803674221039, -0.013329165056347847, 0.022471358999609947, -0.009276637807488441, -0.01326514407992363, 0.006011568941175938, 0.0018550074892118573, -0.010166529566049576, 0.036466341465711594, -0.00040933405398391187, -0.033060427755117416, -0.046658482402563095, 0.004555091727524996, 0.01709359884262085, 0.02252257615327835, 0.02627420425415039, 0.0059347436763346195, 0.007580082397907972, 0.016453389078378677, -0.0019446369260549545, -0.008726057596504688, -0.020089779049158096, 0.013649269938468933, -0.023841407150030136, -0.03516031429171562, -0.0270936731249094, 0.0022279296535998583, -0.023418869823217392, -0.051114339381456375, -0.017554549500346184, -0.04417446628212929, 0.048323024064302444, -0.017849044874310493, -0.0009114985004998744, -0.03623586893081665, -0.009385474026203156, -0.0124520780518651, -0.031908050179481506, -0.0005525809829123318, -0.0277594905346632, -0.0005589830689132214, -0.001266014645807445, 0.019091052934527397, -0.03498105704784393, -0.010416211560368538, 0.012106364592909813, -0.01857888512313366, -0.006104398984462023, 0.013815724290907383, 0.03096053935587406, -0.006024372763931751, 0.02578764595091343, 0.004071733448654413, 0.015301011502742767, 0.022714639082551003, 0.010601872578263283, -0.007317596580833197, -0.004218981601297855, 0.013815724290907383, -0.010307375341653824, -0.03633829951286316, -0.012977049686014652, 0.005128079559653997, -0.015416248701512814, 0.013662074692547321, 0.012240808457136154, -0.012138375081121922, 0.010589067824184895, 0.0032282571773976088, 0.0073239984922111034, -0.031267840415239334, -0.010729913599789143, 0.011952714063227177, -0.014878472313284874, -0.014647996984422207, -0.03831014782190323, 0.008341931737959385, 0.0005133681115694344, 0.01441752165555954, 0.015595507808029652, 0.012131973169744015, -0.019526394084095955, 0.01206155028194189, 0.04220262169837952, -0.03500666469335556, 0.00869404710829258, 0.017477724701166153, -0.02906551957130432, -0.03024350479245186, -0.005512205418199301, 0.002051871968433261, -0.03106297366321087, 0.0204739049077034, 0.02768266573548317, -0.0005313740111887455, 0.038745488971471786, -0.0006330073229037225, -0.034315239638090134, -0.011312505230307579, 0.027221715077757835, -0.016069263219833374, -0.011133246123790741, -0.04053807631134987, -0.01035219058394432, 0.027144890278577805, 0.039001572877168655, 0.009411081671714783, -0.01233683992177248, 0.0008362738881260157, 0.01298985444009304, -0.029295993968844414, 0.017144814133644104, 0.05444343015551567, -0.014878472313284874, 0.037439461797475815, -0.016069263219833374, -0.03444328159093857, -0.013828529044985771, -0.0070807188749313354, 0.009398277848958969, -0.008277910761535168, 0.00999367330223322, -0.011767053976655006, -0.005806701723486185, 0.031677573919296265, 0.032983601093292236, 0.006542942952364683, 0.025429127737879753, -0.017413703724741936, 0.041229501366615295, -0.019500786438584328, -0.02635102905333042, -0.02058914303779602, 0.013777311891317368, -0.02066596783697605, 0.005400168709456921, -0.004231785889714956, 0.00923182349652052, 0.005083264783024788, 0.018886184319853783, -0.003114619990810752, 0.012881018221378326, 0.005489797797054052, -0.011997529305517673, -0.012586521916091442, 0.0016469393158331513, -0.02553156204521656, 0.014622388407588005, 0.0037932423874735832, 0.007272781804203987, 0.02184395305812359, 0.02277866005897522, 0.02192077971994877, -0.012343242764472961, -0.02033305913209915, 0.00020116587984375656, 0.018143542110919952, 0.015339423902332783, 0.008962935768067837, -0.021639086306095123, -0.013982179574668407, 0.04440494254231453, -0.010313778184354305, 0.033060427755117416, -0.021536653861403465, -0.037439461797475815, 0.012272818945348263, -0.010473830625414848, 0.000984322396107018, 0.03362381085753441, 0.027144890278577805, -0.014596780762076378, 0.0034795396495610476, -0.00064701191149652, 0.007452040445059538, 0.03024350479245186, -0.0036716023460030556, 0.008598015643656254, -0.021267764270305634, -0.009097379632294178, 0.026811981573700905, 0.005156889092177153, 0.010896368883550167, -0.015352227725088596, -0.028707001358270645, -0.018105128780007362, -0.011542980559170246, 0.03541639819741249, 0.016286933794617653, 0.03559565916657448, 0.004356626886874437, 0.008233096450567245, 0.01605645939707756, 0.028143616393208504], index=1, object='embedding'), Embedding(embedding=[0.03559696674346924, 0.004427499137818813, 0.009980044327676296, -0.012369186617434025, 0.03263897821307182, 0.011161974631249905, 0.01778584159910679, 0.022248104214668274, -0.020314035937190056, 0.041563503444194794, 0.012173252180218697, -0.015738004818558693, -0.02443499118089676, 0.050791408866643906, 0.014928982593119144, 0.05450785160064697, 0.0054861800745129585, -0.03789762035012245, 0.019277475774288177, 0.023625968024134636, 0.011800343170762062, 0.02038988098502159, -0.012236456386744976, -0.020187625661492348, 0.00182819995097816, -0.04204385727643967, 0.0021379035897552967, 0.032841235399246216, 0.0054482570849359035, -0.028871970251202583, 0.014246370643377304, -0.020731186494231224, -0.03981904685497284, -0.002848958130925894, 0.07357043027877808, 0.0371391624212265, 0.030363604426383972, -0.06330596655607224, 0.010580490343272686, -0.006254118867218494, 0.06937362998723984, -0.0003778464160859585, -0.0016875691944733262, 0.00347310584038496, 0.02596454694867134, 0.013032837770879269, 0.03936397284269333, 0.005347129423171282, 0.03392835706472397, -0.02310768887400627, -0.02821464091539383, 0.007142146583646536, -0.04477430880069733, -0.0031586617697030306, 0.0391869992017746, -0.005445096641778946, 0.02791125699877739, 0.0007142146932892501, -0.013955628499388695, -0.005495660938322544, 0.011591767892241478, 0.023284662514925003, -0.02130003087222576, -0.004272647202014923, -0.03769536688923836, 0.050766125321388245, -0.010194940492510796, -0.033271025866270065, -0.026470186188817024, 0.01042247749865055, 0.02324673905968666, -0.016698718070983887, -0.013942987658083439, 0.0019245872972533107, -0.04285288229584694, -0.022387154400348663, 0.022715819999575615, -0.023347867652773857, 0.06482288241386414, 0.021628696471452713, 0.025572678074240685, 0.021691901609301567, -0.017267562448978424, 0.018974091857671738, -0.06846348196268082, 0.014398062601685524, -0.012369186617434025, -0.020415162667632103, 0.023588046431541443, 0.06623867154121399, -0.004440139979124069, -0.02700110711157322, -0.006469015032052994, -0.05324375629425049, -0.0029342847410589457, -0.02127474918961525, -0.03188052028417587, -0.01615515723824501, -0.017128512263298035, 0.03928812965750694, 0.04831377789378166, -0.0040198275819420815, 0.02639434114098549, -0.03430758789181709, 0.07104223966598511, 0.0010199680691584945, 0.034610968083143234, 0.044875435531139374, 0.0023085568100214005, -0.009524969384074211, -0.05390108749270439, -0.003928180783987045, -0.03979376703500748, 0.023196175694465637, 0.0425494983792305, 0.025104962289333344, -0.00738864578306675, 0.04105786234140396, 0.042650625109672546, -0.0010926536051556468, -0.004572870209813118, -0.017608867958188057, 0.003852335037663579, -0.03638070449233055, -0.016091952100396156, -0.006197234615683556, -0.011395832523703575, -0.012647287920117378, 0.006200394593179226, 0.013803936541080475, 0.015510467812418938, -0.007881643250584602, 0.005315526854246855, -0.03049001470208168, 0.03812515735626221, 0.002624580869451165, -0.03213334083557129, 0.008564256131649017, 0.007224312983453274, -0.04057750478386879, 0.0158644150942564, 0.04750475659966469, 0.03997074067592621, 0.023613328114151955, 0.07503678649663925, -0.009284790605306625, -0.0012870085192844272, 0.0552157461643219, 0.0018534818664193153, -0.03248728811740875, 0.013374144211411476, -0.015421980991959572, -0.03792290389537811, 0.04234724119305611, -0.0009986364748328924, -0.010043248534202576, -0.04229667782783508, -0.012343904934823513, 0.011888829991221428, 0.06684543937444687, -0.016787204891443253, -0.04424338787794113, -0.03304348886013031, 0.021211544051766396, 0.025067038834095, -0.004275807179510593, -0.03016134910285473, 0.026470186188817024, -0.05043746158480644, 0.03150129318237305, 0.04737834632396698, 0.0005411914316937327, -0.0018313601613044739, 0.021944720298051834, 0.00017489964375272393, 5.066262747277506e-05, -0.013690168038010597, -0.005046906415373087, 0.017722636461257935, -0.005982337985187769, -0.049426183104515076, -0.005264963023364544, -0.053799957036972046, 0.0005664733471348882, 0.0235501229763031, -0.025597959756851196, -0.024258017539978027, 0.06259807199239731, 0.01702738367021084, 0.02894781529903412, -0.016243644058704376, 0.08621139824390411, 0.0025771772488951683, -0.027405617758631706, 0.01705266535282135, 0.034661535173654556, -0.02306976541876793, 0.04328267276287079, 0.0045128255151212215, -0.010839629918336868, 0.03516717255115509, -0.05794619768857956, -0.013879782520234585, -0.024346504360437393, -0.0062414780259132385, 0.018000738695263863, -0.025319859385490417, 0.045027125626802444, -0.009202624671161175, -0.04874357208609581, 0.01200891938060522, 0.014638240449130535, 0.031602419912815094, 0.0007912456057965755, -0.010100133717060089, -0.0017965974984690547, 0.036886345595121384, 0.014296934939920902, -0.01259040366858244, 0.02669772319495678, -0.01281794160604477, -0.00874754972755909, 0.051827967166900635, 0.053041499108076096, 0.00822294969111681, 0.0649745762348175, 0.06032269820570946, -0.04871828854084015, 0.0001777636061888188, -0.0013059700140729547, 0.03514188900589943, 0.008728587999939919, -0.05203022435307503, -0.015004828572273254, 0.0051985979080200195, 0.052738118916749954, 0.008279833942651749, -0.010605772025883198, 0.0064216116443276405, -0.007458170875906944, -0.005814845208078623, 0.01570008136332035, 0.004234724212437868, 0.004996342584490776, -0.02564852312207222, 0.008469448424875736, -0.027228644117712975, -0.021211544051766396, 0.04583615064620972, -0.018658068031072617, -0.019580859690904617, 0.006952532101422548, -0.046392351388931274, 0.006412130780518055, -0.060120441019535065, 0.02295599691569805, -0.04659460857510567, -0.03483850881457329, -0.007521376013755798, -0.054710108786821365, 0.08428997546434402, -0.0008177126292139292, -0.0034162215888500214, -0.01274209562689066, 0.06659261882305145, -0.006876686587929726, -0.009929480031132698, 0.0005455367499962449, -0.018594862893223763, 0.0006142720230855048, -0.030970370396971703, -0.016673436388373375, -0.025989830493927002, -0.03094508871436119, -0.033574409782886505, 0.013121324591338634, 0.02521873079240322, -0.01945444941520691, 0.04950203001499176, -0.00284579792059958, 0.021186262369155884, -0.03837797790765762, 0.022564128041267395, -0.009095176123082638, -0.013121324591338634, 0.008159744553267956, 0.03890889883041382, -0.02609095722436905, 0.009840993210673332, -0.012710493057966232, -0.057592250406742096, 0.006908288691192865, 6.458744610426947e-05, -0.03458568826317787, 0.02221018075942993, 0.018304120749235153, -0.031905803829431534, -0.010877552442252636, 0.03974320366978645, 0.01404411531984806, 0.021780386567115784, -0.04252421483397484, -0.0017902770778164268, 0.029706275090575218, -0.03031304106116295, 0.04846547171473503, -0.015801209956407547, -0.0513223297894001, -0.010548887774348259, 0.006415291223675013, -0.022146975621581078, 0.04027412459254265, -0.005413494538515806, -0.023309944197535515, 0.014916341751813889, -0.020743828266859055, -0.04725193604826927, 0.03157713636755943, 0.05010879784822464, -0.04131068289279938, 0.006175112910568714, 0.0030417328234761953, 0.06679487228393555, -0.0011329466942697763, 0.02099664695560932, -0.029807401821017265, 0.01855694130063057, -0.027102235704660416, -0.008602178655564785, -0.007736272178590298, -0.005283924750983715, -0.015004828572273254, 0.013096042908728123, 0.005005823448300362, -0.03408005088567734, -0.03334687277674675, -0.04753004014492035, -0.05597420409321785, 0.05632815137505531, 0.07478396594524384, -0.0699298307299614, 0.02444763109087944, 0.0038017709739506245, 0.022880151867866516, -0.00989155750721693, 0.02851802296936512, 0.017166433855891228, 0.03974320366978645, -0.04260006174445152, 0.00061703723622486, 0.00671235378831625, 0.0413612462580204, -0.003912379499524832, -0.008014373481273651, 0.006311003118753433, 0.002250092336907983, 0.0205162912607193, 0.012312302365899086, -0.029554583132267, 0.02626793086528778, 0.020933441817760468, -0.029327046126127243, -0.03425702452659607, 0.017760559916496277, 0.03726557269692421, 0.002700426848605275, -0.018013378605246544, -0.018898246809840202, -0.010036928579211235, 0.04543163999915123, 0.014208448119461536, 0.051069509238004684, 0.04138652980327606, 0.02141379937529564, 0.03506604582071304, 0.05127176642417908, 0.00482884980738163, 0.009177342988550663, -0.026647159829735756, 0.04075447842478752, -0.026419622823596, 0.05390108749270439, 0.005723197944462299, -0.030717551708221436, 0.03547055646777153, -0.004528626799583435, -0.033599693328142166, 0.002411264693364501, -0.07255915552377701, 0.045204099267721176, 0.00629520183429122, -0.06709825992584229, 0.00876651145517826, -0.010719540528953075, 0.0016030326951295137, 0.0025329338386654854, 0.0037164445966482162, -0.031299035996198654, 0.012773698195815086, -0.02291807532310486, 0.01763414964079857, 0.02578757517039776, -0.04965372011065483, 0.020769109949469566, -0.007142146583646536, 0.024687809869647026, -0.011838266626000404, 0.004478062968701124, -0.04267590865492821, 0.01975783333182335, -0.01990952342748642, 0.032841235399246216, 0.048819418996572495, -0.006070824805647135, -0.013715449720621109, -0.005938094574958086, -0.03711388260126114, -0.02008649706840515, 0.050614435225725174, 0.0019245872972533107, -0.041715193539857864, -0.07205351442098618, 0.03349856287240982, -0.021906796842813492, 0.035976193845272064, 0.05799676105380058, -0.022880151867866516, -0.04421810433268547, -0.010441439226269722, -0.08130670338869095, 0.009910518303513527, -0.021059852093458176, 0.03319518268108368, 0.0025281936395913363, -0.01856958121061325, -0.0374678298830986, 0.027658438310027122, 0.02250092290341854, -0.012438712641596794, -0.02171718329191208, -0.022248104214668274, -0.006304682698100805, -0.06189017742872238, 0.06123284623026848, -0.010055890306830406, 0.027051670476794243, 0.0059602162800729275, 0.019998010247945786, -0.045785583555698395, -0.00906357355415821, 0.010005326010286808, -0.014360139146447182, -0.007230633404105902, 0.01841788925230503, 0.09688037633895874, 0.04682214558124542, -0.004623434040695429, -0.02022554911673069, -0.029529301449656487, -0.03195636719465256, 0.03165298327803612, 0.045204099267721176, -0.01462559960782528, -0.037973467260599136, -0.007635144516825676, 0.003909219056367874, 0.014638240449130535, 0.02325938083231449, 0.004155718255788088, 0.012185893021523952, -0.0061340294778347015, 0.002161605516448617, 0.02535778097808361, 0.020895520225167274, -0.04244837164878845, -0.03076811507344246, 0.02489006519317627, 0.012697852216660976, 0.04527994617819786, -0.004133596550673246, -0.015952901914715767, -0.0006304682465270162, 0.030591141432523727, 0.022892791777849197, -0.06143510341644287, -0.046847425401210785, 0.010011646896600723, 0.0014584516175091267, -0.053648266941308975, -0.012249098159372807, 0.011263102293014526, -0.005678954999893904, -0.035824503749608994, -0.012179572135210037, 0.0022627331782132387, -0.02217225730419159, -0.09784109145402908, -0.027734283357858658, 0.03653239831328392, 0.0004321630985941738, 0.01447390764951706, 0.018367325887084007, -0.005505141336470842, -0.006307843141257763, 0.024245375767350197, -0.02639434114098549, -0.015952901914715767, 0.010220222175121307, 0.027355054393410683, -0.0021726663690060377, 0.023954633623361588, 0.03185524046421051, 0.03729085624217987, -0.02021290734410286, 0.007704670075327158, -0.001905625918880105, -0.029756838455796242, -0.00979674980044365, 0.016193078830838203, -0.003991385456174612, 0.015965541824698448, 0.015270289033651352, 0.018797118216753006, 0.023815583437681198, 0.007085262332111597, 0.02097136527299881, -0.017469817772507668, -0.01328565739095211, 0.04184160381555557, -0.011395832523703575, 0.038074593991041183, 0.02717808075249195, -0.011313666589558125, 0.007976450957357883, 0.004329531453549862, 0.020478367805480957, 0.007919566705822945, 0.00702205765992403, -0.020453086122870445, 0.003507868619635701, -0.02231130748987198, -0.017899610102176666, 0.016976820304989815, 0.020617417991161346, -0.031172625720500946, -0.02324673905968666, 0.0074265687726438046, 0.005404013674706221, 0.034661535173654556, 0.014903700910508633, 0.0031523413490504026, 0.03271482512354851, 0.02356276474893093, -0.0036216373555362225, -0.013462631031870842, 0.026343777775764465, -0.0182409156113863, 0.03736669942736626, -0.04765644669532776, 0.008854998275637627, -0.07351987063884735, -0.032992925494909286, -0.00019563872774597257, 0.004471742548048496, 0.024118967354297638, 0.04447092488408089, 0.027279209345579147, 0.02582549676299095, 0.01812714710831642, 0.011041885241866112, -0.018190352246165276, 0.02384086512029171, -0.028442177921533585, -0.06704769283533096, 0.010194940492510796, 0.005005823448300362, 0.03499019891023636, 0.015801209956407547, -0.00012700221850536764, 0.03274010494351387, -0.0034983877558261156, -0.021679259836673737, 0.011414794251322746, -0.017760559916496277, -0.04783342033624649, 0.025458909571170807, -0.00867170374840498, 0.002752570668235421, 0.01883504167199135, 0.010321349836885929, -0.013829219155013561, 0.02054157294332981, -0.03076811507344246, 0.02004857547581196, -0.006017100531607866, -0.005659993272274733, -0.0014552914071828127, -0.02778484672307968, 0.024207454174757004, -0.007268556393682957, -0.006642828695476055, -0.004579190630465746, -0.011282064020633698, 0.006165632046759129, 0.02218489907681942, 0.0056283907033503056, 0.016332130879163742, -0.029478736221790314, 0.025913983583450317, -0.017103228718042374, -0.005934934597462416, 0.023929351940751076, 0.0249027069658041, -0.0283663310110569, -0.009986364282667637, 0.0016338450368493795, -0.042498935014009476, -0.012438712641596794, 0.007894284091889858, -0.0026877857744693756, 0.019542936235666275, 0.007584580685943365, -0.016863051801919937, -0.04570974037051201, 0.017608867958188057, -0.015573672018945217, 0.00039127745549194515, -0.012798979878425598, -0.01782376505434513, 0.016660794615745544, -0.0016227841842919588, -0.03425702452659607, -0.005008983425796032, -0.01795017346739769, -0.03653239831328392, 0.0018771836766973138, -0.004313730169087648, -0.021160980686545372, 7.317935524042696e-05, 0.015788568183779716, 0.02352484129369259, -0.0015453583328053355, -0.021666618064045906, 0.0015564191853627563, 0.023448994383215904, 0.0034667854197323322, 0.00414939783513546, 0.002850538119673729, 0.03152657300233841, -0.026596596464514732, -0.022905433550477028, 0.028644433245062828, 0.04166463017463684, 0.020124420523643494, 0.013563758693635464, 0.013399425894021988, 0.01616779714822769, -0.005599948577582836, -0.018468454480171204, 0.004689799156039953, -0.007331761531531811, 0.002931124297901988, -0.008779152296483517, 0.031476009637117386, -0.015750646591186523, 0.03286651521921158, 0.03878248855471611, -0.037644803524017334, -0.04512825608253479, 0.012312302365899086, 0.05430559813976288, -0.010011646896600723, 0.021388517692685127, -0.016028746962547302, 0.0037480469327419996, 0.01268521137535572, 0.029225917533040047, 0.027709001675248146, 0.015232366509735584, 0.008817074820399284, 0.0003357756941113621, 0.017014741897583008, 0.0164585392922163, -0.016268925741314888, 0.003962943330407143, -0.014233729802072048, 0.05718773975968361, -0.004345332738012075, -0.015598954632878304, 0.01690097339451313, 0.01599082350730896, 0.008633781224489212, 0.011762420646846294, -0.010599451139569283, 0.007230633404105902, 0.01530821155756712, -0.009335354901850224, 0.013930346816778183, -0.016066670417785645, -0.041892167180776596, 0.03653239831328392, 0.0004376934957690537, 0.008772831410169601, -0.03200693055987358, -0.017722636461257935, -0.023878788575530052, 0.0009480725857429206, -0.005520942620933056, 0.013437348417937756, -0.02171718329191208, -0.009480725973844528, -0.028644433245062828, -0.013171888887882233, 0.0479598306119442, -0.013487912714481354, -0.007300158962607384, 0.022109052166342735, 0.018809759989380836, -0.0416899099946022, -0.007717310916632414, 0.01843053102493286, 0.01977047324180603, -0.020174983888864517, 0.021616054698824883, 0.011869869194924831, -0.011408473365008831, 0.024561399593949318, 0.008741228841245174, 0.022816946730017662, -0.007869002409279346, 0.011534882709383965, 0.0034983877558261156, 0.004522306378930807, 0.0096640195697546, 0.015421980991959572, 0.03473737835884094, -0.013171888887882233, -0.021211544051766396, -0.041133709251880646, -0.027860693633556366, -0.0083619998767972, -0.030237194150686264, 0.011294704861938953, -0.003098617307841778, 0.019087862223386765, -0.029225917533040047, 0.03590034693479538, 0.010359273292124271, -0.05069028213620186, -0.004136756528168917, -0.03167826682329178, 0.01033399160951376, 0.012881145812571049, 0.02988324873149395, 0.018076583743095398, -3.120738983852789e-05, 0.003517349250614643, -0.047479476779699326, 0.038276851177215576, -0.006311003118753433, -0.003258209442719817, 0.0061340294778347015, 0.021691901609301567, -0.012362866662442684, -0.005040585994720459, 0.03572337329387665, 0.0024823700077831745, 0.012640967965126038, 0.012129008769989014, -0.007047339342534542, 0.021628696471452713, 0.029352327808737755, 0.020465726032853127, -0.020162343978881836, 0.06947475671768188, -0.012843223288655281, 0.017596228048205376, 0.0386560782790184, 0.00950600765645504, 0.01168025378137827, 0.023904070258140564, -0.020870238542556763, -0.04032468795776367, 0.008854998275637627, -0.00973986554890871, -0.02310768887400627, 0.039035309106111526, -0.010795386508107185, 0.026899978518486023, -0.005179636646062136, -0.013096042908728123, -0.026621878147125244, 0.04214498773217201, -0.032234467566013336, 0.039591509848833084, -0.01524500735104084, 0.014853137545287609, -0.007154787890613079, 0.024081043899059296, -0.008867639116942883, 0.018051302060484886, -0.007104224059730768, 0.011294704861938953, -0.013247733935713768, -0.0003942401963286102, 0.0012743675615638494, -0.036759935319423676, 0.000295482634101063, 0.006250958424061537, -0.011787702329456806, -0.024093683809041977, 0.02472573332488537, -0.050311051309108734, -0.003608996281400323, 0.018948810175061226, 0.026950543746352196, 0.036608241498470306, -0.026950543746352196, -0.020035933703184128, -0.01870863139629364, 0.01290010754019022, 0.023625968024134636, 0.04088088870048523, -0.012426070868968964, 0.03612788766622543, -0.01992216520011425, 0.025913983583450317, 0.00024946159101091325, -0.014221088960766792, 0.02325938083231449, -0.04310569912195206, 0.006039222236722708, 0.04199329391121864, -0.0033814588095992804, -0.01854429952800274, 0.020743828266859055, 0.0024871104396879673, -0.015409340150654316, 0.0043769353069365025, 0.03332158923149109, 0.043687183409929276, 0.036456551402807236, 0.02535778097808361, -0.030717551708221436, -0.018013378605246544, -0.005618910305202007, -0.03592563048005104, 0.03759423643350601, 0.0056663136929273605, 0.03352384641766548, 0.024384425953030586, -0.001821879530325532, -0.01117461547255516, -0.0023464795667678118, -0.024826860055327415, -0.026596596464514732, 0.015485185198485851, 0.028796125203371048, 0.02894781529903412, -0.018961451947689056, 0.012830582447350025, -0.01993480697274208, 0.033422719687223434, 0.025003833696246147, -0.026798851788043976, -0.010561528615653515, -0.002330678515136242, 0.014031474478542805, -0.036759935319423676, -0.024068402126431465, -0.0022248104214668274, 0.012287020683288574, -0.030136067420244217, -0.0064974576234817505, -0.008753870613873005, -0.005426135379821062, 0.022538846358656883, -0.03124847263097763, 0.030970370396971703, -0.0034478239249438047, 0.0005249952082522213, -0.00498370174318552, -0.01869599148631096, -0.019100502133369446, -0.04692327231168747, -0.051069509238004684, 0.024207454174757004, 0.019947446882724762, 0.0038934180047363043, 0.03911115601658821, -0.054406724870204926, -0.008614819496870041, -0.046088967472314835, -0.031122062355279922, -0.04570974037051201, 0.06355878710746765, -0.005072188097983599, 0.03663352504372597, 0.020149702206254005, -0.0005565976025536656, 0.011256781406700611, 0.02669772319495678, -0.01411996129900217, 0.034484561532735825, 0.01915106549859047, 0.017002101987600327, -0.031450726091861725, -0.024068402126431465, 0.0064532142132520676, -0.0050184642896056175, -0.013791295699775219, -0.004854131489992142, -0.002878980478271842, 0.016938896849751472, 0.002118942327797413, -0.008039655163884163, 0.013740732334554195, -0.008241911418735981, -0.018354685977101326, -0.016205720603466034, -0.031147344037890434, 0.00039404266863130033, -0.003858655458316207, 0.0016156736528500915, 0.014891060069203377, -0.015738004818558693, -0.018493736162781715, -0.005713717546314001, 0.047934550791978836, -0.030970370396971703, 0.05744055658578873, -0.04105786234140396, -0.014992187730967999, 0.0061719524674117565, 0.011882510036230087, -0.016509104520082474, -0.007590901106595993, 0.014296934939920902, 0.007015737239271402, 0.013879782520234585, 0.0006107167573645711, -0.004421178251504898, 0.009518648497760296, 0.01132630743086338, -0.006431092508137226, 0.007812118157744408, 0.004098834004253149, -0.024258017539978027, -0.021375875920057297, -0.005046906415373087, 0.013803936541080475, -0.002343319356441498, -0.014752008952200413, -0.02114833891391754, -0.015927620232105255, -0.0063836886547505856, -0.002254832535982132, -0.02368917316198349, 0.016054028645157814, -0.04404113069176674, -0.03665880486369133, -0.006952532101422548, 0.01072586141526699, -0.0006790569750592113, -0.01949237287044525, -0.025408344343304634, -0.0002702006895560771, 0.0329170785844326, -0.008027014322578907, 0.038833051919937134, 3.745380672626197e-05, -0.006731315515935421, -0.0026956864167004824, 0.0543561615049839, 0.01600346527993679, 0.043712466955184937, 0.0054166545160114765, 0.0027683719526976347, 0.011964675970375538, -0.056833792477846146, 0.005609429441392422, 0.026015112176537514, -0.011395832523703575, 0.01719171553850174, 0.0064658550545573235, -0.030565859749913216, -0.007508734706789255, -0.0028189357835799456, 0.030287759378552437, -0.04576030373573303, -0.0027336091734468937, 0.025989830493927002, -0.015371416695415974, 0.0035931949969381094, 0.025863420218229294, 0.0018787637818604708, -0.027658438310027122, 0.03127375245094299, -0.001904045813716948, 0.046114251017570496, -0.019719909876585007, -0.034610968083143234, -0.0020178144332021475, 0.011553844437003136, 0.009859954938292503, 0.01616779714822769, 0.04376303032040596, -0.014145242981612682, -0.011522241868078709, -0.033094052225351334, 0.029225917533040047, -0.01334886159747839, -0.010959719307720661, -0.016521744430065155, 0.01281794160604477, -0.015902336686849594, 0.003305613063275814, 0.022867510095238686, -0.008804433979094028, 0.011812984012067318, 0.006510098464787006, 0.01658494956791401, -0.011654972098767757, -0.017621509730815887, -0.009076215326786041, -0.02443499118089676, 0.0073254406452178955, 0.015030110254883766, 0.01749509945511818, 0.0036658807657659054, 0.04305513575673103, -0.02006121538579464, 0.013273016549646854, 0.013487912714481354, 0.0024871104396879673, 0.059361983090639114, -0.009550251066684723, -0.02142644114792347, 0.010207581333816051, 0.03279067203402519, 0.0027336091734468937, 0.017684713006019592, 0.0020067535806447268, 0.02521873079240322, -0.01779848337173462, 0.00587804988026619, -0.01993480697274208, -0.016964178532361984, 0.01659759134054184, 0.009449123404920101, -0.002409684471786022, -0.021628696471452713, -0.008779152296483517, -0.013942987658083439, 0.028467459604144096, -0.007976450957357883, -0.0002644727355800569, -0.0029342847410589457, -0.017457175999879837, 0.009310073219239712, 0.0011811404256150126, 0.005707397125661373, 0.023752378299832344, -0.02563588321208954, -0.016572309657931328, 0.02065534144639969, -0.025294575840234756, 0.028619151562452316, -0.009916839189827442, 0.03322046250104904, 0.012381828390061855, -0.005520942620933056, 0.029225917533040047, 0.006775558926165104, 0.023651251569390297, -0.01404411531984806, -0.02142644114792347, -0.0009907358326017857, 0.01749509945511818, 0.013184529729187489, -0.015573672018945217, 0.018809759989380836, -0.045330509543418884, 0.018607504665851593, 0.0017634150572121143, -0.037215009331703186, 0.00869066547602415, -0.010947078466415405, -0.013778654858469963, -0.014865778386592865, -0.01735604926943779, -0.025244012475013733, -0.009645058773458004, 0.03453512489795685, -0.032360877841711044, -0.008627460338175297, 0.00551146175712347, -0.0052744438871741295, 0.003098617307841778, 0.01138319168239832, -0.028619151562452316, 0.03587506711483002, 0.02367653325200081, 0.003299292642623186, -0.007590901106595993, 0.008684344589710236, -0.03246200457215309, -0.0011945714941248298, 0.022703178226947784, 0.02322145737707615, 0.02763315476477146, 0.0009346415754407644, 0.03322046250104904, -0.004278967622667551, -0.03195636719465256, -0.0016322649316862226, 0.014688804745674133, -0.010921795852482319, -2.9553200874943286e-05, -0.021919438615441322, 0.0068577248603105545, -0.05294037237763405, -0.04310569912195206, 0.006541701033711433, -0.0004025358066428453, -0.025686446577310562, 0.0096640195697546, -0.012539840303361416, -0.006560662295669317, -0.03835269808769226, 0.01216061133891344, -0.012653608806431293, -0.0221975389868021, 0.0187339149415493, -0.037038035690784454, 0.01752038113772869, -0.03152657300233841, 0.03868136182427406, -0.010397195816040039, -0.009803070686757565, 0.04588671401143074, -0.011749779805541039, -0.003343536052852869, 0.0028979419730603695, -0.0048320097848773, -0.029478736221790314, 0.029023662209510803, 0.08651478588581085, 0.024700451642274857, -0.007502414286136627, -0.005362930707633495, -0.003234507516026497, 0.029023662209510803, 0.04750475659966469, -0.03820100426673889, 0.015042752027511597, 0.007268556393682957, 0.017330767586827278, 0.006655469536781311, 0.024081043899059296, 0.008576896972954273, 0.0052365208975970745, -0.016104593873023987, -0.014992187730967999, 0.009512328542768955, -0.008551614359021187, 0.005328167695552111, 0.0059222932904958725, -0.032082777470350266, -0.006269920151680708, 0.004797247238457203, -0.04919864609837532, -0.003435183083638549, 0.015548390336334705, 0.047605883330106735, 0.030565859749913216, 0.013045478612184525, -0.0012956991558894515, 0.012640967965126038, -0.044142261147499084, 0.016547026112675667, -0.024333862587809563, -0.012419750913977623, 0.026773570105433464, -0.036153167486190796, 0.00943016167730093, 0.0006632558070123196, -0.02973155677318573, 0.00415255781263113, -0.02324673905968666, 0.006001299247145653, -0.018139788880944252, 0.020339317619800568, -0.01719171553850174, 0.014865778386592865, -0.00207469891756773, 0.03380194678902626, -0.018443172797560692, 0.060272134840488434, -0.0020920801907777786, 0.033903077244758606, 0.01448654942214489, -0.015573672018945217, 0.013336220756173134, -0.004459101241081953, -0.02657131478190422, -0.026849415153265, 0.0019767312332987785, 0.007584580685943365, -0.010454080067574978, -0.05278868228197098, 0.041892167180776596, -0.03198164701461792, -0.0023211976513266563, 0.03842854127287865, 0.021211544051766396, 0.014941624365746975, -0.010100133717060089, -0.013146606273949146, -0.05465954542160034, 0.00712950574234128, 0.023423712700605392, -0.020642699673771858, -0.0017539343098178506, 0.0047624846920371056, 0.017014741897583008, -0.02052893117070198, 0.019998010247945786, -0.00012670595606323332, 0.000889608112629503, 0.013930346816778183, 0.003127059433609247, -0.0173813309520483, -0.02415688894689083, 0.0040135071612894535, 0.012634647078812122, 0.012691531330347061, 0.003022771328687668, 0.023057125508785248, -0.014891060069203377, -0.009152060374617577, 0.011275743134319782, -0.0019719910342246294, -0.03408005088567734, 0.008336718194186687, -0.01305811945348978, -0.005824326071888208, 0.02748146466910839, -0.006374207790941, -0.008557935245335102, -0.030211912468075752, 0.009512328542768955, -0.0024428670294582844, 0.007085262332111597, -0.015889696776866913, -0.052839245647192, 0.03541999310255051, 0.0060297418385744095, 0.02882140688598156, 0.012173252180218697, -0.016698718070983887, -0.002502911724150181, 0.022829588502645493, 0.009069894440472126, -0.027380336076021194, -0.013702808879315853, 0.0005332908476702869, -0.03761951997876167, 0.026520749554038048, 0.006585944443941116, -0.025913983583450317, -0.0025250334292650223, -0.002038356149569154, 0.018076583743095398, 0.026065675541758537, -0.03607732057571411, -0.011724497191607952, 0.01191411167383194, -0.016521744430065155, -0.03744254633784294, 0.004958419594913721, 0.015649517998099327, 0.014069397002458572, -0.007515055127441883, 0.006007620133459568, -0.00509114982560277, 0.029807401821017265, 0.02818935737013817, 0.009897877462208271, 0.000974934664554894, -0.017077947035431862, 0.02942817285656929, 0.03847910463809967, -0.024371786043047905, -0.00645005377009511, -0.00016097482875920832, 0.02639434114098549, -0.021489644423127174, 0.0018945650663226843, 0.01425901148468256, 0.008602178655564785, -0.02352484129369259, 0.0018155589932575822, -0.023739738389849663, -0.006642828695476055, 0.01252719946205616, -0.026444904506206512, 0.036582961678504944, 0.023752378299832344, -0.019960088655352592, -0.011041885241866112, -0.002709907479584217, 0.0368104986846447, 0.007616183254867792, 0.017583586275577545, -0.012919069267809391, -0.014878419227898121, -0.010062210261821747, -0.009253188036382198, -0.01582649163901806, 0.001127416267991066, -0.019694628193974495, 0.01516916137188673, -0.012356545776128769, -0.040223561227321625, -0.0030828160233795643, -0.002128422958776355, -0.032360877841711044, 0.02204584702849388, -0.0008698566234670579, -0.03150129318237305, 0.010529926046729088, -0.002444447251036763, 0.005125912372022867, -0.027835411950945854, -0.023158252239227295, -0.020491009578108788, 0.016268925741314888, -0.03246200457215309, 0.009259508922696114, 0.016951538622379303, -0.006320483982563019, 0.020566854625940323, 0.009853634051978588, -0.013841859996318817, 0.015763286501169205, -0.029655709862709045, -0.004888894502073526, -0.001994112739339471, -0.013462631031870842, 0.04826321452856064, -8.55734251672402e-05, -0.006668110378086567, -0.00785636156797409, 0.03506604582071304, 0.005887530744075775, -0.025623241439461708, -0.032967645674943924, -0.016117233783006668, -0.011496960185468197, 0.0024823700077831745, 0.0021963680628687143, 0.017318125814199448, -0.03188052028417587, 0.034939635545015335, -0.03233559429645538, 0.04464789852499962, -0.04105786234140396, -0.013551117852330208, -0.022816946730017662, -0.018607504665851593, -0.008134462870657444, 0.015194443054497242, -0.01840524934232235, -0.014600317925214767, -0.00011060846736654639, -0.01808922551572323, -0.003177623264491558, 0.04983069375157356, -0.014853137545287609, -0.026925262063741684, -0.00288530089892447, -0.00025341191212646663, -0.013917705975472927, -0.011642331257462502, -0.018202994018793106, -0.03574865683913231, 0.004952099174261093, 0.009923160076141357, -0.03607732057571411, 0.04783342033624649, -0.014575036242604256, -0.008406243287026882, 0.01313396543264389, -0.034029483795166016, 0.015889696776866913, 0.03923756256699562, 0.01102292351424694, 0.006175112910568714, 0.009986364282667637, 0.01389242336153984, 0.03134959936141968, -0.015877055004239082, -0.010605772025883198, -0.028290485963225365, -0.021047212183475494, 0.04032468795776367, -0.027051670476794243, 0.04333323612809181, 0.00626675970852375, 0.0038934180047363043, 0.023158252239227295, 0.008286154828965664, -0.01883504167199135, -0.0023986236192286015, 0.05263698846101761, -0.07549186050891876, 0.011446395888924599, 0.00898140762001276, -0.037644803524017334, -0.009986364282667637, 0.0031017775181680918, 0.005457737948745489, -0.02552211470901966, 0.0038460143841803074, 0.035824503749608994, -0.05713717266917229, 0.0011005542473867536, 0.02204584702849388, -0.007243274711072445, -0.0036690409760922194, 0.0038017709739506245, -0.005097470246255398, -0.0007770244847051799, -0.015156520530581474, -0.01568744145333767, 0.011244140565395355, 0.011180936358869076, 0.007742592599242926, -0.017621509730815887, 0.009082535281777382, 0.006118228193372488, 0.021755104884505272, 0.0033719781786203384, -0.03787234053015709, -0.0019388084765523672, 0.02818935737013817, 0.01643325760960579, 0.015409340150654316, -0.032664261758327484, -0.009701943024992943, -0.01117461547255516, 0.019669346511363983, 0.006743956357240677, 0.07660426199436188, -0.015573672018945217, 0.006813481450080872, -0.01690097339451313, 0.005343968980014324, 0.007717310916632414, 0.007970130071043968, -0.017077947035431862, -0.027532028034329414, 0.02550947293639183, -0.0005538323894143105, 0.00853265356272459, 0.03210805729031563, -0.0018850843189284205, 0.03347328305244446, 0.008052296936511993, -0.03622901439666748, -0.02775956504046917, 0.004904695320874453, -0.010289748199284077, -0.016041388735175133, -0.007906924933195114, 0.013146606273949146, 0.009556571952998638, 0.046999119222164154, -0.0006265179836191237, 0.020288752391934395, -0.02839161455631256, 0.03018663078546524, 0.016420617699623108, 0.02356276474893093, -0.023663891479372978, -0.0005135393003001809, 0.0022232301998883486, -0.04560860991477966, -0.005868569482117891, -0.015788568183779716, -0.0006727364961989224, 0.03180467337369919, 0.000345058913808316, 0.04689798876643181, -0.009575532749295235, 0.0224629994481802, -0.022222820669412613, 0.014309575781226158, 0.013108683750033379, -0.008096539415419102, 0.010036928579211235, 0.017229638993740082, 0.010833309032022953, -0.03888361528515816, -0.02427065744996071, 0.037948183715343475, 0.03708859905600548, 0.029478736221790314, 0.005141713656485081, 0.005713717546314001, -0.03653239831328392, -0.0023053965996950865, 0.01567479968070984, 0.02823992259800434, -0.002807874931022525, 0.0005771392025053501, -0.042195551097393036, -0.01884768344461918, -0.0039755841717123985, -0.048212651163339615, 0.014511831104755402, 0.019239552319049835, -0.021059852093458176, 0.027987102046608925, 0.008892920799553394, 0.01884768344461918, -0.02869499661028385, 0.014435985125601292, 0.0032392479479312897, 0.009341674856841564, -0.010435119271278381, 0.009682981297373772, -0.04196801409125328, 0.020174983888864517, -0.000930691254325211], index=2, object='embedding')], model='text-embedding-3-small', object='list', usage=Usage(prompt_tokens=43, total_tokens=43))"
            ]
          },
          "metadata": {},
          "execution_count": 92
        }
      ],
      "source": [
        "res"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 93,
      "id": "b6602b83",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "b6602b83",
        "outputId": "8df12840-c0b2-4d08-b4f1-1619510ef6ab"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[0.028481855988502502,\n",
              " 0.0037790860515087843,\n",
              " 0.01257640402764082,\n",
              " -0.005234003532677889,\n",
              " -0.02996143326163292,\n",
              " -0.0006234258762560785,\n",
              " 0.02941892109811306,\n",
              " 0.05597732588648796,\n",
              " -0.010548150166869164,\n",
              " -0.04687792807817459,\n",
              " -0.03156430646777153,\n",
              " 0.005606980063021183,\n",
              " -0.013131245039403439,\n",
              " -0.022760825231671333,\n",
              " 0.014191608875989914,\n",
              " -0.0023457459174096584,\n",
              " -0.043746158480644226,\n",
              " 0.039997898042201996,\n",
              " 0.0029606951866298914,\n",
              " -0.01567118614912033,\n",
              " 0.007527347654104233,\n",
              " 0.035213932394981384,\n",
              " -0.03181090205907822,\n",
              " -0.001954274484887719,\n",
              " 0.03511529415845871,\n",
              " -0.033068545162677765,\n",
              " -0.0016167460707947612,\n",
              " -0.034128908067941666,\n",
              " 0.027964003384113312,\n",
              " -0.09479156136512756,\n",
              " 0.04653269425034523,\n",
              " -0.03375901281833649,\n",
              " -0.017939869314432144,\n",
              " -0.007558172103017569,\n",
              " -0.03082451969385147,\n",
              " 0.05153859779238701,\n",
              " -0.007323905825614929,\n",
              " 0.05725962668657303,\n",
              " 0.0024952448438853025,\n",
              " -0.02655840665102005,\n",
              " -0.011201630346477032,\n",
              " 0.01978934183716774,\n",
              " 0.029295623302459717,\n",
              " -0.06362180411815643,\n",
              " -0.03888821229338646,\n",
              " 0.038986850529909134,\n",
              " -0.0032304096966981888,\n",
              " -0.04458458349108696,\n",
              " -0.011546865105628967,\n",
              " 0.014117630198597908,\n",
              " -0.05992286652326584,\n",
              " -0.03955402225255966,\n",
              " -0.05306749418377876,\n",
              " 0.01891392469406128,\n",
              " 0.005141529720276594,\n",
              " -0.03846900165081024,\n",
              " 0.0017462089890614152,\n",
              " -0.010122772306203842,\n",
              " 0.022538889199495316,\n",
              " 0.024560976773500443,\n",
              " 0.018235785886645317,\n",
              " -0.0025152808520942926,\n",
              " 0.007644480559974909,\n",
              " -0.007792438380420208,\n",
              " 0.021268919110298157,\n",
              " 0.025966575369238853,\n",
              " -0.011466721072793007,\n",
              " 0.0366935059428215,\n",
              " -0.05047823116183281,\n",
              " 0.0023873590398579836,\n",
              " -0.015079354867339134,\n",
              " 0.024856891483068466,\n",
              " 0.030060071498155594,\n",
              " 0.007866417057812214,\n",
              " -0.028210600838065147,\n",
              " -0.02922164462506771,\n",
              " -0.03348775953054428,\n",
              " -0.05844328925013542,\n",
              " -0.013390171341598034,\n",
              " 0.014339566230773926,\n",
              " 0.00031787785701453686,\n",
              " -0.04961514472961426,\n",
              " -0.02712557651102543,\n",
              " -0.0392087884247303,\n",
              " 0.004580523353070021,\n",
              " -0.013254542835056782,\n",
              " -0.040910303592681885,\n",
              " 0.03299456462264061,\n",
              " -0.014203938655555248,\n",
              " 0.015473908744752407,\n",
              " 0.0025738473050296307,\n",
              " 0.013797054998576641,\n",
              " 0.02279781363904476,\n",
              " 0.0024012301582843065,\n",
              " 0.01856869086623192,\n",
              " 0.02213200554251671,\n",
              " -0.04729714244604111,\n",
              " -0.016460293903946877,\n",
              " 0.004071918781846762,\n",
              " 0.004623678047209978,\n",
              " 0.013303862884640694,\n",
              " -0.008347279392182827,\n",
              " 0.01310658548027277,\n",
              " -0.02459796704351902,\n",
              " 0.06524933874607086,\n",
              " 0.031441010534763336,\n",
              " 0.010128936730325222,\n",
              " -0.010992023162543774,\n",
              " -0.03442482277750969,\n",
              " -0.014154619537293911,\n",
              " -0.04959048703312874,\n",
              " -0.05247566103935242,\n",
              " 0.013809384778141975,\n",
              " 0.036471571773290634,\n",
              " 0.01711377315223217,\n",
              " 0.026977619156241417,\n",
              " -0.029098346829414368,\n",
              " -0.043746158480644226,\n",
              " -0.01658359169960022,\n",
              " -0.04522573575377464,\n",
              " 0.034671418368816376,\n",
              " -0.002569223754107952,\n",
              " 0.006380675360560417,\n",
              " -0.037186700850725174,\n",
              " -0.02390749752521515,\n",
              " -0.024708934128284454,\n",
              " 0.01329153310507536,\n",
              " 0.015831472352147102,\n",
              " 0.0051908488385379314,\n",
              " -0.010911880061030388,\n",
              " 0.002751088235527277,\n",
              " -0.02924630418419838,\n",
              " -0.022921113297343254,\n",
              " -0.010757757350802422,\n",
              " -0.004155145026743412,\n",
              " 0.003427686635404825,\n",
              " -0.024881551042199135,\n",
              " 0.035065971314907074,\n",
              " -0.0033413779456168413,\n",
              " -0.01904955320060253,\n",
              " -0.013254542835056782,\n",
              " 0.015806812793016434,\n",
              " 0.07136492431163788,\n",
              " -0.0017277143197134137,\n",
              " -0.03957868367433548,\n",
              " -0.014006661251187325,\n",
              " 0.02066475711762905,\n",
              " 0.0194071177393198,\n",
              " 0.0010927291586995125,\n",
              " -0.03834570199251175,\n",
              " 0.0290736872702837,\n",
              " 0.006929351948201656,\n",
              " -0.05474434792995453,\n",
              " -0.050034359097480774,\n",
              " 0.0065347980707883835,\n",
              " -0.005181601736694574,\n",
              " -0.0038993016351014376,\n",
              " 0.03213147819042206,\n",
              " 0.0110598374158144,\n",
              " 0.06337521225214005,\n",
              " -0.0224525798112154,\n",
              " 0.019826330244541168,\n",
              " -0.054990943521261215,\n",
              " 0.013180564157664776,\n",
              " 0.008612371049821377,\n",
              " 0.030947817489504814,\n",
              " -0.07141424715518951,\n",
              " -0.04774101451039314,\n",
              " -0.037704553455114365,\n",
              " 0.016904165968298912,\n",
              " 0.00141407479532063,\n",
              " 0.020973002538084984,\n",
              " -0.025448722764849663,\n",
              " 0.021786769852042198,\n",
              " -0.03829638287425041,\n",
              " -0.024018464609980583,\n",
              " -0.005156942177563906,\n",
              " 0.01210787147283554,\n",
              " 0.029369601979851723,\n",
              " 0.03933208808302879,\n",
              " -0.08300426602363586,\n",
              " 0.021712791174650192,\n",
              " 0.030923157930374146,\n",
              " 0.016842518001794815,\n",
              " 0.018038509413599968,\n",
              " 0.02835855819284916,\n",
              " 0.019481096416711807,\n",
              " 0.014154619537293911,\n",
              " -0.028284579515457153,\n",
              " 0.03696476295590401,\n",
              " 0.021441536024212837,\n",
              " 0.02532542496919632,\n",
              " 0.005286404862999916,\n",
              " 0.0370880626142025,\n",
              " -0.023438964039087296,\n",
              " 0.031391691416502,\n",
              " -0.013747735880315304,\n",
              " 0.03208215907216072,\n",
              " -0.009604920633137226,\n",
              " 0.0038869718555361032,\n",
              " 0.03834570199251175,\n",
              " -0.008113013580441475,\n",
              " 0.004084249027073383,\n",
              " 0.05824601277709007,\n",
              " -0.04275977239012718,\n",
              " 0.010233740322291851,\n",
              " -0.00234420457854867,\n",
              " 0.029912114143371582,\n",
              " 0.040910303592681885,\n",
              " -0.03225477784872055,\n",
              " 0.014820428565144539,\n",
              " -0.031169753521680832,\n",
              " -0.09030351042747498,\n",
              " -0.016497282311320305,\n",
              " -0.005754937883466482,\n",
              " 0.03299456462264061,\n",
              " 0.013797054998576641,\n",
              " -0.01588079147040844,\n",
              " -0.022711506113409996,\n",
              " 0.004099661018699408,\n",
              " 0.021145619451999664,\n",
              " 0.009765207767486572,\n",
              " 0.03528790920972824,\n",
              " -0.005813504569232464,\n",
              " -0.015991760417819023,\n",
              " 0.05656915903091431,\n",
              " 0.023451294749975204,\n",
              " -0.009870011359453201,\n",
              " 0.005539166275411844,\n",
              " -0.025202127173542976,\n",
              " 0.0288764089345932,\n",
              " 0.015362940728664398,\n",
              " -0.03851832076907158,\n",
              " 0.012194179929792881,\n",
              " -0.0190742127597332,\n",
              " 0.02692830003798008,\n",
              " -0.01139890681952238,\n",
              " -0.018827617168426514,\n",
              " -0.05578004941344261,\n",
              " -0.007835593074560165,\n",
              " -0.008717173710465431,\n",
              " 0.0445106066763401,\n",
              " 0.0042414539493620396,\n",
              " 0.021811429411172867,\n",
              " -0.0027587944641709328,\n",
              " -0.023660901933908463,\n",
              " 0.017027463763952255,\n",
              " -0.016460293903946877,\n",
              " 0.02244025096297264,\n",
              " 0.07082241773605347,\n",
              " 0.0034153566230088472,\n",
              " -0.023660901933908463,\n",
              " 0.0013701498974114656,\n",
              " -0.01678086817264557,\n",
              " -0.04100894182920456,\n",
              " -0.010326214134693146,\n",
              " -0.020208554342389107,\n",
              " 0.015042365528643131,\n",
              " 0.002862056717276573,\n",
              " 0.011608514003455639,\n",
              " 0.06258610635995865,\n",
              " 0.0024736677296459675,\n",
              " -0.03279728814959526,\n",
              " -0.02266218699514866,\n",
              " 0.03104645572602749,\n",
              " -0.04828352853655815,\n",
              " -0.015399930067360401,\n",
              " 0.005579237826168537,\n",
              " -0.055188219994306564,\n",
              " 0.02012224681675434,\n",
              " 0.006744404789060354,\n",
              " -0.007071144878864288,\n",
              " 0.04488050192594528,\n",
              " 0.0044541428796947,\n",
              " -0.06968807429075241,\n",
              " -0.028259919956326485,\n",
              " -0.05104540288448334,\n",
              " -0.021515514701604843,\n",
              " 0.02354993298649788,\n",
              " 0.043943434953689575,\n",
              " -0.05790077522397041,\n",
              " -0.011263279244303703,\n",
              " -0.007188277784734964,\n",
              " 0.023599252104759216,\n",
              " -0.028851749375462532,\n",
              " -0.01763162575662136,\n",
              " -0.014647811651229858,\n",
              " -0.04811090975999832,\n",
              " 0.014598492532968521,\n",
              " 0.07072377949953079,\n",
              " 0.015190322883427143,\n",
              " 0.02584327757358551,\n",
              " -0.03903616964817047,\n",
              " -0.020442821085453033,\n",
              " 0.025399403646588326,\n",
              " -0.10228808224201202,\n",
              " -0.022785484790802002,\n",
              " -0.02267451584339142,\n",
              " 0.0606626532971859,\n",
              " 0.023093730211257935,\n",
              " -0.009315169416368008,\n",
              " 0.01691649667918682,\n",
              " 0.06021878123283386,\n",
              " 0.025645999237895012,\n",
              " -0.029566878452897072,\n",
              " 0.018593350425362587,\n",
              " -0.012397621758282185,\n",
              " -0.007761613931506872,\n",
              " 0.0050367265939712524,\n",
              " -0.03671816736459732,\n",
              " -0.023586921393871307,\n",
              " -0.025892596691846848,\n",
              " 0.05883784219622612,\n",
              " -0.029270963743329048,\n",
              " 0.001975851599127054,\n",
              " 0.04283375293016434,\n",
              " -0.00548984669148922,\n",
              " 0.008174662478268147,\n",
              " 0.00016914955631364137,\n",
              " -0.0047685531899333,\n",
              " -0.0001601911790203303,\n",
              " -0.00588748324662447,\n",
              " 0.012773680500686169,\n",
              " 0.007021825294941664,\n",
              " 0.08058762550354004,\n",
              " -0.01639864407479763,\n",
              " 0.03760591521859169,\n",
              " 0.028827089816331863,\n",
              " 0.00557307293638587,\n",
              " -0.046113479882478714,\n",
              " -0.03223011642694473,\n",
              " -0.019875649362802505,\n",
              " 0.013032606802880764,\n",
              " 0.010819406248629093,\n",
              " -0.02569531835615635,\n",
              " 0.018408402800559998,\n",
              " 0.02493087202310562,\n",
              " 0.02530076541006565,\n",
              " 0.016189036890864372,\n",
              " 0.043400924652814865,\n",
              " 0.003062416100874543,\n",
              " -0.02421574294567108,\n",
              " 0.05494162440299988,\n",
              " -0.00821165181696415,\n",
              " 0.01017209142446518,\n",
              " -0.013698416762053967,\n",
              " 0.04779033362865448,\n",
              " 0.02369789034128189,\n",
              " -0.0022995092440396547,\n",
              " 0.006633436772972345,\n",
              " -0.027347514405846596,\n",
              " 0.033241160213947296,\n",
              " 0.0377538725733757,\n",
              " 0.030553262680768967,\n",
              " 0.006559457629919052,\n",
              " 0.03639759123325348,\n",
              " -0.008285630494356155,\n",
              " 0.022748494520783424,\n",
              " -0.024203412234783173,\n",
              " 0.010098112747073174,\n",
              " 0.01061596442013979,\n",
              " 0.02870379202067852,\n",
              " -0.020405832678079605,\n",
              " -0.024906212463974953,\n",
              " 0.04855478182435036,\n",
              " 0.019542744383215904,\n",
              " -0.015313621610403061,\n",
              " -0.010881055146455765,\n",
              " 0.02801332250237465,\n",
              " 0.009882341139018536,\n",
              " 0.0018032343359664083,\n",
              " -0.048579443246126175,\n",
              " -0.0020929849706590176,\n",
              " 0.01166399847716093,\n",
              " -0.0036003037821501493,\n",
              " 0.02835855819284916,\n",
              " 0.015572546981275082,\n",
              " 0.018124816939234734,\n",
              " 0.060169462114572525,\n",
              " 0.017163092270493507,\n",
              " 0.0221196748316288,\n",
              " -0.010708438232541084,\n",
              " 0.0125825684517622,\n",
              " -0.0036989422515034676,\n",
              " 0.024844562634825706,\n",
              " 0.005021314136683941,\n",
              " 0.01998661831021309,\n",
              " -0.04406673461198807,\n",
              " 0.05474434792995453,\n",
              " -0.012613393366336823,\n",
              " 0.07240062952041626,\n",
              " -0.00441098865121603,\n",
              " 0.02569531835615635,\n",
              " -0.004777800291776657,\n",
              " -0.006473149172961712,\n",
              " -0.020566118881106377,\n",
              " 0.03321650251746178,\n",
              " 0.04246385768055916,\n",
              " -0.05222906544804573,\n",
              " -0.050996083766222,\n",
              " 0.0031687605660408735,\n",
              " 0.008304125629365444,\n",
              " -0.05868988484144211,\n",
              " -0.02867913246154785,\n",
              " 0.029813475906848907,\n",
              " 0.06643300503492355,\n",
              " 0.0030809107702225447,\n",
              " -0.05114404112100601,\n",
              " -0.016287675127387047,\n",
              " -0.041625432670116425,\n",
              " 0.017717933282256126,\n",
              " -0.026336468756198883,\n",
              " 0.03240273520350456,\n",
              " -0.0033783672843128443,\n",
              " -0.011405072174966335,\n",
              " 0.0004985866253264248,\n",
              " 0.01114614587277174,\n",
              " -0.012274323962628841,\n",
              " 0.025399403646588326,\n",
              " 0.015560217201709747,\n",
              " -0.003979445435106754,\n",
              " -0.023118389770388603,\n",
              " -0.025892596691846848,\n",
              " 0.030947817489504814,\n",
              " 0.009518611244857311,\n",
              " 0.02315537817776203,\n",
              " -0.037334658205509186,\n",
              " -0.002735676011070609,\n",
              " -0.018654998391866684,\n",
              " -0.0417240709066391,\n",
              " -0.010215246118605137,\n",
              " -0.04391877353191376,\n",
              " -0.009715888649225235,\n",
              " 0.0224525798112154,\n",
              " -0.0044911326840519905,\n",
              " 0.013032606802880764,\n",
              " 0.01166399847716093,\n",
              " 0.00314564211294055,\n",
              " 0.001790904556401074,\n",
              " -0.006787559017539024,\n",
              " -0.05380728095769882,\n",
              " 0.010400192812085152,\n",
              " 0.010276895016431808,\n",
              " 0.05173587426543236,\n",
              " 0.0024397606030106544,\n",
              " 0.002133056754246354,\n",
              " 0.02784070558845997,\n",
              " -0.017680944874882698,\n",
              " 0.02655840665102005,\n",
              " 0.05217974632978439,\n",
              " 0.0021222680807113647,\n",
              " -0.05666779726743698,\n",
              " -0.012958628125488758,\n",
              " 0.008982265368103981,\n",
              " 0.0013462608912959695,\n",
              " 0.013439490459859371,\n",
              " 0.014117630198597908,\n",
              " 0.04243919998407364,\n",
              " -0.009722053073346615,\n",
              " 0.02121959999203682,\n",
              " 0.023599252104759216,\n",
              " 0.03454812243580818,\n",
              " 0.05104540288448334,\n",
              " 0.06983602792024612,\n",
              " -0.011010518297553062,\n",
              " 0.022958101704716682,\n",
              " 0.008772658184170723,\n",
              " 0.047149185091257095,\n",
              " 0.034326184540987015,\n",
              " -0.014462864026427269,\n",
              " 0.011793460696935654,\n",
              " -0.012761350721120834,\n",
              " 0.02195938676595688,\n",
              " 0.06603845208883286,\n",
              " -0.003529407549649477,\n",
              " -0.04670531302690506,\n",
              " 0.005415868014097214,\n",
              " -0.03674282878637314,\n",
              " -0.038616959005594254,\n",
              " 0.006127914413809776,\n",
              " -0.031145093962550163,\n",
              " -0.04058972746133804,\n",
              " -0.019308479502797127,\n",
              " -0.018297433853149414,\n",
              " -0.004078083671629429,\n",
              " 0.007761613931506872,\n",
              " 0.004694574512541294,\n",
              " 0.026065213605761528,\n",
              " -0.04917127266526222,\n",
              " -0.008612371049821377,\n",
              " 0.046976566314697266,\n",
              " 0.06751802563667297,\n",
              " -0.007083474658429623,\n",
              " -0.010652953758835793,\n",
              " 0.012712031602859497,\n",
              " 0.012594898231327534,\n",
              " -0.024659615010023117,\n",
              " -0.04246385768055916,\n",
              " 0.025004850700497627,\n",
              " -0.00198355782777071,\n",
              " -0.007293081376701593,\n",
              " 0.019505755975842476,\n",
              " -0.020430492237210274,\n",
              " 0.010560479946434498,\n",
              " -0.03940606489777565,\n",
              " -0.03494267538189888,\n",
              " -0.011737977154552937,\n",
              " -0.03454812243580818,\n",
              " 0.024462338536977768,\n",
              " 0.0031687605660408735,\n",
              " 0.009567930363118649,\n",
              " 0.004938087891787291,\n",
              " -0.03262466937303543,\n",
              " 0.014240927994251251,\n",
              " -0.01203389186412096,\n",
              " 0.02850651554763317,\n",
              " -0.004435648210346699,\n",
              " 0.02798866294324398,\n",
              " 0.0009655780741013587,\n",
              " 0.0035972213372588158,\n",
              " 0.028654472902417183,\n",
              " 0.03652089089155197,\n",
              " 0.031120434403419495,\n",
              " -0.0029730249661952257,\n",
              " -0.004016434773802757,\n",
              " -0.004614430479705334,\n",
              " -0.009629580192267895,\n",
              " 0.016349324956536293,\n",
              " 0.05065084993839264,\n",
              " 0.01523964200168848,\n",
              " 0.02244025096297264,\n",
              " -0.006118666846305132,\n",
              " -0.01622602716088295,\n",
              " -0.032032839953899384,\n",
              " 0.014906737953424454,\n",
              " -0.03580576181411743,\n",
              " -0.017015134915709496,\n",
              " 0.02658306621015072,\n",
              " 0.02514047734439373,\n",
              " -0.005471352022141218,\n",
              " 0.006621106527745724,\n",
              " -0.014684800989925861,\n",
              " -0.03050394356250763,\n",
              " -0.016534272581338882,\n",
              " -0.017693273723125458,\n",
              " -0.03597838059067726,\n",
              " -0.0045743584632873535,\n",
              " 0.009296675212681293,\n",
              " 0.008415093645453453,\n",
              " 0.0311944130808115,\n",
              " -0.001041098148562014,\n",
              " 0.020418161526322365,\n",
              " 0.0019357798155397177,\n",
              " -0.017409687861800194,\n",
              " -0.02569531835615635,\n",
              " 0.006423829589039087,\n",
              " -0.00548984669148922,\n",
              " -0.02475825324654579,\n",
              " -0.001610581181012094,\n",
              " -0.025424063205718994,\n",
              " 0.0035787266679108143,\n",
              " -0.045176416635513306,\n",
              " 0.009253520518541336,\n",
              " -0.001439505023881793,\n",
              " -0.01363676693290472,\n",
              " 0.015572546981275082,\n",
              " 0.02653374709188938,\n",
              " -0.023808859288692474,\n",
              " 4.895800520898774e-05,\n",
              " -0.013760065659880638,\n",
              " 0.006608776748180389,\n",
              " 0.023969145491719246,\n",
              " 0.0029976845253258944,\n",
              " -0.01290930900722742,\n",
              " -0.004864109214395285,\n",
              " 0.030627243220806122,\n",
              " -0.02315537817776203,\n",
              " 0.0015812978381291032,\n",
              " 0.018482381477952003,\n",
              " 0.04224191978573799,\n",
              " 0.02264985628426075,\n",
              " -0.053363408893346786,\n",
              " 0.015387600287795067,\n",
              " -0.02409244515001774,\n",
              " 0.005372713785618544,\n",
              " 0.020775726065039635,\n",
              " 0.012101706117391586,\n",
              " -0.014105300419032574,\n",
              " 0.018778298050165176,\n",
              " -0.04261181503534317,\n",
              " -0.016152048483490944,\n",
              " 0.01872897706925869,\n",
              " 0.02012224681675434,\n",
              " 0.01605341024696827,\n",
              " 0.006738239899277687,\n",
              " 0.002877468941733241,\n",
              " -0.037359315901994705,\n",
              " 0.04372149705886841,\n",
              " 0.056766435503959656,\n",
              " 0.025892596691846848,\n",
              " -0.022896453738212585,\n",
              " 0.011972242966294289,\n",
              " -0.03319184109568596,\n",
              " -0.016632910817861557,\n",
              " -0.015979431569576263,\n",
              " -0.011639338918030262,\n",
              " 0.035238590091466904,\n",
              " -0.03316718339920044,\n",
              " 0.0008376563200727105,\n",
              " 0.0011004353873431683,\n",
              " 0.006540962960571051,\n",
              " 0.015251971781253815,\n",
              " 0.02744615264236927,\n",
              " -0.02029486373066902,\n",
              " 0.002179293427616358,\n",
              " 0.008347279392182827,\n",
              " -0.030972477048635483,\n",
              " 0.021268919110298157,\n",
              " -0.005828916560858488,\n",
              " 0.05222906544804573,\n",
              " -0.004605183377861977,\n",
              " 0.045743588358163834,\n",
              " 0.006824548356235027,\n",
              " 0.0235129427164793,\n",
              " 0.004762388300150633,\n",
              " 0.04904797673225403,\n",
              " 0.02334032580256462,\n",
              " -0.017039794474840164,\n",
              " -0.02511581778526306,\n",
              " 0.029665516689419746,\n",
              " -0.030429964885115623,\n",
              " 0.02653374709188938,\n",
              " 0.033265821635723114,\n",
              " -0.03560848534107208,\n",
              " -0.03277263045310974,\n",
              " 0.013340852223336697,\n",
              " -0.004540451802313328,\n",
              " -0.016275346279144287,\n",
              " -0.007761613931506872,\n",
              " -0.012798340059816837,\n",
              " 0.030627243220806122,\n",
              " -0.04996038228273392,\n",
              " -0.0251651369035244,\n",
              " -0.007588996551930904,\n",
              " 0.03186022490262985,\n",
              " 0.017952200025320053,\n",
              " 0.015942441299557686,\n",
              " 0.032032839953899384,\n",
              " 0.032575350254774094,\n",
              " -0.017175422981381416,\n",
              " -0.00280503137037158,\n",
              " 0.03528790920972824,\n",
              " 0.034523461014032364,\n",
              " -0.0035047477576881647,\n",
              " 0.019850989803671837,\n",
              " -0.011873604729771614,\n",
              " 0.03494267538189888,\n",
              " -0.022230643779039383,\n",
              " 0.014462864026427269,\n",
              " 0.04988640174269676,\n",
              " -0.0198016706854105,\n",
              " 0.006559457629919052,\n",
              " 0.013612107373774052,\n",
              " 0.03400560840964317,\n",
              " 5.928903556196019e-05,\n",
              " 0.0016861011972650886,\n",
              " -0.025078829377889633,\n",
              " -0.009765207767486572,\n",
              " 0.022501898929476738,\n",
              " -0.014869747683405876,\n",
              " -0.050157658755779266,\n",
              " -0.005785762332379818,\n",
              " 0.024006135761737823,\n",
              " -0.02638578787446022,\n",
              " -0.000974054797552526,\n",
              " -0.00032808847026899457,\n",
              " -0.003637293353676796,\n",
              " -0.01293396856635809,\n",
              " -0.023130718618631363,\n",
              " -0.02049214020371437,\n",
              " 0.0606626532971859,\n",
              " 0.0037482616025954485,\n",
              " 0.013328522443771362,\n",
              " -0.005455940030515194,\n",
              " -0.01872897706925869,\n",
              " -0.008359609171748161,\n",
              " 0.07092105597257614,\n",
              " 0.010628294199705124,\n",
              " -0.009080903604626656,\n",
              " 0.033956289291381836,\n",
              " 0.007761613931506872,\n",
              " 0.013772395439445972,\n",
              " 0.047864314168691635,\n",
              " -0.017323380336165428,\n",
              " -0.01114614587277174,\n",
              " 0.022908782586455345,\n",
              " 0.0018356001237407327,\n",
              " -0.03425220400094986,\n",
              " -0.016657570376992226,\n",
              " -0.027668088674545288,\n",
              " -0.01691649667918682,\n",
              " -0.017261730507016182,\n",
              " -0.0010202915873378515,\n",
              " 0.0020035938359797,\n",
              " -0.007027990184724331,\n",
              " -0.011066002771258354,\n",
              " -0.004158227704465389,\n",
              " 0.008914451114833355,\n",
              " 0.02959153801202774,\n",
              " -0.00972821842879057,\n",
              " 0.03553450480103493,\n",
              " -0.011805790476500988,\n",
              " -0.006118666846305132,\n",
              " 0.001034933258779347,\n",
              " -0.003772921161726117,\n",
              " 0.0038931367453187704,\n",
              " -0.02263752743601799,\n",
              " -0.017964530736207962,\n",
              " -0.01639864407479763,\n",
              " -0.05079880729317665,\n",
              " -0.005582320503890514,\n",
              " 0.02047981135547161,\n",
              " 0.023747209459543228,\n",
              " -0.04293239116668701,\n",
              " 0.003717436920851469,\n",
              " -0.013131245039403439,\n",
              " -0.017039794474840164,\n",
              " 0.004099661018699408,\n",
              " 0.025041839107871056,\n",
              " 0.007650645915418863,\n",
              " -0.015486238524317741,\n",
              " 0.025399403646588326,\n",
              " -0.0016059573972597718,\n",
              " -0.008846636861562729,\n",
              " -0.007212937343865633,\n",
              " -0.019912639632821083,\n",
              " -0.044658564031124115,\n",
              " -0.010813241824507713,\n",
              " 0.007903406396508217,\n",
              " -0.0041274032555520535,\n",
              " -0.02673102356493473,\n",
              " -0.01489440817385912,\n",
              " -0.004543534014374018,\n",
              " 0.005070633254945278,\n",
              " -0.020960673689842224,\n",
              " -0.05474434792995453,\n",
              " 0.03615099564194679,\n",
              " 0.0014541466953232884,\n",
              " -0.0065717874094843864,\n",
              " -0.0014371932484209538,\n",
              " -0.015806812793016434,\n",
              " 0.009604920633137226,\n",
              " 0.02422807179391384,\n",
              " 0.008180827833712101,\n",
              " 0.04140349477529526,\n",
              " -0.02621317096054554,\n",
              " -0.009296675212681293,\n",
              " -0.024819903075695038,\n",
              " 0.012477765791118145,\n",
              " 0.020800385624170303,\n",
              " -0.009019254706799984,\n",
              " -0.013365511782467365,\n",
              " 0.0016922660870477557,\n",
              " 0.013390171341598034,\n",
              " -0.0160287506878376,\n",
              " -0.012810669839382172,\n",
              " -0.040367789566516876,\n",
              " -0.00409349612891674,\n",
              " 0.00548676447942853,\n",
              " 0.016435634344816208,\n",
              " 0.03585508093237877,\n",
              " 0.008131507784128189,\n",
              " 0.010492666624486446,\n",
              " -0.01238529197871685,\n",
              " 0.037852510809898376,\n",
              " -0.046458713710308075,\n",
              " -0.014068310149013996,\n",
              " -0.011232455261051655,\n",
              " -0.000767915858887136,\n",
              " -0.025645999237895012,\n",
              " -0.004762388300150633,\n",
              " 0.024560976773500443,\n",
              " 0.01061596442013979,\n",
              " 0.017002804204821587,\n",
              " 0.016793198883533478,\n",
              " 0.012274323962628841,\n",
              " 0.008341114968061447,\n",
              " -0.008439753204584122,\n",
              " 0.02029486373066902,\n",
              " 0.0345727801322937,\n",
              " -0.006343686021864414,\n",
              " -0.03067656233906746,\n",
              " 0.017261730507016182,\n",
              " -0.005585402715951204,\n",
              " 0.05780213698744774,\n",
              " 0.000608784263022244,\n",
              " 0.0005752625875174999,\n",
              " -0.0035263251047581434,\n",
              " 0.0019943465013056993,\n",
              " 0.0029052109457552433,\n",
              " 0.005807339213788509,\n",
              " -0.027396833524107933,\n",
              " -0.003680447582155466,\n",
              " 0.022514229640364647,\n",
              " 0.018235785886645317,\n",
              " 0.025239115580916405,\n",
              " 0.013094255700707436,\n",
              " -9.10286616999656e-05,\n",
              " -0.012822999618947506,\n",
              " -0.04229123890399933,\n",
              " 0.00917954184114933,\n",
              " 0.016263015568256378,\n",
              " -0.02976415492594242,\n",
              " 0.012638052925467491,\n",
              " 0.014191608875989914,\n",
              " 0.019579734653234482,\n",
              " 0.008957604877650738,\n",
              " -0.05188383162021637,\n",
              " -0.008002045564353466,\n",
              " -0.03696476295590401,\n",
              " 0.022859463468194008,\n",
              " -0.018987903371453285,\n",
              " -0.029813475906848907,\n",
              " -0.015658855438232422,\n",
              " 0.018667329102754593,\n",
              " -0.03587973862886429,\n",
              " 0.006115584634244442,\n",
              " 0.03918413072824478,\n",
              " 0.027717407792806625,\n",
              " -0.02191006764769554,\n",
              " -0.009382983669638634,\n",
              " -0.010431017726659775,\n",
              " 0.017052123323082924,\n",
              " -0.013365511782467365,\n",
              " 0.002225530333817005,\n",
              " -0.021170279011130333,\n",
              " 0.02499251998960972,\n",
              " -0.018075497820973396,\n",
              " 0.023648571223020554,\n",
              " -0.006707415450364351,\n",
              " 0.008476742543280125,\n",
              " 0.018839946016669273,\n",
              " 0.025793958455324173,\n",
              " 0.02316770888864994,\n",
              " 0.008402763865888119,\n",
              " 0.029098346829414368,\n",
              " -0.003954785875976086,\n",
              " 0.04779033362865448,\n",
              " 0.008704843930900097,\n",
              " 0.007952725514769554,\n",
              " 0.010918044485151768,\n",
              " -0.003193420125171542,\n",
              " -0.012675042264163494,\n",
              " -0.0301340501755476,\n",
              " 0.016904165968298912,\n",
              " 0.01133109349757433,\n",
              " 0.013279203325510025,\n",
              " 0.027742067351937294,\n",
              " -0.01523964200168848,\n",
              " -0.004142815247178078,\n",
              " 0.015005376189947128,\n",
              " 0.022329282015562057,\n",
              " 0.01053582038730383,\n",
              " -0.016176708042621613,\n",
              " -0.023660901933908463,\n",
              " 0.026163851842284203,\n",
              " 0.004737728741019964,\n",
              " -0.05188383162021637,\n",
              " 0.00794039573520422,\n",
              " 0.017557647079229355,\n",
              " 0.010017968714237213,\n",
              " -0.024696605280041695,\n",
              " -0.0335124172270298,\n",
              " -0.024560976773500443,\n",
              " -0.0019234500359743834,\n",
              " 0.03526325151324272,\n",
              " -0.010276895016431808,\n",
              " 0.03250137344002724,\n",
              " 0.008581546135246754,\n",
              " -0.04672997072339058,\n",
              " -0.023056739941239357,\n",
              " -0.015325951389968395,\n",
              " -0.030725881457328796,\n",
              " 0.0385429784655571,\n",
              " -0.004950417671352625,\n",
              " -0.04320364445447922,\n",
              " -0.010091947391629219,\n",
              " -0.0068985274992883205,\n",
              " -0.05030561611056328,\n",
              " 0.010449511930346489,\n",
              " 0.0118551105260849,\n",
              " 0.02104698121547699,\n",
              " 0.002714098896831274,\n",
              " -0.0288764089345932,\n",
              " -0.008279466070234776,\n",
              " 0.052524980157613754,\n",
              " 0.008711009286344051,\n",
              " 0.05183451250195503,\n",
              " -0.029862795025110245,\n",
              " 9.040253644343466e-05,\n",
              " 0.0018032343359664083,\n",
              " -0.017323380336165428,\n",
              " -0.02941892109811306,\n",
              " 0.033808331936597824,\n",
              " -0.04275977239012718,\n",
              " -0.0023673230316489935,\n",
              " 0.003016179194673896,\n",
              " 0.017027463763952255,\n",
              " 0.024844562634825706,\n",
              " 0.02049214020371437,\n",
              " 0.014758779667317867,\n",
              " -0.004898016341030598,\n",
              " 0.018605679273605347,\n",
              " -0.0026293315459042788,\n",
              " -0.006349850911647081,\n",
              " -0.009241190738976002,\n",
              " 0.014573832973837852,\n",
              " 0.00023022062669042498,\n",
              " -0.0031410185620188713,\n",
              " 0.022329282015562057,\n",
              " -0.045546308159828186,\n",
              " -0.02100999280810356,\n",
              " 0.022736165672540665,\n",
              " 0.000487027398776263,\n",
              " -0.00508912792429328,\n",
              " 0.04586688429117203,\n",
              " -0.04488050192594528,\n",
              " 0.008347279392182827,\n",
              " 0.028210600838065147,\n",
              " -0.02569531835615635,\n",
              " 0.014240927994251251,\n",
              " -0.009765207767486572,\n",
              " -0.027766726911067963,\n",
              " -0.015634195879101753,\n",
              " -0.021811429411172867,\n",
              " 0.01923450082540512,\n",
              " 0.012083211913704872,\n",
              " 0.0036619529128074646,\n",
              " -0.017964530736207962,\n",
              " -0.006232718005776405,\n",
              " 0.024474667385220528,\n",
              " -0.01959206536412239,\n",
              " -0.010689943097531796,\n",
              " -0.011435897089540958,\n",
              " 0.0006750569446012378,\n",
              " -0.03943072631955147,\n",
              " 0.01802617870271206,\n",
              " 0.00516927195712924,\n",
              " 0.02944358065724373,\n",
              " -0.014339566230773926,\n",
              " 0.003264316590502858,\n",
              " -0.024388359859585762,\n",
              " -0.03839502111077309,\n",
              " -0.0194687657058239,\n",
              " 0.03526325151324272,\n",
              " 0.0406637042760849,\n",
              " 0.02303208038210869,\n",
              " 0.021120959892868996,\n",
              " 0.035756442695856094,\n",
              " 0.012434611096978188,\n",
              " -0.04885069653391838,\n",
              " -0.017052123323082924,\n",
              " 0.013747735880315304,\n",
              " -0.030035411939024925,\n",
              " 0.009752877987921238,\n",
              " -0.01745900698006153,\n",
              " -0.011466721072793007,\n",
              " 0.012335972860455513,\n",
              " 0.038444340229034424,\n",
              " 0.06480547040700912,\n",
              " -0.02462262660264969,\n",
              " 0.029838135465979576,\n",
              " 0.031268391758203506,\n",
              " 0.04004721716046333,\n",
              " -0.02494320087134838,\n",
              " 0.013205223716795444,\n",
              " -0.0051168701611459255,\n",
              " -0.00810684822499752,\n",
              " 0.0042815255001187325,\n",
              " 0.03822240233421326,\n",
              " 0.012083211913704872,\n",
              " 0.00633135624229908,\n",
              " 0.01222500391304493,\n",
              " 0.053412728011608124,\n",
              " 0.026829661801457405,\n",
              " 0.03992391750216484,\n",
              " 0.012847659178078175,\n",
              " -0.03065190277993679,\n",
              " -0.020603109151124954,\n",
              " -0.01660825125873089,\n",
              " -0.009364488534629345,\n",
              " 0.007471863646060228,\n",
              " 0.026681704446673393,\n",
              " 0.012360632419586182,\n",
              " -0.004028764553368092,\n",
              " -0.048406824469566345,\n",
              " 0.00047007392277009785,\n",
              " -0.00677522923797369,\n",
              " 0.04419003054499626,\n",
              " 0.004078083671629429,\n",
              " ...]"
            ]
          },
          "metadata": {},
          "execution_count": 93
        }
      ],
      "source": [
        "res.data[0].embedding"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 94,
      "id": "d61c57ce-74d9-4377-9200-fc21492a214a",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "d61c57ce-74d9-4377-9200-fc21492a214a",
        "outputId": "3896a657-15cc-4d12-d6d4-3fa6ee1501be"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: scikit-learn in /usr/local/lib/python3.10/dist-packages (1.5.2)\n",
            "Requirement already satisfied: numpy>=1.19.5 in /usr/local/lib/python3.10/dist-packages (from scikit-learn) (1.26.4)\n",
            "Requirement already satisfied: scipy>=1.6.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn) (1.13.1)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn) (1.4.2)\n",
            "Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn) (3.5.0)\n"
          ]
        }
      ],
      "source": [
        "!pip install scikit-learn"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 95,
      "id": "7d18836d",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7d18836d",
        "outputId": "ef88e6a1-15ce-41d5-db4a-82f9a910168b"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Cosine Similarity of 1st sentence and 2nd: 0.6762885838161012\n",
            "Cosine similarity of 2nd sentence and 3rd: 0.23804375187833038\n"
          ]
        }
      ],
      "source": [
        "import numpy as np\n",
        "from sklearn.metrics.pairwise import cosine_similarity\n",
        "\n",
        "# Function to calculate cosine similarity between two vectors\n",
        "def cosine_similarity_vectors(vector1, vector2):\n",
        "    # Calculate the cosine similarity between the vectors\n",
        "    similarity = cosine_similarity([vector1], [vector2])\n",
        "    return similarity[0][0]\n",
        "\n",
        "# Example usage:\n",
        "vector1 = np.array(res.data[0].embedding)\n",
        "vector2 = np.array(res.data[1].embedding)\n",
        "vector3 = np.array(res.data[2].embedding)\n",
        "\n",
        "similarity_score = cosine_similarity_vectors(vector1, vector2)\n",
        "print(\"Cosine Similarity of 1st sentence and 2nd:\", similarity_score)\n",
        "\n",
        "similarity_score = cosine_similarity_vectors(vector2, vector3)\n",
        "print(\"Cosine similarity of 2nd sentence and 3rd:\", similarity_score)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "fbf2d8ae",
      "metadata": {
        "id": "fbf2d8ae"
      },
      "source": [
        "# 2.1 Vector database list and describe index sjsunlp-kb"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "ee01c4d8",
      "metadata": {
        "id": "ee01c4d8"
      },
      "source": [
        "**You could have your own vector database index name**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 100,
      "id": "18a033e1",
      "metadata": {
        "id": "18a033e1"
      },
      "outputs": [],
      "source": [
        "import pinecone\n",
        "from pinecone import Pinecone, ServerlessSpec, PodSpec\n",
        "\n",
        "pc = Pinecone(api_key=pinecone_api_key)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 120,
      "id": "60e29d48-0f10-4238-816e-d84ac0347232",
      "metadata": {
        "id": "60e29d48-0f10-4238-816e-d84ac0347232"
      },
      "outputs": [],
      "source": [
        "index_name = 'breastcancer-kb'\n",
        "#sjsunlp-kb"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 121,
      "id": "57a1b48b-1e5a-45c2-bf91-148cef3e1007",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "57a1b48b-1e5a-45c2-bf91-148cef3e1007",
        "outputId": "2539dade-2cb4-43a8-a41b-ef826af2dab0"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'indexes': [{'deletion_protection': 'disabled',\n",
              "              'dimension': 1536,\n",
              "              'host': 'breastcancer-kb-tr357d9.svc.aped-4627-b74a.pinecone.io',\n",
              "              'metric': 'cosine',\n",
              "              'name': 'breastcancer-kb',\n",
              "              'spec': {'serverless': {'cloud': 'aws', 'region': 'us-east-1'}},\n",
              "              'status': {'ready': True, 'state': 'Ready'}},\n",
              "             {'deletion_protection': 'disabled',\n",
              "              'dimension': 1536,\n",
              "              'host': 'sjsunlp-kb-tr357d9.svc.gcp-starter.pinecone.io',\n",
              "              'metric': 'cosine',\n",
              "              'name': 'sjsunlp-kb',\n",
              "              'spec': {'pod': {'environment': 'gcp-starter',\n",
              "                               'pod_type': 'starter',\n",
              "                               'pods': 1,\n",
              "                               'replicas': 1,\n",
              "                               'shards': 1}},\n",
              "              'status': {'ready': True, 'state': 'Ready'}}]}"
            ]
          },
          "metadata": {},
          "execution_count": 121
        }
      ],
      "source": [
        "indexes_info = pc.list_indexes()\n",
        "indexes_info"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "3c403c36",
      "metadata": {
        "id": "3c403c36"
      },
      "source": [
        "# 2.2 Initialize connection to vector database, if not exist and create one"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "624ebf36",
      "metadata": {
        "id": "624ebf36"
      },
      "source": [
        "***The following is initial setup and class demo.***"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 122,
      "id": "bfdddb86-3c47-402a-8e66-a77f340047df",
      "metadata": {
        "id": "bfdddb86-3c47-402a-8e66-a77f340047df"
      },
      "outputs": [],
      "source": [
        "def index_exists(index_name):\n",
        "    # Retrieve the list of indexes and store in a variable\n",
        "\n",
        "\n",
        "    # Access the 'indexes' key which contains the list of index dictionaries\n",
        "    for index in indexes_info:\n",
        "        # Check if the 'name' key in each index dictionary matches the index_name\n",
        "        if index['name'] == index_name:\n",
        "            return True\n",
        "    return False"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 123,
      "id": "8f93721e",
      "metadata": {
        "id": "8f93721e"
      },
      "outputs": [],
      "source": [
        "if not index_exists(index_name):\n",
        "    print(f\"Index {index_name} does not exist.\")\n",
        "    pc.create_index(\n",
        "        name= index_name,\n",
        "        dimension=len(res.data[0].embedding), #actually, it is 1536\n",
        "        metric=\"cosine\",\n",
        "        spec=PodSpec(\n",
        "            environment=\"gcp-starter\"\n",
        "            )\n",
        "        )"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 124,
      "id": "2a0fb9f3",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2a0fb9f3",
        "outputId": "1153b81c-f8f2-4057-bbb3-53d4cf02b266"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'dimension': 1536,\n",
              " 'index_fullness': 0.0,\n",
              " 'namespaces': {},\n",
              " 'total_vector_count': 0}"
            ]
          },
          "metadata": {},
          "execution_count": 124
        }
      ],
      "source": [
        "# connect to index\n",
        "index = pc.Index(index_name)\n",
        "# view index stats\n",
        "index.describe_index_stats()"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "48ee1a3d",
      "metadata": {
        "id": "48ee1a3d"
      },
      "source": [
        "**Upsert one chunk of information to the Knowledge Base**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 169,
      "id": "687f4b8c",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "687f4b8c",
        "outputId": "a34119b4-3029-4b10-912b-8db372b7e1ef"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'What are the breast cancer signs?'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 169
        }
      ],
      "source": [
        "texts = \"What are the breast cancer signs?\"\n",
        "texts"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 170,
      "id": "c52a9f0e-9c7a-4a9f-9c93-b87f29733947",
      "metadata": {
        "id": "c52a9f0e-9c7a-4a9f-9c93-b87f29733947"
      },
      "outputs": [],
      "source": [
        "model=\"text-embedding-3-small\"\n",
        "\n",
        "res = client.embeddings.create(input = texts, model=embed_model)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 171,
      "id": "4b76e4a6",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "4b76e4a6",
        "outputId": "0b992677-f2d2-4d6c-d97a-4e263ebe7f36"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Embeds length: 1536\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'upserted_count': 1}"
            ]
          },
          "metadata": {},
          "execution_count": 171
        }
      ],
      "source": [
        "res = client.embeddings.create(input=texts, model=embed_model)\n",
        "\n",
        "embed = res.data[0].embedding\n",
        "print(\"Embeds length:\", len(embed))\n",
        "\n",
        "count = 1\n",
        "# Meta data preparation\n",
        "metadata = {\n",
        "            \"text\": texts\n",
        "}\n",
        "index.upsert(vectors=[{\"id\": \"breastcancer\" + '_' + str(count), \"metadata\": metadata, \"values\": res.data[0].embedding}],\n",
        "             namespace=\"sjsunlp\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 172,
      "id": "6fdf2b02",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6fdf2b02",
        "outputId": "ca75eb20-d603-400e-f4b9-59042bd26118"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'dimension': 1536,\n",
              " 'index_fullness': 0.0,\n",
              " 'namespaces': {'breastcancer': {'vector_count': 274}},\n",
              " 'total_vector_count': 274}"
            ]
          },
          "metadata": {},
          "execution_count": 172
        }
      ],
      "source": [
        "index.describe_index_stats()"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "7391f978",
      "metadata": {
        "id": "7391f978"
      },
      "source": [
        "### Delete corresponding namespace if needed"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 173,
      "id": "73b09eee",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "73b09eee",
        "outputId": "04f8b691-7a96-4a66-95b1-17b7041ff389"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'dimension': 1536,\n",
              " 'index_fullness': 0.0,\n",
              " 'namespaces': {'breastcancer': {'vector_count': 274},\n",
              "                'sjsunlp': {'vector_count': 1}},\n",
              " 'total_vector_count': 275}"
            ]
          },
          "metadata": {},
          "execution_count": 173
        }
      ],
      "source": [
        "index.delete(delete_all=True, namespace=\"sjsunlp\")\n",
        "index.describe_index_stats()"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "747f077f-8398-4875-81c2-405c66c11b2a",
      "metadata": {
        "id": "747f077f-8398-4875-81c2-405c66c11b2a"
      },
      "source": [
        "**Delete the whole index if really needed. PLEASE BE CAREFUL**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "d5ec19d0-8935-4128-bae3-61c3edb2c110",
      "metadata": {
        "id": "d5ec19d0-8935-4128-bae3-61c3edb2c110"
      },
      "outputs": [],
      "source": [
        "#pc.delete_index(index_name)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "627be3ac",
      "metadata": {
        "id": "627be3ac"
      },
      "source": [
        "**May need to install the following PyPDF2 if not yet installed**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 174,
      "id": "f482e852",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "f482e852",
        "outputId": "2b8a191e-7d34-4e9f-e1a6-c89b16b02335"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: PyPDF2 in /usr/local/lib/python3.10/dist-packages (3.0.1)\n"
          ]
        }
      ],
      "source": [
        "!pip install PyPDF2"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "53729963",
      "metadata": {
        "id": "53729963"
      },
      "source": [
        "# 3. Feeding document to vector database"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 175,
      "id": "f128d900",
      "metadata": {
        "id": "f128d900"
      },
      "outputs": [],
      "source": [
        "from PyPDF2 import PdfReader\n",
        "import re"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 176,
      "id": "7c7d2809-3591-4fe1-a65c-061da5da2ac2",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7c7d2809-3591-4fe1-a65c-061da5da2ac2",
        "outputId": "3c682f8e-044d-45ec-85f7-dd18a17912dd"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (4.66.5)\n"
          ]
        }
      ],
      "source": [
        "!pip install tqdm"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 177,
      "id": "cf976891-ed26-45af-bd72-e90bb4f0c60e",
      "metadata": {
        "id": "cf976891-ed26-45af-bd72-e90bb4f0c60e"
      },
      "outputs": [],
      "source": [
        "def split_text_into_lines(input_text, max_words_per_line):\n",
        "    words = input_text.split()\n",
        "    lines = []\n",
        "    current_line = []\n",
        "\n",
        "    for word in words:\n",
        "        if len(current_line) + len(word) + 1 <= max_words_per_line:\n",
        "            current_line.append(word)\n",
        "        else:\n",
        "            lines.append(\" \".join(current_line))\n",
        "            current_line = [word]\n",
        "\n",
        "    if current_line:\n",
        "        lines.append(\" \".join(current_line))\n",
        "\n",
        "    return lines"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 179,
      "id": "79aefa5f",
      "metadata": {
        "id": "79aefa5f"
      },
      "outputs": [],
      "source": [
        "#process the knowledge base file upsert to a namespace\n",
        "#from tqdm import tqdm\n",
        "\n",
        "def nlp_upsert(filename, index_name, name_space, nlp_id, chunk_size, stride, page_begin, page_end):\n",
        "    \"\"\"\n",
        "    upsert a whole PDF file (with begin page and end page information) to the pinecone vector database\n",
        "\n",
        "    Parameters:\n",
        "    filename (str): The file name.\n",
        "    index_name (str): The pinecone index name.\n",
        "    name_space (str): The namespace we want to place for all related docuement.\n",
        "    nlp_id (str): A common ID prefix to reference to document.\n",
        "    chunk_size (int): The chunk size, how many lines as one chunks.\n",
        "    stride (int): The overlap side, how many lines as overlap between chunks.\n",
        "    page_begin (int): Which page in the PDF file to begin for upsert.\n",
        "    page_end (int): Which page is the ending page for upsert.\n",
        "\n",
        "    Returns:\n",
        "    None: No return.\n",
        "    \"\"\"\n",
        "    doc = \"\"\n",
        "\n",
        "    reader = PdfReader(filename)\n",
        "\n",
        "    for i in range(page_begin, page_end):\n",
        "        doc += reader.pages[i].extract_text()\n",
        "        print(\"page completed:\", i)\n",
        "\n",
        "\n",
        "    doc = split_text_into_lines(doc, 30)\n",
        "    print(\"The total lines: \", len(doc))\n",
        "\n",
        "\n",
        "    #Connect to index\n",
        "    index = pc.Index(index_name)\n",
        "\n",
        "    count = 0\n",
        "    for i in range(0, len(doc), chunk_size):\n",
        "        #find begining and end of the chunk\n",
        "        i_begin = max(0, i-stride)\n",
        "        i_end = min(len(doc), i_begin+chunk_size)\n",
        "\n",
        "        doc_chunk = doc[i_begin:i_end]\n",
        "        print(\"-\"*80)\n",
        "        print(\"The \", i//chunk_size + 1, \" doc chunk text:\", doc_chunk)\n",
        "\n",
        "\n",
        "        texts = \"\"\n",
        "        for x in doc_chunk:\n",
        "            texts += x\n",
        "        print(\"Texts:\", texts)\n",
        "\n",
        "        #Create embeddings of the chunk texts\n",
        "        try:\n",
        "            res = client.embeddings.create(input=texts, model=embed_model)\n",
        "        except:\n",
        "            done = False\n",
        "            while not done:\n",
        "                time.sleep(10)\n",
        "                try:\n",
        "                    res = client.embeddings.create(input=texts, model=embed_model)\n",
        "                    done = True\n",
        "                except:\n",
        "                    pass\n",
        "        embed = res.data[0].embedding\n",
        "        print(\"Embeds length:\", len(embed))\n",
        "\n",
        "        # Meta data preparation\n",
        "        metadata = {\n",
        "            \"text\": texts\n",
        "        }\n",
        "\n",
        "        count += 1\n",
        "        print(\"Upserted vector count is: \", count)\n",
        "        print(\"=\"*80)\n",
        "\n",
        "        #upsert to pinecone and corresponding namespace\n",
        "\n",
        "        index.upsert(vectors=[{\"id\": nlp_id + '_' + str(count), \"metadata\": metadata, \"values\": embed}], namespace=name_space)\n"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "9511c3c7",
      "metadata": {
        "id": "9511c3c7"
      },
      "source": [
        "### <span style=\"color:#00FF00\">Building Knowledge Base, check the status or delete the data</span>"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "88fbc16f",
      "metadata": {
        "id": "88fbc16f"
      },
      "source": [
        "**You are required to update the file name with your prepared \".pdf\" file for the week 6 homework. It's important to be aware that various operating systems might slightly alter the format for entering the file name. If you encounter any difficulties, ChatGPT can provide assistance. <br>**\n",
        "\n",
        "**Additionally, you have the option to insert multiple files into the Knowledge Base by executing the command in the following cell multiple times with distinct file names.**"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install pyCryptodome\n",
        "!pip install PyPDF2\n",
        "from PyPDF2 import PdfReader\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "9-Es6WwbZUUJ",
        "outputId": "7fcdbc98-8cc3-4b46-cd1a-bbd2068859dc"
      },
      "id": "9-Es6WwbZUUJ",
      "execution_count": 180,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: pyCryptodome in /usr/local/lib/python3.10/dist-packages (3.21.0)\n",
            "Requirement already satisfied: PyPDF2 in /usr/local/lib/python3.10/dist-packages (3.0.1)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install -U PyPDF2 pycryptodome\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mBXmvFq7a1zc",
        "outputId": "fd1363bc-4804-471b-c18e-f2480d50852d"
      },
      "id": "mBXmvFq7a1zc",
      "execution_count": 181,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: PyPDF2 in /usr/local/lib/python3.10/dist-packages (3.0.1)\n",
            "Requirement already satisfied: pycryptodome in /usr/local/lib/python3.10/dist-packages (3.21.0)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 182,
      "id": "5928742a-7f32-4dd5-871a-5037589920c4",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5928742a-7f32-4dd5-871a-5037589920c4",
        "outputId": "7bfbb35d-fc87-40eb-e995-03cb2bf6c8d2"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Knowledge base file name: /content/breast-cancer-fact-sheet-patient-version.pdf\n",
            "Knowledge base file name: /content/2022-2024-breast-cancer-fact-figures-acs.pdf\n",
            "length of the knowledge base file1: 2\n",
            "length of the knowledge base file2: 48\n"
          ]
        }
      ],
      "source": [
        "filename1 = r\"/content/breast-cancer-fact-sheet-patient-version.pdf\"\n",
        "print(\"Knowledge base file name:\", filename1)\n",
        "filename2 = r\"/content/2022-2024-breast-cancer-fact-figures-acs.pdf\"\n",
        "print(\"Knowledge base file name:\", filename2)\n",
        "\n",
        "reader = PdfReader(filename1)\n",
        "page_len = len(reader.pages)\n",
        "\n",
        "print(\"length of the knowledge base file1:\", page_len)\n",
        "reader = PdfReader(filename2)\n",
        "\n",
        "page_len = len(reader.pages)\n",
        "print(\"length of the knowledge base file2:\", page_len)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 183,
      "id": "3a1264a0",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3a1264a0",
        "outputId": "f8c82812-d4c2-49f6-a720-bfc50d8c5698"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "page completed: 0\n",
            "page completed: 1\n",
            "page completed: 2\n",
            "page completed: 3\n",
            "page completed: 4\n",
            "page completed: 5\n",
            "page completed: 6\n",
            "page completed: 7\n",
            "page completed: 8\n",
            "page completed: 9\n",
            "page completed: 10\n",
            "page completed: 11\n",
            "page completed: 12\n",
            "page completed: 13\n",
            "page completed: 14\n",
            "page completed: 15\n",
            "page completed: 16\n",
            "page completed: 17\n",
            "page completed: 18\n",
            "page completed: 19\n",
            "page completed: 20\n",
            "page completed: 21\n",
            "page completed: 22\n",
            "page completed: 23\n",
            "page completed: 24\n",
            "page completed: 25\n",
            "page completed: 26\n",
            "page completed: 27\n",
            "page completed: 28\n",
            "page completed: 29\n",
            "page completed: 30\n",
            "page completed: 31\n",
            "page completed: 32\n",
            "page completed: 33\n",
            "page completed: 34\n",
            "page completed: 35\n",
            "page completed: 36\n",
            "page completed: 37\n",
            "page completed: 38\n",
            "page completed: 39\n",
            "page completed: 40\n",
            "page completed: 41\n",
            "page completed: 42\n",
            "page completed: 43\n",
            "page completed: 44\n",
            "page completed: 45\n",
            "page completed: 46\n",
            "page completed: 47\n",
            "The total lines:  1369\n",
            "--------------------------------------------------------------------------------\n",
            "The  1  doc chunk text: ['Breast Cancer Facts & Figures 2022-2024 Contents Breast Cancer Basic Facts 1 What is breast cancer? 1 What are the signs and', 'symptoms of breast cancer? 1 How is breast cancer diagnosed? 1 How is breast cancer staged? 1 What are the types of breast', 'cancer? 2 Breast Cancer Occurrence 3 How many cases and deaths are expected to occur in 2022? 3 How many women alive today have ever had', 'breast cancer? 3 What is the risk of breast cancer diagnosis or death? 3 What percentage of women are diagnosed with', 'early-stage breast cancer? 5 How has breast cancer occurrence changed over time? 5 Are there geographic differences in breast cancer rates? 7 Breast cancer']\n",
            "Texts: Breast Cancer Facts & Figures 2022-2024 Contents Breast Cancer Basic Facts 1 What is breast cancer? 1 What are the signs andsymptoms of breast cancer? 1 How is breast cancer diagnosed? 1 How is breast cancer staged? 1 What are the types of breastcancer? 2 Breast Cancer Occurrence 3 How many cases and deaths are expected to occur in 2022? 3 How many women alive today have ever hadbreast cancer? 3 What is the risk of breast cancer diagnosis or death? 3 What percentage of women are diagnosed withearly-stage breast cancer? 5 How has breast cancer occurrence changed over time? 5 Are there geographic differences in breast cancer rates? 7 Breast cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  1\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  2  doc chunk text: ['breast cancer? 3 What is the risk of breast cancer diagnosis or death? 3 What percentage of women are diagnosed with', 'early-stage breast cancer? 5 How has breast cancer occurrence changed over time? 5 Are there geographic differences in breast cancer rates? 7 Breast cancer', 'survival 9 Male breast cancer 11 Breast Cancer Risk Factors 12 Family history, personal', 'characteristics, and medical history 13 Reproductive factors 17 Body weight, physical inactivity, diet, alcohol, and tobacco 18', 'Environmental and other risk factors 19 Factors that are not associated with breast cancer risk 20']\n",
            "Texts: breast cancer? 3 What is the risk of breast cancer diagnosis or death? 3 What percentage of women are diagnosed withearly-stage breast cancer? 5 How has breast cancer occurrence changed over time? 5 Are there geographic differences in breast cancer rates? 7 Breast cancersurvival 9 Male breast cancer 11 Breast Cancer Risk Factors 12 Family history, personalcharacteristics, and medical history 13 Reproductive factors 17 Body weight, physical inactivity, diet, alcohol, and tobacco 18Environmental and other risk factors 19 Factors that are not associated with breast cancer risk 20\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  2\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  3  doc chunk text: ['Chemoprevention and prophylactic surgery 20Breast Cancer Screening 21 Mammography 21 Magnetic resonance imaging (MRI) 23 Breast ultrasound 24 Clinical breast', 'examination (CBE) 24 Breast self-awareness 24 Breast Cancer Treatment 25 Ductal carcinoma in situ (DCIS) 25 Invasive breast cancer 25 What Is the', 'American Cancer Society Doing About Breast Cancer? 29 Patient support 30 Programs and services 30 Research 31 Advocacy 32 Sources of', 'Statistics 34 References 35 ©2022, American Cancer Society, Inc. All rights reserved, including the right to reproduce this publication or portions thereof in any form. For', 'permission, email the American Cancer Society Legal department at']\n",
            "Texts: Chemoprevention and prophylactic surgery 20Breast Cancer Screening 21 Mammography 21 Magnetic resonance imaging (MRI) 23 Breast ultrasound 24 Clinical breastexamination (CBE) 24 Breast self-awareness 24 Breast Cancer Treatment 25 Ductal carcinoma in situ (DCIS) 25 Invasive breast cancer 25 What Is theAmerican Cancer Society Doing About Breast Cancer? 29 Patient support 30 Programs and services 30 Research 31 Advocacy 32 Sources ofStatistics 34 References 35 ©2022, American Cancer Society, Inc. All rights reserved, including the right to reproduce this publication or portions thereof in any form. Forpermission, email the American Cancer Society Legal department at\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  3\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  4  doc chunk text: ['permissionsrequests@cancer.org.This publication attempts to summarize current scientific information about breast cancer. Except when specified, it does not represent the official policy of the', 'American Cancer Society. Suggested citation: American Cancer Society. Breast Cancer Facts & Figures 2022-2024 . Atlanta: American Cancer Society, Inc.', '2022.Breast Cancer Facts & Figures 2022-2024 1Breast Cancer Basic Facts What is breast cancer? Breast cancer is a group of diseases in which cells in a', 'person’s breast tissue change and divide uncontrolled, typically resulting in a lump or mass. Most breast cancers begin in the milk glands', '(lobules) or in the tubes (ducts) that connect the milk glands to the nipple. What are the signs and symptoms of breast cancer? Breast']\n",
            "Texts: permissionsrequests@cancer.org.This publication attempts to summarize current scientific information about breast cancer. Except when specified, it does not represent the official policy of theAmerican Cancer Society. Suggested citation: American Cancer Society. Breast Cancer Facts & Figures 2022-2024 . Atlanta: American Cancer Society, Inc.2022.Breast Cancer Facts & Figures 2022-2024 1Breast Cancer Basic Facts What is breast cancer? Breast cancer is a group of diseases in which cells in aperson’s breast tissue change and divide uncontrolled, typically resulting in a lump or mass. Most breast cancers begin in the milk glands(lobules) or in the tubes (ducts) that connect the milk glands to the nipple. What are the signs and symptoms of breast cancer? Breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  4\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  5  doc chunk text: ['cancer typically has no symptoms when the tumor is small and most easily treated, which is why breast cancer screening is', 'important for early detection. The most common physical sign is a painless lump. Sometimes breast cancer can spread to underarm lymph nodes and cause a lump or', 'swelling even before the original breast tumor is large enough to be felt. Less common signs and symptoms include breast pain or', 'heaviness; dimpling, swelling, thickening, or redness of the breast skin; and nipple changes, such as spontaneous discharge (especially if bloody),', 'scaliness, or retraction. Any persistent change in the breast should be evaluated by a physician. How is breast cancer diagnosed? Breast cancer is']\n",
            "Texts: cancer typically has no symptoms when the tumor is small and most easily treated, which is why breast cancer screening isimportant for early detection. The most common physical sign is a painless lump. Sometimes breast cancer can spread to underarm lymph nodes and cause a lump orswelling even before the original breast tumor is large enough to be felt. Less common signs and symptoms include breast pain orheaviness; dimpling, swelling, thickening, or redness of the breast skin; and nipple changes, such as spontaneous discharge (especially if bloody),scaliness, or retraction. Any persistent change in the breast should be evaluated by a physician. How is breast cancer diagnosed? Breast cancer is\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  5\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  6  doc chunk text: ['typically detected during mammography screening, before symptoms have developed (asymptomatic), or after a woman notices a lump or change in the breast', '(symptomatic). Detection after symptoms develop is more common among younger women who have not started breast cancer screening, older women who are no longer', 'recommended for screening, and those who lack access to preventive screening. Most screen-detected masses turn out to be benign (not', 'cancerous). When cancer is suspected, a biopsy is needed to establish the diagnosis through microscopic analysis. A needle biopsy', '(fine-needle or larger core-needle) is most common, but sometimes a surgical biopsy is performed. Selection of the type of biopsy is based on']\n",
            "Texts: typically detected during mammography screening, before symptoms have developed (asymptomatic), or after a woman notices a lump or change in the breast(symptomatic). Detection after symptoms develop is more common among younger women who have not started breast cancer screening, older women who are no longerrecommended for screening, and those who lack access to preventive screening. Most screen-detected masses turn out to be benign (notcancerous). When cancer is suspected, a biopsy is needed to establish the diagnosis through microscopic analysis. A needle biopsy(fine-needle or larger core-needle) is most common, but sometimes a surgical biopsy is performed. Selection of the type of biopsy is based on\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  6\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  7  doc chunk text: ['multiple factors, including the size and location of the mass, patient factors and preferences, and resources.How is breast cancer staged? The extent of cancer and its', 'spread at the time of diagnosis, as well as microscopic characteristics of the tumor, determine its stage. Cancer stage is the best', 'predictor of prognosis (disease outcome) and is essential for guiding treatment options. The two main staging systems for breast cancer are the', 'American Joint Committee on Cancer (AJCC) staging system, typically used in clinical settings, and the Surveillance, Epidemiology, and End Results (SEER) summary staging', 'system, reported by cancer registries and used in surveillance research to measure the success of cancer control efforts. The AJCC staging system']\n",
            "Texts: multiple factors, including the size and location of the mass, patient factors and preferences, and resources.How is breast cancer staged? The extent of cancer and itsspread at the time of diagnosis, as well as microscopic characteristics of the tumor, determine its stage. Cancer stage is the bestpredictor of prognosis (disease outcome) and is essential for guiding treatment options. The two main staging systems for breast cancer are theAmerican Joint Committee on Cancer (AJCC) staging system, typically used in clinical settings, and the Surveillance, Epidemiology, and End Results (SEER) summary stagingsystem, reported by cancer registries and used in surveillance research to measure the success of cancer control efforts. The AJCC staging system\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  7\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  8  doc chunk text: ['incorporates anatomic and biologic information about the cancer to create a prognostic stage. Anatomic stage is based on TNM', 'classification, including the size of the tumor (T) and whether cancer cells have spread to regional lymph nodes (N) or have', 'metastasized (M) to distant lymph nodes and/or organs. Prognostic stage additionally includes information on biomarkers, such as estrogen receptor (ER) and', 'progesterone receptor (PR) status, level of human epidermal growth factor 2 (HER2, a growth- promoting protein), and grade (similarity of the cancer’s', 'microscopic appearance to normal breast tissue).1 In this document, we refer to SEER summary stage except in the section on breast cancer']\n",
            "Texts: incorporates anatomic and biologic information about the cancer to create a prognostic stage. Anatomic stage is based on TNMclassification, including the size of the tumor (T) and whether cancer cells have spread to regional lymph nodes (N) or havemetastasized (M) to distant lymph nodes and/or organs. Prognostic stage additionally includes information on biomarkers, such as estrogen receptor (ER) andprogesterone receptor (PR) status, level of human epidermal growth factor 2 (HER2, a growth- promoting protein), and grade (similarity of the cancer’smicroscopic appearance to normal breast tissue).1 In this document, we refer to SEER summary stage except in the section on breast cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  8\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  9  doc chunk text: ['treatment ( page 25), which is described using AJCC staging. According to the SEER summary stage system: • In situ refers to the', 'presence of abnormal cells that are confined to the layer of cells where they originated. • Local stage refers to invasive cancer that is', 'confined to the breast. • Regional stage refers to cancer that has spread to surrounding tissue and/or lymph nodes. • Distant stage refers to', 'cancer that has spread to distant organs and/or lymph nodes, including nodes above the collarbone.2 Breast Cancer Facts & Figures', '2022-2024What are the types of breast cancer? Breast cancer is a collection of many related diseases with different biologic, clinical, and']\n",
            "Texts: treatment ( page 25), which is described using AJCC staging. According to the SEER summary stage system: • In situ refers to thepresence of abnormal cells that are confined to the layer of cells where they originated. • Local stage refers to invasive cancer that isconfined to the breast. • Regional stage refers to cancer that has spread to surrounding tissue and/or lymph nodes. • Distant stage refers tocancer that has spread to distant organs and/or lymph nodes, including nodes above the collarbone.2 Breast Cancer Facts & Figures2022-2024What are the types of breast cancer? Breast cancer is a collection of many related diseases with different biologic, clinical, and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  9\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  10  doc chunk text: ['prognostic characteristics. In addition to being classified by their stage (as previously described), breast cancers are further grouped based on', 'microscopic appearance and molecular traits. Ductal carcinoma in situ Although ductal carcinoma in situ (DCIS) is not a true cancer, it', 'represents about one in six newly diagnosed breast cancers overall, and even more screen-detected cancers. DCIS, or stage 0 breast cancer, refers to', 'presumably malignant cells that are confined to the mammary ducts. It is considered a precursor to invasive cancer and is', 'associated with increased risk of subsequent invasive breast cancer. However, not all DCIS lesions progress to invasive cancer.1, 2 Although long-term']\n",
            "Texts: prognostic characteristics. In addition to being classified by their stage (as previously described), breast cancers are further grouped based onmicroscopic appearance and molecular traits. Ductal carcinoma in situ Although ductal carcinoma in situ (DCIS) is not a true cancer, itrepresents about one in six newly diagnosed breast cancers overall, and even more screen-detected cancers. DCIS, or stage 0 breast cancer, refers topresumably malignant cells that are confined to the mammary ducts. It is considered a precursor to invasive cancer and isassociated with increased risk of subsequent invasive breast cancer. However, not all DCIS lesions progress to invasive cancer.1, 2 Although long-term\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  10\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  11  doc chunk text: ['follow-up studies of women with untreated DCIS report progression to invasive breast cancer ranging from 10% to 53%,3-5, 6 a recent modeling study', 'suggests that over 64% of DCIS progresses.7 The wide range is likely due to the heterogeneity of DCIS. Women with DCIS who are', 'premenopausal and those with large or high-grade masses that can be felt are at greatest risk of future invasive breast cancer.8, 9', 'Multiple studies are investigating how to distinguish high-risk DCIS that requires treatment from low-risk DCIS that can be safely managed with active', 'surveillance (close monitoring) to reduce risk of overtreatment.6 See breast cancer risk factors on page 12 for information on LCIS (lobular']\n",
            "Texts: follow-up studies of women with untreated DCIS report progression to invasive breast cancer ranging from 10% to 53%,3-5, 6 a recent modeling studysuggests that over 64% of DCIS progresses.7 The wide range is likely due to the heterogeneity of DCIS. Women with DCIS who arepremenopausal and those with large or high-grade masses that can be felt are at greatest risk of future invasive breast cancer.8, 9Multiple studies are investigating how to distinguish high-risk DCIS that requires treatment from low-risk DCIS that can be safely managed with activesurveillance (close monitoring) to reduce risk of overtreatment.6 See breast cancer risk factors on page 12 for information on LCIS (lobular\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  11\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  12  doc chunk text: ['carcinoma in situ) and additional information on DCIS. Invasive Most (83%) breast cancers are invasive, or infiltrating, which means the cancer cells have broken', 'through the wall of the glands or ducts where they originated and grown into surrounding breast tissue with the potential to spread to other parts of the', 'body. Histologic subtypes Histologic subtypes are based on the size, shape, and arrangement of cancer cells. Approximately 75% of invasive breast cancers are', 'histologically categorized as “invasive ductal carcinoma.” The second most common subtype is invasive lobular carcinoma, representing about 10% of invasive breast cancers.', 'Medullary, tubular, mucinous, and cribriform carcinomas are rare subtypes that are generally associated with a favorable']\n",
            "Texts: carcinoma in situ) and additional information on DCIS. Invasive Most (83%) breast cancers are invasive, or infiltrating, which means the cancer cells have brokenthrough the wall of the glands or ducts where they originated and grown into surrounding breast tissue with the potential to spread to other parts of thebody. Histologic subtypes Histologic subtypes are based on the size, shape, and arrangement of cancer cells. Approximately 75% of invasive breast cancers arehistologically categorized as “invasive ductal carcinoma.” The second most common subtype is invasive lobular carcinoma, representing about 10% of invasive breast cancers.Medullary, tubular, mucinous, and cribriform carcinomas are rare subtypes that are generally associated with a favorable\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  12\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  13  doc chunk text: ['prognosis.10-12 Inflammatory breast carcinoma is an uncommon (0.3% of invasive breast cancers) but aggressive subtype that spreads to the skin of the breast, which', 'becomes red and swollen. Molecular subtypes Breast cancer is further classified by molecular characteristics that are associated with clinical', 'presentation, response to therapy, and prognosis. The four broad molecular subtypes are Luminal A, Luminal B, basal-like, and', 'HER2-enriched. These subtypes were originally defined by gene expression profiling but are often approximated based on simpler tests that determine ER, PR, and HER2', 'status. Hormone receptor positive (HR+) cancers are those that test positive for ER or PR, or both. Information about tumor grade and']\n",
            "Texts: prognosis.10-12 Inflammatory breast carcinoma is an uncommon (0.3% of invasive breast cancers) but aggressive subtype that spreads to the skin of the breast, whichbecomes red and swollen. Molecular subtypes Breast cancer is further classified by molecular characteristics that are associated with clinicalpresentation, response to therapy, and prognosis. The four broad molecular subtypes are Luminal A, Luminal B, basal-like, andHER2-enriched. These subtypes were originally defined by gene expression profiling but are often approximated based on simpler tests that determine ER, PR, and HER2status. Hormone receptor positive (HR+) cancers are those that test positive for ER or PR, or both. Information about tumor grade and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  13\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  14  doc chunk text: ['proliferation (rate of cell division) is also sometimes used to assign subtype.13HR = hormone receptor; HER2 = human epidermal growth factor receptor 2.', 'Source: North American Association of Central Cancer Registries (NAACCR), 2022. ©2022, American Cancer Society, Inc., Surveillance and Health Equity', 'ScienceFigure 1. Distribution of Female Breast Cancer Subtypes, US, 2015-2019 HR+/HER2- 68%HR+/HER2+ 10%HR-/HER2- 10%HR-/HER2+ 4% Unknown 8% Breast Cancer Facts & Figures', '2022-2024 3• HR+/HER2- Surrogate for Luminal A. This is the most common molecular subtype of breast cancer, accounting for 68% of all cases (', 'Figure 1 ). This subtype tends to be slower-growing and less aggressive than other subtypes and responds to hormone therapy (see page 28).14 •']\n",
            "Texts: proliferation (rate of cell division) is also sometimes used to assign subtype.13HR = hormone receptor; HER2 = human epidermal growth factor receptor 2.Source: North American Association of Central Cancer Registries (NAACCR), 2022. ©2022, American Cancer Society, Inc., Surveillance and Health EquityScienceFigure 1. Distribution of Female Breast Cancer Subtypes, US, 2015-2019 HR+/HER2- 68%HR+/HER2+ 10%HR-/HER2- 10%HR-/HER2+ 4% Unknown 8% Breast Cancer Facts & Figures2022-2024 3• HR+/HER2- Surrogate for Luminal A. This is the most common molecular subtype of breast cancer, accounting for 68% of all cases (Figure 1 ). This subtype tends to be slower-growing and less aggressive than other subtypes and responds to hormone therapy (see page 28).14 •\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  14\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  15  doc chunk text: ['HR+/HER2+ Surrogate for Luminal B. This subtype was originally characterized as always HER2+, but is now defined as being positive for HER2 and/or a', 'specific protein indicative of rapidly dividing cells (Ki67). It accounts for approximately 10% of all breast cancers and is often higher grade than', 'Luminal A and associated with poorer outcomes.15 • HR-/HER2- Surrogate for basal-like. These cancers are also called', 'triple-negative breast cancer (TNBC) because they are negative for all three biomarkers. This is generally a more aggressive type of tumor, with higher risk of', 'metastasis and recurrence.16, 17 TNBC accounts for 10% of breast cancers overall, but nearly 20% among African American women, who have the highest']\n",
            "Texts: HR+/HER2+ Surrogate for Luminal B. This subtype was originally characterized as always HER2+, but is now defined as being positive for HER2 and/or aspecific protein indicative of rapidly dividing cells (Ki67). It accounts for approximately 10% of all breast cancers and is often higher grade thanLuminal A and associated with poorer outcomes.15 • HR-/HER2- Surrogate for basal-like. These cancers are also calledtriple-negative breast cancer (TNBC) because they are negative for all three biomarkers. This is generally a more aggressive type of tumor, with higher risk ofmetastasis and recurrence.16, 17 TNBC accounts for 10% of breast cancers overall, but nearly 20% among African American women, who have the highest\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  15\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  16  doc chunk text: ['incidence. Risk is also higher among young women and those with a BRCA1 gene variant.18-20 • HR-/HER2+ Surrogate for', 'HER2-enriched. This is the least common breast cancer subtype, accounting for 4% of all diagnoses. In the past, this subtype had the worst', 'prognosis; however, the development of targeted therapies for HER2+ cancers has substantially improved outcomes.3, 21, 22 For information about the treatment of breast cancer', 'subtypes, see page 25. Breast Cancer Occurrence How many cases and deaths are expected to occur in 2022? In the US in 2022, an', 'estimated 287,850 new cases of invasive breast cancer will be diagnosed among women and 43,250 women will die from the disease ( Table 1 ). In']\n",
            "Texts: incidence. Risk is also higher among young women and those with a BRCA1 gene variant.18-20 • HR-/HER2+ Surrogate forHER2-enriched. This is the least common breast cancer subtype, accounting for 4% of all diagnoses. In the past, this subtype had the worstprognosis; however, the development of targeted therapies for HER2+ cancers has substantially improved outcomes.3, 21, 22 For information about the treatment of breast cancersubtypes, see page 25. Breast Cancer Occurrence How many cases and deaths are expected to occur in 2022? In the US in 2022, anestimated 287,850 new cases of invasive breast cancer will be diagnosed among women and 43,250 women will die from the disease ( Table 1 ). In\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  16\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  17  doc chunk text: ['addition, an estimated 51,400 cases of DCIS will be diagnosed among women. Although breast cancer is predominantly a female disease,', 'approximately 2,710 new cases and 530 deaths (about 1% of all breast cancer cases and deaths) will occur among men. How many women alive today have', 'ever had breast cancer? More than 4 million US women with a history of invasive breast cancer were alive on January 1, 2022.23 Some of', 'these women were cancer-free, while others still had evidence of cancer and may have been undergoing treatment. More than 150,000 breast cancer', 'survivors are living with metastatic (stage IV) disease, three-fourths of whom were originally diagnosed with stage I-III']\n",
            "Texts: addition, an estimated 51,400 cases of DCIS will be diagnosed among women. Although breast cancer is predominantly a female disease,approximately 2,710 new cases and 530 deaths (about 1% of all breast cancer cases and deaths) will occur among men. How many women alive today haveever had breast cancer? More than 4 million US women with a history of invasive breast cancer were alive on January 1, 2022.23 Some ofthese women were cancer-free, while others still had evidence of cancer and may have been undergoing treatment. More than 150,000 breast cancersurvivors are living with metastatic (stage IV) disease, three-fourths of whom were originally diagnosed with stage I-III\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  17\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  18  doc chunk text: ['cancer.24What is the risk of breast cancer diagnosis or death? Approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer in her', 'lifetime and 1 in 39 women (3%) will die from breast cancer ( Table 2 ). Life- time risk is an average risk for all', 'women and accounts Table 1. Estimated New DCIS and Invasive Breast Cancer Cases and Deaths Among Women by Age, US, 2022 DCIS cases', 'Invasive cases Deaths Age Number % Number % Number % <40 1,230 2% 10,850 4% 1,090 3% 40-49 8,050 16% 36,710 13% 2,950 7% 50-59', '12,830 26% 65,980 23% 7,150 17% 60-69 16,030 31% 84,200 29% 10,270 24% 70-79 10,450 20% 61,470 21% 10,010 23% 80+ 2,810 5% 28,640 10%']\n",
            "Texts: cancer.24What is the risk of breast cancer diagnosis or death? Approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer in herlifetime and 1 in 39 women (3%) will die from breast cancer ( Table 2 ). Life- time risk is an average risk for allwomen and accounts Table 1. Estimated New DCIS and Invasive Breast Cancer Cases and Deaths Among Women by Age, US, 2022 DCIS casesInvasive cases Deaths Age Number % Number % Number % <40 1,230 2% 10,850 4% 1,090 3% 40-49 8,050 16% 36,710 13% 2,950 7% 50-5912,830 26% 65,980 23% 7,150 17% 60-69 16,030 31% 84,200 29% 10,270 24% 70-79 10,450 20% 61,470 21% 10,010 23% 80+ 2,810 5% 28,640 10%\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  18\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  19  doc chunk text: ['11,780 27% All ages 51,400 287,850 43,250 Estimates are rounded to the nearest 10. Percentages may not sum to 100 due to', 'rounding. DCIS = Ductal carcinoma in situ. ©2022, American Cancer Society, Inc., Surveillance and Health Equity Science4 Breast Cancer Facts & Figures', '2022-2024for deaths from other causes that may preempt a breast cancer diagnosis. A woman’s individual risk varies by age and', 'race/ethnicity, as well as family, medical, and reproductive history.25 Age Breast cancer incidence increases with age until the seventh decade of life ( Figure 2 ). The', 'decrease in incidence that occurs in women 80 years of age and older likely reflects lower rates of screening. During']\n",
            "Texts: 11,780 27% All ages 51,400 287,850 43,250 Estimates are rounded to the nearest 10. Percentages may not sum to 100 due torounding. DCIS = Ductal carcinoma in situ. ©2022, American Cancer Society, Inc., Surveillance and Health Equity Science4 Breast Cancer Facts & Figures2022-2024for deaths from other causes that may preempt a breast cancer diagnosis. A woman’s individual risk varies by age andrace/ethnicity, as well as family, medical, and reproductive history.25 Age Breast cancer incidence increases with age until the seventh decade of life ( Figure 2 ). Thedecrease in incidence that occurs in women 80 years of age and older likely reflects lower rates of screening. During\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  19\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  20  doc chunk text: ['2015-2019, the median age at breast cancer diagnosis was 62. This means that half of women who developed breast cancer were 62 years of age or', 'younger at the time of diagnosis. The median age of diagnosis is younger for Hispanic (57), Asian/Pacific Islander (58), Black (60), and', 'American Indian/Alaska Native (61) women than White women (64), partly reflecting differences in population age structure, as well as', 'age-specific risk. Race/Ethnicity Breast cancer incidence and death rates differ substantially by race and ethnicity ( Figure 3 ). Incidence rates are highest among White', 'women (133.7 per 100,000), followed closely by Black women (127.8), then America Indian/Alaska Native (111.3), Asian/Pacific Islander (101.3), and Hispanic (99.2) women. In']\n",
            "Texts: 2015-2019, the median age at breast cancer diagnosis was 62. This means that half of women who developed breast cancer were 62 years of age oryounger at the time of diagnosis. The median age of diagnosis is younger for Hispanic (57), Asian/Pacific Islander (58), Black (60), andAmerican Indian/Alaska Native (61) women than White women (64), partly reflecting differences in population age structure, as well asage-specific risk. Race/Ethnicity Breast cancer incidence and death rates differ substantially by race and ethnicity ( Figure 3 ). Incidence rates are highest among Whitewomen (133.7 per 100,000), followed closely by Black women (127.8), then America Indian/Alaska Native (111.3), Asian/Pacific Islander (101.3), and Hispanic (99.2) women. In\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  20\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  21  doc chunk text: ['contrast, death rates are highest among Black women, exceeding those in White women by 40% and almost 2.5 times higher than', 'Asian/Pacific Islander (API) women, who have the lowest rates. Thus, both Black and American Indian/Alaska Native women have higher mortality rates than White women', 'despite lower incidence. The disproportionate mortality burden among Black women in part reflects the higher risk of TNBC ( Figure 4 ) and', 'later-stage diagnosis ( Figure 5 ), although Black women have worse survival across all stages and subtypes. Breast cancer is the leading cause of', 'cancer death in the US for Black and Hispanic women (due to lower lung cancer mortality rates) and the']\n",
            "Texts: contrast, death rates are highest among Black women, exceeding those in White women by 40% and almost 2.5 times higher thanAsian/Pacific Islander (API) women, who have the lowest rates. Thus, both Black and American Indian/Alaska Native women have higher mortality rates than White womendespite lower incidence. The disproportionate mortality burden among Black women in part reflects the higher risk of TNBC ( Figure 4 ) andlater-stage diagnosis ( Figure 5 ), although Black women have worse survival across all stages and subtypes. Breast cancer is the leading cause ofcancer death in the US for Black and Hispanic women (due to lower lung cancer mortality rates) and the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  21\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  22  doc chunk text: ['second-leading cause of cancer death, following lung cancer, among API, American Indian/Alaska Native (AIAN), and White women. Globally, breast cancer has', 'surpassed lung cancer as the leading cause of cancer death among women.26 Figure 2. Age-specific Female Breast Cancer Incidence Rates by', 'Race/Ethnicity, US, 2015-2019Rate per 100,000 Age at diagnosis Note: Rates are per 100,000 and age adjusted to the 2000 US standard', 'population. Race is exclusive of Hispanic origin. Data for American Indians/ Alaska Natives are based on', 'Purchased/Referred Care Delivery Area (PRCDA) counties. Source: NAACCR, 2022. ©2022, American Cancer Society, Inc., Surveillance and Health Equity']\n",
            "Texts: second-leading cause of cancer death, following lung cancer, among API, American Indian/Alaska Native (AIAN), and White women. Globally, breast cancer hassurpassed lung cancer as the leading cause of cancer death among women.26 Figure 2. Age-specific Female Breast Cancer Incidence Rates byRace/Ethnicity, US, 2015-2019Rate per 100,000 Age at diagnosis Note: Rates are per 100,000 and age adjusted to the 2000 US standardpopulation. Race is exclusive of Hispanic origin. Data for American Indians/ Alaska Natives are based onPurchased/Referred Care Delivery Area (PRCDA) counties. Source: NAACCR, 2022. ©2022, American Cancer Society, Inc., Surveillance and Health Equity\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  22\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  23  doc chunk text: ['ScienceWhite Black American Indian/Alaska Native Hispanic Asian/Pacific Islander 0100200300400500 85+ 80-84 75-79 70-74 65-69 60-64 55-59 50-54 45-49 40-44 35-39 30-34 25-29 20-24 Table 2.', 'Age-specific Ten-year Probabilities of Breast Cancer Diagnosis or Death for US Women, 2017-2019 Current ageDiagnosed with invasive breast cancerDying from breast cancer 20 0.1% (1 in', '1,439) <0.1% (1 in 18,029) 30 0.5% (1 in 204) <0.1% (1 in 2,045) 40 1.6% (1 in 63) 0.1% (1 in 674) 50 2.4% (1 in', '41) 0.3% (1 in 324) 60 3.5% (1 in 28) 0.5% (1 in 203) 70 4.1% (1 in 24) 0.7% (1 in 137) 80 3.0% (1 in', '33) 1.0% (1 in 100) Lifetime risk 12.9% (1 in 8) 2.5% (1 in 39) Note: Probability is among those who have not been']\n",
            "Texts: ScienceWhite Black American Indian/Alaska Native Hispanic Asian/Pacific Islander 0100200300400500 85+ 80-84 75-79 70-74 65-69 60-64 55-59 50-54 45-49 40-44 35-39 30-34 25-29 20-24 Table 2.Age-specific Ten-year Probabilities of Breast Cancer Diagnosis or Death for US Women, 2017-2019 Current ageDiagnosed with invasive breast cancerDying from breast cancer 20 0.1% (1 in1,439) <0.1% (1 in 18,029) 30 0.5% (1 in 204) <0.1% (1 in 2,045) 40 1.6% (1 in 63) 0.1% (1 in 674) 50 2.4% (1 in41) 0.3% (1 in 324) 60 3.5% (1 in 28) 0.5% (1 in 203) 70 4.1% (1 in 24) 0.7% (1 in 137) 80 3.0% (1 in33) 1.0% (1 in 100) Lifetime risk 12.9% (1 in 8) 2.5% (1 in 39) Note: Probability is among those who have not been\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  23\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  24  doc chunk text: ['previously diagnosed with breast cancer and reflects the likelihood of diagnosis/death within 10 years of current age. Percentages and “1 in” numbers may not be', 'numerically equivalent due to rounding. Source: DevCan, Version 6.8.0 ©2022, American Cancer Society, Inc., Surveillance and Health Equity', 'ScienceBreast Cancer Facts & Figures 2022-2024 5What percentage of women are diagnosed with early-stage breast cancer? Two-thirds (66%) of female breast cancer', 'patients in the US are diagnosed with localized-stage disease, when treatment is more likely to be successful and less extensive. Black,', 'Hispanic, and AIAN women are less likely to be diagnosed with localized-stage disease (57%-60%), compared to API and White women (65%-68%) ( Figure 5 ).']\n",
            "Texts: previously diagnosed with breast cancer and reflects the likelihood of diagnosis/death within 10 years of current age. Percentages and “1 in” numbers may not benumerically equivalent due to rounding. Source: DevCan, Version 6.8.0 ©2022, American Cancer Society, Inc., Surveillance and Health EquityScienceBreast Cancer Facts & Figures 2022-2024 5What percentage of women are diagnosed with early-stage breast cancer? Two-thirds (66%) of female breast cancerpatients in the US are diagnosed with localized-stage disease, when treatment is more likely to be successful and less extensive. Black,Hispanic, and AIAN women are less likely to be diagnosed with localized-stage disease (57%-60%), compared to API and White women (65%-68%) ( Figure 5 ).\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  24\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  25  doc chunk text: ['Differences in stage at diagnosis by race/ethnicity reflect inequities in access and quality of breast cancer screening 27 and varying risk of', 'aggressive forms of cancer. How has breast cancer occurrence changed over time? Incidence Breast cancer incidence rates have been increasing in the United States for the', 'past several decades. The rapid rise during the 1980s and 1990s ( Figure 6 ) largely reflects the widespread', 'dissemination and rapid uptake of mammography screening, mostly in women 50 years of age and older.28 From 1980 to 2000, rates of', 'invasive breast cancer increased by nearly 40% among women ages 50 and older (from 275 cases to 380 cases per 100,000), compared to an']\n",
            "Texts: Differences in stage at diagnosis by race/ethnicity reflect inequities in access and quality of breast cancer screening 27 and varying risk ofaggressive forms of cancer. How has breast cancer occurrence changed over time? Incidence Breast cancer incidence rates have been increasing in the United States for thepast several decades. The rapid rise during the 1980s and 1990s ( Figure 6 ) largely reflects the widespreaddissemination and rapid uptake of mammography screening, mostly in women 50 years of age and older.28 From 1980 to 2000, rates ofinvasive breast cancer increased by nearly 40% among women ages 50 and older (from 275 cases to 380 cases per 100,000), compared to an\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  25\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  26  doc chunk text: ['increase of 15% (from 63 to 72 cases per 100,000) among younger women. During the same time period, the diagnosis of DCIS, which is', 'almost exclusively diagnosed during screening mammograms, increased among both women 50 years of age and older (10-fold; from 7 cases to 73 cases per', '100,000) and women ages 20 to 49 years (5-fold; from 3 cases to 15 cases per 100,000). Among women older than 20 years of age, the', 'long-term, steady increase of invasive breast cancer incidence was interrupted by a brief drop in the early 2000s. This decline is likely due to', 'decreased use of menopausal hormone therapy following the 2002 publication of results from a clinical trial that found an']\n",
            "Texts: increase of 15% (from 63 to 72 cases per 100,000) among younger women. During the same time period, the diagnosis of DCIS, which isalmost exclusively diagnosed during screening mammograms, increased among both women 50 years of age and older (10-fold; from 7 cases to 73 cases per100,000) and women ages 20 to 49 years (5-fold; from 3 cases to 15 cases per 100,000). Among women older than 20 years of age, thelong-term, steady increase of invasive breast cancer incidence was interrupted by a brief drop in the early 2000s. This decline is likely due todecreased use of menopausal hormone therapy following the 2002 publication of results from a clinical trial that found an\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  26\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  27  doc chunk text: ['association Note: Rates are per 100,000 and age adjusted to the 2000 US standard population. Race is exclusive of Hispanic origin. *To reduce racial', 'misclassiﬁcation, incidence data are conﬁned to PRCDA counties, while mortality data are for the entire US with adjustment factors for racial', 'misclassiﬁcation applied. (See Sources of Statistics, page 34 ). Sources: Incidence – NAACCR, 2022. Mortality – National Center for Health', 'Statistics (NCHS), Centers for Disease Control and Prevention, 2022. ©2022, American Cancer Society, Inc., Surveillance and Health Equity Science Rate per', '100,000Incidence Mortality 0306090120150 Hispanic Asian/ Pacific IslanderAmerican Indian/ Alaska Native*Black White19.727.6 20.5 11.713.7133.7 127.8 111.3']\n",
            "Texts: association Note: Rates are per 100,000 and age adjusted to the 2000 US standard population. Race is exclusive of Hispanic origin. *To reduce racialmisclassiﬁcation, incidence data are conﬁned to PRCDA counties, while mortality data are for the entire US with adjustment factors for racialmisclassiﬁcation applied. (See Sources of Statistics, page 34 ). Sources: Incidence – NAACCR, 2022. Mortality – National Center for HealthStatistics (NCHS), Centers for Disease Control and Prevention, 2022. ©2022, American Cancer Society, Inc., Surveillance and Health Equity Science Rate per100,000Incidence Mortality 0306090120150 Hispanic Asian/ Pacific IslanderAmerican Indian/ Alaska Native*Black White19.727.6 20.5 11.713.7133.7 127.8 111.3\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  27\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  28  doc chunk text: ['101.399.2Figure 3. Female Breast Cancer Incidence (2015-2019) and Death (2016-2020) Rates by Race/Ethnicity, US HR = hormone receptor; HER2 = human', 'epidermal growth factor receptor 2. Note: Except for all races, race is exclusive of Hispanic origin. Data for American', 'Indians/Alaska Natives are based on Purchased/Referred Care Delivery Area (PRCDA) counties. Source: NAACCR, 2022. ©2022, American Cancer Society, Inc.,', 'Surveillance and Health Equity Science PercentFigure 4. Distribution of Breast Cancer Subtypes by Race/Ethnicity, Ages 20 and Older, US 2015-2019', '020406080100 Hispanic American Indian/ Alaska NativeAsian/ Pacific IslanderBlack White All Races681048 10 719497 6612697 631151110 66105119']\n",
            "Texts: 101.399.2Figure 3. Female Breast Cancer Incidence (2015-2019) and Death (2016-2020) Rates by Race/Ethnicity, US HR = hormone receptor; HER2 = humanepidermal growth factor receptor 2. Note: Except for all races, race is exclusive of Hispanic origin. Data for AmericanIndians/Alaska Natives are based on Purchased/Referred Care Delivery Area (PRCDA) counties. Source: NAACCR, 2022. ©2022, American Cancer Society, Inc.,Surveillance and Health Equity Science PercentFigure 4. Distribution of Breast Cancer Subtypes by Race/Ethnicity, Ages 20 and Older, US 2015-2019020406080100 Hispanic American Indian/ Alaska NativeAsian/ Pacific IslanderBlack White All Races681048 10 719497 6612697 631151110 66105119\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  28\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  29  doc chunk text: ['57105198HR+/HER2- HR+/HER2+HR-/HER2+HR-/HER2- Unknown6 Breast Cancer Facts & Figures 2022-2024between use of estrogen and progestin therapy and increased risk of breast', 'cancer.29, 30 After 2004, invasive breast cancer incidence began to increase again steadily. During the most recent decade of data', '(2010-2019), invasive breast cancer incidence rose by 0.4% per year among women older than 50 and 1% per year among women ages 20-49 years', 'compared to declines in DCIS of 0.7% and 0.8% per year in each age group, respectively. The increase in invasive breast cancer is', 'largely driven by hormone-receptor positive cancer, a disease that is more easily detected by screening and less aggressive compared to other']\n",
            "Texts: 57105198HR+/HER2- HR+/HER2+HR-/HER2+HR-/HER2- Unknown6 Breast Cancer Facts & Figures 2022-2024between use of estrogen and progestin therapy and increased risk of breastcancer.29, 30 After 2004, invasive breast cancer incidence began to increase again steadily. During the most recent decade of data(2010-2019), invasive breast cancer incidence rose by 0.4% per year among women older than 50 and 1% per year among women ages 20-49 yearscompared to declines in DCIS of 0.7% and 0.8% per year in each age group, respectively. The increase in invasive breast cancer islargely driven by hormone-receptor positive cancer, a disease that is more easily detected by screening and less aggressive compared to other\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  29\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  30  doc chunk text: ['subtypes. Behavioral risk factors for hormone- receptor positive breast cancer include no childbirths, older age at first birth, excess body weight', '(postmenopausal), physical inactivity, and alcohol consumption, all of which have been increasing in the US.31, 32', 'Race/Ethnicity Figure 7 presents trends in invasive female breast cancer incidence by race and ethnicity since 2000. (The shorter time period compared to Figure 6', 'allows for greater population coverage, 48% versus 9%). During the most recent 5 years of available data (2015-2019), breast cancer incidence rates', 'increased among all racial and ethnic groups, with a faster pace among API (2.1% per year), AIAN (2.0% per year), and Hispanic (1.4% per year)']\n",
            "Texts: subtypes. Behavioral risk factors for hormone- receptor positive breast cancer include no childbirths, older age at first birth, excess body weight(postmenopausal), physical inactivity, and alcohol consumption, all of which have been increasing in the US.31, 32Race/Ethnicity Figure 7 presents trends in invasive female breast cancer incidence by race and ethnicity since 2000. (The shorter time period compared to Figure 6allows for greater population coverage, 48% versus 9%). During the most recent 5 years of available data (2015-2019), breast cancer incidence ratesincreased among all racial and ethnic groups, with a faster pace among API (2.1% per year), AIAN (2.0% per year), and Hispanic (1.4% per year)\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  30\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  31  doc chunk text: ['women than White (0.5% per year) and Black (0.7% per year) women. Stage The increase in breast cancer incidence is largely driven by', 'localized-stage disease, which increased by 0.9% annually from 2015 to 2019. Regional-stage disease decreased by 0.7% annually, and', 'distant-stage disease increased by 0.9% annually, from 7.3 per 100,000 in 2015 to 7.7 per 100,000 in 2019. Mortality The overall breast cancer death rate', 'increased by 0.4% per year from 1975 to 1989, but since has decreased steadily, for a total decline of 43% through 2020. As a', 'result, 460,000 breast cancer deaths were averted in US women from 1989 through 2020. The decline in breast cancer mortality has been']\n",
            "Texts: women than White (0.5% per year) and Black (0.7% per year) women. Stage The increase in breast cancer incidence is largely driven bylocalized-stage disease, which increased by 0.9% annually from 2015 to 2019. Regional-stage disease decreased by 0.7% annually, anddistant-stage disease increased by 0.9% annually, from 7.3 per 100,000 in 2015 to 7.7 per 100,000 in 2019. Mortality The overall breast cancer death rateincreased by 0.4% per year from 1975 to 1989, but since has decreased steadily, for a total decline of 43% through 2020. As aresult, 460,000 breast cancer deaths were averted in US women from 1989 through 2020. The decline in breast cancer mortality has been\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  31\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  32  doc chunk text: ['attributed to better and more targeted treatment and earlier detection.33-35 The decline in breast cancer mortality has slowed slightly in the most recent time', 'period, from an annual decrease of 1.9% during 2002-2011 to 1.3% during 2011-2020. Breast cancer death rates declined in Hispanic, Black, and White women by 1% to', '1.4% per year, in API women by 0.6% per year, and were stable among AIAN women ( Figure 8 ).', 'Race/Ethnicity All women have not benefited equally from advancements in breast cancer early detection and treatment, as indicated by the striking', 'divergence in mortality trends between Black and White women beginning in the early 1980s ( Figure 8 ). This disparity also likely']\n",
            "Texts: attributed to better and more targeted treatment and earlier detection.33-35 The decline in breast cancer mortality has slowed slightly in the most recent timeperiod, from an annual decrease of 1.9% during 2002-2011 to 1.3% during 2011-2020. Breast cancer death rates declined in Hispanic, Black, and White women by 1% to1.4% per year, in API women by 0.6% per year, and were stable among AIAN women ( Figure 8 ).Race/Ethnicity All women have not benefited equally from advancements in breast cancer early detection and treatment, as indicated by the strikingdivergence in mortality trends between Black and White women beginning in the early 1980s ( Figure 8 ). This disparity also likely\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  32\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  33  doc chunk text: ['reflects a combination of factors, including later stage at diagnosis, higher rates of unfavorable tumor', 'characteristics (e.g., TNBC), and higher prevalence of other health conditions among Black women. These inequities are largely underpinned by less access to', 'high-quality health care across the cancer continuum from prevention to treatment because of longstanding systemic racism and its impact on the social', 'determinants of health, such as Note: Race is exclusive of Hispanic origin. Estimates may not sum to 100 due to rounding. Data for', 'American Indians/Alaska Natives are based on Purchased/ Referred Care Delivery Area (PRCDA) counties. Source: NAACCR, 2022. ©2022, American Cancer Society, Inc.,']\n",
            "Texts: reflects a combination of factors, including later stage at diagnosis, higher rates of unfavorable tumorcharacteristics (e.g., TNBC), and higher prevalence of other health conditions among Black women. These inequities are largely underpinned by less access tohigh-quality health care across the cancer continuum from prevention to treatment because of longstanding systemic racism and its impact on the socialdeterminants of health, such as Note: Race is exclusive of Hispanic origin. Estimates may not sum to 100 due to rounding. Data forAmerican Indians/Alaska Natives are based on Purchased/ Referred Care Delivery Area (PRCDA) counties. Source: NAACCR, 2022. ©2022, American Cancer Society, Inc.,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  33\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  34  doc chunk text: ['Surveillance and Health Equity Science PercentDistant Unknown Regional Localized', '0102030405060708090100 Hispanic American Indian/ Alaska NativeAsian/ Pacific IslanderBlack White24 31 57683 53 8 27 652 5 29 604 7 31 604 6Figure 5. Female', 'Breast Cancer Stage Distribution, by Race/Ethnicity, Ages 20 and Older, US, 2015-2019 Breast Cancer Facts & Figures 2022-2024 7health insurance', 'coverage.36-39 Although national screening rates are similar between White and Black women, Black women are more likely to be screened at lower', 'resourced and nonaccredited facilities and also to experience longer intervals between mammograms and between abnormal results and']\n",
            "Texts: Surveillance and Health Equity Science PercentDistant Unknown Regional Localized0102030405060708090100 Hispanic American Indian/ Alaska NativeAsian/ Pacific IslanderBlack White24 31 57683 53 8 27 652 5 29 604 7 31 604 6Figure 5. FemaleBreast Cancer Stage Distribution, by Race/Ethnicity, Ages 20 and Older, US, 2015-2019 Breast Cancer Facts & Figures 2022-2024 7health insurancecoverage.36-39 Although national screening rates are similar between White and Black women, Black women are more likely to be screened at lowerresourced and nonaccredited facilities and also to experience longer intervals between mammograms and between abnormal results and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  34\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  35  doc chunk text: ['follow-up.27, 40-42 The Black- White breast cancer mortality disparity continued to widen through the 2000s as breast cancer treatment improved, peaking in 2011 with rates in', 'Black women 44% higher than those in Whites. In the most recent period (2016-2020), the breast cancer death rate was 40% higher in Black women', 'versus White women ( Figure 3 ). Are there geographic differences in breast cancer rates? Table 3 shows variation in', 'state-level breast cancer incidence and death rates by race/ethnicity. Although the national incidence rate for breast cancer remains slightly higher in White women', 'compared to Black women, rates are higher in Black women in 4 of the 42 states with sufficient data (Alabama,']\n",
            "Texts: follow-up.27, 40-42 The Black- White breast cancer mortality disparity continued to widen through the 2000s as breast cancer treatment improved, peaking in 2011 with rates inBlack women 44% higher than those in Whites. In the most recent period (2016-2020), the breast cancer death rate was 40% higher in Black womenversus White women ( Figure 3 ). Are there geographic differences in breast cancer rates? Table 3 shows variation instate-level breast cancer incidence and death rates by race/ethnicity. Although the national incidence rate for breast cancer remains slightly higher in White womencompared to Black women, rates are higher in Black women in 4 of the 42 states with sufficient data (Alabama,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  35\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  36  doc chunk text: ['Louisiana, Mississippi, and Virginia), and are not statistically different in 21 other states and the District of Columbia. Figure 6. Trends in', 'Incidence Rates of Ductal Carcinoma In Situ (DCIS) and Invasive Female Breast Cancer by Age, US, 1975-2019 a. DCIS YearRate per', '100,000b. Invasive YearRate per 100,000 Note: Rates are age adjusted to the 2000 US standard population. Rates for invasive breast cancer are', 'adjusted for delays in reporting. Source: Surveillance, Epidemiology, and End Results (SEER) Program, SEER 8 Registries, National Cancer Institute, 2022. ©2022, American Cancer', 'Society, Inc., Surveillance and Health Equity']\n",
            "Texts: Louisiana, Mississippi, and Virginia), and are not statistically different in 21 other states and the District of Columbia. Figure 6. Trends inIncidence Rates of Ductal Carcinoma In Situ (DCIS) and Invasive Female Breast Cancer by Age, US, 1975-2019 a. DCIS YearRate per100,000b. Invasive YearRate per 100,000 Note: Rates are age adjusted to the 2000 US standard population. Rates for invasive breast cancer areadjusted for delays in reporting. Source: Surveillance, Epidemiology, and End Results (SEER) Program, SEER 8 Registries, National Cancer Institute, 2022. ©2022, American CancerSociety, Inc., Surveillance and Health Equity\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  36\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  37  doc chunk text: ['Science050100150200250300350400 2015 2010 2005 2000 1995 1990 1985 1980', '19750102030405060708090 2015 2010 2005 2000 1995 1990 1985 1980 1975Ages 20+ Ages 20-49 Ages 50+ Figure 7. Trends in Female Breast Cancer', 'Incidence Rates by Race/Ethnicity, US, 2000-2019 Rate per 100,000 Year Note: Rates are per 100,000 and age adjusted to 2000 US standard', 'population and adjusted for delays in reporting. Race is exclusive of Hispanic origin. Data for American', 'Indians/Alaska Natives are based on Purchased/Referred Care Delivery Area (PRCDA) counties. Source: SEER Program, SEER 22 Registries, National Cancer Institute, 2022. ©2022,']\n",
            "Texts: Science050100150200250300350400 2015 2010 2005 2000 1995 1990 1985 198019750102030405060708090 2015 2010 2005 2000 1995 1990 1985 1980 1975Ages 20+ Ages 20-49 Ages 50+ Figure 7. Trends in Female Breast CancerIncidence Rates by Race/Ethnicity, US, 2000-2019 Rate per 100,000 Year Note: Rates are per 100,000 and age adjusted to 2000 US standardpopulation and adjusted for delays in reporting. Race is exclusive of Hispanic origin. Data for AmericanIndians/Alaska Natives are based on Purchased/Referred Care Delivery Area (PRCDA) counties. Source: SEER Program, SEER 22 Registries, National Cancer Institute, 2022. ©2022,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  37\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  38  doc chunk text: ['American Cancer Society, Inc., Surveillance and Health Equity ScienceWhite Black American Indian/Alaska Native Asian/Pacific Islander Hispanic', '020406080100120140160 2018 2015 2012 2009 2006 2003 2000 8 Breast Cancer Facts & Figures 2022-2024Table 3. Female Breast Cancer Incidence and Death Rates by', 'Race/Ethnicity and State Incidence Rates (2015-2019) Death Rates (2016-2020) State White Black HispanicAsian/ Pacific Islander White Black', 'HispanicAsian/ Pacific Islander Alabama 121.9 128.0 56.6 80.7 19.4 26.6 * * Alaska 122.4 98.2 133.0 80.1 17.0 * * * Arizona 124.0 104.0 95.1 85.0', '18.8 28.1 14.5 13.8 Arkansas 121.0 123.9 94.2 106.7 18.7 27.6 * * California 138.9 126.1 96.5 108.4 21.5 29.3 14.1 13.0']\n",
            "Texts: American Cancer Society, Inc., Surveillance and Health Equity ScienceWhite Black American Indian/Alaska Native Asian/Pacific Islander Hispanic020406080100120140160 2018 2015 2012 2009 2006 2003 2000 8 Breast Cancer Facts & Figures 2022-2024Table 3. Female Breast Cancer Incidence and Death Rates byRace/Ethnicity and State Incidence Rates (2015-2019) Death Rates (2016-2020) State White Black HispanicAsian/ Pacific Islander White BlackHispanicAsian/ Pacific Islander Alabama 121.9 128.0 56.6 80.7 19.4 26.6 * * Alaska 122.4 98.2 133.0 80.1 17.0 * * * Arizona 124.0 104.0 95.1 85.018.8 28.1 14.5 13.8 Arkansas 121.0 123.9 94.2 106.7 18.7 27.6 * * California 138.9 126.1 96.5 108.4 21.5 29.3 14.1 13.0\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  38\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  39  doc chunk text: ['Colorado 135.3 119.5 108.5 89.3 19.2 24.9 16.4 8.4 Connecticut 145.5 132.2 123.8 88.8 17.5 24.0 11.4 7.7 Delaware 138.2 139.6 101.9 99.6 20.4 26.8 * *', 'District of Columbia 145.4 137.9 80.3 82.4 15.6 31.0 * * Florida 127.9 112.9 106.8 79.3 18.9 25.3 13.5 11.2 Georgia 130.0 132.0 114.8 94.9 18.9', '27.0 11.3 11.8 Hawaii 139.2 126.3 165.1 141.3 21.1 * 23.7 14.5 Idaho 130.7 * 105.6 104.9 20.8 * 7.7 * Illinois 139.2 136.6 101.7', '105.5 20.0 31.6 11.6 11.0 Indiana 125.8 122.2 95.4 88.0 20.2 28.7 12.5 * Iowa 137.1 133.1 72.5 94.3 18.2 19.5 12.4 * Kansas 134.9', '130.3 96.7 81.6 19.7 26.5 14.6 * Kentucky 128.7 132.9 96.2 73.7 21.6 26.7 * * Louisiana 128.2 135.6 91.7 85.3 20.2 29.1 11.3 *']\n",
            "Texts: Colorado 135.3 119.5 108.5 89.3 19.2 24.9 16.4 8.4 Connecticut 145.5 132.2 123.8 88.8 17.5 24.0 11.4 7.7 Delaware 138.2 139.6 101.9 99.6 20.4 26.8 * *District of Columbia 145.4 137.9 80.3 82.4 15.6 31.0 * * Florida 127.9 112.9 106.8 79.3 18.9 25.3 13.5 11.2 Georgia 130.0 132.0 114.8 94.9 18.927.0 11.3 11.8 Hawaii 139.2 126.3 165.1 141.3 21.1 * 23.7 14.5 Idaho 130.7 * 105.6 104.9 20.8 * 7.7 * Illinois 139.2 136.6 101.7105.5 20.0 31.6 11.6 11.0 Indiana 125.8 122.2 95.4 88.0 20.2 28.7 12.5 * Iowa 137.1 133.1 72.5 94.3 18.2 19.5 12.4 * Kansas 134.9130.3 96.7 81.6 19.7 26.5 14.6 * Kentucky 128.7 132.9 96.2 73.7 21.6 26.7 * * Louisiana 128.2 135.6 91.7 85.3 20.2 29.1 11.3 *\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  39\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  40  doc chunk text: ['Maine 128.7 79.4 92.0 69.6 17.7 * * * Maryland 140.9 133.9 88.2 100.1 19.3 27.6 11.2 11.0', 'Massachusetts 142.9 122.4 92.3 96.8 16.6 19.5 11.7 8.6 Michigan 127.0 119.6 73.5 89.1 19.4 28.4 12.6 10.1 Minnesota 139.0 105.6 103.4 82.9 17.5 23.2 9.6 7.6', 'Mississippi 122.0 129.1 49.6 81.0 20.0 30.9 * * Missouri 133.3 133.0 77.1 99.1 19.1 28.4 9.4 9.8 Montana 136.8 * 104.4 94.7 18.0 * * *', 'Nebraska 134.3 121.7 103.3 69.0 20.8 29.5 * * Nevada † 185.5 107.1 77.7 92.9 23.9 31.4 12.1 16.9 New Hampshire 144.3 96.0 121.0 74.8 18.2 * * *', 'New Jersey 148.6 136.0 110.3 106.1 21.1 28.0 12.8 10.3 New Mexico 123.6 114.0 106.4 87.9 22.9 26.0 17.5 * New York 146.1 127.6 109.3']\n",
            "Texts: Maine 128.7 79.4 92.0 69.6 17.7 * * * Maryland 140.9 133.9 88.2 100.1 19.3 27.6 11.2 11.0Massachusetts 142.9 122.4 92.3 96.8 16.6 19.5 11.7 8.6 Michigan 127.0 119.6 73.5 89.1 19.4 28.4 12.6 10.1 Minnesota 139.0 105.6 103.4 82.9 17.5 23.2 9.6 7.6Mississippi 122.0 129.1 49.6 81.0 20.0 30.9 * * Missouri 133.3 133.0 77.1 99.1 19.1 28.4 9.4 9.8 Montana 136.8 * 104.4 94.7 18.0 * * *Nebraska 134.3 121.7 103.3 69.0 20.8 29.5 * * Nevada † 185.5 107.1 77.7 92.9 23.9 31.4 12.1 16.9 New Hampshire 144.3 96.0 121.0 74.8 18.2 * * *New Jersey 148.6 136.0 110.3 106.1 21.1 28.0 12.8 10.3 New Mexico 123.6 114.0 106.4 87.9 22.9 26.0 17.5 * New York 146.1 127.6 109.3\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  40\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  41  doc chunk text: ['106.3 18.8 25.1 12.8 9.7 North Carolina 140.6 136.5 97.5 85.3 18.8 26.3 10.4 8.6 North Dakota 136.1 * * * 17.3 * * * Ohio', '132.8 127.1 71.9 86.2 20.7 27.4 9.0 10.3 Oklahoma 123.4 126.2 91.8 92.4 22.5 28.9 14.6 12.4 Oregon 133.8 110.7 107.3 95.1 19.8 24.4 11.2 12.9', 'Pennsylvania 135.0 127.4 98.9 83.3 19.9 28.8 11.9 8.4 Rhode Island 147.5 121.0 98.5 110.5 17.7 20.7 9.1 * South Carolina 132.9 129.3 88.6 80.6 19.9', '27.6 8.2 10.7 South Dakota 127.8 * 74.1 107.9 18.9 * * * Tennessee 125.1 122.0 91.1 73.0 20.7 29.1 11.6 8.6 Texas 130.1 123.6 93.5', '84.1 20.3 29.0 15.2 12.0 Utah 116.7 96.1 115.4 85.8 20.4 * 14.5 11.2 Vermont 132.6 * * * 16.7 * * *']\n",
            "Texts: 106.3 18.8 25.1 12.8 9.7 North Carolina 140.6 136.5 97.5 85.3 18.8 26.3 10.4 8.6 North Dakota 136.1 * * * 17.3 * * * Ohio132.8 127.1 71.9 86.2 20.7 27.4 9.0 10.3 Oklahoma 123.4 126.2 91.8 92.4 22.5 28.9 14.6 12.4 Oregon 133.8 110.7 107.3 95.1 19.8 24.4 11.2 12.9Pennsylvania 135.0 127.4 98.9 83.3 19.9 28.8 11.9 8.4 Rhode Island 147.5 121.0 98.5 110.5 17.7 20.7 9.1 * South Carolina 132.9 129.3 88.6 80.6 19.927.6 8.2 10.7 South Dakota 127.8 * 74.1 107.9 18.9 * * * Tennessee 125.1 122.0 91.1 73.0 20.7 29.1 11.6 8.6 Texas 130.1 123.6 93.584.1 20.3 29.0 15.2 12.0 Utah 116.7 96.1 115.4 85.8 20.4 * 14.5 11.2 Vermont 132.6 * * * 16.7 * * *\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  41\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  42  doc chunk text: ['Virginia 129.3 132.3 77.9 77.9 20.0 27.9 9.0 10.4 Washington 136.7 112.0 106.5 102.6 20.2 19.1 12.2 11.3 West Virginia 122.2 122.4 70.1 89.9 21.1 30.9 * *', 'Wisconsin 136.7 141.1 94.6 81.1 18.3 26.0 12.7 * Wyoming 115.5 * 83.2 * 18.9 * * * United States 133.7 127.8 99.2 101.3 19.7 27.6', '13.7 11.7 Note: Race is exclusive of Hispanic origin. Rates are per 100,000 and age adjusted to 2000 US standard', 'population. *Statistic not displayed due to fewer than 25 cases or deaths. †Incidence data from this registry did not meet NAACCR', 'high-quality standards and were obtained from Cancer in North America CINA Volumes 2015-2019 , and are not included in the overall US']\n",
            "Texts: Virginia 129.3 132.3 77.9 77.9 20.0 27.9 9.0 10.4 Washington 136.7 112.0 106.5 102.6 20.2 19.1 12.2 11.3 West Virginia 122.2 122.4 70.1 89.9 21.1 30.9 * *Wisconsin 136.7 141.1 94.6 81.1 18.3 26.0 12.7 * Wyoming 115.5 * 83.2 * 18.9 * * * United States 133.7 127.8 99.2 101.3 19.7 27.613.7 11.7 Note: Race is exclusive of Hispanic origin. Rates are per 100,000 and age adjusted to 2000 US standardpopulation. *Statistic not displayed due to fewer than 25 cases or deaths. †Incidence data from this registry did not meet NAACCRhigh-quality standards and were obtained from Cancer in North America CINA Volumes 2015-2019 , and are not included in the overall US\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  42\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  43  doc chunk text: ['incidence rate. US rates also do not include Puerto Rico, which identifies as 99% Hispanic but does not report cancer data by race or', 'ethnicity. In 2015-2019, breast cancer incidence was 98.5 per 100,000 and mortality 17.3 per 100,000 for women in Puerto Rico. Sources:', 'Incidence: NAACCR, 2022. Mortality: NCHS, 2022. ©2022, American Cancer Society, Inc., Surveillance and Health Equity ScienceBreast Cancer Facts & Figures 2022-2024 9In', 'contrast to incidence, breast cancer death rates are higher among Black women than White women in every state except', 'Washington, with rates 50% higher in some states (e.g., Mississippi and Illinois) and two-fold higher in the District of Columbia ( Table 3 ).']\n",
            "Texts: incidence rate. US rates also do not include Puerto Rico, which identifies as 99% Hispanic but does not report cancer data by race orethnicity. In 2015-2019, breast cancer incidence was 98.5 per 100,000 and mortality 17.3 per 100,000 for women in Puerto Rico. Sources:Incidence: NAACCR, 2022. Mortality: NCHS, 2022. ©2022, American Cancer Society, Inc., Surveillance and Health Equity ScienceBreast Cancer Facts & Figures 2022-2024 9Incontrast to incidence, breast cancer death rates are higher among Black women than White women in every state exceptWashington, with rates 50% higher in some states (e.g., Mississippi and Illinois) and two-fold higher in the District of Columbia ( Table 3 ).\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  43\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  44  doc chunk text: ['Breast cancer death rates among API and Hispanic women did not surpass Black or White women in any state. Among White women, rates tend to be', 'highest in the North Central, Mid-Atlantic, and Western regions of the US, whereas among Black women they are highest in some of the South', 'Central and Mid-Atlantic states, as well as California. Factors that contribute to geographic disparities in incidence and mortality include variations in risk factors and', 'access to screening and treatment, which are influenced by socioeconomic status, legislative policies, and distance to medical services.43 Data for AIAN women are too', 'sparse to analyze by state; however, a recent study that examined breast cancer incidence by region found that rates during 2014-2018 were more than']\n",
            "Texts: Breast cancer death rates among API and Hispanic women did not surpass Black or White women in any state. Among White women, rates tend to behighest in the North Central, Mid-Atlantic, and Western regions of the US, whereas among Black women they are highest in some of the SouthCentral and Mid-Atlantic states, as well as California. Factors that contribute to geographic disparities in incidence and mortality include variations in risk factors andaccess to screening and treatment, which are influenced by socioeconomic status, legislative policies, and distance to medical services.43 Data for AIAN women are toosparse to analyze by state; however, a recent study that examined breast cancer incidence by region found that rates during 2014-2018 were more than\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  44\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  45  doc chunk text: ['two-fold higher in the Southern Plains (166.8 per 100,000), where rates were highest, than in the Southwest (69.9 per 100,000), where they were', 'lowest.44Breast cancer survival Relative survival rates are an estimate of the percentage of patients who survive for a given time period (usually 5 years)', 'following cancer diagnosis, after accounting for death from all causes based on the experience of people of the same age who have not been', 'diagnosed with cancer. Relative survival rates should be interpreted with caution because they are based on the average experience of all patients with breast', 'cancer and do not account for individual variation in factors that influence survival, such as excess body weight and other']\n",
            "Texts: two-fold higher in the Southern Plains (166.8 per 100,000), where rates were highest, than in the Southwest (69.9 per 100,000), where they werelowest.44Breast cancer survival Relative survival rates are an estimate of the percentage of patients who survive for a given time period (usually 5 years)following cancer diagnosis, after accounting for death from all causes based on the experience of people of the same age who have not beendiagnosed with cancer. Relative survival rates should be interpreted with caution because they are based on the average experience of all patients with breastcancer and do not account for individual variation in factors that influence survival, such as excess body weight and other\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  45\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  46  doc chunk text: ['illnesses. In addition, long-term survival rates are based on data from patients diagnosed and treated many years ago and thus, do not reflect the most', 'recent improvements in early detection and treatment. Based on the most recent data, overall relative survival rates for women diagnosed with breast cancer are: • 91% at 5', 'years after diagnosis • 84% at 10 years after diagnosis • 80% at 15 years after', 'diagnosisFigure 8. Trends in Female Breast Cancer Death Rates by Race/Ethnicity, US, 1975-2020 Rate per 100,000 Year Note: Rates are per 100,000 and age', 'adjusted to the 2000 US standard population. Race is exclusive of Hispanic origin, except for 1975-1989 for Black and White women. Rates for']\n",
            "Texts: illnesses. In addition, long-term survival rates are based on data from patients diagnosed and treated many years ago and thus, do not reflect the mostrecent improvements in early detection and treatment. Based on the most recent data, overall relative survival rates for women diagnosed with breast cancer are: • 91% at 5years after diagnosis • 84% at 10 years after diagnosis • 80% at 15 years afterdiagnosisFigure 8. Trends in Female Breast Cancer Death Rates by Race/Ethnicity, US, 1975-2020 Rate per 100,000 Year Note: Rates are per 100,000 and ageadjusted to the 2000 US standard population. Race is exclusive of Hispanic origin, except for 1975-1989 for Black and White women. Rates for\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  46\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  47  doc chunk text: ['American Indian/Alaska Native are 3-year moving averages and are adjusted for racial misclassiﬁcation (see Sources of Statistics, page 34 ). Source: NCHS, 2022. ©2022,', 'American Cancer Society, Inc., Surveillance and Health Equity ScienceAmerican Indian/Alaska Native Asian/Pacific IslanderHispanic White Black', '051015202530354045 2020 2015 2010 2005 2000 1995 1990 1985 1980 1975 10 Breast Cancer Facts & Figures 2022-2024 ALAZ ARCOCT DE FLGAID INIA KS KY LAME', 'MDMAMN MSMOMT NENH NJ NMNY NCND OR PARI SCSD TN TXUTVT VAWA WI WY DC AK HIMI Note: Rates are per 100,000 and age', 'adjusted to the 2000 US standard population. Race is exclusive of Hispanic origin. Source: NCHS, 2022. ©2022, American Cancer Society, Inc.,']\n",
            "Texts: American Indian/Alaska Native are 3-year moving averages and are adjusted for racial misclassiﬁcation (see Sources of Statistics, page 34 ). Source: NCHS, 2022. ©2022,American Cancer Society, Inc., Surveillance and Health Equity ScienceAmerican Indian/Alaska Native Asian/Pacific IslanderHispanic White Black051015202530354045 2020 2015 2010 2005 2000 1995 1990 1985 1980 1975 10 Breast Cancer Facts & Figures 2022-2024 ALAZ ARCOCT DE FLGAID INIA KS KY LAMEMDMAMN MSMOMT NENH NJ NMNY NCND OR PARI SCSD TN TXUTVT VAWA WI WY DC AK HIMI Note: Rates are per 100,000 and ageadjusted to the 2000 US standard population. Race is exclusive of Hispanic origin. Source: NCHS, 2022. ©2022, American Cancer Society, Inc.,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  47\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  48  doc chunk text: ['Surveillance and Health Equity ScienceDeaths per 100,000 15.6- 17.7 17.8 - 19.3 19.4 - 20.4 20.5 - 21.6 21.7 - 23.9 Deaths per', '100,000 19.1 - 20.7 20.8 - 25.5 25.6 - 27.6 27.7 - 29.5 29.6 - 31.6 Not available (<25 deaths) ALAZ ARCA COCT DE', 'FLGAID INIA KS KY LAME MDMAMN MSMOMT NENH NJ NMNY NCND OH OKOR PA RI SCSD TN TXUTVT VAWA WVWI WY DC AK', 'HIMIBlack WomenWhite WomenFigure 9. Geographic Variation in Female Breast Cancer Death Rates by Race/Ethnicity, 2016-2020 OH WVIL OKCANV NV IL Breast Cancer Facts &', 'Figures 2022-2024 11Thus, although 5-year cancer survival is often considered “cured,” death can occur well after 5 years. Stage at diagnosis Stage at']\n",
            "Texts: Surveillance and Health Equity ScienceDeaths per 100,000 15.6- 17.7 17.8 - 19.3 19.4 - 20.4 20.5 - 21.6 21.7 - 23.9 Deaths per100,000 19.1 - 20.7 20.8 - 25.5 25.6 - 27.6 27.7 - 29.5 29.6 - 31.6 Not available (<25 deaths) ALAZ ARCA COCT DEFLGAID INIA KS KY LAME MDMAMN MSMOMT NENH NJ NMNY NCND OH OKOR PA RI SCSD TN TXUTVT VAWA WVWI WY DC AKHIMIBlack WomenWhite WomenFigure 9. Geographic Variation in Female Breast Cancer Death Rates by Race/Ethnicity, 2016-2020 OH WVIL OKCANV NV IL Breast Cancer Facts &Figures 2022-2024 11Thus, although 5-year cancer survival is often considered “cured,” death can occur well after 5 years. Stage at diagnosis Stage at\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  48\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  49  doc chunk text: ['diagnosis is one of the most important factors affecting prognosis because treatment is typically more effective when the cancer is less', 'extensive. Five-year relative survival rates for breast cancer are: • 99% for localized disease • 86% for regional disease • 30% for distant', 'disease Breast cancer subtype (HR/HER2) Breast cancer survival also varies by tumor subtype. Five-year relative survival rates are: • 94% for', 'HR+/HER2- • 91% for HR+/HER2+ • 85% for HR-/HER2+ • 77% for HR-/HER2- Importantly, 5-year relative survival is 90% or greater for all', 'subtypes when diagnosed at a localized stage. Race/ethnicity Since the 1970s, breast cancer survival has improved significantly in both Black and White women in the US']\n",
            "Texts: diagnosis is one of the most important factors affecting prognosis because treatment is typically more effective when the cancer is lessextensive. Five-year relative survival rates for breast cancer are: • 99% for localized disease • 86% for regional disease • 30% for distantdisease Breast cancer subtype (HR/HER2) Breast cancer survival also varies by tumor subtype. Five-year relative survival rates are: • 94% forHR+/HER2- • 91% for HR+/HER2+ • 85% for HR-/HER2+ • 77% for HR-/HER2- Importantly, 5-year relative survival is 90% or greater for allsubtypes when diagnosed at a localized stage. Race/ethnicity Since the 1970s, breast cancer survival has improved significantly in both Black and White women in the US\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  49\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  50  doc chunk text: ['(Figure 10 ). However, the most recent data show that progress continues to lag among Black women. The 5-year relative survival rate during', '2012-2018 was only 83% among Black women, compared to 92% among White and API women. Black women have the lowest survival for every stage at', 'diagnosis ( Figure 11 ) and breast cancer subtype compared to women of other racial/ethnic groups. (Importantly, survival rates may be', 'underestimated for Hispanic and API women, who are more likely to be foreign-born, and thus have less complete follow-up', 'information in cancer registry data.45, 46) Thus, in addition to reflecting differences in tumor biology, racial and ethnic disparities in breast cancer']\n",
            "Texts: (Figure 10 ). However, the most recent data show that progress continues to lag among Black women. The 5-year relative survival rate during2012-2018 was only 83% among Black women, compared to 92% among White and API women. Black women have the lowest survival for every stage atdiagnosis ( Figure 11 ) and breast cancer subtype compared to women of other racial/ethnic groups. (Importantly, survival rates may beunderestimated for Hispanic and API women, who are more likely to be foreign-born, and thus have less complete follow-upinformation in cancer registry data.45, 46) Thus, in addition to reflecting differences in tumor biology, racial and ethnic disparities in breast cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  50\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  51  doc chunk text: ['survival also reflect differences in access to care and insurance status, which in turn are associated with a history of', 'structural racism in the US.47-49 A recent study found that among stage IV breast cancer patients, survival disparities between White women and other', 'racial/ethnic groups were no longer present after Medicaid expansion.50 Male breast cancer Breast cancer in men is rare, accounting for less than 1% of', 'breast cancer cases in the US. Male breast cancer incidence was 1.2 cases per 100,000 men during 2015-2019, a rate that has held steady over the', 'past 3 decades. Men are more likely than women to be diagnosed with advanced (regional- or']\n",
            "Texts: survival also reflect differences in access to care and insurance status, which in turn are associated with a history ofstructural racism in the US.47-49 A recent study found that among stage IV breast cancer patients, survival disparities between White women and otherracial/ethnic groups were no longer present after Medicaid expansion.50 Male breast cancer Breast cancer in men is rare, accounting for less than 1% ofbreast cancer cases in the US. Male breast cancer incidence was 1.2 cases per 100,000 men during 2015-2019, a rate that has held steady over thepast 3 decades. Men are more likely than women to be diagnosed with advanced (regional- or\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  51\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  52  doc chunk text: ['distant-stage) breast cancer (49% versus 33%),51 which likely reflects delayed detection due to lack of awareness in addition to the absence of', 'screening.52 The death rate for male breast cancer has decreased slightly from 0.4 (per 100,000) during 1975-1979 to 0.3 (per 100,000) during', '2016-2020 due to improvements in treatment.53 Survival rates for men with breast cancer are lower compared with those of women, possibly', 'reflecting unfavorable stage distribution and limited knowledge about effective treatment.54 Figure 10. Trends in Female Breast Cancer 5-year Relative Survival Rates (%) by Race, US,', '1975-2018Percent 0102030405060708090100 2012- 20182008- 20112005- 20072002- 20041999- 20011996- 19981993- 19951990- 19921987- 19891984- 19861981- 19831978- 19801975- 1977 Year Source: SEER Program, 17 SEER']\n",
            "Texts: distant-stage) breast cancer (49% versus 33%),51 which likely reflects delayed detection due to lack of awareness in addition to the absence ofscreening.52 The death rate for male breast cancer has decreased slightly from 0.4 (per 100,000) during 1975-1979 to 0.3 (per 100,000) during2016-2020 due to improvements in treatment.53 Survival rates for men with breast cancer are lower compared with those of women, possiblyreflecting unfavorable stage distribution and limited knowledge about effective treatment.54 Figure 10. Trends in Female Breast Cancer 5-year Relative Survival Rates (%) by Race, US,1975-2018Percent 0102030405060708090100 2012- 20182008- 20112005- 20072002- 20041999- 20011996- 19981993- 19951990- 19921987- 19891984- 19861981- 19831978- 19801975- 1977 Year Source: SEER Program, 17 SEER\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  52\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  53  doc chunk text: ['registries for 2002-2018, 8 SEER registries for 1975-2001, National Cancer Institute, 2022. SEER 17-based survival rates are exclusive of Hispanic', 'ethnicity. ©2022, American Cancer Society, Inc., Surveillance and Health Equity ScienceWhite Black 92 77 6583 12 Breast Cancer Facts & Figures', '2022-2024Much less is known about breast cancer in men than in women. Similar to women, the incidence of male breast cancer', 'increases with age. Other risk factors include radiation exposure, BRCA1/2 gene variations, family history of breast or ovarian cancer (likely due to genetic', 'predisposition), Klinefelter syndrome, testicular disorders, diabetes, gynecomastia (enlarged breasts), and obesity.55-57 In contrast to women, Black men appear to have the highest breast cancer']\n",
            "Texts: registries for 2002-2018, 8 SEER registries for 1975-2001, National Cancer Institute, 2022. SEER 17-based survival rates are exclusive of Hispanicethnicity. ©2022, American Cancer Society, Inc., Surveillance and Health Equity ScienceWhite Black 92 77 6583 12 Breast Cancer Facts & Figures2022-2024Much less is known about breast cancer in men than in women. Similar to women, the incidence of male breast cancerincreases with age. Other risk factors include radiation exposure, BRCA1/2 gene variations, family history of breast or ovarian cancer (likely due to geneticpredisposition), Klinefelter syndrome, testicular disorders, diabetes, gynecomastia (enlarged breasts), and obesity.55-57 In contrast to women, Black men appear to have the highest breast cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  53\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  54  doc chunk text: ['incidence rates among men, both overall and across molecular subtype.58 Studies suggest that risk factors for breast cancer among women, such as', 'smoking, alcohol consumption, and physical inactivity, do not increase risk in men.59-61 Breast Cancer Risk Factors The most', 'well-established risk factors for breast cancers are summarized in Table 4 . Approximately 30% of postmenopausal breast cancer cases can be', 'attributed to potentially modifiable risk factors, such as excess body weight, physical inactivity, and alcohol consumption.62 Other potentially modifiable factors that', 'influence risk include use of menopausal hormones and breastfeeding.63, 64 Many risk factors affect lifetime exposure of breast tissue to hormones, which are']\n",
            "Texts: incidence rates among men, both overall and across molecular subtype.58 Studies suggest that risk factors for breast cancer among women, such assmoking, alcohol consumption, and physical inactivity, do not increase risk in men.59-61 Breast Cancer Risk Factors The mostwell-established risk factors for breast cancers are summarized in Table 4 . Approximately 30% of postmenopausal breast cancer cases can beattributed to potentially modifiable risk factors, such as excess body weight, physical inactivity, and alcohol consumption.62 Other potentially modifiable factors thatinfluence risk include use of menopausal hormones and breastfeeding.63, 64 Many risk factors affect lifetime exposure of breast tissue to hormones, which are\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  54\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  55  doc chunk text: ['thought to influence breast cancer risk by increasing cell division and thus the likelihood of DNA damage, as well as promoting cancer growth.', 'Although exposures that influence risk accumulate throughout a woman’s life, research suggests that early-life exposures during breast development may be', 'particularly critical.65 Many established risk factors for breast cancer have been consistently associated with HR+/luminal breast cancer; less is known about risk factors for HR-,', 'HER2+, and basal-like breast cancers.66 The following sections present current knowledge about factors associated with breast cancer risk.Note: Race is exclusive of', 'Hispanic origin. Survival rates are based on patients diagnosed during 2012-2018 and followed through 2019. Survival for AIAN individuals is based on']\n",
            "Texts: thought to influence breast cancer risk by increasing cell division and thus the likelihood of DNA damage, as well as promoting cancer growth.Although exposures that influence risk accumulate throughout a woman’s life, research suggests that early-life exposures during breast development may beparticularly critical.65 Many established risk factors for breast cancer have been consistently associated with HR+/luminal breast cancer; less is known about risk factors for HR-,HER2+, and basal-like breast cancers.66 The following sections present current knowledge about factors associated with breast cancer risk.Note: Race is exclusive ofHispanic origin. Survival rates are based on patients diagnosed during 2012-2018 and followed through 2019. Survival for AIAN individuals is based on\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  55\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  56  doc chunk text: ['patients diagnosed in PRCDA counties. Source: SEER Program, 17 SEER registries, National Cancer Institute, 2022. ©2022, American Cancer Society, Inc.,', 'Surveillance and Health Equity SciencePercentFigure 11. Five-year Relative Survival Rates (%) by Stage at Diagnosis and', 'Race/Ethnicity, US, 2012-2018 0102030405060708090100 Unstaged Distant Regional Localized All StagesWhite Black American Indian/Alaska Native Asian/Pacific Islander Hispanic>99 9697 98 98 92 83889092 88 788587 87 32', '213035 355655 486365 Breast Cancer Facts & Figures 2022-2024 13Family history, personal characteristics, and medical history Family history and genetic', 'predisposition Women (and men) with a family history of breast cancer, especially in a first-degree relative (parent, child, or sibling), are at']\n",
            "Texts: patients diagnosed in PRCDA counties. Source: SEER Program, 17 SEER registries, National Cancer Institute, 2022. ©2022, American Cancer Society, Inc.,Surveillance and Health Equity SciencePercentFigure 11. Five-year Relative Survival Rates (%) by Stage at Diagnosis andRace/Ethnicity, US, 2012-2018 0102030405060708090100 Unstaged Distant Regional Localized All StagesWhite Black American Indian/Alaska Native Asian/Pacific Islander Hispanic>99 9697 98 98 92 83889092 88 788587 87 32213035 355655 486365 Breast Cancer Facts & Figures 2022-2024 13Family history, personal characteristics, and medical history Family history and geneticpredisposition Women (and men) with a family history of breast cancer, especially in a first-degree relative (parent, child, or sibling), are at\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  56\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  57  doc chunk text: ['increased risk for the disease. Compared to women without a family history, risk of breast cancer is about 1.5 times higher for women with one', 'affected first-degree female relative and 2-4 times higher for women with more than one first-degree relative.70-72 Risk is further increased when the', 'affected female relative was diagnosed at a young age or was diagnosed with cancer in both breasts, or if the affected relative is male.', 'However, the majority of women with one or more affected first- degree relatives will never develop breast cancer, and most women who develop breast', 'cancer do not have a family history of the disease.70 Women should discuss their family history with their health care provider because it may']\n",
            "Texts: increased risk for the disease. Compared to women without a family history, risk of breast cancer is about 1.5 times higher for women with oneaffected first-degree female relative and 2-4 times higher for women with more than one first-degree relative.70-72 Risk is further increased when theaffected female relative was diagnosed at a young age or was diagnosed with cancer in both breasts, or if the affected relative is male.However, the majority of women with one or more affected first- degree relatives will never develop breast cancer, and most women who develop breastcancer do not have a family history of the disease.70 Women should discuss their family history with their health care provider because it may\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  57\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  58  doc chunk text: ['signal the presence of a genetic predisposition to cancer and the need for individualized screening and risk reduction. For example, a family history of', 'ovarian, endometrial, pancreatic, or prostate cancer, and possibly gastric or biliary cancer, is associated with increased breast cancer risk, at least some of which has a', 'genetic component.68, 73 Inherited pathogenic (disease-causing) genetic variations in BRCA1 and BRCA2 , the most well-studied breast cancer', 'susceptibility genes, account for 5%-10% of all female breast cancers and 15%-20% of all familial breast cancers.74, 75 These variations are rare (about 1 in 400) in', 'the general population, but occur slightly more often in certain ethnic or geographically isolated groups, such as those of Ashkenazi (Eastern']\n",
            "Texts: signal the presence of a genetic predisposition to cancer and the need for individualized screening and risk reduction. For example, a family history ofovarian, endometrial, pancreatic, or prostate cancer, and possibly gastric or biliary cancer, is associated with increased breast cancer risk, at least some of which has agenetic component.68, 73 Inherited pathogenic (disease-causing) genetic variations in BRCA1 and BRCA2 , the most well-studied breast cancersusceptibility genes, account for 5%-10% of all female breast cancers and 15%-20% of all familial breast cancers.74, 75 These variations are rare (about 1 in 400) inthe general population, but occur slightly more often in certain ethnic or geographically isolated groups, such as those of Ashkenazi (Eastern\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  58\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  59  doc chunk text: ['European) Jewish descent (about 1 in 40).76 BRCA1/2 variations may occur more frequently in Black and Hispanic breast cancer patients compared to those who are', 'White,77, 78 although the prevalence of pathogenic variants overall is similar in Black and White women.79, 80 Frequency of genetic testing has', 'historically been lower among Black compared to White women, which previously resulted in misleading information about BRCA mutation patterns by race.81, 82', 'Compared to women in the general population, who have a 10% risk of developing breast cancer by 80 years of age, risk in women with', 'BRCA1/2 variations is estimated to be about 70% by the same age.83 The risk of developing breast cancer by age 70 in women with']\n",
            "Texts: European) Jewish descent (about 1 in 40).76 BRCA1/2 variations may occur more frequently in Black and Hispanic breast cancer patients compared to those who areWhite,77, 78 although the prevalence of pathogenic variants overall is similar in Black and White women.79, 80 Frequency of genetic testing hashistorically been lower among Black compared to White women, which previously resulted in misleading information about BRCA mutation patterns by race.81, 82Compared to women in the general population, who have a 10% risk of developing breast cancer by 80 years of age, risk in women withBRCA1/2 variations is estimated to be about 70% by the same age.83 The risk of developing breast cancer by age 70 in women with\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  59\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  60  doc chunk text: ['variations in PALB2 , a gene related to BRCA2 , is estimated to range from 35% to 53%.84, 85 Inherited', 'variations in other genes are also associated with increased breast cancer risk, including TP53 (associated with Li-Fraumeni syndrome), PTEN (Cowden', 'syndrome/PTEN hamartoma tumor syndrome), STK11 (Peutz-Jeghers syndrome), ATM , CHEK2 , Table 4. Factors That Increase the Relative Risk for Invasive Breast Cancer in Women', 'Relative risk Factor >4.0 Age (65+ versus <65 years, although risk increases across all ages until age 80)', 'Biopsy-confirmed atypical hyperplasia Certain inherited genetic mutations for breast cancer (e.g., BRCA1 , BRCA2 , PALB2 , TP53 ) Lobular neoplasia Personal history of']\n",
            "Texts: variations in PALB2 , a gene related to BRCA2 , is estimated to range from 35% to 53%.84, 85 Inheritedvariations in other genes are also associated with increased breast cancer risk, including TP53 (associated with Li-Fraumeni syndrome), PTEN (Cowdensyndrome/PTEN hamartoma tumor syndrome), STK11 (Peutz-Jeghers syndrome), ATM , CHEK2 , Table 4. Factors That Increase the Relative Risk for Invasive Breast Cancer in WomenRelative risk Factor >4.0 Age (65+ versus <65 years, although risk increases across all ages until age 80)Biopsy-confirmed atypical hyperplasia Certain inherited genetic mutations for breast cancer (e.g., BRCA1 , BRCA2 , PALB2 , TP53 ) Lobular neoplasia Personal history of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  60\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  61  doc chunk text: ['early-onset (<40 years) breast cancer 2.1-4.0 Ductal carcinoma in situ High endogenous estrogen or testosterone levels', '(postmenopausal) High-dose radiation to chest (e.g., Hodgkin lymphoma treatment) Mammographically dense (26% or more) breasts (compared to 11%-25% breast density) Personal history of breast', 'cancer (40+ years) Two or more first-degree relatives with breast cancer 1.1-2.0 Alcohol consumption Early menarche (<11 years) Height (tall) Late age at first', 'full-term pregnancy (>30 years) Late menopause (≥55 years) Never breastfed a child No full-term pregnancies One first-degree relative with breast cancer Obesity', '(postmenopausal) Personal history of endometrium or ovarian cancer Physical inactivity Proliferative breast disease without atypia (usual ductal hyperplasia,']\n",
            "Texts: early-onset (<40 years) breast cancer 2.1-4.0 Ductal carcinoma in situ High endogenous estrogen or testosterone levels(postmenopausal) High-dose radiation to chest (e.g., Hodgkin lymphoma treatment) Mammographically dense (26% or more) breasts (compared to 11%-25% breast density) Personal history of breastcancer (40+ years) Two or more first-degree relatives with breast cancer 1.1-2.0 Alcohol consumption Early menarche (<11 years) Height (tall) Late age at firstfull-term pregnancy (>30 years) Late menopause (≥55 years) Never breastfed a child No full-term pregnancies One first-degree relative with breast cancer Obesity(postmenopausal) Personal history of endometrium or ovarian cancer Physical inactivity Proliferative breast disease without atypia (usual ductal hyperplasia,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  61\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  62  doc chunk text: ['fibroadenoma) Recent and long-term use of menopausal hormone therapy containing estrogen and progestin Recent hormonal contraceptive use Type 2 diabetes Weight gain in', 'adulthood Note: Relative risks for some factors vary by breast cancer molecular subtype. ©2022, American Cancer Society, Inc.,', 'Surveillance and Health Equity Science14 Breast Cancer Facts & Figures 2022-2024and CDH1 (associated with diffuse gastric and lobular breast cancer', 'syndrome). In addition, there are 300-plus more common genetic variants that are associated with a slightly elevated risk, ranging from a lifetime risk of 10% to', '50%.86-88 Genetic variations are often associated with specific molecular subtypes.89 For example, women with BRCA1/2 variations are more likely than the general']\n",
            "Texts: fibroadenoma) Recent and long-term use of menopausal hormone therapy containing estrogen and progestin Recent hormonal contraceptive use Type 2 diabetes Weight gain inadulthood Note: Relative risks for some factors vary by breast cancer molecular subtype. ©2022, American Cancer Society, Inc.,Surveillance and Health Equity Science14 Breast Cancer Facts & Figures 2022-2024and CDH1 (associated with diffuse gastric and lobular breast cancersyndrome). In addition, there are 300-plus more common genetic variants that are associated with a slightly elevated risk, ranging from a lifetime risk of 10% to50%.86-88 Genetic variations are often associated with specific molecular subtypes.89 For example, women with BRCA1/2 variations are more likely than the general\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  62\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  63  doc chunk text: ['population to be diagnosed with triple-negative disease, with the highest risk among BRCA1 variation carriers.90 Variations in ATM and CHEK2 are more', 'commonly associated with ER+ breast cancer.86, 89 The US Preventive Services Task Force recommends that primary care providers routinely collect and update family', 'medical history, as well as ancestry. Women with a personal or family history of breast, ovarian, tubal, or primary peritoneal cancer or those with', 'ancestry associated with BRCA1/2 gene variations should be screened with one of several brief questionnaires to determine if there is a need for', 'genetic counseling.91, 92 Genetic counseling is strongly encouraged to help in the decision making about testing so that the benefits and']\n",
            "Texts: population to be diagnosed with triple-negative disease, with the highest risk among BRCA1 variation carriers.90 Variations in ATM and CHEK2 are morecommonly associated with ER+ breast cancer.86, 89 The US Preventive Services Task Force recommends that primary care providers routinely collect and update familymedical history, as well as ancestry. Women with a personal or family history of breast, ovarian, tubal, or primary peritoneal cancer or those withancestry associated with BRCA1/2 gene variations should be screened with one of several brief questionnaires to determine if there is a need forgenetic counseling.91, 92 Genetic counseling is strongly encouraged to help in the decision making about testing so that the benefits and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  63\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  64  doc chunk text: ['potential consequences can be understood and carefully considered. Personal history of breast cancer About 5% of breast cancer survivors will develop a new breast', 'cancer (also referred to as a subsequent primary breast cancer), with 70% of these occurring in the opposite', '(contralateral) breast.93, 94 One population-based study found that Black and Hispanic breast cancer survivors have a 44% and 11% higher risk,', 'respectively, of developing subsequent contralateral breast cancer compared to Whites.95 Notably, the incidence of contralateral breast cancer has been declining steadily since 1985,96', 'predominantly among ER+ breast cancer survivors. This may reflect advances in hormone therapy (i.e., tamoxifen and aromatase inhibitors) and other adjuvant']\n",
            "Texts: potential consequences can be understood and carefully considered. Personal history of breast cancer About 5% of breast cancer survivors will develop a new breastcancer (also referred to as a subsequent primary breast cancer), with 70% of these occurring in the opposite(contralateral) breast.93, 94 One population-based study found that Black and Hispanic breast cancer survivors have a 44% and 11% higher risk,respectively, of developing subsequent contralateral breast cancer compared to Whites.95 Notably, the incidence of contralateral breast cancer has been declining steadily since 1985,96predominantly among ER+ breast cancer survivors. This may reflect advances in hormone therapy (i.e., tamoxifen and aromatase inhibitors) and other adjuvant\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  64\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  65  doc chunk text: ['treatments used to lower risk of breast cancer recurrence, as well as steep increases in the election of bilateral mastectomy for breast cancer', 'treatment (see page 26).94, 97, 98What is the difference between absolute, lifetime, and relative risk? Absolute risk is the likelihood of being', 'diagnosed with cancer over a certain period of time. For example, the absolute risk of breast cancer increases with age: 13 out of 10,000 women ages', '40-44 versus 23 out of 10,000 women ages 50-54 will be diagnosed with breast cancer in the next year.67 Lifetime risk is the', 'absolute risk of being diagnosed with cancer anytime between birth and death. Lifetime risk of breast cancer reflects the average']\n",
            "Texts: treatments used to lower risk of breast cancer recurrence, as well as steep increases in the election of bilateral mastectomy for breast cancertreatment (see page 26).94, 97, 98What is the difference between absolute, lifetime, and relative risk? Absolute risk is the likelihood of beingdiagnosed with cancer over a certain period of time. For example, the absolute risk of breast cancer increases with age: 13 out of 10,000 women ages40-44 versus 23 out of 10,000 women ages 50-54 will be diagnosed with breast cancer in the next year.67 Lifetime risk is theabsolute risk of being diagnosed with cancer anytime between birth and death. Lifetime risk of breast cancer reflects the average\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  65\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  66  doc chunk text: ['probability of a female being diagnosed with breast cancer in the US. A woman living in the US has a 13% chance of being', 'diagnosed with invasive breast cancer in her lifetime (Table 2 ). Another way to say this is that 1 out of every 8 women will be', 'diagnosed with breast cancer in her lifetime. However, it is important to keep in mind that risk varies', 'substantially based on individual factors. Relative risk compares the absolute risk of disease among people with a particular exposure to the risk among people', 'without that exposure. If the relative risk is above 1.0, then risk is higher among those with the exposure than without it, whereas if the']\n",
            "Texts: probability of a female being diagnosed with breast cancer in the US. A woman living in the US has a 13% chance of beingdiagnosed with invasive breast cancer in her lifetime (Table 2 ). Another way to say this is that 1 out of every 8 women will bediagnosed with breast cancer in her lifetime. However, it is important to keep in mind that risk variessubstantially based on individual factors. Relative risk compares the absolute risk of disease among people with a particular exposure to the risk among peoplewithout that exposure. If the relative risk is above 1.0, then risk is higher among those with the exposure than without it, whereas if the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  66\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  67  doc chunk text: ['relative risk is below 1.0, the exposure reduces the risk of disease. For example, one study found women ages 50-59 who were current users of', 'combined estrogen and progestin menopausal hormones had a relative risk of developing breast cancer of 1.2, meaning they had a 20% higher risk', 'compared to women who have not used hormone therapy.69 While relative risks are useful for comparisons, they do not provide', 'information about the absolute risk of the exposed group. In fact, when the absolute risk is low, even a large relative risk has little', 'influence. In this example, 27 breast cancers per year would be expected to be diagnosed among 10,000 women ages 50-59 who had never used']\n",
            "Texts: relative risk is below 1.0, the exposure reduces the risk of disease. For example, one study found women ages 50-59 who were current users ofcombined estrogen and progestin menopausal hormones had a relative risk of developing breast cancer of 1.2, meaning they had a 20% higher riskcompared to women who have not used hormone therapy.69 While relative risks are useful for comparisons, they do not provideinformation about the absolute risk of the exposed group. In fact, when the absolute risk is low, even a large relative risk has littleinfluence. In this example, 27 breast cancers per year would be expected to be diagnosed among 10,000 women ages 50-59 who had never used\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  67\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  68  doc chunk text: ['menopausal hormones compared to 33 breast cancers among 10,000 women of the same age who had used estrogen and progestin. Thus, the 20%', 'increased relative risk is the equivalent of 6 additional breast cancers per 10,000 women per year.Breast Cancer Facts & Figures 2022-2024 15DCIS and LCIS DCIS is', 'considered a potential precursor to invasive cancer.99 Similar to women with a prior invasive breast cancer, women diagnosed with DCIS have a small excess risk of', 'developing a new invasive breast cancer that is greatest near the site of DCIS. Although the natural progression is difficult to study because most women with', 'DCIS undergo treatment, a recent study of untreated women found a 10-year risk of invasive breast cancer of 10.5% in the same breast and 3.9% in the']\n",
            "Texts: menopausal hormones compared to 33 breast cancers among 10,000 women of the same age who had used estrogen and progestin. Thus, the 20%increased relative risk is the equivalent of 6 additional breast cancers per 10,000 women per year.Breast Cancer Facts & Figures 2022-2024 15DCIS and LCIS DCIS isconsidered a potential precursor to invasive cancer.99 Similar to women with a prior invasive breast cancer, women diagnosed with DCIS have a small excess risk ofdeveloping a new invasive breast cancer that is greatest near the site of DCIS. Although the natural progression is difficult to study because most women withDCIS undergo treatment, a recent study of untreated women found a 10-year risk of invasive breast cancer of 10.5% in the same breast and 3.9% in the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  68\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  69  doc chunk text: ['opposite breast.6 Invasive cancer may be more likely with ER-positive DCIS.100 In contrast, LCIS is not generally considered a breast cancer', 'precursor, but it is associated with an increased risk of developing breast cancer. Classic LCIS likely reflects', 'hyperproliferative (rapidly growing) breast tissue, evidenced by the comparable risk of developing cancer in either breast regardless of the site where LCIS was', 'detected. The 10- and 20-year risks of being diagnosed with DCIS or an invasive breast cancer after LCIS are 11% and 20%,', 'respectively.101 102 Risk may be higher among Black and Asian women, compared to other racial/ethnic groups.102, 103 Pleomorphic and/or florid LCIS are more']\n",
            "Texts: opposite breast.6 Invasive cancer may be more likely with ER-positive DCIS.100 In contrast, LCIS is not generally considered a breast cancerprecursor, but it is associated with an increased risk of developing breast cancer. Classic LCIS likely reflectshyperproliferative (rapidly growing) breast tissue, evidenced by the comparable risk of developing cancer in either breast regardless of the site where LCIS wasdetected. The 10- and 20-year risks of being diagnosed with DCIS or an invasive breast cancer after LCIS are 11% and 20%,respectively.101 102 Risk may be higher among Black and Asian women, compared to other racial/ethnic groups.102, 103 Pleomorphic and/or florid LCIS are more\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  69\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  70  doc chunk text: ['aggressive subtypes that are linked to a higher risk of invasive cancer than classic LCIS and are often treated as a cancer', 'precursors (similarly to DCIS).104 Benign breast disease Doctors often categorize benign breast conditions into 3 general groups reflecting the associated degree of cancer risk:', 'nonproliferative lesions, proliferative lesions without atypia (abnormal cells or patterns of cells), and proliferative lesions with atypia. •', 'Nonproliferative lesions are not associated with overgrowth of breast tissue and include fibrosis and simple cysts (also known as', 'fibrocystic changes) and mild hyperplasia. Nonproliferative conditions are associated with little to no increased breast cancer risk.105 •']\n",
            "Texts: aggressive subtypes that are linked to a higher risk of invasive cancer than classic LCIS and are often treated as a cancerprecursors (similarly to DCIS).104 Benign breast disease Doctors often categorize benign breast conditions into 3 general groups reflecting the associated degree of cancer risk:nonproliferative lesions, proliferative lesions without atypia (abnormal cells or patterns of cells), and proliferative lesions with atypia. •Nonproliferative lesions are not associated with overgrowth of breast tissue and include fibrosis and simple cysts (also known asfibrocystic changes) and mild hyperplasia. Nonproliferative conditions are associated with little to no increased breast cancer risk.105 •\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  70\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  71  doc chunk text: ['Proliferative lesions without atypia are associated with a small (1.5 to 2 times higher) increased breast cancer risk and include usual ductal', 'hyperplasia (without atypia) and fibroadenoma.105• Proliferative lesions with atypia are associated with about 4 times higher than average breast cancer risk. These include', 'atypical ductal hyperplasia, atypical lobular hyperplasia, and florid epithelial atypia.105, 106 The 15-year risk of developing in situ or invasive breast cancer exceeds 30% in', 'women diagnosed with atypical hyperplasia.106, 107 When atypia is detected in a needle biopsy, a follow-up surgery is usually necessary to rule out a', 'co-existing breast cancer. A recent study found that benign breast disease is also associated with increased risk of interval cancer, which is a breast']\n",
            "Texts: Proliferative lesions without atypia are associated with a small (1.5 to 2 times higher) increased breast cancer risk and include usual ductalhyperplasia (without atypia) and fibroadenoma.105• Proliferative lesions with atypia are associated with about 4 times higher than average breast cancer risk. These includeatypical ductal hyperplasia, atypical lobular hyperplasia, and florid epithelial atypia.105, 106 The 15-year risk of developing in situ or invasive breast cancer exceeds 30% inwomen diagnosed with atypical hyperplasia.106, 107 When atypia is detected in a needle biopsy, a follow-up surgery is usually necessary to rule out aco-existing breast cancer. A recent study found that benign breast disease is also associated with increased risk of interval cancer, which is a breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  71\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  72  doc chunk text: ['cancer diagnosis after a normal routine screening.108 This suggests that benign disease may be associated with', 'faster-growing tumors or that it may decrease screening sensitivity. Women should keep detailed records of any benign breast biopsy results because they are', 'valuable for risk assessment, screening, and counseling for chemoprevention and other risk- reduction strategies. The majority of breast cancers that develop among women with a', 'history of benign breast disease are ER+; however, Black women with a history of the condition are four times more likely than White women to', 'develop triple-negative breast cancer.109 Mammographic breast density Mammographic breast tissue density is determined based on the amount of glandular and']\n",
            "Texts: cancer diagnosis after a normal routine screening.108 This suggests that benign disease may be associated withfaster-growing tumors or that it may decrease screening sensitivity. Women should keep detailed records of any benign breast biopsy results because they arevaluable for risk assessment, screening, and counseling for chemoprevention and other risk- reduction strategies. The majority of breast cancers that develop among women with ahistory of benign breast disease are ER+; however, Black women with a history of the condition are four times more likely than White women todevelop triple-negative breast cancer.109 Mammographic breast density Mammographic breast tissue density is determined based on the amount of glandular and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  72\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  73  doc chunk text: ['connective tissue relative to fatty tissue measured during a mammogram. Breast tissue is categorized according to a standardized system developed by the', 'American College of Radiology called the Breast Imaging-Reporting and Data System (BI-RADS). The categories include A) almost entirely fatty; B) scattered areas of', 'fibroglandular density; C) heterogeneously dense; and D) extremely dense. Women with breasts classified as BI-RADS C or D are referred to as having', '“mammographically dense breasts.” The risk of breast cancer increases with mammographic breast density, and women with BI-RADS C or D have a 1.5 to', '2-fold higher risk of breast cancer compared to those with average density (BI-RADS B).110 High mammographic breast density can also mask the']\n",
            "Texts: connective tissue relative to fatty tissue measured during a mammogram. Breast tissue is categorized according to a standardized system developed by theAmerican College of Radiology called the Breast Imaging-Reporting and Data System (BI-RADS). The categories include A) almost entirely fatty; B) scattered areas offibroglandular density; C) heterogeneously dense; and D) extremely dense. Women with breasts classified as BI-RADS C or D are referred to as having“mammographically dense breasts.” The risk of breast cancer increases with mammographic breast density, and women with BI-RADS C or D have a 1.5 to2-fold higher risk of breast cancer compared to those with average density (BI-RADS B).110 High mammographic breast density can also mask the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  73\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  74  doc chunk text: ['appearance of breast tumors on a mammogram.111, 11216 Breast Cancer Facts & Figures', '2022-2024Mammographic dense breasts are common. About 36% of US women ages 40-74 have heterogeneously dense breasts, and about 7% have extremely dense', 'breasts.113 Breast density is influenced by genetics and other factors and typically decreases with age, higher body weight, and after pregnancy and', 'menopause.114 Some drugs also affect breast density, including tamoxifen (decreases density) and combined menopausal hormone therapy, estrogen and progestin, (increases', 'density).111, 114 In early 2019, Congress passed legislation directing the US Food and Drug Administration to ensure that mammogram reports include']\n",
            "Texts: appearance of breast tumors on a mammogram.111, 11216 Breast Cancer Facts & Figures2022-2024Mammographic dense breasts are common. About 36% of US women ages 40-74 have heterogeneously dense breasts, and about 7% have extremely densebreasts.113 Breast density is influenced by genetics and other factors and typically decreases with age, higher body weight, and after pregnancy andmenopause.114 Some drugs also affect breast density, including tamoxifen (decreases density) and combined menopausal hormone therapy, estrogen and progestin, (increasesdensity).111, 114 In early 2019, Congress passed legislation directing the US Food and Drug Administration to ensure that mammogram reports include\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  74\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  75  doc chunk text: ['information about breast density.115 Thirty-eight states and the District of Columbia have passed some form of breast density', 'legislation. Research has found that additional testing, such as ultrasound or MRI, may improve cancer detection among women with dense breasts, and some state laws', 'require that these women be told they may benefit from these supplement imaging tests.116-119 A recent study found that among women with dense', 'breasts, digital breast tomosynthesis (DBT) screening decreased the need for additional diagnostic imaging and increased cancer detection compared to', 'conventional digital mammography alone.120 See page 22 for more information on DBT. Height Many studies have found that taller women have a higher risk of']\n",
            "Texts: information about breast density.115 Thirty-eight states and the District of Columbia have passed some form of breast densitylegislation. Research has found that additional testing, such as ultrasound or MRI, may improve cancer detection among women with dense breasts, and some state lawsrequire that these women be told they may benefit from these supplement imaging tests.116-119 A recent study found that among women with densebreasts, digital breast tomosynthesis (DBT) screening decreased the need for additional diagnostic imaging and increased cancer detection compared toconventional digital mammography alone.120 See page 22 for more information on DBT. Height Many studies have found that taller women have a higher risk of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  75\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  76  doc chunk text: ['breast cancer than shorter women.121-123 A pooled study of more than 5 million women estimated that every 10 centimeters (about 4 inches)', 'increase in height was associated with a 17% higher risk of breast cancer.122 Although reasons are not fully understood, this may reflect', 'differences in early growth, as well as hormonal or genetic factors. Height is also associated with increased risk for a number of other', 'cancers. Puberty and menstruation Breast cancer risk increases with earlier breast development,124 earlier menstruation, and later', 'menopause.124, 125 Breast cancer risk is about 20% higher among those who begin menstruating before age 11, compared to those who begin at age 14 or']\n",
            "Texts: breast cancer than shorter women.121-123 A pooled study of more than 5 million women estimated that every 10 centimeters (about 4 inches)increase in height was associated with a 17% higher risk of breast cancer.122 Although reasons are not fully understood, this may reflectdifferences in early growth, as well as hormonal or genetic factors. Height is also associated with increased risk for a number of othercancers. Puberty and menstruation Breast cancer risk increases with earlier breast development,124 earlier menstruation, and latermenopause.124, 125 Breast cancer risk is about 20% higher among those who begin menstruating before age 11, compared to those who begin at age 14 or\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  76\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  77  doc chunk text: ['older. Likewise, women who experience menopause at age 55 or older have about a 12% higher risk compared to those who do so', 'between ages 50 and 54.125 The increased risk is likely due to longer lifetime exposure to reproductive hormones and has been more', 'strongly linked to HR+ breast cancer than other subtypes.66 Bone mineral density High bone mineral density in', 'postmenopausal women has been associated with a 60% to 80% increased risk for breast cancer compared to low bone density, which appears to be', 'strongest for HR+ disease.126, 127 Bone density is not thought to be an independent risk factor but rather a marker of']\n",
            "Texts: older. Likewise, women who experience menopause at age 55 or older have about a 12% higher risk compared to those who do sobetween ages 50 and 54.125 The increased risk is likely due to longer lifetime exposure to reproductive hormones and has been morestrongly linked to HR+ breast cancer than other subtypes.66 Bone mineral density High bone mineral density inpostmenopausal women has been associated with a 60% to 80% increased risk for breast cancer compared to low bone density, which appears to bestrongest for HR+ disease.126, 127 Bone density is not thought to be an independent risk factor but rather a marker of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  77\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  78  doc chunk text: ['cumulative estrogen exposure.128, 129 However, routine bone density testing that is often conducted to screen for osteoporosis may help identify women at', 'increased risk of breast cancer. Type 2 diabetes Type 2 diabetes shares several modifiable risk factors with cancer, including excess body weight, poor diet, and lack of', 'physical activity. Evidence suggests that type 2 diabetes independently increases risk for several cancers, including breast cancer.130 A recent', 'prospective study reported a 26% increased risk of breast cancer among women with diabetes compared to those without the disease after', 'controlling for demographic and lifestyle factors and body weight.131 Although early studies of women treated with metformin (the most common drug used to treat']\n",
            "Texts: cumulative estrogen exposure.128, 129 However, routine bone density testing that is often conducted to screen for osteoporosis may help identify women atincreased risk of breast cancer. Type 2 diabetes Type 2 diabetes shares several modifiable risk factors with cancer, including excess body weight, poor diet, and lack ofphysical activity. Evidence suggests that type 2 diabetes independently increases risk for several cancers, including breast cancer.130 A recentprospective study reported a 26% increased risk of breast cancer among women with diabetes compared to those without the disease aftercontrolling for demographic and lifestyle factors and body weight.131 Although early studies of women treated with metformin (the most common drug used to treat\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  78\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  79  doc chunk text: ['diabetes) found it to be associated with decreased breast cancer risk, more recent research is', 'inconclusive.132 Endogenous sex hormones Postmenopausal women with naturally high levels of certain endogenous sex hormones (e.g., estrogen,', 'progesterone) have about twice the risk of developing breast cancer compared to women with the lowest levels, with the strongest', 'association for HR+ tumors.133, 134 High levels of endogenous testosterone also appear to increase breast cancer risk among', 'postmenopausal women.135, 136 High circulating hormone levels are associated with, and may reflect, the effects of other breast cancer risk factors, such as']\n",
            "Texts: diabetes) found it to be associated with decreased breast cancer risk, more recent research isinconclusive.132 Endogenous sex hormones Postmenopausal women with naturally high levels of certain endogenous sex hormones (e.g., estrogen,progesterone) have about twice the risk of developing breast cancer compared to women with the lowest levels, with the strongestassociation for HR+ tumors.133, 134 High levels of endogenous testosterone also appear to increase breast cancer risk amongpostmenopausal women.135, 136 High circulating hormone levels are associated with, and may reflect, the effects of other breast cancer risk factors, such as\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  79\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  80  doc chunk text: ['postmenopausal obesity137 and alcohol use.134 Breast Cancer Facts & Figures 2022-2024 17Although it is challenging to study endogenous hormones in', 'premenopausal women because of variation across the menstrual cycle, there is some evidence that high levels of circulating estrogens and androgens are', 'associated with a small excess risk in premenopausal women, particularly for HR+ breast cancer.134, 138, 139', 'Postmenopausal hormones Use of combined estrogen and progestin hormones after menopause (also referred to as hormone therapy or hormone', 'replacement therapy) increases breast cancer incidence66, 137, 140, 141 and mortality.142, 143 Discontinuation of menopausal hormones diminishes but does not eliminate excess']\n",
            "Texts: postmenopausal obesity137 and alcohol use.134 Breast Cancer Facts & Figures 2022-2024 17Although it is challenging to study endogenous hormones inpremenopausal women because of variation across the menstrual cycle, there is some evidence that high levels of circulating estrogens and androgens areassociated with a small excess risk in premenopausal women, particularly for HR+ breast cancer.134, 138, 139Postmenopausal hormones Use of combined estrogen and progestin hormones after menopause (also referred to as hormone therapy or hormonereplacement therapy) increases breast cancer incidence66, 137, 140, 141 and mortality.142, 143 Discontinuation of menopausal hormones diminishes but does not eliminate excess\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  80\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  81  doc chunk text: ['risk.137, 144 Combined hormone therapy also increases mammographic breast density.111 Postmenopausal estrogen-only therapy increases risk of endometrial cancer and is therefore only', 'prescribed to women who have undergone a hysterectomy. Studies are conflicted about the effect of estrogen-only therapy on breast cancer risk. Clinical trial data', 'indicate a reduction in both breast cancer incidence and mortality143 with estrogen-only therapy, whereas observational studies report an increase in both.137, 142 Reasons for the', 'disagreement may include differences in the age of study participants or study methodology; in the utilization of mammography; and in the timing and', 'duration of hormone use. Gender-affirming hormone therapy Gender-affirming hormone therapy is a medical intervention to help align the']\n",
            "Texts: risk.137, 144 Combined hormone therapy also increases mammographic breast density.111 Postmenopausal estrogen-only therapy increases risk of endometrial cancer and is therefore onlyprescribed to women who have undergone a hysterectomy. Studies are conflicted about the effect of estrogen-only therapy on breast cancer risk. Clinical trial dataindicate a reduction in both breast cancer incidence and mortality143 with estrogen-only therapy, whereas observational studies report an increase in both.137, 142 Reasons for thedisagreement may include differences in the age of study participants or study methodology; in the utilization of mammography; and in the timing andduration of hormone use. Gender-affirming hormone therapy Gender-affirming hormone therapy is a medical intervention to help align the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  81\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  82  doc chunk text: ['characteristics of an individual with their gender identity. Although data are sparse, one long-term retrospective cohort study in the', 'Netherlands found that transgender women who received hormone therapy, including antiandrogens and estrogens, had increased breast cancer risk compared to cisgender men, while both', 'transgender men and women receiving therapy had a lower risk of breast cancer compared to cisgender women.145 There are currently no breast cancer', 'screening recommendations for transgender individuals, so these patients and their health care providers should be aware of the risks associated with', 'exogenous hormones and alert to the signs and symptoms of breast']\n",
            "Texts: characteristics of an individual with their gender identity. Although data are sparse, one long-term retrospective cohort study in theNetherlands found that transgender women who received hormone therapy, including antiandrogens and estrogens, had increased breast cancer risk compared to cisgender men, while bothtransgender men and women receiving therapy had a lower risk of breast cancer compared to cisgender women.145 There are currently no breast cancerscreening recommendations for transgender individuals, so these patients and their health care providers should be aware of the risks associated withexogenous hormones and alert to the signs and symptoms of breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  82\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  83  doc chunk text: ['cancer.Reproductive factors Pregnancy Pregnancy has a dual effect on breast cancer risk.146 In the short term, women who have had a', 'full-term pregnancy have an increased risk of both HR+ and HR- breast cancers that peaks 5 years after childbirth. However, after about two', 'decades, the relative risk of HR+ breast cancer becomes slightly lower (by about 20%-25%) in women who have given birth compared to those who have not.', 'Risk is further reduced among women who have their first child at a younger age or have a greater number of', 'children. In contrast, the increased risk for HR- breast cancer persists following a full-term pregnancy except among women who']\n",
            "Texts: cancer.Reproductive factors Pregnancy Pregnancy has a dual effect on breast cancer risk.146 In the short term, women who have had afull-term pregnancy have an increased risk of both HR+ and HR- breast cancers that peaks 5 years after childbirth. However, after about twodecades, the relative risk of HR+ breast cancer becomes slightly lower (by about 20%-25%) in women who have given birth compared to those who have not.Risk is further reduced among women who have their first child at a younger age or have a greater number ofchildren. In contrast, the increased risk for HR- breast cancer persists following a full-term pregnancy except among women who\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  83\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  84  doc chunk text: ['breastfeed.147 See below for more information on breastfeeding and breast cancer risk. Fertility drugs More research is needed on the', 'relationship between the use of ovulation-stimulating drugs and breast cancer risk.148, 149 Most studies to date have found that breast cancer risk is not', 'elevated in women who undergo in vitro fertilization.150-155 However, the data are less clear for clomiphene (Clomid), a drug that is often used as a', 'first-line treatment for infertility.151, 153, 154 A recent study from Norway found no association between fertility drugs, including clomiphene, and breast cancer risk after 20', 'years of follow- up,155 while other studies have reported an elevated risk for certain subgroups, such as women who underwent more than 12']\n",
            "Texts: breastfeed.147 See below for more information on breastfeeding and breast cancer risk. Fertility drugs More research is needed on therelationship between the use of ovulation-stimulating drugs and breast cancer risk.148, 149 Most studies to date have found that breast cancer risk is notelevated in women who undergo in vitro fertilization.150-155 However, the data are less clear for clomiphene (Clomid), a drug that is often used as afirst-line treatment for infertility.151, 153, 154 A recent study from Norway found no association between fertility drugs, including clomiphene, and breast cancer risk after 20years of follow- up,155 while other studies have reported an elevated risk for certain subgroups, such as women who underwent more than 12\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  84\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  85  doc chunk text: ['clomiphene treatment cycles,153 or who had given birth.154 Breastfeeding Most studies suggest that breastfeeding for a year or more slightly reduces a woman’s', 'overall risk of breast cancer, with longer duration associated with greater reduction. In a review of 47 studies in 30', 'countries, the risk of breast cancer was reduced by 4% for every 12 months of', 'breastfeeding.156 The protective effect may be stronger for, or even limited to, triple-negative cancers.147, 157-15918 Breast Cancer Facts & Figures', '2022-2024Hormonal birth control Most studies have found that current or recent use of oral contraceptives (combined estrogen and']\n",
            "Texts: clomiphene treatment cycles,153 or who had given birth.154 Breastfeeding Most studies suggest that breastfeeding for a year or more slightly reduces a woman’soverall risk of breast cancer, with longer duration associated with greater reduction. In a review of 47 studies in 30countries, the risk of breast cancer was reduced by 4% for every 12 months ofbreastfeeding.156 The protective effect may be stronger for, or even limited to, triple-negative cancers.147, 157-15918 Breast Cancer Facts & Figures2022-2024Hormonal birth control Most studies have found that current or recent use of oral contraceptives (combined estrogen and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  85\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  86  doc chunk text: ['progesterone) is associated with a small (about 20%) relative increase in breast cancer risk, particularly among women who begin use before first', 'pregnancy.160, 161 Results from studies evaluating whether this risk is modified by genetic factors, such as among BRCA variant carriers, are', 'inconsistent.162 Risk appears to diminish when women stop use, and at about 10 years is similar to never-users. Data are limited and less clear for', '“ultra low-dose” (20 micrograms) estrogen formulations.163 Studies of the progestin-only intrauterine device have produced conflicting', 'results,164-167 but a large study from Denmark found that use increases breast cancer risk by about 20%.160 In contrast, the']\n",
            "Texts: progesterone) is associated with a small (about 20%) relative increase in breast cancer risk, particularly among women who begin use before firstpregnancy.160, 161 Results from studies evaluating whether this risk is modified by genetic factors, such as among BRCA variant carriers, areinconsistent.162 Risk appears to diminish when women stop use, and at about 10 years is similar to never-users. Data are limited and less clear for“ultra low-dose” (20 micrograms) estrogen formulations.163 Studies of the progestin-only intrauterine device have produced conflictingresults,164-167 but a large study from Denmark found that use increases breast cancer risk by about 20%.160 In contrast, the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  86\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  87  doc chunk text: ['injectable progestin-only contraceptive depot-medroxyprogesterone acetate (Depo-Provera) does not seem to be linked with breast cancer, although the number of users may be', 'insufficient to detect an association.160, 168 Overall, it has been estimated that one extra breast cancer is diagnosed for every 7,690 women using', 'hormonal contraception for one year.160 Body weight, physical inactivity, diet, alcohol, and tobacco Body weight The risk of', 'postmenopausal HR+ breast cancer is about 1½ to 2 times higher in women who are overweight or obese than in those who are a', 'healthy weight.169 Even within the normal range of BMI (18.5-24.9), higher levels of body fat are associated with increased risk of breast cancer after']\n",
            "Texts: injectable progestin-only contraceptive depot-medroxyprogesterone acetate (Depo-Provera) does not seem to be linked with breast cancer, although the number of users may beinsufficient to detect an association.160, 168 Overall, it has been estimated that one extra breast cancer is diagnosed for every 7,690 women usinghormonal contraception for one year.160 Body weight, physical inactivity, diet, alcohol, and tobacco Body weight The risk ofpostmenopausal HR+ breast cancer is about 1½ to 2 times higher in women who are overweight or obese than in those who are ahealthy weight.169 Even within the normal range of BMI (18.5-24.9), higher levels of body fat are associated with increased risk of breast cancer after\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  87\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  88  doc chunk text: ['menopause.170 This is likely due, in part, to higher estrogen levels because fat tissue is the largest source of estrogen in', 'postmenopausal women, but may also be related to other mechanisms, including higher levels of insulin among heavier', 'women.170-172 Weight gain also increases risk of postmenopausal breast cancer.173, 174 A large meta-analysis found that for each 5 kilograms (about 11 pounds) gained', 'during adulthood, risk of postmenopausal breast cancer increases by 11%.174 The increased risk was only observed among women who did not use', 'menopausal hormones. Weight loss in early adulthood and after menopause is associated with reduced breast cancer risk in some, but not all']\n",
            "Texts: menopause.170 This is likely due, in part, to higher estrogen levels because fat tissue is the largest source of estrogen inpostmenopausal women, but may also be related to other mechanisms, including higher levels of insulin among heavierwomen.170-172 Weight gain also increases risk of postmenopausal breast cancer.173, 174 A large meta-analysis found that for each 5 kilograms (about 11 pounds) gainedduring adulthood, risk of postmenopausal breast cancer increases by 11%.174 The increased risk was only observed among women who did not usemenopausal hormones. Weight loss in early adulthood and after menopause is associated with reduced breast cancer risk in some, but not all\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  88\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  89  doc chunk text: ['studies.171, 172 Weight loss is more difficult to examine because it is often not sustained long term. In contrast, studies have found that excess body', 'weight reduces risk of breast cancer in premenopausal women. One large observational study found that the risk reduction occurred even among heavier women who were', 'classified as a healthy weight and was strongest for the youngest women (ages 18 to 24) and for HR+ tumors.175 The', 'underlying mechanisms for this inverse relationship are not well understood, but may be related to interrupted menstrual cycles and lower estrogen levels', 'associated with excess body weight among premenopausal women.176, 177 Physical inactivity Women who get regular physical activity have a 10%-20% lower risk of breast']\n",
            "Texts: studies.171, 172 Weight loss is more difficult to examine because it is often not sustained long term. In contrast, studies have found that excess bodyweight reduces risk of breast cancer in premenopausal women. One large observational study found that the risk reduction occurred even among heavier women who wereclassified as a healthy weight and was strongest for the youngest women (ages 18 to 24) and for HR+ tumors.175 Theunderlying mechanisms for this inverse relationship are not well understood, but may be related to interrupted menstrual cycles and lower estrogen levelsassociated with excess body weight among premenopausal women.176, 177 Physical inactivity Women who get regular physical activity have a 10%-20% lower risk of breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  89\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  90  doc chunk text: ['cancer compared to women who are inactive, with greater risk reduction associated with increasing levels of', 'activity.178-182 The protective effect is likely independent of BMI and may be limited to women who have never used menopausal hormone', 'therapy.181, 182 The benefit may be due to the effects of physical activity on systemic inflammation, hormone levels, and energy', 'balance.181, 183 Diet Numerous studies have examined the relationship between food consumption (including fat, fiber, soy, dairy, meat, and fruits and', 'vegetables) and breast cancer, with mixed results. A limitation of most of these studies is that they are based on']\n",
            "Texts: cancer compared to women who are inactive, with greater risk reduction associated with increasing levels ofactivity.178-182 The protective effect is likely independent of BMI and may be limited to women who have never used menopausal hormonetherapy.181, 182 The benefit may be due to the effects of physical activity on systemic inflammation, hormone levels, and energybalance.181, 183 Diet Numerous studies have examined the relationship between food consumption (including fat, fiber, soy, dairy, meat, and fruits andvegetables) and breast cancer, with mixed results. A limitation of most of these studies is that they are based on\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  90\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  91  doc chunk text: ['self-reported information in food frequency questionnaires. A meta-analysis concluded there was no association between breast cancer risk and overall dietary fat', 'consumption, but was suggestive of differences by fat type,184 similar to findings of other studies.185-187 It has been suggested that soy', 'consumption may reduce breast cancer risk, in part because of historically low breast cancer rates among Asian women, who have a diet high in soy.', 'Another meta-analysis showed that soy intake was inversely associated with breast cancer risk in Asian but not Western', 'populations, perhaps because Asian women generally consume more soy Breast Cancer Facts & Figures 2022-2024 19products beginning at an earlier age than Western']\n",
            "Texts: self-reported information in food frequency questionnaires. A meta-analysis concluded there was no association between breast cancer risk and overall dietary fatconsumption, but was suggestive of differences by fat type,184 similar to findings of other studies.185-187 It has been suggested that soyconsumption may reduce breast cancer risk, in part because of historically low breast cancer rates among Asian women, who have a diet high in soy.Another meta-analysis showed that soy intake was inversely associated with breast cancer risk in Asian but not Westernpopulations, perhaps because Asian women generally consume more soy Breast Cancer Facts & Figures 2022-2024 19products beginning at an earlier age than Western\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  91\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  92  doc chunk text: ['women.188 Further, a recent cohort study among women in the US found no association between soy consumption and breast cancer.189 There is limited but', 'growing evidence that high levels of fruit and/or vegetable consumption may reduce the risk of HR- breast', 'cancer.190-192 These findings are supported by studies linking lower breast cancer risk to higher blood levels of carotenoids', '(micronutrients found in fruits and vegetables).193-196 Some studies also suggest that calcium-rich diets may be linked to a lower risk of breast', 'cancer,191 although a pooled analysis of over 1 million women found no association.197 The effect of diet on breast cancer risk remains an active area of']\n",
            "Texts: women.188 Further, a recent cohort study among women in the US found no association between soy consumption and breast cancer.189 There is limited butgrowing evidence that high levels of fruit and/or vegetable consumption may reduce the risk of HR- breastcancer.190-192 These findings are supported by studies linking lower breast cancer risk to higher blood levels of carotenoids(micronutrients found in fruits and vegetables).193-196 Some studies also suggest that calcium-rich diets may be linked to a lower risk of breastcancer,191 although a pooled analysis of over 1 million women found no association.197 The effect of diet on breast cancer risk remains an active area of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  92\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  93  doc chunk text: ['research, with studies particularly focused on the timing of exposure, specific dietary components, and risk differences by cancer subtype. Alcohol Alcohol is', 'estimated to account for approximately 16% of breast cancer cases in the US.62 Alcohol consumption increases the risk of breast cancer in women by about', '7%-10% for each 10 grams (roughly one drink) of alcohol consumed per day on average.191, 198 Women who have 2-3 alcoholic drinks per day have a 20%', 'higher risk of breast cancer compared to non-drinkers. There is also some evidence that alcohol consumption before first pregnancy may', 'particularly affect risk.198, 199 Although mechanisms are not well understood, alcohol may increase risk indirectly by increasing estrogen and other hormone']\n",
            "Texts: research, with studies particularly focused on the timing of exposure, specific dietary components, and risk differences by cancer subtype. Alcohol Alcohol isestimated to account for approximately 16% of breast cancer cases in the US.62 Alcohol consumption increases the risk of breast cancer in women by about7%-10% for each 10 grams (roughly one drink) of alcohol consumed per day on average.191, 198 Women who have 2-3 alcoholic drinks per day have a 20%higher risk of breast cancer compared to non-drinkers. There is also some evidence that alcohol consumption before first pregnancy mayparticularly affect risk.198, 199 Although mechanisms are not well understood, alcohol may increase risk indirectly by increasing estrogen and other hormone\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  93\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  94  doc chunk text: ['levels200 and/or increasing breast density.201 Alcohol use appears more strongly associated with risk for HR+ than HR- breast cancer.66, 202 Tobacco', 'Accumulating research indicates that smoking may slightly increase breast cancer risk, particularly among women with a heavy smoking history and who start smoking at a', 'young age.203, 204 A family history of breast cancer may heighten this risk.205 Some studies suggest secondhand smoke may increase risk,', 'particularly when exposure happens in childhood and for premenopausal breast', 'cancer.206-208Environmental and other risk factors Radiation Radiation exposure has been shown to increase breast cancer risk in studies of atomic bomb']\n",
            "Texts: levels200 and/or increasing breast density.201 Alcohol use appears more strongly associated with risk for HR+ than HR- breast cancer.66, 202 TobaccoAccumulating research indicates that smoking may slightly increase breast cancer risk, particularly among women with a heavy smoking history and who start smoking at ayoung age.203, 204 A family history of breast cancer may heighten this risk.205 Some studies suggest secondhand smoke may increase risk,particularly when exposure happens in childhood and for premenopausal breastcancer.206-208Environmental and other risk factors Radiation Radiation exposure has been shown to increase breast cancer risk in studies of atomic bomb\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  94\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  95  doc chunk text: ['survivors and females treated with high-dose radiation therapy to the chest between 10 and 30 years of age, such as for Hodgkin', 'lymphoma. This may be because breast tissue is most susceptible to carcinogens before it is fully', 'differentiated, which occurs with first childbirth. Breast cancer risk starts to rise about 8 years after radiation treatment and continues to be', 'elevated for more than 35 years.209 Although radiation treatments have evolved to include lower doses given over smaller areas, recent studies suggest that', 'elevated breast cancer risk persists.210 In 2020, the International Late Effects of Childhood Cancer Guideline Harmonization Group recommended that young female cancer']\n",
            "Texts: survivors and females treated with high-dose radiation therapy to the chest between 10 and 30 years of age, such as for Hodgkinlymphoma. This may be because breast tissue is most susceptible to carcinogens before it is fullydifferentiated, which occurs with first childbirth. Breast cancer risk starts to rise about 8 years after radiation treatment and continues to beelevated for more than 35 years.209 Although radiation treatments have evolved to include lower doses given over smaller areas, recent studies suggest thatelevated breast cancer risk persists.210 In 2020, the International Late Effects of Childhood Cancer Guideline Harmonization Group recommended that young female cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  95\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  96  doc chunk text: ['survivors who were treated with chest radiation begin yearly breast cancer screenings at age 25.211 In 2007, the American Cancer Society', 'recommended that such young female cancer survivors should be considered “high risk” and begin screening at age 30.', 'Diethylstilbestrol (DES) exposure From the 1940s through 1971, some pregnant women were given the drug', 'diethylstilbestrol (DES) because it was thought to lower the risk of miscarriage. These women have about a 30% increased risk of', 'developing breast cancer compared to women who have not taken DES.212 It remains unclear whether women born to mothers who took DES also have a']\n",
            "Texts: survivors who were treated with chest radiation begin yearly breast cancer screenings at age 25.211 In 2007, the American Cancer Societyrecommended that such young female cancer survivors should be considered “high risk” and begin screening at age 30.Diethylstilbestrol (DES) exposure From the 1940s through 1971, some pregnant women were given the drugdiethylstilbestrol (DES) because it was thought to lower the risk of miscarriage. These women have about a 30% increased risk ofdeveloping breast cancer compared to women who have not taken DES.212 It remains unclear whether women born to mothers who took DES also have a\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  96\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  97  doc chunk text: ['higher risk.212-215 Environmental chemicals and pollutants Many occupational, environmental, and chemical exposures have been proposed as causes of breast cancer. In general,', 'epidemiological studies have not found clear relationships between environmental pollutants, such as organochlorine pesticides, and breast cancer. Studies to date have found no', 'association between increased concentrations of organochlorines (e.g., dichloro diphenyl - trichloroethane, or DDT) in blood and fat tissue of adults and breast cancer', 'risk,216 although exposure to DDT during certain developmental windows, such as in utero, during infancy, or prior to puberty, is', 'associated with elevated breast cancer risk later in life.217, 218 Animal 20 Breast Cancer Facts & Figures']\n",
            "Texts: higher risk.212-215 Environmental chemicals and pollutants Many occupational, environmental, and chemical exposures have been proposed as causes of breast cancer. In general,epidemiological studies have not found clear relationships between environmental pollutants, such as organochlorine pesticides, and breast cancer. Studies to date have found noassociation between increased concentrations of organochlorines (e.g., dichloro diphenyl - trichloroethane, or DDT) in blood and fat tissue of adults and breast cancerrisk,216 although exposure to DDT during certain developmental windows, such as in utero, during infancy, or prior to puberty, isassociated with elevated breast cancer risk later in life.217, 218 Animal 20 Breast Cancer Facts & Figures\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  97\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  98  doc chunk text: ['2022-2024studies have demonstrated that prolonged, high-dose exposure to many chemicals can increase mammary tumor development, but it is unknown whether the much lower dose', 'exposures that occur in the general environment increase human breast cancer risk. Many relevant chemicals have not been adequately studied in humans, and this is an', 'active area of research.219-223 Study results from examinations of a relationship between hair dyes/ relaxers and breast cancer risk are', 'inconsistent, and more research is needed.224-226 Night shift work A recent meta-analysis reported that short-term (but not long-term) night shift', 'employment was associated with a slight increase in breast cancer risk.227 Elevated risk appears to be most strongly associated with shift working during early']\n",
            "Texts: 2022-2024studies have demonstrated that prolonged, high-dose exposure to many chemicals can increase mammary tumor development, but it is unknown whether the much lower doseexposures that occur in the general environment increase human breast cancer risk. Many relevant chemicals have not been adequately studied in humans, and this is anactive area of research.219-223 Study results from examinations of a relationship between hair dyes/ relaxers and breast cancer risk areinconsistent, and more research is needed.224-226 Night shift work A recent meta-analysis reported that short-term (but not long-term) night shiftemployment was associated with a slight increase in breast cancer risk.227 Elevated risk appears to be most strongly associated with shift working during early\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  98\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  99  doc chunk text: ['adulthood.228, 229 Exposure to light at night disrupts the production of melatonin, a hormone that regulates sleep. Experimental evidence suggests that', 'melatonin may also inhibit the growth of small, established tumors and prevent new tumors from developing.230 In 2019, based on an updated review of', 'studies in humans and animals, the International Agency for Research on Cancer concluded that “night shift work,” as opposed to “shift work”', 'identified in 2007, was probably carcinogenic to humans based on its association with breast, prostate, and colorectal cancers.231 Factors that are not', 'associated with breast cancer risk Abortion There are persistent claims that women who have had an abortion are at increased risk for']\n",
            "Texts: adulthood.228, 229 Exposure to light at night disrupts the production of melatonin, a hormone that regulates sleep. Experimental evidence suggests thatmelatonin may also inhibit the growth of small, established tumors and prevent new tumors from developing.230 In 2019, based on an updated review ofstudies in humans and animals, the International Agency for Research on Cancer concluded that “night shift work,” as opposed to “shift work”identified in 2007, was probably carcinogenic to humans based on its association with breast, prostate, and colorectal cancers.231 Factors that are notassociated with breast cancer risk Abortion There are persistent claims that women who have had an abortion are at increased risk for\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  99\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  100  doc chunk text: ['developing breast cancer based on early studies that have since been deemed methodologically flawed by the American College of', 'Obstetricians and Gynecology.232, 233 Indeed, a large body of scientific evidence, including an expert panel review convened in 2003 by the National Cancer', 'Institute, confirms that there is no link between breast cancer and abortion (either spontaneous or', 'induced).234Bras Although internet rumors have suggested that bras cause breast cancer by obstructing lymph flow, there is no scientific basis or evidence to', 'support this claim. The only credible study investigating this relationship found no association between wearing a bra and breast cancer.235 Breast implants No']\n",
            "Texts: developing breast cancer based on early studies that have since been deemed methodologically flawed by the American College ofObstetricians and Gynecology.232, 233 Indeed, a large body of scientific evidence, including an expert panel review convened in 2003 by the National CancerInstitute, confirms that there is no link between breast cancer and abortion (either spontaneous orinduced).234Bras Although internet rumors have suggested that bras cause breast cancer by obstructing lymph flow, there is no scientific basis or evidence tosupport this claim. The only credible study investigating this relationship found no association between wearing a bra and breast cancer.235 Breast implants No\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  100\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  101  doc chunk text: ['association has been found between breast implants and risk of breast cancer; however, there is evidence that women with textured implants are at', 'increased risk for a rare type of lymphoma that occurs in the breast.236, 237 In addition, breast implants can obstruct the view of breast', 'tissue during mammography. Women with breast implants should inform the mammography facility about the implants during scheduling so that additional x-ray pictures (called', 'implant displacement views) may be collected to allow for more complete breast imaging. Chemoprevention and prophylactic surgery', 'Chemoprevention The use of drugs to reduce the risk of disease is called chemoprevention. Currently, the US Food and Drug']\n",
            "Texts: association has been found between breast implants and risk of breast cancer; however, there is evidence that women with textured implants are atincreased risk for a rare type of lymphoma that occurs in the breast.236, 237 In addition, breast implants can obstruct the view of breasttissue during mammography. Women with breast implants should inform the mammography facility about the implants during scheduling so that additional x-ray pictures (calledimplant displacement views) may be collected to allow for more complete breast imaging. Chemoprevention and prophylactic surgeryChemoprevention The use of drugs to reduce the risk of disease is called chemoprevention. Currently, the US Food and Drug\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  101\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  102  doc chunk text: ['Administration (FDA) has approved two drugs to help lower the risk of breast cancer in high-risk women: tamoxifen and raloxifene (for', 'postmenopausal women only). These drugs are classified as selective estrogen receptor modulators (SERMs) because they block estrogen in some tissues of the body, but act like', 'estrogen in others. A large meta-analysis including more than 83,000 high- risk women found that SERMs reduced in situ and invasive breast cancer risk by 38%', 'over 10 years,238 although the benefit was limited to ER+ disease. SERMs are associated with some side effects, including hot flashes, nausea, and', 'fatigue. Premenopausal women taking tamoxifen can also experience menstrual changes. More serious side effects are rare but include blood clots and']\n",
            "Texts: Administration (FDA) has approved two drugs to help lower the risk of breast cancer in high-risk women: tamoxifen and raloxifene (forpostmenopausal women only). These drugs are classified as selective estrogen receptor modulators (SERMs) because they block estrogen in some tissues of the body, but act likeestrogen in others. A large meta-analysis including more than 83,000 high- risk women found that SERMs reduced in situ and invasive breast cancer risk by 38%over 10 years,238 although the benefit was limited to ER+ disease. SERMs are associated with some side effects, including hot flashes, nausea, andfatigue. Premenopausal women taking tamoxifen can also experience menstrual changes. More serious side effects are rare but include blood clots and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  102\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  103  doc chunk text: ['endometrial cancer, particularly in women over 50.238Breast Cancer Facts & Figures 2022-2024 21Aromatase inhibitors have also been shown to reduce breast cancer risk (by more than', 'half) among high-risk postmenopausal women in clinical trials.239 While these drugs have not yet been approved by the FDA for this purpose, the US', 'Preventive Services Task Force recommendation for breast cancer risk reduction in high- risk women includes aromatase inhibitors and SERMS.240 Aromatase', 'inhibitors can decrease bone density, so women taking these drugs must be monitored for osteoporosis. Prophylactic surgery Women at very high risk of breast', 'cancer (such as those with pathogenic BRCA gene variants) may elect prophylactic (preventive) mastectomy. Removal of both breasts reduces the risk of breast cancer by 90% or']\n",
            "Texts: endometrial cancer, particularly in women over 50.238Breast Cancer Facts & Figures 2022-2024 21Aromatase inhibitors have also been shown to reduce breast cancer risk (by more thanhalf) among high-risk postmenopausal women in clinical trials.239 While these drugs have not yet been approved by the FDA for this purpose, the USPreventive Services Task Force recommendation for breast cancer risk reduction in high- risk women includes aromatase inhibitors and SERMS.240 Aromataseinhibitors can decrease bone density, so women taking these drugs must be monitored for osteoporosis. Prophylactic surgery Women at very high risk of breastcancer (such as those with pathogenic BRCA gene variants) may elect prophylactic (preventive) mastectomy. Removal of both breasts reduces the risk of breast cancer by 90% or\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  103\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  104  doc chunk text: ['more,241 depending upon the type of mastectomy and the amount of tissue removed. Since prophylactic mastectomy is', 'risk-reducing but not risk-eliminating (because residual breast tissue can be hidden in the mastectomy skin flaps and/or axillary fat pad), women', 'undergoing this surgery should continue to be aware of breast cancer symptoms and seek medical attention if any develop.', 'Prophylactic salpingo- oophorectomy (surgical removal of the fallopian tubes and ovaries) reduces the risk of ovarian cancer, but the benefit for breast cancer in', 'high-risk women is less clear and may be limited to BRCA2 variant carriers.242 Importantly, not all women who elect']\n",
            "Texts: more,241 depending upon the type of mastectomy and the amount of tissue removed. Since prophylactic mastectomy isrisk-reducing but not risk-eliminating (because residual breast tissue can be hidden in the mastectomy skin flaps and/or axillary fat pad), womenundergoing this surgery should continue to be aware of breast cancer symptoms and seek medical attention if any develop.Prophylactic salpingo- oophorectomy (surgical removal of the fallopian tubes and ovaries) reduces the risk of ovarian cancer, but the benefit for breast cancer inhigh-risk women is less clear and may be limited to BRCA2 variant carriers.242 Importantly, not all women who elect\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  104\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  105  doc chunk text: ['prophylactic surgery would have developed cancer, and surveillance may be just as effective for reducing breast cancer mortality for some women.243 Women', 'considering these options should discuss the benefits and limitations with their doctor, and a second opinion is strongly', 'recommended. See page 26 for further discussion of contralateral prophylactic mastectomy in women diagnosed with unilateral breast cancer. Breast Cancer Screening American Cancer', 'Society recommendations for the early detection of breast cancer vary depending on a woman’s age and include mammography, as well as magnetic', 'resonance imaging (MRI) for women at high risk. The recommendations for average-risk women were most recently updated in 2015 (see sidebar,']\n",
            "Texts: prophylactic surgery would have developed cancer, and surveillance may be just as effective for reducing breast cancer mortality for some women.243 Womenconsidering these options should discuss the benefits and limitations with their doctor, and a second opinion is stronglyrecommended. See page 26 for further discussion of contralateral prophylactic mastectomy in women diagnosed with unilateral breast cancer. Breast Cancer Screening American CancerSociety recommendations for the early detection of breast cancer vary depending on a woman’s age and include mammography, as well as magneticresonance imaging (MRI) for women at high risk. The recommendations for average-risk women were most recently updated in 2015 (see sidebar,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  105\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  106  doc chunk text: ['right),244 and for high-risk women in 2007.245 Mammography Mammography is a low-dose x-ray image of breast tissue. Although early', 'mammographic images were on x-ray film, digital mammography (DM), in which a 2-dimensional (2D) image of breast tissue is captured', 'electronically and viewed on a monitor, has largely replaced screen-film mammography. DM has improved sensitivity for women under age 50 and those with', 'mammographically dense breast tissue.246 2D mammography is more commonly being accompanied with digital breast tomosynthesis (DBT) to create 3D images of the breast. More', 'information on DBT can be found on page 22.American Cancer Society Guideline for Breast Cancer Screening, 2015244 The following']\n",
            "Texts: right),244 and for high-risk women in 2007.245 Mammography Mammography is a low-dose x-ray image of breast tissue. Although earlymammographic images were on x-ray film, digital mammography (DM), in which a 2-dimensional (2D) image of breast tissue is capturedelectronically and viewed on a monitor, has largely replaced screen-film mammography. DM has improved sensitivity for women under age 50 and those withmammographically dense breast tissue.246 2D mammography is more commonly being accompanied with digital breast tomosynthesis (DBT) to create 3D images of the breast. Moreinformation on DBT can be found on page 22.American Cancer Society Guideline for Breast Cancer Screening, 2015244 The following\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  106\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  107  doc chunk text: ['recommendations are for women at average risk of breast cancer (i.e., women without a personal history of breast cancer, a suspected or a', 'confirmed genetic variant known to increase risk of breast cancer [e.g., BRCA1 or BRCA2 ], a strong family history, or a history of', 'previous radiotherapy to the chest at a young age). All women should become familiar with the benefits, limitations, and potential harms', 'associated with breast cancer screening. • Women should have the opportunity to begin annual screening between the ages of 40 and 44. • Women ages 45 to 54', 'should be screened annually. • Women ages 55 and older should transition to biennial screening or have the opportunity to continue']\n",
            "Texts: recommendations are for women at average risk of breast cancer (i.e., women without a personal history of breast cancer, a suspected or aconfirmed genetic variant known to increase risk of breast cancer [e.g., BRCA1 or BRCA2 ], a strong family history, or a history ofprevious radiotherapy to the chest at a young age). All women should become familiar with the benefits, limitations, and potential harmsassociated with breast cancer screening. • Women should have the opportunity to begin annual screening between the ages of 40 and 44. • Women ages 45 to 54should be screened annually. • Women ages 55 and older should transition to biennial screening or have the opportunity to continue\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  107\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  108  doc chunk text: ['screening annually. • Women should continue screening mammography as long as their overall health is good and they have a life', 'expectancy of 10 years or more.22 Breast Cancer Facts & Figures 2022-2024Early detection of breast cancer by mammography reduces the risk of breast cancer death as it', 'increases treatment options, including less extensive surgery and/ or the use of chemotherapy. This can result in fewer side effects, and', 'sometimes even the option to forgo chemotherapy. Beginning in the late 1960s, a succession of randomized trials demonstrated the efficacy of early breast cancer', 'detection with mammography, and breast cancer screening with mammography was adopted as a preventive health strategy.247 More recent results from organized']\n",
            "Texts: screening annually. • Women should continue screening mammography as long as their overall health is good and they have a lifeexpectancy of 10 years or more.22 Breast Cancer Facts & Figures 2022-2024Early detection of breast cancer by mammography reduces the risk of breast cancer death as itincreases treatment options, including less extensive surgery and/ or the use of chemotherapy. This can result in fewer side effects, andsometimes even the option to forgo chemotherapy. Beginning in the late 1960s, a succession of randomized trials demonstrated the efficacy of early breast cancerdetection with mammography, and breast cancer screening with mammography was adopted as a preventive health strategy.247 More recent results from organized\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  108\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  109  doc chunk text: ['mammography programs in Europe and Canada indicate that the risk of breast cancer death is reduced by more than 40% among women who', 'participated in screening.248-251 Additionally, women who undergo mammography screening have a 25% reduction in advanced-stage breast cancers compared to women who received no', 'screening.251 Women should be informed of the limitations of mammography. Mammography will not detect all breast cancers, and some breast cancers detected by', 'screening still have a poor prognosis. Mammography screening can also lead to overdiagnosis. That is, some breast tumors or lesions detected by', 'mammography, particularly ductal carcinoma in situ (DCIS), would never have progressed or otherwise been detected in the absence of screening.']\n",
            "Texts: mammography programs in Europe and Canada indicate that the risk of breast cancer death is reduced by more than 40% among women whoparticipated in screening.248-251 Additionally, women who undergo mammography screening have a 25% reduction in advanced-stage breast cancers compared to women who received noscreening.251 Women should be informed of the limitations of mammography. Mammography will not detect all breast cancers, and some breast cancers detected byscreening still have a poor prognosis. Mammography screening can also lead to overdiagnosis. That is, some breast tumors or lesions detected bymammography, particularly ductal carcinoma in situ (DCIS), would never have progressed or otherwise been detected in the absence of screening.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  109\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  110  doc chunk text: ['Unfortunately, however, we are currently unable to distinguish the biologically indolent breast cancers from the majority of cases that will progress in the', 'absence of treatment. Ongoing research seeks to clarify this distinction. The prevalence of overdiagnosis is difficult to measure, but a recent study found that among', 'women 50 to 74 years of age, overdiagnosis occurs in about 1 out of 7, or 15%, of', 'screen-detected breast cancers.252 Mammography may also result in false-positive results, which lead to follow-up examinations, including biopsies, when there is no cancer. False', 'positives are most likely at the first screening. About 12% of women screened with modern digital mammograms require follow-up imaging or biopsy, but most (95%) do not']\n",
            "Texts: Unfortunately, however, we are currently unable to distinguish the biologically indolent breast cancers from the majority of cases that will progress in theabsence of treatment. Ongoing research seeks to clarify this distinction. The prevalence of overdiagnosis is difficult to measure, but a recent study found that amongwomen 50 to 74 years of age, overdiagnosis occurs in about 1 out of 7, or 15%, ofscreen-detected breast cancers.252 Mammography may also result in false-positive results, which lead to follow-up examinations, including biopsies, when there is no cancer. Falsepositives are most likely at the first screening. About 12% of women screened with modern digital mammograms require follow-up imaging or biopsy, but most (95%) do not\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  110\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  111  doc chunk text: ['have cancer.253 Cumulative radiation exposure from repeated mammograms slightly increases the risk of breast cancer;254 however, the dose of radiation during a', 'mammogram is relatively small and the benefit of screening substantially outweighs the harm.255 Reducing radiation exposure through more effective imaging is an area of', 'current research. For example, use of artificial intelligence to analyze images can lower the need for unnecessary follow-up testing.256 The', 'Affordable Care Act requires that Medicare and all new private health insurance plans fully cover biannual screening mammograms for women 50 and older', 'without any out-of-pocket expense for patients. There are also programs, such as the Centers for Disease Control and']\n",
            "Texts: have cancer.253 Cumulative radiation exposure from repeated mammograms slightly increases the risk of breast cancer;254 however, the dose of radiation during amammogram is relatively small and the benefit of screening substantially outweighs the harm.255 Reducing radiation exposure through more effective imaging is an area ofcurrent research. For example, use of artificial intelligence to analyze images can lower the need for unnecessary follow-up testing.256 TheAffordable Care Act requires that Medicare and all new private health insurance plans fully cover biannual screening mammograms for women 50 and olderwithout any out-of-pocket expense for patients. There are also programs, such as the Centers for Disease Control and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  111\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  112  doc chunk text: ['Prevention’s National Breast and Cervical Cancer Early Detection Program, that offer mammography services for low-income, uninsured, and underserved women. For help locating a free or', 'low-cost screening mammogram in your area, contact the American Cancer Society at 1-800-227-2345. Digital breast tomosynthesis (DBT) In 2011, the FDA approved the use of DBT', '(also referred to as 3D mammography) for breast cancer screening. DBT takes multiple breast images, in combination with digital 2D', 'mammography, which can be used to construct a 3D image of the breast. Some studies have found that DBT may be more', 'sensitive (i.e., detects more cancers); has fewer false positives; reduces advanced-staged cancers among women with extremely mammographic dense breasts; and has lower recall rates than 2D']\n",
            "Texts: Prevention’s National Breast and Cervical Cancer Early Detection Program, that offer mammography services for low-income, uninsured, and underserved women. For help locating a free orlow-cost screening mammogram in your area, contact the American Cancer Society at 1-800-227-2345. Digital breast tomosynthesis (DBT) In 2011, the FDA approved the use of DBT(also referred to as 3D mammography) for breast cancer screening. DBT takes multiple breast images, in combination with digital 2Dmammography, which can be used to construct a 3D image of the breast. Some studies have found that DBT may be moresensitive (i.e., detects more cancers); has fewer false positives; reduces advanced-staged cancers among women with extremely mammographic dense breasts; and has lower recall rates than 2D\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  112\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  113  doc chunk text: ['mammography alone.116, 257, 258 However, when DBT is performed with a 2D mammogram, women receive about twice the dose of radiation compared to', 'standard mammogram. The FDA has approved the use of tomographic images to produce synthetic 2D images, which reduces the radiation dose to that', 'similar to conventional digital mammography, although this practice is not yet widespread. Approximately 83% of mammography facilities have at least one DBT unit;', 'however not all health plans cover reimbursement for DBT.259 Mammography prevalence • In 2019, 54% of women ages 45-54 had received a', 'mammogram within the past year, and about 76%-78% of women ages 55-74 had received a mammogram within the past two years ( Table 5 ).']\n",
            "Texts: mammography alone.116, 257, 258 However, when DBT is performed with a 2D mammogram, women receive about twice the dose of radiation compared tostandard mammogram. The FDA has approved the use of tomographic images to produce synthetic 2D images, which reduces the radiation dose to thatsimilar to conventional digital mammography, although this practice is not yet widespread. Approximately 83% of mammography facilities have at least one DBT unit;however not all health plans cover reimbursement for DBT.259 Mammography prevalence • In 2019, 54% of women ages 45-54 had received amammogram within the past year, and about 76%-78% of women ages 55-74 had received a mammogram within the past two years ( Table 5 ).\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  113\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  114  doc chunk text: ['Overall, 65% of women ages 45 and older were up to date with breast cancer screening according to the American Cancer Society', 'recommendations. Breast Cancer Facts & Figures 2022-2024 23• In 2019, the prevalence of up-to-date mammography was lower in AIAN (54%) and Asian (60%) women than', 'among White (65%), Hispanic (67%), and Black (69%) women ( Table 5 ). However, studies have documented that', 'self-reported survey data overestimate mammography screening prevalence, particularly among Black and Hispanic women.260-262 • In 2019, only 37% of uninsured women were up to date with', 'breast cancer screening, compared to 70% of privately insured women ( Table 5 ). Screening rates were also among the lowest in recent']\n",
            "Texts: Overall, 65% of women ages 45 and older were up to date with breast cancer screening according to the American Cancer Societyrecommendations. Breast Cancer Facts & Figures 2022-2024 23• In 2019, the prevalence of up-to-date mammography was lower in AIAN (54%) and Asian (60%) women thanamong White (65%), Hispanic (67%), and Black (69%) women ( Table 5 ). However, studies have documented thatself-reported survey data overestimate mammography screening prevalence, particularly among Black and Hispanic women.260-262 • In 2019, only 37% of uninsured women were up to date withbreast cancer screening, compared to 70% of privately insured women ( Table 5 ). Screening rates were also among the lowest in recent\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  114\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  115  doc chunk text: ['immigrants (47%) and women without a high school education (57%). • Recent studies have provided evidence of declines in breast cancer', 'screening during the COVID-19 pandemic; receipt of a mammogram within the past two years declined from 62% in 2018 to 58% in 2020 among women ages', '50-74.263 • In 2020, the prevalence of up-to-date mammography among women ages 45 and older ranged from 56% in Wyoming to 76% in Hawaii (', 'Table 6 ). Magnetic resonance imaging (MRI) Breast MRI uses high-powered magnets along with radio waves instead of x-rays to produce an image. In 2007, the', 'American Cancer Society published recommendations for the use of MRI for screening women at high risk of breast cancer.245 Beginning at age 30, annual']\n",
            "Texts: immigrants (47%) and women without a high school education (57%). • Recent studies have provided evidence of declines in breast cancerscreening during the COVID-19 pandemic; receipt of a mammogram within the past two years declined from 62% in 2018 to 58% in 2020 among women ages50-74.263 • In 2020, the prevalence of up-to-date mammography among women ages 45 and older ranged from 56% in Wyoming to 76% in Hawaii (Table 6 ). Magnetic resonance imaging (MRI) Breast MRI uses high-powered magnets along with radio waves instead of x-rays to produce an image. In 2007, theAmerican Cancer Society published recommendations for the use of MRI for screening women at high risk of breast cancer.245 Beginning at age 30, annual\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  115\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  116  doc chunk text: ['screening with MRI, in addition to mammography, is recommended for women with an estimated lifetime risk of breast cancer of at least 20%-25% due to the', 'presence of a high-risk variation in the breast cancer susceptibility genes BRCA1 or BRCA2 , a first-degree relative with a BRCA1 or BRCA2', 'variant (if the woman herself has not been tested), a strong family history of breast and/or ovarian cancer, and prior chest', 'radiation therapy (e.g. for Hodgkin lymphoma), as well as women with Li-Fraumeni, Cowden, and Bannayan-Riley- Ruvalcaba syndromes and their', 'first-degree relatives.245 Women with an estimated 15%-20% lifetime risk264 should talk with their doctors about the benefits and limitations of adding MRI']\n",
            "Texts: screening with MRI, in addition to mammography, is recommended for women with an estimated lifetime risk of breast cancer of at least 20%-25% due to thepresence of a high-risk variation in the breast cancer susceptibility genes BRCA1 or BRCA2 , a first-degree relative with a BRCA1 or BRCA2variant (if the woman herself has not been tested), a strong family history of breast and/or ovarian cancer, and prior chestradiation therapy (e.g. for Hodgkin lymphoma), as well as women with Li-Fraumeni, Cowden, and Bannayan-Riley- Ruvalcaba syndromes and theirfirst-degree relatives.245 Women with an estimated 15%-20% lifetime risk264 should talk with their doctors about the benefits and limitations of adding MRI\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  116\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  117  doc chunk text: ['screening to their annual mammogram. MRI screening is not recommended for Table 5. Mammography (%), Women 45 and Older, US, 2019', 'Up-to-date* (≥ 45 years)Within the past 2 years (50-74 years) Overall 65 76 Age (years) 45-54 54 – 55-64 76 – 65-74 78 78 75+ 54 –', 'Race/Ethnicity Hispanic/Latina 67 79 White 65 76 Black 69 79 Asian/Pacific Islander 60 74 American Indian/Alaska Native 54 63 Education Some high school or less 57 69', 'High school diploma or GED 61 73 Some college/Assoc. degree 66 76 College graduate 72 83 Sexual orientation Gay/Lesbian 57 74 Straight 66 77', 'Bisexual 65 † Health insurance status (age ≤64 years) Uninsured (ages < 65 years) 36 44 Private 70 80']\n",
            "Texts: screening to their annual mammogram. MRI screening is not recommended for Table 5. Mammography (%), Women 45 and Older, US, 2019Up-to-date* (≥ 45 years)Within the past 2 years (50-74 years) Overall 65 76 Age (years) 45-54 54 – 55-64 76 – 65-74 78 78 75+ 54 –Race/Ethnicity Hispanic/Latina 67 79 White 65 76 Black 69 79 Asian/Pacific Islander 60 74 American Indian/Alaska Native 54 63 Education Some high school or less 57 69High school diploma or GED 61 73 Some college/Assoc. degree 66 76 College graduate 72 83 Sexual orientation Gay/Lesbian 57 74 Straight 66 77Bisexual 65 † Health insurance status (age ≤64 years) Uninsured (ages < 65 years) 36 44 Private 70 80\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  117\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  118  doc chunk text: ['Medicaid/pub/dual 61 72 Medicare (ages ≥65 years) 68 78 Other 69 79 Immigration Born in US/US Territory 65 77 In US fewer than 10 years 47 59 In', 'US 10 or more years 67 78 Region Northeast 68 81 Midwest 66 76 South 64 75 West 65 75 GED = General', 'Educational Development high school equivalency. *According to the American Cancer Society recommendations: mammogram within the past year (ages 45-54 years) or past two years (ages ≥55', 'years). †Estimate not provided due to instability. Note: Race is exclusive of Hispanic origin. Mammography prevalence estimates do not', 'distinguish between examinations for screening and diagnosis. Source: National Health Interview Survey, 2019. ©2022, American Cancer Society, Inc.,']\n",
            "Texts: Medicaid/pub/dual 61 72 Medicare (ages ≥65 years) 68 78 Other 69 79 Immigration Born in US/US Territory 65 77 In US fewer than 10 years 47 59 InUS 10 or more years 67 78 Region Northeast 68 81 Midwest 66 76 South 64 75 West 65 75 GED = GeneralEducational Development high school equivalency. *According to the American Cancer Society recommendations: mammogram within the past year (ages 45-54 years) or past two years (ages ≥55years). †Estimate not provided due to instability. Note: Race is exclusive of Hispanic origin. Mammography prevalence estimates do notdistinguish between examinations for screening and diagnosis. Source: National Health Interview Survey, 2019. ©2022, American Cancer Society, Inc.,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  118\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  119  doc chunk text: ['Surveillance and Health Equity Science24 Breast Cancer Facts & Figures 2022-2024women whose lifetime risk of breast cancer is less than 15%. Studies', 'indicate that MRI is underutilized among high-risk women265 and overutilized by women who are not at high risk for breast', 'cancer.266 MRI should supplement – not replace – mammography screening and should be done at facilities that are accredited by the American College of', 'Radiology. Although MRI is more expensive than mammography, most major insurance companies will cover some portion of the cost if a woman is', 'demonstrated to be at sufficiently high risk. Breast ultrasound Breast ultrasound is sometimes used to evaluate abnormal findings from a mammogram or']\n",
            "Texts: Surveillance and Health Equity Science24 Breast Cancer Facts & Figures 2022-2024women whose lifetime risk of breast cancer is less than 15%. Studiesindicate that MRI is underutilized among high-risk women265 and overutilized by women who are not at high risk for breastcancer.266 MRI should supplement – not replace – mammography screening and should be done at facilities that are accredited by the American College ofRadiology. Although MRI is more expensive than mammography, most major insurance companies will cover some portion of the cost if a woman isdemonstrated to be at sufficiently high risk. Breast ultrasound Breast ultrasound is sometimes used to evaluate abnormal findings from a mammogram or\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  119\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  120  doc chunk text: ['physical exam. Most often, it is done with a device that captures images of the breast using sound waves. For women with', 'mammographically dense breast tissue, ultrasound combined with mammography may be more sensitive than mammography alone; however, it also increases the', 'likelihood of false-positive results.267 The use of ultrasound instead of mammograms for breast cancer screening is not recommended at this time. However, using', 'artificial intelligence to improve accuracy of breast ultrasound results and reduce false positives is a current area of', 'research.268 Clinical breast examination (CBE) The American Cancer Society no longer recommends CBE for breast cancer screening in']\n",
            "Texts: physical exam. Most often, it is done with a device that captures images of the breast using sound waves. For women withmammographically dense breast tissue, ultrasound combined with mammography may be more sensitive than mammography alone; however, it also increases thelikelihood of false-positive results.267 The use of ultrasound instead of mammograms for breast cancer screening is not recommended at this time. However, usingartificial intelligence to improve accuracy of breast ultrasound results and reduce false positives is a current area ofresearch.268 Clinical breast examination (CBE) The American Cancer Society no longer recommends CBE for breast cancer screening in\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  120\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  121  doc chunk text: ['average-risk asymptomatic women because of a lack of clear benefits for CBE alone or in conjunction with', 'mammography.244 Furthermore, there is some evidence that adding CBE to mammography screening increases the rate of false positives. Breast', 'self-awareness Although the American Cancer Society also no longer recommends that women perform monthly breast self-exams (BSE), all women should become familiar with both the', 'appearance and feel of their breasts and report any changes promptly to their doctor. If a lump or other symptoms develop, women should', 'contact a doctor immediately, even after a recent normal mammogram.Table 6. Mammography (%) by State, Women 45 and Older, 2020']\n",
            "Texts: average-risk asymptomatic women because of a lack of clear benefits for CBE alone or in conjunction withmammography.244 Furthermore, there is some evidence that adding CBE to mammography screening increases the rate of false positives. Breastself-awareness Although the American Cancer Society also no longer recommends that women perform monthly breast self-exams (BSE), all women should become familiar with both theappearance and feel of their breasts and report any changes promptly to their doctor. If a lump or other symptoms develop, women shouldcontact a doctor immediately, even after a recent normal mammogram.Table 6. Mammography (%) by State, Women 45 and Older, 2020\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  121\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  122  doc chunk text: ['Up-to-date* (≥ 45 years)Within the past 2 years (50-74 years) AllUninsured (Ages 45-64) AllUninsured (Ages 50-64) Alabama 67 28 73 38 Alaska 56 27 65 40', 'Arizona 63 42 66 49 Arkansas 66 50 67 54 California 60 25 69 ^ Colorado 60 31 66 37', 'Connecticut 73 44 74 60 Delaware 68 51 70 † District of Columbia 66 † 72 † Florida 65 35 72 35 Georgia 67 35 70 45', 'Hawaii 76 56 78 † Idaho 60 30 65 40 Illinois 67 † 76 † Indiana 62 32 67 37 Iowa 70 25 75 28', 'Kansas 64 29 70 36 Kentucky 66 † 70 † Louisiana 74 44 73 56 Maine 72 23 76 34 Maryland 70 43 69 39']\n",
            "Texts: Up-to-date* (≥ 45 years)Within the past 2 years (50-74 years) AllUninsured (Ages 45-64) AllUninsured (Ages 50-64) Alabama 67 28 73 38 Alaska 56 27 65 40Arizona 63 42 66 49 Arkansas 66 50 67 54 California 60 25 69 ^ Colorado 60 31 66 37Connecticut 73 44 74 60 Delaware 68 51 70 † District of Columbia 66 † 72 † Florida 65 35 72 35 Georgia 67 35 70 45Hawaii 76 56 78 † Idaho 60 30 65 40 Illinois 67 † 76 † Indiana 62 32 67 37 Iowa 70 25 75 28Kansas 64 29 70 36 Kentucky 66 † 70 † Louisiana 74 44 73 56 Maine 72 23 76 34 Maryland 70 43 69 39\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  122\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  123  doc chunk text: ['Massachusetts 75 † 80 † Michigan 64 42 75 70 Minnesota 67 40 72 47 Mississippi 64 36 70 40 Missouri 67 26 72 35', 'Montana 63 21 69 35 Nebraska 64 36 72 42 Nevada 65 † 71 † New Hampshire 67 23 69 28 New Jersey 66 38 68 50', 'New Mexico 61 32 71 39 New York 71 48 71 58 North Carolina 70 44 76 50 North Dakota 72 † 76 † Ohio 67 35 69', '40 Oklahoma 62 35 66 33 Oregon 67 39 73 56 Pennsylvania 68 † 70 † Rhode Island 74 39 76 † South', 'Carolina 70 41 73 53 South Dakota 72 30 75 45 Tennessee 67 46 69 29 Texas 65 35 70 49 Utah 60 35 66 41']\n",
            "Texts: Massachusetts 75 † 80 † Michigan 64 42 75 70 Minnesota 67 40 72 47 Mississippi 64 36 70 40 Missouri 67 26 72 35Montana 63 21 69 35 Nebraska 64 36 72 42 Nevada 65 † 71 † New Hampshire 67 23 69 28 New Jersey 66 38 68 50New Mexico 61 32 71 39 New York 71 48 71 58 North Carolina 70 44 76 50 North Dakota 72 † 76 † Ohio 67 35 6940 Oklahoma 62 35 66 33 Oregon 67 39 73 56 Pennsylvania 68 † 70 † Rhode Island 74 39 76 † SouthCarolina 70 41 73 53 South Dakota 72 30 75 45 Tennessee 67 46 69 29 Texas 65 35 70 49 Utah 60 35 66 41\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  123\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  124  doc chunk text: ['Vermont 63 46 69 † Virginia 70 39 72 43 Washington 63 35 67 40 West Virginia 68 36 75 55', 'Wisconsin 70 53 76 † Wyoming 56 27 60 33 United States (median) 67 35 71 40 *According to American Cancer Society', 'recommendations: mammogram within the past year (ages 45-54 years) or past two years (ages ≥55 years). Note: Mammography prevalence estimates do not', 'distinguish between examinations for screening and diagnosis. Source: Behavioral Risk Factor Surveillance System, 2016. ©2019, American Cancer Society,', 'Surveillance ResearchBreast Cancer Facts & Figures 2022-2024 25Breast Cancer Treatment Treatment decisions should be made jointly by the patient and the']\n",
            "Texts: Vermont 63 46 69 † Virginia 70 39 72 43 Washington 63 35 67 40 West Virginia 68 36 75 55Wisconsin 70 53 76 † Wyoming 56 27 60 33 United States (median) 67 35 71 40 *According to American Cancer Societyrecommendations: mammogram within the past year (ages 45-54 years) or past two years (ages ≥55 years). Note: Mammography prevalence estimates do notdistinguish between examinations for screening and diagnosis. Source: Behavioral Risk Factor Surveillance System, 2016. ©2019, American Cancer Society,Surveillance ResearchBreast Cancer Facts & Figures 2022-2024 25Breast Cancer Treatment Treatment decisions should be made jointly by the patient and the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  124\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  125  doc chunk text: ['physician after consideration of the cancer stage and biological characteristics; patient age, menopausal status, and preferences; and the risks and benefits', 'associated with each option. Ductal carcinoma in situ (DCIS) There is currently no certain way to determine the progressive potential of DCIS, so these', 'lesions are usually treated with surgery and sometimes radiation and/or hormone therapy after surgery. However, there is likely a group of DCIS', 'patients who could safely forgo surgery.6 Several clinical trials currently underway in the US and', 'internationally are comparing standard treatment to active monitoring (with or without hormone therapy) in women with “low-risk” DCIS, although results will not be']\n",
            "Texts: physician after consideration of the cancer stage and biological characteristics; patient age, menopausal status, and preferences; and the risks and benefitsassociated with each option. Ductal carcinoma in situ (DCIS) There is currently no certain way to determine the progressive potential of DCIS, so theselesions are usually treated with surgery and sometimes radiation and/or hormone therapy after surgery. However, there is likely a group of DCISpatients who could safely forgo surgery.6 Several clinical trials currently underway in the US andinternationally are comparing standard treatment to active monitoring (with or without hormone therapy) in women with “low-risk” DCIS, although results will not be\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  125\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  126  doc chunk text: ['available for several years.269 Ongoing research also seeks to identify molecular markers of DCIS that could predict recurrence or', 'progression to invasive cancer. Currently, active monitoring is extremely rare; a national study found that <1% of DCIS patients diagnosed from 2004 to 2015', 'underwent active surveillance.270 Invasive breast cancer Figure 12 shows treatment patterns among US women with invasive breast cancer in 2018 by stage at', 'diagnosis and race. Most women with non-metastatic breast cancer will have some type of surgery, which is often combined with other', 'treatments, such as radiation therapy, chemotherapy, hormone therapy, and/or targeted drug therapy, to reduce the risk of recurrence. Patients with']\n",
            "Texts: available for several years.269 Ongoing research also seeks to identify molecular markers of DCIS that could predict recurrence orprogression to invasive cancer. Currently, active monitoring is extremely rare; a national study found that <1% of DCIS patients diagnosed from 2004 to 2015underwent active surveillance.270 Invasive breast cancer Figure 12 shows treatment patterns among US women with invasive breast cancer in 2018 by stage atdiagnosis and race. Most women with non-metastatic breast cancer will have some type of surgery, which is often combined with othertreatments, such as radiation therapy, chemotherapy, hormone therapy, and/or targeted drug therapy, to reduce the risk of recurrence. Patients with\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  126\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  127  doc chunk text: ['metastatic disease are primarily treated with systemic therapies, which can include chemotherapy, targeted drug therapy, hormonal therapy, and/or', 'immunotherapy. Figure 12. Female Breast Cancer Treatment Patterns (%), by Stage, 2018 White and Black race excludes persons of Hispanic', 'ethnicity. BCS = breast conserving surgery, i.e., lumpectomy/partial mastectomy, in which only cancerous tissue plus a surrounding layer of normal tissue is', 'removed; Mastectomy = surgical removal of the entire breast(s); RT = radiation therapy; Chemo = chemotherapy and includes targeted therapy and', 'immunotherapy. *A small number of these patients received chemotherapy. †A small number of these patients received radiation therapy. NOTE: Many patients may have']\n",
            "Texts: metastatic disease are primarily treated with systemic therapies, which can include chemotherapy, targeted drug therapy, hormonal therapy, and/orimmunotherapy. Figure 12. Female Breast Cancer Treatment Patterns (%), by Stage, 2018 White and Black race excludes persons of Hispanicethnicity. BCS = breast conserving surgery, i.e., lumpectomy/partial mastectomy, in which only cancerous tissue plus a surrounding layer of normal tissue isremoved; Mastectomy = surgical removal of the entire breast(s); RT = radiation therapy; Chemo = chemotherapy and includes targeted therapy andimmunotherapy. *A small number of these patients received chemotherapy. †A small number of these patients received radiation therapy. NOTE: Many patients may have\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  127\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  128  doc chunk text: ['received hormonal therapy in addition to the above treatments. Source: National Cancer Data Base, 2021. ©2022, American Cancer Society, Inc.,', 'Surveillance and Health Equity SciencePercent Percent Percent12918 <1 3 3 332 <13 3112650 6 65660 23 15 51 1318 1923 10 115659 6614 4 423 750 97', '2211062 23 250 10161920 3 3 2BCS, no RT* BCS + RT* Mastectomy, no chemo† Mastectomy + chemo (+/- RT) RT and/or chemo No RT,', 'chemo, or cancer-directed surgery010203040506070 Stage IV Stage III Stages I & IIAll races/ethnicities White Black', '010203040506070 Stage IV Stage III Stages I & II010203040506070 Stage IV Stage III Stages I & II 26 Breast Cancer Facts & Figures']\n",
            "Texts: received hormonal therapy in addition to the above treatments. Source: National Cancer Data Base, 2021. ©2022, American Cancer Society, Inc.,Surveillance and Health Equity SciencePercent Percent Percent12918 <1 3 3 332 <13 3112650 6 65660 23 15 51 1318 1923 10 115659 6614 4 423 750 972211062 23 250 10161920 3 3 2BCS, no RT* BCS + RT* Mastectomy, no chemo† Mastectomy + chemo (+/- RT) RT and/or chemo No RT,chemo, or cancer-directed surgery010203040506070 Stage IV Stage III Stages I & IIAll races/ethnicities White Black010203040506070 Stage IV Stage III Stages I & II010203040506070 Stage IV Stage III Stages I & II 26 Breast Cancer Facts & Figures\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  128\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  129  doc chunk text: ['2022-2024Surgery The primary goals of breast cancer surgery are to remove the cancer and determine its stage. Surgical treatment involves', 'mastectomy (surgical removal of the entire breast) or breast-conserving surgery (BCS). With BCS (also known as partial mastectomy or', 'lumpectomy), only cancerous tissue, plus a rim of normal tissue (tumor margin), is removed. BCS is generally not an option in patients with high', 'tumor-to-breast ratio, multiple tumors within the same breast, or inflammatory or locally advanced cancers. In most cases, BCS is coupled with', 'radiation to the breast, whereas mastectomy is more commonly preceded or followed by chemotherapy, particularly for stage III disease. However, receipt of']\n",
            "Texts: 2022-2024Surgery The primary goals of breast cancer surgery are to remove the cancer and determine its stage. Surgical treatment involvesmastectomy (surgical removal of the entire breast) or breast-conserving surgery (BCS). With BCS (also known as partial mastectomy orlumpectomy), only cancerous tissue, plus a rim of normal tissue (tumor margin), is removed. BCS is generally not an option in patients with hightumor-to-breast ratio, multiple tumors within the same breast, or inflammatory or locally advanced cancers. In most cases, BCS is coupled withradiation to the breast, whereas mastectomy is more commonly preceded or followed by chemotherapy, particularly for stage III disease. However, receipt of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  129\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  130  doc chunk text: ['treatment differs by race; Black women are less likely than White women to receive surgery (56% versus 64%) and more likely to receive', 'radiation or chemotherapy alone (9% versus 6%) for stage III disease, which has the largest stage-specific survival disparity.23', 'BCS-eligible patients in the US are increasingly electing contralateral mastectomy, which has risen among women with breast cancer from 4% in the early 2000s to 13% in', '2012, despite equivalent survival when BCS is combined with radiation.271 Reasons for this include fear of recurrence, reluctance or', 'contraindication to receiving radiation (e.g., prior ipsilateral radiation), and desire for breast symmetry.272-274 Structural obstacles to receiving radiation therapy, such as distance to']\n",
            "Texts: treatment differs by race; Black women are less likely than White women to receive surgery (56% versus 64%) and more likely to receiveradiation or chemotherapy alone (9% versus 6%) for stage III disease, which has the largest stage-specific survival disparity.23BCS-eligible patients in the US are increasingly electing contralateral mastectomy, which has risen among women with breast cancer from 4% in the early 2000s to 13% in2012, despite equivalent survival when BCS is combined with radiation.271 Reasons for this include fear of recurrence, reluctance orcontraindication to receiving radiation (e.g., prior ipsilateral radiation), and desire for breast symmetry.272-274 Structural obstacles to receiving radiation therapy, such as distance to\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  130\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  131  doc chunk text: ['treatment and/or transportation availability, also play a role.275 Some women who are diagnosed with breast cancer in one breast also choose to have the', 'unaffected breast removed, which is known as bilateral mastectomy or contralateral prophylactic mastectomy (CPM). Younger women (<40 years of age) and patients with larger', 'and/or more aggressive tumors are more likely to be treated with mastectomy276, 277 and to have a', 'contralateral prophylactic mastectomy (CPM).278 Among women with early-stage disease who choose mastectomy, the percentage who also underwent CPM increased from <2% in 1998 to', '28%-30% in 2010-2012,277 but appears to have leveled off in recent years.279 Although a proportion of this increase may be due to the']\n",
            "Texts: treatment and/or transportation availability, also play a role.275 Some women who are diagnosed with breast cancer in one breast also choose to have theunaffected breast removed, which is known as bilateral mastectomy or contralateral prophylactic mastectomy (CPM). Younger women (<40 years of age) and patients with largerand/or more aggressive tumors are more likely to be treated with mastectomy276, 277 and to have acontralateral prophylactic mastectomy (CPM).278 Among women with early-stage disease who choose mastectomy, the percentage who also underwent CPM increased from <2% in 1998 to28%-30% in 2010-2012,277 but appears to have leveled off in recent years.279 Although a proportion of this increase may be due to the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  131\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  132  doc chunk text: ['broader availability of genetic testing and increased awareness among women at high risk of contralateral disease,280 CPM rates in Europe are', 'remarkably lower than those in the US.281 Decision-making tools to help women better understand their individual risk of', 'contralateral breast cancer currently in development may help reduce unnecessary CPM.282 Women who undergo mastectomy may have breast', 'reconstruction, which is done either at the time of mastectomy or after further cancer treatment. Reconstruction is done with either a saline or', 'silicone implant, tissue from another part of the body, or a combination of the two. A woman considering breast']\n",
            "Texts: broader availability of genetic testing and increased awareness among women at high risk of contralateral disease,280 CPM rates in Europe areremarkably lower than those in the US.281 Decision-making tools to help women better understand their individual risk ofcontralateral breast cancer currently in development may help reduce unnecessary CPM.282 Women who undergo mastectomy may have breastreconstruction, which is done either at the time of mastectomy or after further cancer treatment. Reconstruction is done with either a saline orsilicone implant, tissue from another part of the body, or a combination of the two. A woman considering breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  132\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  133  doc chunk text: ['reconstruction should discuss this option with her breast surgeon and a trained breast plastic surgeon prior to the mastectomy in order to', 'coordinate the treatment. Both BCS and mastectomy are usually accompanied by removal of one or a few regional lymph nodes from the armpit', '(axilla) to determine if the disease has spread beyond the breast. This procedure, called sentinel lymph node biopsy (SLNB), identifies the lymph node(s) to which', 'cancer is most likely to spread. The presence of cancer cells in the lymph nodes increases the risk of', 'recurrence, so results from the SLNB can help determine whether further treatment is needed. Breast cancer patients who are ≥70 years of age who have']\n",
            "Texts: reconstruction should discuss this option with her breast surgeon and a trained breast plastic surgeon prior to the mastectomy in order tocoordinate the treatment. Both BCS and mastectomy are usually accompanied by removal of one or a few regional lymph nodes from the armpit(axilla) to determine if the disease has spread beyond the breast. This procedure, called sentinel lymph node biopsy (SLNB), identifies the lymph node(s) to whichcancer is most likely to spread. The presence of cancer cells in the lymph nodes increases the risk ofrecurrence, so results from the SLNB can help determine whether further treatment is needed. Breast cancer patients who are ≥70 years of age who have\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  133\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  134  doc chunk text: ['early-stage HR+ tumors may not require an SLNB.277 Some breast cancer patients need more extensive lymph node surgery, called an axillary lymph node', 'dissection (ALND). However, ALND use has rapidly declined across the US, from 44% in 2011 to 25%-28% in 2013, following clinical trial results that the', 'procedure does not improve survival or recurrence in low-risk patients appropriately treated with BCS and radiation.277 Patients with a', 'negative/non-cancerous SLNB do not need to consider ALND, and axillary radiation can be considered as a substitute for the ALND in patients that are found to', 'have cancer in the SLNB. Surgery involving the axillary lymph nodes is the primary risk factor for the development of']\n",
            "Texts: early-stage HR+ tumors may not require an SLNB.277 Some breast cancer patients need more extensive lymph node surgery, called an axillary lymph nodedissection (ALND). However, ALND use has rapidly declined across the US, from 44% in 2011 to 25%-28% in 2013, following clinical trial results that theprocedure does not improve survival or recurrence in low-risk patients appropriately treated with BCS and radiation.277 Patients with anegative/non-cancerous SLNB do not need to consider ALND, and axillary radiation can be considered as a substitute for the ALND in patients that are found tohave cancer in the SLNB. Surgery involving the axillary lymph nodes is the primary risk factor for the development of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  134\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  135  doc chunk text: ['lymphedema, a serious swelling of the arm caused by retention of lymph fluid. Other risk factors may include axillary radiation, excess body weight, and older', 'age.283, 284 The precise incidence of breast cancer-related lymphedema is difficult to determine due to the condition’s long latency, with incidence', 'generally peaking 12-30 months following initial treatment.283 Studies estimate that lymphedema affects Breast Cancer Facts & Figures 2022-2024 27about 20% of women who', 'undergo ALND and about 6% of patients who receive SLNB.285 However, the risk of chronic lymphedema may be greatly reduced through', 'prospective surveillance and early management; in one meta-analysis examining the efficacy of this approach, the cumulative incidence of chronic arm']\n",
            "Texts: lymphedema, a serious swelling of the arm caused by retention of lymph fluid. Other risk factors may include axillary radiation, excess body weight, and olderage.283, 284 The precise incidence of breast cancer-related lymphedema is difficult to determine due to the condition’s long latency, with incidencegenerally peaking 12-30 months following initial treatment.283 Studies estimate that lymphedema affects Breast Cancer Facts & Figures 2022-2024 27about 20% of women whoundergo ALND and about 6% of patients who receive SLNB.285 However, the risk of chronic lymphedema may be greatly reduced throughprospective surveillance and early management; in one meta-analysis examining the efficacy of this approach, the cumulative incidence of chronic arm\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  135\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  136  doc chunk text: ['lymphedema at 2 years follow-up among women who underwent ALND was only 6%.286 Among the clinical trials included in the analysis,', 'surveillance and early management reduced the risk of chronic lymphedema by nearly 70%. The use of early preventive measures, such as', 'compression sleeves, also reduces the risk of swelling in high-risk patients.287 However, in large part because of limited access to these', 'services, Women of lower socioeconomic status, including Black and Hispanic women, are', 'disproportionately burdened by the condition; for example, Medicare does not provide coverage for compression sleeves even among symptomatic']\n",
            "Texts: lymphedema at 2 years follow-up among women who underwent ALND was only 6%.286 Among the clinical trials included in the analysis,surveillance and early management reduced the risk of chronic lymphedema by nearly 70%. The use of early preventive measures, such ascompression sleeves, also reduces the risk of swelling in high-risk patients.287 However, in large part because of limited access to theseservices, Women of lower socioeconomic status, including Black and Hispanic women, aredisproportionately burdened by the condition; for example, Medicare does not provide coverage for compression sleeves even among symptomatic\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  136\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  137  doc chunk text: ['patients.284 For more information about breast cancer survivorship and the side effects of treatment, visit', 'cancer.org/statistics to see Cancer Treatment & Survivorship Facts & Figures . Radiation therapy Radiation therapy is often used after surgery to destroy cancer cells', 'remaining in the breast, chest wall, or underarm area and reduce the risk local of recurrence. Radiation therapy after BCS is standard for most', 'patients, as it has been shown to reduce the risk of cancer recurrence by about 50% at 10 years and the risk of breast', 'cancer death by almost 20% at 15 years.288 However, evidence from randomized control trials has suggested adjuvant radiation may be omitted without']\n",
            "Texts: patients.284 For more information about breast cancer survivorship and the side effects of treatment, visitcancer.org/statistics to see Cancer Treatment & Survivorship Facts & Figures . Radiation therapy Radiation therapy is often used after surgery to destroy cancer cellsremaining in the breast, chest wall, or underarm area and reduce the risk local of recurrence. Radiation therapy after BCS is standard for mostpatients, as it has been shown to reduce the risk of cancer recurrence by about 50% at 10 years and the risk of breastcancer death by almost 20% at 15 years.288 However, evidence from randomized control trials has suggested adjuvant radiation may be omitted without\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  137\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  138  doc chunk text: ['impacting survival in certain subsets of patients receiving BCS, such as women ≥70 years of age with small, localized, hormone receptor (HR)', 'positive tumors taking hormone therapy.289, 290 Older patients with HR+ tumors who opt to omit radiation must be aware of the', 'heightened importance of adhering to their prescribed hormone therapy regimen. Patients treated with mastectomy can also benefit from radiation if their tumor is larger than 5', 'centimeters, growing into nearby tissues, or if cancer is found in the lymph nodes. Radiation can also be used to treat the', 'symptoms of advanced breast cancer, especially when it has spread to the central nervous system or bones. Radiation therapy may be']\n",
            "Texts: impacting survival in certain subsets of patients receiving BCS, such as women ≥70 years of age with small, localized, hormone receptor (HR)positive tumors taking hormone therapy.289, 290 Older patients with HR+ tumors who opt to omit radiation must be aware of theheightened importance of adhering to their prescribed hormone therapy regimen. Patients treated with mastectomy can also benefit from radiation if their tumor is larger than 5centimeters, growing into nearby tissues, or if cancer is found in the lymph nodes. Radiation can also be used to treat thesymptoms of advanced breast cancer, especially when it has spread to the central nervous system or bones. Radiation therapy may be\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  138\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  139  doc chunk text: ['administered as external beam radiation or internal radiation therapy (brachytherapy). The method depends on the type, stage, and location of the tumor, as well as', 'patient characteristics and doctor and patient preferences. External beam radiation is the standard type of radiation, whereby radiation from a machine outside the body is', 'focused on the area affected by cancer.291 Brachytherapy uses a radioactive source placed in catheters or other devices that are put into the breast', 'cavity left after BCS and is sometimes an option for patients with early-stage cancers. Accumulating evidence suggests that radiation therapy given in', 'hypofractionated schedules (in which the total dose of radiation is divided into a smaller number of larger doses compared to standard']\n",
            "Texts: administered as external beam radiation or internal radiation therapy (brachytherapy). The method depends on the type, stage, and location of the tumor, as well aspatient characteristics and doctor and patient preferences. External beam radiation is the standard type of radiation, whereby radiation from a machine outside the body isfocused on the area affected by cancer.291 Brachytherapy uses a radioactive source placed in catheters or other devices that are put into the breastcavity left after BCS and is sometimes an option for patients with early-stage cancers. Accumulating evidence suggests that radiation therapy given inhypofractionated schedules (in which the total dose of radiation is divided into a smaller number of larger doses compared to standard\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  139\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  140  doc chunk text: ['schedules) over fewer days may be as effective as conventional therapy.292-294 Intraoperative radiation therapy, in which a single fraction of radiation is given', 'directly into the breast cavity after BCS, is also sometimes an option in very select cancers. Systemic drug therapy Systemic therapies are drugs that', 'travel through the bloodstream, reaching most parts of the body, and work using different mechanisms. For example, chemotherapy drugs generally attack all cells that grow', 'quickly, such as cancer cells, but may attack normal cells (e.g., those that produce hair) as well. Hormonal therapy works by either', 'blocking or decreasing the level of the body’s natural hormones, which sometimes promote cancer growth. Targeted drug therapies work by attacking specific']\n",
            "Texts: schedules) over fewer days may be as effective as conventional therapy.292-294 Intraoperative radiation therapy, in which a single fraction of radiation is givendirectly into the breast cavity after BCS, is also sometimes an option in very select cancers. Systemic drug therapy Systemic therapies are drugs thattravel through the bloodstream, reaching most parts of the body, and work using different mechanisms. For example, chemotherapy drugs generally attack all cells that growquickly, such as cancer cells, but may attack normal cells (e.g., those that produce hair) as well. Hormonal therapy works by eitherblocking or decreasing the level of the body’s natural hormones, which sometimes promote cancer growth. Targeted drug therapies work by attacking specific\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  140\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  141  doc chunk text: ['proteins on cancer cells (or nearby cells) that help them grow. Immunotherapy stimulates the patient’s immune system to attack cancer cells. Systemic', 'therapies often are used in combination with each other, particularly for advanced or recurrent disease. When systemic drug therapy is given to', 'patients before surgery, it is called neoadjuvant or preoperative therapy. For larger breast tumors, it is often used to shrink the tumor enough to make', 'surgical removal easier and less extensive (such as BCS in women who would otherwise have required', 'mastectomy).295 Systemic drug treatment 28 Breast Cancer Facts & Figures 2022-2024given to patients after surgery is called adjuvant drug therapy. Systemic drug therapy']\n",
            "Texts: proteins on cancer cells (or nearby cells) that help them grow. Immunotherapy stimulates the patient’s immune system to attack cancer cells. Systemictherapies often are used in combination with each other, particularly for advanced or recurrent disease. When systemic drug therapy is given topatients before surgery, it is called neoadjuvant or preoperative therapy. For larger breast tumors, it is often used to shrink the tumor enough to makesurgical removal easier and less extensive (such as BCS in women who would otherwise have requiredmastectomy).295 Systemic drug treatment 28 Breast Cancer Facts & Figures 2022-2024given to patients after surgery is called adjuvant drug therapy. Systemic drug therapy\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  141\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  142  doc chunk text: ['destroys any undetected tumor cells (micrometastases) that may have migrated to other parts of the body and is the main treatment option for women with', 'metastatic breast cancer. Systemic drug therapy can affect fertility in premenopausal women, so young breast cancer patients who are interested in future', 'childbearing should consult with a reproductive endocrinologist as soon as possible to determine fertility preservation strategies. Recent studies have suggested that modest breast cancer', 'treatment delays to allow for fertility preservation (e.g., cryopreservation of eggs) do not significantly increase all-cause or breast', 'cancer-specific mortality or recurrence.296-298 Chemotherapy can also lead to premature ovarian failure. Hormone therapy for breast cancer can lead to menstrual']\n",
            "Texts: destroys any undetected tumor cells (micrometastases) that may have migrated to other parts of the body and is the main treatment option for women withmetastatic breast cancer. Systemic drug therapy can affect fertility in premenopausal women, so young breast cancer patients who are interested in futurechildbearing should consult with a reproductive endocrinologist as soon as possible to determine fertility preservation strategies. Recent studies have suggested that modest breast cancertreatment delays to allow for fertility preservation (e.g., cryopreservation of eggs) do not significantly increase all-cause or breastcancer-specific mortality or recurrence.296-298 Chemotherapy can also lead to premature ovarian failure. Hormone therapy for breast cancer can lead to menstrual\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  142\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  143  doc chunk text: ['irregularities and even amenorrhea, but normal ovarian function can return once the medication is stopped. However, the drugs used for hormone therapy can affect the', 'fetus, so treatment is delayed for women who are pregnant. Chemotherapy The benefit of chemotherapy depends on multiple factors, including the size of the tumor and the', 'number of lymph nodes involved, as well as HR and HER2 status. Triple- negative and HER2+ breast cancers tend to be more', 'sensitive to chemotherapy than HR+ tumors.299 Gene expression panels (such as Oncotype DX, and MammaPrint) may help assess the risk of distant', 'recurrence and potentially identify those who would more likely benefit from adjuvant chemotherapy. The Oncotype Dx 21-Gene Recurrence Score is used most widely in the US, but it']\n",
            "Texts: irregularities and even amenorrhea, but normal ovarian function can return once the medication is stopped. However, the drugs used for hormone therapy can affect thefetus, so treatment is delayed for women who are pregnant. Chemotherapy The benefit of chemotherapy depends on multiple factors, including the size of the tumor and thenumber of lymph nodes involved, as well as HR and HER2 status. Triple- negative and HER2+ breast cancers tend to be moresensitive to chemotherapy than HR+ tumors.299 Gene expression panels (such as Oncotype DX, and MammaPrint) may help assess the risk of distantrecurrence and potentially identify those who would more likely benefit from adjuvant chemotherapy. The Oncotype Dx 21-Gene Recurrence Score is used most widely in the US, but it\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  143\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  144  doc chunk text: ['is only applicable for patients with HR+/HER2- breast cancer. A high recurrence score identifies women who are more likely to benefit from', 'adjuvant chemotherapy (in addition to hormone therapy), whereas a low score identifies women who could safely avoid it. Evidence is less clear for', 'patients with intermediate risk scores, although recent clinical trial results based on 9 years of follow-up suggest that most patients over age 50 with', 'intermediate scores are unlikely to benefit from the addition of chemotherapy.300 Although most women who are treated with', 'chemotherapy receive it after surgery, the use of neoadjuvant chemotherapy, particularly among patients with HER2+ and']\n",
            "Texts: is only applicable for patients with HR+/HER2- breast cancer. A high recurrence score identifies women who are more likely to benefit fromadjuvant chemotherapy (in addition to hormone therapy), whereas a low score identifies women who could safely avoid it. Evidence is less clear forpatients with intermediate risk scores, although recent clinical trial results based on 9 years of follow-up suggest that most patients over age 50 withintermediate scores are unlikely to benefit from the addition of chemotherapy.300 Although most women who are treated withchemotherapy receive it after surgery, the use of neoadjuvant chemotherapy, particularly among patients with HER2+ and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  144\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  145  doc chunk text: ['triple-negative breast cancers, appears to be increasing.301 A meta-analysis of 10 clinical trials concluded that neoadjuvant chemotherapy is as effective as the same', 'therapy given after surgery in terms of breast cancer-specific survival and distant recurrence.295 Although surgery is still necessary after', 'neoadjuvant chemotherapy, even when the preoperative treatment appears to have completely cleared all clinical evidence of the cancer, studies are exploring whether they may be less', 'invasive if disease becomes substantially reduced.302 Recent clinical trials have identified therapies that can improve outcomes among', 'neoadjuvant-treated breast cancer patients (with triple-negative and HER2 positive cancers) who have residual disease detected during surgery.303, 304 Hormone']\n",
            "Texts: triple-negative breast cancers, appears to be increasing.301 A meta-analysis of 10 clinical trials concluded that neoadjuvant chemotherapy is as effective as the sametherapy given after surgery in terms of breast cancer-specific survival and distant recurrence.295 Although surgery is still necessary afterneoadjuvant chemotherapy, even when the preoperative treatment appears to have completely cleared all clinical evidence of the cancer, studies are exploring whether they may be lessinvasive if disease becomes substantially reduced.302 Recent clinical trials have identified therapies that can improve outcomes amongneoadjuvant-treated breast cancer patients (with triple-negative and HER2 positive cancers) who have residual disease detected during surgery.303, 304 Hormone\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  145\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  146  doc chunk text: ['(endocrine) therapy About 77% of breast cancers are HR+ ( Figure 1 ) and can be treated with hormone therapy to block or lower the', 'effects of estrogen and progesterone on the growth of breast cancer cells. These drugs are different than menopausal hormone therapies, which actually', 'increase hormone levels. About 84% of women with HR+ tumors receive hormone therapy, although receipt is lower for Black women compared to White women,', 'especially for those diagnosed with metastatic disease (69% versus 77%).305 For premenopausal women, tamoxifen for up to 10 years is standard', 'treatment; however, for women with a high risk of recurrence, the combination of ovarian suppression and either tamoxifen or an aromatase']\n",
            "Texts: (endocrine) therapy About 77% of breast cancers are HR+ ( Figure 1 ) and can be treated with hormone therapy to block or lower theeffects of estrogen and progesterone on the growth of breast cancer cells. These drugs are different than menopausal hormone therapies, which actuallyincrease hormone levels. About 84% of women with HR+ tumors receive hormone therapy, although receipt is lower for Black women compared to White women,especially for those diagnosed with metastatic disease (69% versus 77%).305 For premenopausal women, tamoxifen for up to 10 years is standardtreatment; however, for women with a high risk of recurrence, the combination of ovarian suppression and either tamoxifen or an aromatase\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  146\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  147  doc chunk text: ['inhibitor (i.e., letrozole, anastrozole, and exemestane) is recommended.306 For postmenopausal women, aromatase inhibitors are the preferred hormone treatment. The decision to treat with an', 'aromatase inhibitor beyond 5 years is individualized based on patient factors and the expected benefit from the reduction in risk of', 'subsequent breast cancers. Studies have found that adherence to hormone therapies remains suboptimal, particularly among Black women, and is due in part to side', 'effects, and perhaps the out-of- pocket cost.307-309Breast Cancer Facts & Figures 2022-2024 29Targeted drug therapy Multiple medications are available for the', 'treatment of HER2+ cancers, which account for about 14% of all female breast cancers in the US ( Figure 1 ). All']\n",
            "Texts: inhibitor (i.e., letrozole, anastrozole, and exemestane) is recommended.306 For postmenopausal women, aromatase inhibitors are the preferred hormone treatment. The decision to treat with anaromatase inhibitor beyond 5 years is individualized based on patient factors and the expected benefit from the reduction in risk ofsubsequent breast cancers. Studies have found that adherence to hormone therapies remains suboptimal, particularly among Black women, and is due in part to sideeffects, and perhaps the out-of- pocket cost.307-309Breast Cancer Facts & Figures 2022-2024 29Targeted drug therapy Multiple medications are available for thetreatment of HER2+ cancers, which account for about 14% of all female breast cancers in the US ( Figure 1 ). All\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  147\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  148  doc chunk text: ['invasive breast cancers should be tested for HER2 to identify women who would benefit from targeted drug therapies.', 'Trastuzumab, the first approved targeted drug for breast cancer, is a monoclonal antibody that directly targets the HER2 protein. Several new drugs that target the HER2', 'protein are now available and can be used in combination with trastuzumab or if trastuzumab is no longer working.310 For example,', 'trastuzumab emtansine and trastuzumab deruxtecan are antibody-drug conjugates (drugs that include both a targeted antibody and a chemotherapy agent) that may be used in', 'patients with metastatic HER2+ disease, typically after other treatments have been tried.311 Trastuzumab deruxtecan was also recently found to improve overall survival in']\n",
            "Texts: invasive breast cancers should be tested for HER2 to identify women who would benefit from targeted drug therapies.Trastuzumab, the first approved targeted drug for breast cancer, is a monoclonal antibody that directly targets the HER2 protein. Several new drugs that target the HER2protein are now available and can be used in combination with trastuzumab or if trastuzumab is no longer working.310 For example,trastuzumab emtansine and trastuzumab deruxtecan are antibody-drug conjugates (drugs that include both a targeted antibody and a chemotherapy agent) that may be used inpatients with metastatic HER2+ disease, typically after other treatments have been tried.311 Trastuzumab deruxtecan was also recently found to improve overall survival in\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  148\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  149  doc chunk text: ['previously treated metastatic patients with very low levels of HER2 expression (referred to as HER2-low disease) compared to standard', 'chemotherapy.312 Additional targeted therapy drugs, such as CDK4/6 and PI3K inhibitors, are available for treatment of select patients with advanced disease, often along with', 'hormone therapy. Targeted drugs known as PARP inhibitors are also available to patients with germline BRCA', 'variations,313, 314 and an antibody-drug conjugate (sacituzumab govitecan) may be used in patients with metastatic', 'triple-negative breast cancer that has recurred or progressed.315 Immunotherapy Immunotherapy drugs are an emerging area of breast cancer treatment. These drugs']\n",
            "Texts: previously treated metastatic patients with very low levels of HER2 expression (referred to as HER2-low disease) compared to standardchemotherapy.312 Additional targeted therapy drugs, such as CDK4/6 and PI3K inhibitors, are available for treatment of select patients with advanced disease, often along withhormone therapy. Targeted drugs known as PARP inhibitors are also available to patients with germline BRCAvariations,313, 314 and an antibody-drug conjugate (sacituzumab govitecan) may be used in patients with metastatictriple-negative breast cancer that has recurred or progressed.315 Immunotherapy Immunotherapy drugs are an emerging area of breast cancer treatment. These drugs\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  149\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  150  doc chunk text: ['stimulate a person’s own immune system to recognize and destroy cancer cells more effectively. For example, the immune system normally uses certain', '“checkpoint” proteins to keep the immune system in check, which can stop it from attacking cancer cells.', 'Immunotherapy drugs known as checkpoint inhibitors, such as pembrolizumab, can be used to treat some', 'triple-negative breast cancers.316-318 Research is ongoing to develop novel immunotherapy drugs and regimens, particularly for metastatic and', 'triple-negative disease. However, several challenges remain, including identifying effective biomarker targets.319, 320 What Is the American Cancer Society Doing About Breast Cancer? For more than 100']\n",
            "Texts: stimulate a person’s own immune system to recognize and destroy cancer cells more effectively. For example, the immune system normally uses certain“checkpoint” proteins to keep the immune system in check, which can stop it from attacking cancer cells.Immunotherapy drugs known as checkpoint inhibitors, such as pembrolizumab, can be used to treat sometriple-negative breast cancers.316-318 Research is ongoing to develop novel immunotherapy drugs and regimens, particularly for metastatic andtriple-negative disease. However, several challenges remain, including identifying effective biomarker targets.319, 320 What Is the American Cancer Society Doing About Breast Cancer? For more than 100\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  150\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  151  doc chunk text: ['years, the American Cancer Society (ACS) has helped lead an evolution in the way the world prevents, detects, treats, and thinks about breast cancer – and all', 'cancers. As the nation’s preeminent cancer-fighting organization, we fund and conduct research, share expert information, support people impacted by cancer, spread the word about ways to', 'reduce cancer risk, and through our advocacy affiliate, the American Cancer Society Cancer Action NetworkSM (ACS CAN), advocate for public policy change. We are the only', 'organization that integrates discovery, advocacy, and direct patient support to measurably improve lives. ACS is working to ensure that all people have a fair and just', 'opportunity to prevent, find, treat, and survive cancer. ACS and ACS CAN also believe all people should have a fair and just']\n",
            "Texts: years, the American Cancer Society (ACS) has helped lead an evolution in the way the world prevents, detects, treats, and thinks about breast cancer – and allcancers. As the nation’s preeminent cancer-fighting organization, we fund and conduct research, share expert information, support people impacted by cancer, spread the word about ways toreduce cancer risk, and through our advocacy affiliate, the American Cancer Society Cancer Action NetworkSM (ACS CAN), advocate for public policy change. We are the onlyorganization that integrates discovery, advocacy, and direct patient support to measurably improve lives. ACS is working to ensure that all people have a fair and justopportunity to prevent, find, treat, and survive cancer. ACS and ACS CAN also believe all people should have a fair and just\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  151\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  152  doc chunk text: ['opportunity to live a longer, healthier life free from cancer regardless of how much money they make, the color of their skin, their sexual', 'orientation, gender identity, their disability status, or where they live. (For more information on these initiatives, see the Advocacy section on page 32.) This work', 'could not be accomplished without the strength of our dedicated volunteers to drive every part of our mission. With the support of our', 'professional staff, volunteers raise funds to support innovative research, provide rides to treatment for people with cancer, and offer', 'peer-to-peer support to those facing a cancer diagnosis – and that’s just the beginning. Thanks in part to our']\n",
            "Texts: opportunity to live a longer, healthier life free from cancer regardless of how much money they make, the color of their skin, their sexualorientation, gender identity, their disability status, or where they live. (For more information on these initiatives, see the Advocacy section on page 32.) This workcould not be accomplished without the strength of our dedicated volunteers to drive every part of our mission. With the support of ourprofessional staff, volunteers raise funds to support innovative research, provide rides to treatment for people with cancer, and offerpeer-to-peer support to those facing a cancer diagnosis – and that’s just the beginning. Thanks in part to our\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  152\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  153  doc chunk text: ['contributions, 3.2 million cancer deaths have been 30 Breast Cancer Facts & Figures 2022-2024averted in the US since 1991, when cancer death rates were at', 'their peak. Patient support The American Cancer Society works to ensure no one feels alone at any point on their cancer journey, from', 'prevention to detection and diagnosis, through treatment and survivorship, and for some, the end of life. We ensure people impacted by cancer have the', 'support, information, and resources they need, all aimed toward eliminating cancer disparities. Cancer information Caring, trained American Cancer Society staff provide people with', 'information and support about breast cancer when they need it, including a free 24/7 cancer helpline, cancer.org website, and online peer']\n",
            "Texts: contributions, 3.2 million cancer deaths have been 30 Breast Cancer Facts & Figures 2022-2024averted in the US since 1991, when cancer death rates were attheir peak. Patient support The American Cancer Society works to ensure no one feels alone at any point on their cancer journey, fromprevention to detection and diagnosis, through treatment and survivorship, and for some, the end of life. We ensure people impacted by cancer have thesupport, information, and resources they need, all aimed toward eliminating cancer disparities. Cancer information Caring, trained American Cancer Society staff provide people withinformation and support about breast cancer when they need it, including a free 24/7 cancer helpline, cancer.org website, and online peer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  153\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  154  doc chunk text: ['communities for people with cancer, caregivers, and survivors. Our website, cancer.org , offers reliable and accurate breast cancer information and news,', 'including current information on treatments and side effects, and programs and services available nearby. We can also help people who speak', 'languages other than English or Spanish find the assistance they need at', 'cancer.org/cancer-information-in-other-languages . People can visit cancer.org/breastcancer to find information on every aspect of the breast cancer experience, from prevention to', 'survivorship. We also publish a wide variety of pamphlets and books that cover a multitude of topics, from patient education,']\n",
            "Texts: communities for people with cancer, caregivers, and survivors. Our website, cancer.org , offers reliable and accurate breast cancer information and news,including current information on treatments and side effects, and programs and services available nearby. We can also help people who speaklanguages other than English or Spanish find the assistance they need atcancer.org/cancer-information-in-other-languages . People can visit cancer.org/breastcancer to find information on every aspect of the breast cancer experience, from prevention tosurvivorship. We also publish a wide variety of pamphlets and books that cover a multitude of topics, from patient education,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  154\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  155  doc chunk text: ['quality-of-life, and caregiving issues to healthy living. Visit cancer.org/ bookstore for a complete list of books that are available for order. All of our books are', 'also available from all major book retailers such as Amazon and Barnes & Noble. Call 1-800-227-2345 or visit cancer.org for', 'brochures. Programs and services Survivorship: The American Cancer Society’s survivorship work aims to help people living with and beyond cancer from', 'diagnosis through long-term survivorship to the end of life. Efforts focus on helping survivors understand and access treatment; manage their ongoing', 'physical, psychosocial, and functional problems; and engage in healthy behaviors to optimize their wellness. Our post-treatment survivorship care guidelines are designed to promote']\n",
            "Texts: quality-of-life, and caregiving issues to healthy living. Visit cancer.org/ bookstore for a complete list of books that are available for order. All of our books arealso available from all major book retailers such as Amazon and Barnes & Noble. Call 1-800-227-2345 or visit cancer.org forbrochures. Programs and services Survivorship: The American Cancer Society’s survivorship work aims to help people living with and beyond cancer fromdiagnosis through long-term survivorship to the end of life. Efforts focus on helping survivors understand and access treatment; manage their ongoingphysical, psychosocial, and functional problems; and engage in healthy behaviors to optimize their wellness. Our post-treatment survivorship care guidelines are designed to promote\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  155\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  156  doc chunk text: ['survivor health and quality of life by facilitating the delivery of high-quality, comprehensive, coordinated clinical follow-up care. Our', 'survivorship research efforts focus on understanding the impact of cancer on multiple facets of survivors’ lives and on developing and testing', 'interventions to help survivors actively engage in their health care and improve their health and well-being through and beyond treatment. Through the', 'National Cancer Survivorship Resource Center, a collaboration between the American Cancer Society and the George Washington University Cancer Center funded by the Centers for', 'Disease Control and Prevention, we created the Cancer Survivorship E-Learning Series for Primary Care Providers. The free e-learning program is designed to teach']\n",
            "Texts: survivor health and quality of life by facilitating the delivery of high-quality, comprehensive, coordinated clinical follow-up care. Oursurvivorship research efforts focus on understanding the impact of cancer on multiple facets of survivors’ lives and on developing and testinginterventions to help survivors actively engage in their health care and improve their health and well-being through and beyond treatment. Through theNational Cancer Survivorship Resource Center, a collaboration between the American Cancer Society and the George Washington University Cancer Center funded by the Centers forDisease Control and Prevention, we created the Cancer Survivorship E-Learning Series for Primary Care Providers. The free e-learning program is designed to teach\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  156\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  157  doc chunk text: ['clinicians how to care for survivors of adult-onset cancers. Support for caregivers: Contemporary estimates of caregiver prevalence range between 1.1 million and 6.1', 'million individuals, and the American Cancer Society is committed to meeting their information, education, and support needs. We support the notion that cancer is not', 'isolated only to the individual diagnosed, but also impacts an entire family unit and network of close friends. One of the', 'informational tools we offer caregivers is our Caregiver Resource Guide', '(cancer.org/caregiverguide ), which can help them: learn to care for themselves as a caregiver, better understand what their loved one is going']\n",
            "Texts: clinicians how to care for survivors of adult-onset cancers. Support for caregivers: Contemporary estimates of caregiver prevalence range between 1.1 million and 6.1million individuals, and the American Cancer Society is committed to meeting their information, education, and support needs. We support the notion that cancer is notisolated only to the individual diagnosed, but also impacts an entire family unit and network of close friends. One of theinformational tools we offer caregivers is our Caregiver Resource Guide(cancer.org/caregiverguide ), which can help them: learn to care for themselves as a caregiver, better understand what their loved one is going\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  157\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  158  doc chunk text: ['through, develop skills for coping and caring, and take steps to help protect their own health and well-being. Also, our Caregiver Support Video Series', '(cancer.org/caregivervideos ) provides educational support to caregivers as they assist with the everyday needs of people with cancer and provide self-care', 'techniques to improve their quality of life. Help navigating the health care system Learning how to navigate the cancer journey and the health care', 'system can be overwhelming for anyone, but it is particularly difficult for those who are medically underserved, those who experience language or health', 'literacy barriers, and those with limited resources. The Breast Cancer Facts & Figures 2022-2024 31American Cancer Society aims to reach those most in need']\n",
            "Texts: through, develop skills for coping and caring, and take steps to help protect their own health and well-being. Also, our Caregiver Support Video Series(cancer.org/caregivervideos ) provides educational support to caregivers as they assist with the everyday needs of people with cancer and provide self-caretechniques to improve their quality of life. Help navigating the health care system Learning how to navigate the cancer journey and the health caresystem can be overwhelming for anyone, but it is particularly difficult for those who are medically underserved, those who experience language or healthliteracy barriers, and those with limited resources. The Breast Cancer Facts & Figures 2022-2024 31American Cancer Society aims to reach those most in need\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  158\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  159  doc chunk text: ['through our National Cancer Information Center (NCIC), where we can help find transportation to treatment and other', 'cancer-related appointments; assist with medical financial issues, including insurance navigation; identify resources; and provide information on a patient’s cancer diagnosis and', 'treatment process. Breast cancer support The American Cancer Society connects people facing breast cancer with one-on-one support – from diagnosis through', 'survivorship – with trained volunteers who are breast cancer survivors. Our Reach To Recovery® volunteers help people facing breast cancer cope with', 'diagnosis, treatment, side effects, and more. Visit reach.cancer.org for more information. Finding hope and inspiration The American Cancer Society provides']\n",
            "Texts: through our National Cancer Information Center (NCIC), where we can help find transportation to treatment and othercancer-related appointments; assist with medical financial issues, including insurance navigation; identify resources; and provide information on a patient’s cancer diagnosis andtreatment process. Breast cancer support The American Cancer Society connects people facing breast cancer with one-on-one support – from diagnosis throughsurvivorship – with trained volunteers who are breast cancer survivors. Our Reach To Recovery® volunteers help people facing breast cancer cope withdiagnosis, treatment, side effects, and more. Visit reach.cancer.org for more information. Finding hope and inspiration The American Cancer Society provides\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  159\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  160  doc chunk text: ['information and support through our online communities. These virtual communities provide people facing breast cancer – or any cancer – and', 'survivors the opportunity to learn more and connect with others who can be a source of support and comfort. Our Cancer', 'Survivors Network ( csn.cancer.org ) is a safe online community where survivors and caregivers can share their stories, ask questions, and support each other.', 'Transportation to treatment American Cancer Society volunteers help people with cancer get free transportation to medical appointments and treatment. Our Road To', 'Recovery® program removes barriers to cancer treatment by providing people with cancer transportation through volunteer drivers. Lodging during treatment American Cancer Society Hope Lodge®']\n",
            "Texts: information and support through our online communities. These virtual communities provide people facing breast cancer – or any cancer – andsurvivors the opportunity to learn more and connect with others who can be a source of support and comfort. Our CancerSurvivors Network ( csn.cancer.org ) is a safe online community where survivors and caregivers can share their stories, ask questions, and support each other.Transportation to treatment American Cancer Society volunteers help people with cancer get free transportation to medical appointments and treatment. Our Road ToRecovery® program removes barriers to cancer treatment by providing people with cancer transportation through volunteer drivers. Lodging during treatment American Cancer Society Hope Lodge®\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  160\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  161  doc chunk text: ['communities provide free, temporary lodging for people facing cancer and their caregivers when treatment is far from home. Hope Lodge guests don’t just find a', 'place to stay – they find a community of support and an emotional connection with others facing the same', 'journey.Hair-loss and mastectomy products The American Cancer Society helps women cope with', 'appearance-related side effects of cancer treatment through our “tlc” Tender Loving Care® program. The “tlc”TM program offers a variety of', 'affordable wigs, hats, and scarves, as well as a full range of mastectomy programs – all available for purchase from the privacy of home. Call']\n",
            "Texts: communities provide free, temporary lodging for people facing cancer and their caregivers when treatment is far from home. Hope Lodge guests don’t just find aplace to stay – they find a community of support and an emotional connection with others facing the samejourney.Hair-loss and mastectomy products The American Cancer Society helps women cope withappearance-related side effects of cancer treatment through our “tlc” Tender Loving Care® program. The “tlc”TM program offers a variety ofaffordable wigs, hats, and scarves, as well as a full range of mastectomy programs – all available for purchase from the privacy of home. Call\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  161\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  162  doc chunk text: ['1-800-850-9445 or visit the “tlc” website at tlcdirect.org to order products or catalogs. Support after treatment The end of breast cancer', 'treatment does not mean the end of a cancer journey. Cancer survivors may experience long-term or late effects resulting from the disease or its', 'treatment. The Life After Treatment: The Next Chapter in Your Survivorship Journey guide may help cancer survivors as they begin the next phase of their', 'journey. Visit cancer.org/ survivorshipguide to download a free copy of the guide. The American Cancer Society offers a follow-up care guideline for breast cancer', 'survivors based on available evidence, surveillance guidelines, and standard clinical practice and designed to facilitate the provision of']\n",
            "Texts: 1-800-850-9445 or visit the “tlc” website at tlcdirect.org to order products or catalogs. Support after treatment The end of breast cancertreatment does not mean the end of a cancer journey. Cancer survivors may experience long-term or late effects resulting from the disease or itstreatment. The Life After Treatment: The Next Chapter in Your Survivorship Journey guide may help cancer survivors as they begin the next phase of theirjourney. Visit cancer.org/ survivorshipguide to download a free copy of the guide. The American Cancer Society offers a follow-up care guideline for breast cancersurvivors based on available evidence, surveillance guidelines, and standard clinical practice and designed to facilitate the provision of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  162\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  163  doc chunk text: ['high-quality, standardized, clinical care by primary care providers.321 The breast cancer guideline addresses the assessment and management of potential long-term and late', 'effects, as well as recommendations for health promotion, surveillance for recurrence, screening for second primary cancers, and the', 'coordination of care between specialists and primary care clinicians. Research The American Cancer Society has played a role in most of the cancer', 'research breakthroughs in recent history. We invest more in breast cancer research than any other cancer type. Our funded research has led to the', 'development of potentially lifesaving breast cancer drugs such as tamoxifen and Herceptin, as well as improved understanding of genes linked to breast cancer.']\n",
            "Texts: high-quality, standardized, clinical care by primary care providers.321 The breast cancer guideline addresses the assessment and management of potential long-term and lateeffects, as well as recommendations for health promotion, surveillance for recurrence, screening for second primary cancers, and thecoordination of care between specialists and primary care clinicians. Research The American Cancer Society has played a role in most of the cancerresearch breakthroughs in recent history. We invest more in breast cancer research than any other cancer type. Our funded research has led to thedevelopment of potentially lifesaving breast cancer drugs such as tamoxifen and Herceptin, as well as improved understanding of genes linked to breast cancer.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  163\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  164  doc chunk text: ['Ongoing research studies span the cancer continuum from prevention and early detection to treatment and beyond. As of March 31, 2022, the', 'American Cancer Society is funding more than $72 million in breast cancer research through 162 research and training grants. 32 Breast Cancer Facts &', 'Figures 2022-2024Examples of projects in which researchers in Extramural Discovery Science are engaged span the six ACS Research Priority Areas', '(indicated in parentheses below) and include: • Identifying new targets for treating triple-negative breast cancers (treatment) • Developing a wearable device to image breast', 'cancers for assessing effectiveness of ongoing treatments (treatment) • Understanding the role of the immune system in the spread of breast cancer to other parts of the']\n",
            "Texts: Ongoing research studies span the cancer continuum from prevention and early detection to treatment and beyond. As of March 31, 2022, theAmerican Cancer Society is funding more than $72 million in breast cancer research through 162 research and training grants. 32 Breast Cancer Facts &Figures 2022-2024Examples of projects in which researchers in Extramural Discovery Science are engaged span the six ACS Research Priority Areas(indicated in parentheses below) and include: • Identifying new targets for treating triple-negative breast cancers (treatment) • Developing a wearable device to image breastcancers for assessing effectiveness of ongoing treatments (treatment) • Understanding the role of the immune system in the spread of breast cancer to other parts of the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  164\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  165  doc chunk text: ['body (etiology/causes of cancer) • Evaluating the effects of a high-protein, low-calorie diet on breast tissue and the risk of breast cancer', 'recurrence (etiology/causes of cancer; survivorship) • Examining the impact of breast density legislation on women’s breast cancer knowledge and screening decisions', '(screening and diagnosis) • Elucidating biobehavioral mechanisms of breast cancer racial disparities (health equity across the cancer continuum) • Testing', 'strategies to improved participation in exercise for Hispanic breast cancer survivors (health equity across the cancer continuum; obesity and Healthy Eating and Active Living', '[HEAL]) • Addressing gaps and disparities in genetic risk prevention in breast cancer patients and their families Internally, the American Cancer Society also']\n",
            "Texts: body (etiology/causes of cancer) • Evaluating the effects of a high-protein, low-calorie diet on breast tissue and the risk of breast cancerrecurrence (etiology/causes of cancer; survivorship) • Examining the impact of breast density legislation on women’s breast cancer knowledge and screening decisions(screening and diagnosis) • Elucidating biobehavioral mechanisms of breast cancer racial disparities (health equity across the cancer continuum) • Testingstrategies to improved participation in exercise for Hispanic breast cancer survivors (health equity across the cancer continuum; obesity and Healthy Eating and Active Living[HEAL]) • Addressing gaps and disparities in genetic risk prevention in breast cancer patients and their families Internally, the American Cancer Society also\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  165\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  166  doc chunk text: ['conducts epidemiologic studies of breast cancer and performs surveillance and health services research to understand the factors that underlie racial and', 'socioeconomic disparities in breast cancer screening, incidence, treatment, survival, and mortality. Using information collected from more than 600,000 women in the American Cancer', 'Society Cancer Prevention Study-II, our epidemiologists study the influence of many risk factors, including alcohol consumption, physical activity, menopausal hormones, family history of', 'cancer, obesity, smoking, and spontaneous abortion on the risk of death from breast cancer. In order to continue to explore the effects of', 'changing exposures and to provide greater opportunity to integrate biological and genetic factors into studies of other risk factors, more than 304,000 men and women were']\n",
            "Texts: conducts epidemiologic studies of breast cancer and performs surveillance and health services research to understand the factors that underlie racial andsocioeconomic disparities in breast cancer screening, incidence, treatment, survival, and mortality. Using information collected from more than 600,000 women in the American CancerSociety Cancer Prevention Study-II, our epidemiologists study the influence of many risk factors, including alcohol consumption, physical activity, menopausal hormones, family history ofcancer, obesity, smoking, and spontaneous abortion on the risk of death from breast cancer. In order to continue to explore the effects ofchanging exposures and to provide greater opportunity to integrate biological and genetic factors into studies of other risk factors, more than 304,000 men and women were\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  166\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  167  doc chunk text: ['enrolled in the American Cancer Society Cancer Prevention Study-3 (CPS-3), and nearly all provided a blood sample at the time of', 'enrollment. When female participants are diagnosed with breast cancer, consent is requested to bank tumor tissue specimens to better understand', 'differences in risk and prognostic factors by molecular subtypes of breast cancer. The blood and tissue specimens together with the', 'questionnaire data collected from CPS-3 participants will provide unique opportunities for research in the US. Advocacy The American Cancer Society Cancer Action', 'NetworkSM (ACS CAN), the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society, advocates in city halls, statehouses, and Congress to increase access to']\n",
            "Texts: enrolled in the American Cancer Society Cancer Prevention Study-3 (CPS-3), and nearly all provided a blood sample at the time ofenrollment. When female participants are diagnosed with breast cancer, consent is requested to bank tumor tissue specimens to better understanddifferences in risk and prognostic factors by molecular subtypes of breast cancer. The blood and tissue specimens together with thequestionnaire data collected from CPS-3 participants will provide unique opportunities for research in the US. Advocacy The American Cancer Society Cancer ActionNetworkSM (ACS CAN), the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society, advocates in city halls, statehouses, and Congress to increase access to\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  167\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  168  doc chunk text: ['quality breast cancer screenings, diagnostic and treatment services, and care for all women; increase government funding for breast cancer research; and provide a voice for the', 'concerns of breast cancer patients and survivors. Following are some of the efforts that ACS CAN has been involved with in the past few', 'years: Improving Access to Affordable Care through Health Care Reform: The Affordable Care Act (ACA) was signed into law on March 23, 2010, giving', 'people with cancer access to quality, affordable health care. All health insurance plans that must comply with the ACA, including those offered through state', 'health insurance exchanges, are required to cover preventive services rated “A” or “B” by the US Preventive Services Task Force, including']\n",
            "Texts: quality breast cancer screenings, diagnostic and treatment services, and care for all women; increase government funding for breast cancer research; and provide a voice for theconcerns of breast cancer patients and survivors. Following are some of the efforts that ACS CAN has been involved with in the past fewyears: Improving Access to Affordable Care through Health Care Reform: The Affordable Care Act (ACA) was signed into law on March 23, 2010, givingpeople with cancer access to quality, affordable health care. All health insurance plans that must comply with the ACA, including those offered through statehealth insurance exchanges, are required to cover preventive services rated “A” or “B” by the US Preventive Services Task Force, including\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  168\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  169  doc chunk text: ['mammography screening, at no cost to patients. Additionally, the ACA removed cost sharing for any preventive services covered by Medicare. ACS CAN', 'advocates for clear, comprehensive coverage of these preventive services, including breast cancer screening, and encourages states to broaden access to health care', 'coverage for all low-income Americans through state Medicaid programs.Breast Cancer Facts & Figures 2022-2024 33The National Breast and Cervical Cancer Early', 'Detection Program (NBCCEDP): Protecting and increasing funding for the NBCCEDP is a high priority for ACS CAN at both the state and federal', 'levels. Administered by the Centers for Disease Control and Prevention, this successful program provides community-based breast and cervical cancer screenings to']\n",
            "Texts: mammography screening, at no cost to patients. Additionally, the ACA removed cost sharing for any preventive services covered by Medicare. ACS CANadvocates for clear, comprehensive coverage of these preventive services, including breast cancer screening, and encourages states to broaden access to health carecoverage for all low-income Americans through state Medicaid programs.Breast Cancer Facts & Figures 2022-2024 33The National Breast and Cervical Cancer EarlyDetection Program (NBCCEDP): Protecting and increasing funding for the NBCCEDP is a high priority for ACS CAN at both the state and federallevels. Administered by the Centers for Disease Control and Prevention, this successful program provides community-based breast and cervical cancer screenings to\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  169\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  170  doc chunk text: ['low-income, uninsured, and underinsured women. Women who are uninsured are much less likely to be screened for cervical and breast cancer than those who are', 'insured. The NBCCEDP helps to decrease this disparity in screening. Unfortunately, only one in 10 eligible women can be served by the program due to lack of', 'federal and state funding. ACS CAN is asking Congress and state legislatures to increase funding to ensure that more women have access to cancer', 'screening. Protecting the Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA): In 2000, Congress passed the BCCPTA, ensuring that', 'low-income women diagnosed with cancer through the NBCCEDP were provided a pathway to treatment services through their state Medicaid program. In recent years, a']\n",
            "Texts: low-income, uninsured, and underinsured women. Women who are uninsured are much less likely to be screened for cervical and breast cancer than those who areinsured. The NBCCEDP helps to decrease this disparity in screening. Unfortunately, only one in 10 eligible women can be served by the program due to lack offederal and state funding. ACS CAN is asking Congress and state legislatures to increase funding to ensure that more women have access to cancerscreening. Protecting the Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA): In 2000, Congress passed the BCCPTA, ensuring thatlow-income women diagnosed with cancer through the NBCCEDP were provided a pathway to treatment services through their state Medicaid program. In recent years, a\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  170\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  171  doc chunk text: ['number of states have considered proposals to eliminate the treatment program due to misconceptions around coverage needs following', 'implementation of the ACA. Additionally, states have considered proposals that could jeopardize access to this program through the 1115', 'demonstration waiver process. ACS CAN has opposed these efforts and is working to protect this Medicaid eligibility category. Breast Density and', 'Mammography Reporting: Mammography sensitivity is lower for women with mammographically dense breasts because dense breast tissue makes it harder for doctors to see cancer on', 'mammograms. The Food and Drug Administration proposed a rule to incorporate breast density reporting on mammography reports for the first time in 2019. That rule has not']\n",
            "Texts: number of states have considered proposals to eliminate the treatment program due to misconceptions around coverage needs followingimplementation of the ACA. Additionally, states have considered proposals that could jeopardize access to this program through the 1115demonstration waiver process. ACS CAN has opposed these efforts and is working to protect this Medicaid eligibility category. Breast Density andMammography Reporting: Mammography sensitivity is lower for women with mammographically dense breasts because dense breast tissue makes it harder for doctors to see cancer onmammograms. The Food and Drug Administration proposed a rule to incorporate breast density reporting on mammography reports for the first time in 2019. That rule has not\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  171\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  172  doc chunk text: ['been finalized yet. ACS CAN has advocated for several years for a national standard developed through an', 'evidence-based process to inform women about breast density and risk.Patient Navigation: Patient navigation can improve quality of cancer care,', 'particularly in vulnerable populations. In 2017, the American Cancer Society established the National Navigation Roundtable (NNRT), a national coalition of over 100', 'organizations dedicated to achieving health equity and access to quality care across the cancer continuum through effective patient navigation. ACS CAN', 'advocates for the coverage of patient navigation services because clinical navigation services are not covered by most insurers. The']\n",
            "Texts: been finalized yet. ACS CAN has advocated for several years for a national standard developed through anevidence-based process to inform women about breast density and risk.Patient Navigation: Patient navigation can improve quality of cancer care,particularly in vulnerable populations. In 2017, the American Cancer Society established the National Navigation Roundtable (NNRT), a national coalition of over 100organizations dedicated to achieving health equity and access to quality care across the cancer continuum through effective patient navigation. ACS CANadvocates for the coverage of patient navigation services because clinical navigation services are not covered by most insurers. The\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  172\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  173  doc chunk text: ['organization also advocates to improve health equity by increasing access to quality cancer care among communities that have been', 'marginalized and to extend the reach of navigation services to populations that have been underserved so that they can access resources that help', 'eliminate other barriers to care. ACS CAN supports the federal Patient Navigation Assistance Act, which would require state Medicaid programs to cover', 'navigation services. In collaboration with the NNRT, the organization also is working on proposals to encourage public and private insurance coverage of patient', 'navigation services to ensure the financial stability of patient navigation programs because patient navigation services are not covered by most insurers and are']\n",
            "Texts: organization also advocates to improve health equity by increasing access to quality cancer care among communities that have beenmarginalized and to extend the reach of navigation services to populations that have been underserved so that they can access resources that helpeliminate other barriers to care. ACS CAN supports the federal Patient Navigation Assistance Act, which would require state Medicaid programs to covernavigation services. In collaboration with the NNRT, the organization also is working on proposals to encourage public and private insurance coverage of patientnavigation services to ensure the financial stability of patient navigation programs because patient navigation services are not covered by most insurers and are\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  173\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  174  doc chunk text: ['frequently supported through short-term grant funding. Funding for Cancer Research: ACS CAN continues to work to increase government funding for cancer research at the', 'National Institutes of Health, including the National Cancer Institute and the National Center on Minority Health and Health', 'Disparities. It is important to note that the preceding references to ACA provisions and other federal laws and guidance reflect current law as of 2022, and do', 'not take into account potential changes to the ACA or other federal laws and guidance subsequently considered by Congress and the', 'administration.34 Breast Cancer Facts & Figures 2022-2024Sources of Statistics Unless otherwise stated, the statistics and statements in this publication refer to invasive (not in situ)']\n",
            "Texts: frequently supported through short-term grant funding. Funding for Cancer Research: ACS CAN continues to work to increase government funding for cancer research at theNational Institutes of Health, including the National Cancer Institute and the National Center on Minority Health and HealthDisparities. It is important to note that the preceding references to ACA provisions and other federal laws and guidance reflect current law as of 2022, and donot take into account potential changes to the ACA or other federal laws and guidance subsequently considered by Congress and theadministration.34 Breast Cancer Facts & Figures 2022-2024Sources of Statistics Unless otherwise stated, the statistics and statements in this publication refer to invasive (not in situ)\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  174\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  175  doc chunk text: ['female breast cancer. Estimated new breast cancer cases. The number of invasive breast cancer cases and DCIS diagnosed in 2022 was', 'calculated by estimating complete case counts during 2004-2018 in all 50 states and the District of Columbia using a', 'spatiotemporal model that considers state variation in sociodemographic and lifestyle factors, medical settings, and cancer screening behaviors, and also accounts for expected delays in case', 'reporting. Input data for the model was cancer occurrence information from cancer registries that consented to participate and met the North American', 'Association of Central Cancer Registries’ (NAACCR) high-quality data standards. The NAACCR is an umbrella organization that sets standards and aggregates and']\n",
            "Texts: female breast cancer. Estimated new breast cancer cases. The number of invasive breast cancer cases and DCIS diagnosed in 2022 wascalculated by estimating complete case counts during 2004-2018 in all 50 states and the District of Columbia using aspatiotemporal model that considers state variation in sociodemographic and lifestyle factors, medical settings, and cancer screening behaviors, and also accounts for expected delays in casereporting. Input data for the model was cancer occurrence information from cancer registries that consented to participate and met the North AmericanAssociation of Central Cancer Registries’ (NAACCR) high-quality data standards. The NAACCR is an umbrella organization that sets standards and aggregates and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  175\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  176  doc chunk text: ['disseminates incidence data collected by cancer registries in the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) program and/or the Centers for', 'Disease Control and Prevention’s National Program of Cancer Registries. Modeled counts are then projected forward 4 years based on the most recent 4-year', 'average annual percent change (AAPC) in cases. Age-specific estimates were calculated using the proportions of cases that occurred in each age group during', '2015-2019 applied to the overall 2022 estimate. Incidence rates. Breast cancer incidence rates are defined as the number of people who are', 'diagnosed with cancer divided by the number of people who are at risk for the disease in the population during a given time']\n",
            "Texts: disseminates incidence data collected by cancer registries in the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) program and/or the Centers forDisease Control and Prevention’s National Program of Cancer Registries. Modeled counts are then projected forward 4 years based on the most recent 4-yearaverage annual percent change (AAPC) in cases. Age-specific estimates were calculated using the proportions of cases that occurred in each age group during2015-2019 applied to the overall 2022 estimate. Incidence rates. Breast cancer incidence rates are defined as the number of people who arediagnosed with cancer divided by the number of people who are at risk for the disease in the population during a given time\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  176\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  177  doc chunk text: ['period. Incidence rates in this publication are typically presented per 100,000 female population per year (or 100,000 male population for male breast cancer) and are age', 'adjusted to the 2000 US standard population based on 19 age groups. Breast cancer incidence rates for the US in the most recent time', 'period (2015-2019) were based on nationwide cancer registry data provided by NAACCR. Incidence rates presented herein may differ slightly from those on the NAACCR', 'website ( naaccr.org ) because NAACCR has begun adjusting rates based on 20 age groups instead of 19, which is the standard of the', 'National Cancer Institute and the Centers for Disease Control and Prevention. Long-term (1975-2019) incidence trends are based on the National Cancer']\n",
            "Texts: period. Incidence rates in this publication are typically presented per 100,000 female population per year (or 100,000 male population for male breast cancer) and are ageadjusted to the 2000 US standard population based on 19 age groups. Breast cancer incidence rates for the US in the most recent timeperiod (2015-2019) were based on nationwide cancer registry data provided by NAACCR. Incidence rates presented herein may differ slightly from those on the NAACCRwebsite ( naaccr.org ) because NAACCR has begun adjusting rates based on 20 age groups instead of 19, which is the standard of theNational Cancer Institute and the Centers for Disease Control and Prevention. Long-term (1975-2019) incidence trends are based on the National Cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  177\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  178  doc chunk text: ['Institute’s Surveillance, Epidemiology, and End Results (SEER) 8 registries, which account for about 8% of the US population. Analyses of trends by', 'race/ethnicity (2000-2019) and by stage at diagnosis (2004-2019) were based on SEER 22 and 17 registry incidence data,', 'respectively, and adjusted for reporting delay using delay factors. Estimated cancer deaths. The overall estimated number of breast cancer deaths in the US is', 'calculated by fitting the number of breast cancer deaths for 2006-2020 to a statistical model that forecasts the number of deaths expected to occur in', '2022. Data on the number of deaths are obtained from the National Center for Health Statistics (NCHS) at the Centers for Disease Control and']\n",
            "Texts: Institute’s Surveillance, Epidemiology, and End Results (SEER) 8 registries, which account for about 8% of the US population. Analyses of trends byrace/ethnicity (2000-2019) and by stage at diagnosis (2004-2019) were based on SEER 22 and 17 registry incidence data,respectively, and adjusted for reporting delay using delay factors. Estimated cancer deaths. The overall estimated number of breast cancer deaths in the US iscalculated by fitting the number of breast cancer deaths for 2006-2020 to a statistical model that forecasts the number of deaths expected to occur in2022. Data on the number of deaths are obtained from the National Center for Health Statistics (NCHS) at the Centers for Disease Control and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  178\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  179  doc chunk text: ['Prevention (CDC). Similar to cases, proportions of breast cancer deaths by age (2016-2020) were applied to obtain age- specific estimates. Mortality rates. Similar to', 'incidence rates, breast cancer mortality rates (or death rates) are defined as the number of people who die from cancer divided by the number of', 'people at risk in the population during a given time period. Breast cancer death rates were calculated using data on cancer deaths', 'compiled by NCHS and population data collected by the US Census Bureau. Death rates specific to the AIAN population were adjusted with', 'classification ratios by using the approach of Arias, et al.322 due to known issues with']\n",
            "Texts: Prevention (CDC). Similar to cases, proportions of breast cancer deaths by age (2016-2020) were applied to obtain age- specific estimates. Mortality rates. Similar toincidence rates, breast cancer mortality rates (or death rates) are defined as the number of people who die from cancer divided by the number ofpeople at risk in the population during a given time period. Breast cancer death rates were calculated using data on cancer deathscompiled by NCHS and population data collected by the US Census Bureau. Death rates specific to the AIAN population were adjusted withclassification ratios by using the approach of Arias, et al.322 due to known issues with\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  179\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  180  doc chunk text: ['misclassification of AIAN race on death certificates. All death rates in this publication were age adjusted to the 2000 US standard', 'population. Mortality rates for Puerto Rico were obtained from the NCI’s State Cancer Profiles, which also includes incidence rates and risk factors for states and', 'counties. Trends of mortality rates from 1990 onward by race and ethnicity exclude states during years they did not collect Hispanic', 'ethnicity data: Louisiana (1990); New Hampshire (1990-1992); and Oklahoma (1990-1996).Breast Cancer Facts & Figures 2022-2024 35Survival. Five-year survival statistics are based on breast cancer', 'patients diagnosed during 2012-2018; 10-year survival rates are based on diagnoses during 2004-2018; and 15-year survival rates are based on diagnoses during']\n",
            "Texts: misclassification of AIAN race on death certificates. All death rates in this publication were age adjusted to the 2000 US standardpopulation. Mortality rates for Puerto Rico were obtained from the NCI’s State Cancer Profiles, which also includes incidence rates and risk factors for states andcounties. Trends of mortality rates from 1990 onward by race and ethnicity exclude states during years they did not collect Hispanicethnicity data: Louisiana (1990); New Hampshire (1990-1992); and Oklahoma (1990-1996).Breast Cancer Facts & Figures 2022-2024 35Survival. Five-year survival statistics are based on breast cancerpatients diagnosed during 2012-2018; 10-year survival rates are based on diagnoses during 2004-2018; and 15-year survival rates are based on diagnoses during\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  180\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  181  doc chunk text: ['2001-2018. All patients were followed through 2019. Probability of breast cancer diagnosis or death. Probabilities of developing or dying from breast cancer were', 'calculated using DevCan 6.8.0 (Probability of Developing Cancer Software), developed by the National Cancer Institute. These probabilities reflect the average', 'experience of women in the US who were not previously diagnosed with breast cancer and do not take into account', 'individual behaviors and risk factors (e.g., utilization of mammography screening and family history of breast cancer). Screening. State-level prevalence estimates of', 'mammography are based on Behavioral Risk Factor Surveillance System (BRFSS) data. The BRFSS is an ongoing system of surveys conducted by the state health']\n",
            "Texts: 2001-2018. All patients were followed through 2019. Probability of breast cancer diagnosis or death. Probabilities of developing or dying from breast cancer werecalculated using DevCan 6.8.0 (Probability of Developing Cancer Software), developed by the National Cancer Institute. These probabilities reflect the averageexperience of women in the US who were not previously diagnosed with breast cancer and do not take into accountindividual behaviors and risk factors (e.g., utilization of mammography screening and family history of breast cancer). Screening. State-level prevalence estimates ofmammography are based on Behavioral Risk Factor Surveillance System (BRFSS) data. The BRFSS is an ongoing system of surveys conducted by the state health\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  181\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  182  doc chunk text: ['departments in cooperation with the CDC. Data from the CDC’s National Health Interview Survey were used to generate national prevalence estimates of', 'mammography. Important note about estimated cases and deaths. While these estimates provide a reasonably accurate portrayal of the current cancer burden in the', 'absence of actual data, they should be interpreted with caution because they are model-based projections that may vary from year to year for', 'reasons other than changes in cancer occurrence. As such, they are not informative for tracking cancer trends. Instead, trends in cancer', 'occurrence should be analyzed using age-adjusted incidence rates reported by population-based cancer registries and mortality rates reported by the NCHS.']\n",
            "Texts: departments in cooperation with the CDC. Data from the CDC’s National Health Interview Survey were used to generate national prevalence estimates ofmammography. Important note about estimated cases and deaths. While these estimates provide a reasonably accurate portrayal of the current cancer burden in theabsence of actual data, they should be interpreted with caution because they are model-based projections that may vary from year to year forreasons other than changes in cancer occurrence. As such, they are not informative for tracking cancer trends. Instead, trends in canceroccurrence should be analyzed using age-adjusted incidence rates reported by population-based cancer registries and mortality rates reported by the NCHS.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  182\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  183  doc chunk text: ['References 1. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a', 'population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin . 2017;67:93-99. 2. Giuliano AE, Connolly JL, Edge SB, et al.', 'Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin .', '2017;67:290-303. 3. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast', 'Cancer Res Treat . 2006;97:135-144. 4. Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of']\n",
            "Texts: References 1. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from apopulation-based to a more “personalized” approach to cancer staging. CA Cancer J Clin . 2017;67:93-99. 2. Giuliano AE, Connolly JL, Edge SB, et al.Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin .2017;67:290-303. 3. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. BreastCancer Res Treat . 2006;97:135-144. 4. Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  183\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  184  doc chunk text: ['low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol .', '2015;28:662-669. 5. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ', 'untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer .', '2005;103:1778-1784. 6. Ryser MD, Weaver DL, Zhao F, et al. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst .', '2019;111:952-960. 7. Chootipongchaivat S, van Ravesteyn NT, Li X, et al. Modeling the natural history of ductal carcinoma in situ based on']\n",
            "Texts: low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol .2015;28:662-669. 5. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situuntreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer .2005;103:1778-1784. 6. Ryser MD, Weaver DL, Zhao F, et al. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst .2019;111:952-960. 7. Chootipongchaivat S, van Ravesteyn NT, Li X, et al. Modeling the natural history of ductal carcinoma in situ based on\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  184\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  185  doc chunk text: ['population data. Breast Cancer Res . 2020;22:53-53. 8. Punglia RS, Bifolck K, Golshan M, et al. Epidemiology, Biology, Treatment, and', 'Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr . 2018;2:pky063.9. Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK,', 'Wesseling J. Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. Cancer Epidemiol Biomarkers Prev .', '2019;28:835-845. 10. Jenkins S, Kachur ME, Rechache K, Wells JM, Lipkowitz S. Rare Breast Cancer Subtypes. Curr Oncol Rep .', '2021;23:54. 11. Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: Histological, molecular, and clinical']\n",
            "Texts: population data. Breast Cancer Res . 2020;22:53-53. 8. Punglia RS, Bifolck K, Golshan M, et al. Epidemiology, Biology, Treatment, andPrevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr . 2018;2:pky063.9. Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK,Wesseling J. Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. Cancer Epidemiol Biomarkers Prev .2019;28:835-845. 10. Jenkins S, Kachur ME, Rechache K, Wells JM, Lipkowitz S. Rare Breast Cancer Subtypes. Curr Oncol Rep .2021;23:54. 11. Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: Histological, molecular, and clinical\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  185\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  186  doc chunk text: ['peculiarities. Oncologist . 2014;19:805-813. 12. Renshaw A. Rosen’s Breast Pathology, 4th Edition . Philadelphia PA: Wolters Kluwer; 2014. 13. Cheang MCU, Martin M,', 'Nielsen TO, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist .', '2015;20:474-482. 14. Parise CA, Caggiano V. Risk of mortality of node-negative, ER/PR/ HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Res', 'Treat . 2017;165:743-750. 15. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United', 'States. Cancer Epidemiol Biomarkers Prev . 2018;28:28. 16. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular']\n",
            "Texts: peculiarities. Oncologist . 2014;19:805-813. 12. Renshaw A. Rosen’s Breast Pathology, 4th Edition . Philadelphia PA: Wolters Kluwer; 2014. 13. Cheang MCU, Martin M,Nielsen TO, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist .2015;20:474-482. 14. Parise CA, Caggiano V. Risk of mortality of node-negative, ER/PR/ HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer ResTreat . 2017;165:743-750. 15. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the UnitedStates. Cancer Epidemiol Biomarkers Prev . 2018;28:28. 16. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  186\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  187  doc chunk text: ['characterization of basal-like and non-basal-like triple- negative breast cancer. Oncologist . 2013;18:123-133. 17. Yin L, Duan JJ, Bian XW, Yu SC.', 'Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res . 2020;22:61.36 Breast Cancer Facts & Figures', '2022-202418. Sharma P. Biology and Management of Patients With Triple- Negative Breast Cancer. Oncologist .', '2016;21:1050-1062. 19. Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J . 2021;27:8-16. 20. Emborgo TS, Saporito D, Muse KI, et al.', 'Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. JNCI Cancer Spectr .']\n",
            "Texts: characterization of basal-like and non-basal-like triple- negative breast cancer. Oncologist . 2013;18:123-133. 17. Yin L, Duan JJ, Bian XW, Yu SC.Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res . 2020;22:61.36 Breast Cancer Facts & Figures2022-202418. Sharma P. Biology and Management of Patients With Triple- Negative Breast Cancer. Oncologist .2016;21:1050-1062. 19. Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J . 2021;27:8-16. 20. Emborgo TS, Saporito D, Muse KI, et al.Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. JNCI Cancer Spectr .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  187\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  188  doc chunk text: ['2020;4:pkaa002-pkaa002. 21. Pernas S, Tolaney SM. Management of Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. JCO Oncol Pract .', '2021;17:320-330. 22. Plevritis SK, Munoz D, Kurian AW, et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US', 'Women, 2000-2012. JAMA . 2018;319:154-164. 23. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin .', '2022:1-23. 24. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of Women Living with', 'Metastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev . 2017;26:809-815. 25. National Cancer Institute. Breast cancer risk']\n",
            "Texts: 2020;4:pkaa002-pkaa002. 21. Pernas S, Tolaney SM. Management of Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. JCO Oncol Pract .2021;17:320-330. 22. Plevritis SK, Munoz D, Kurian AW, et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in USWomen, 2000-2012. JAMA . 2018;319:154-164. 23. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin .2022:1-23. 24. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of Women Living withMetastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev . 2017;26:809-815. 25. National Cancer Institute. Breast cancer risk\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  188\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  189  doc chunk text: ['assessment tool. Available at:', 'https://bcrisktool.cancer.gov . Accessed May 31 2022. 26. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer', 'statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin .', '2018;68:394-424. 27. Warnecke RB, Campbell RT, Vijayasiri G, Barrett RE, Rauscher GH. Multilevel Examination of Health Disparity: The Role of Policy', 'Implementation in Neighborhood Context, in Patient Resources, and in Healthcare Facilities on Later Stage of Breast Cancer Diagnosis. Cancer Epidemiol']\n",
            "Texts: assessment tool. Available at:https://bcrisktool.cancer.gov . Accessed May 31 2022. 26. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancerstatistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin .2018;68:394-424. 27. Warnecke RB, Campbell RT, Vijayasiri G, Barrett RE, Rauscher GH. Multilevel Examination of Health Disparity: The Role of PolicyImplementation in Neighborhood Context, in Patient Resources, and in Healthcare Facilities on Later Stage of Breast Cancer Diagnosis. Cancer Epidemiol\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  189\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  190  doc chunk text: ['Biomarkers Prev . 2019;28:59-66. 28. Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer .', '2011;117:2209-2218. 29. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med .', '2007;356:1670-1674. 30. Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J. The impact of changes in hormone therapy on breast cancer', 'incidence in the US population. Cancer Causes Control . 2010;21:83-90. 31. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. Trends in', 'Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions. Cancer Epidemiol Biomarkers Prev . 2018;1:1. 32. Anderson WF, Katki HA,']\n",
            "Texts: Biomarkers Prev . 2019;28:59-66. 28. Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer .2011;117:2209-2218. 29. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med .2007;356:1670-1674. 30. Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J. The impact of changes in hormone therapy on breast cancerincidence in the US population. Cancer Causes Control . 2010;21:83-90. 31. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. Trends inBreast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions. Cancer Epidemiol Biomarkers Prev . 2018;1:1. 32. Anderson WF, Katki HA,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  190\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  191  doc chunk text: ['Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst .', '2011;103:1397-1402. 33.Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer', 'mortality. J Natl Cancer Inst . 2014;106. 34.Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Front Oncol .', '2018;8. 35. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med .', '2005;353:1784-1792.36. Krieger N, Wright E, Chen JT, Waterman PD, Huntley ER, Arcaya M. Cancer Stage at Diagnosis, Historical Redlining, and Current']\n",
            "Texts: Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst .2011;103:1397-1402. 33.Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancermortality. J Natl Cancer Inst . 2014;106. 34.Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Front Oncol .2018;8. 35. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med .2005;353:1784-1792.36. Krieger N, Wright E, Chen JT, Waterman PD, Huntley ER, Arcaya M. Cancer Stage at Diagnosis, Historical Redlining, and Current\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  191\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  192  doc chunk text: ['Neighborhood Characteristics: Breast, Cervical, Lung, and Colorectal Cancers, Massachusetts, 2001–2015. Am J Epidemiol . 2020;189:1065- 1075. 37. Ellis L, Canchola AJ, Spiegel D,', 'Ladabaum U, Haile R, Gomez SL. Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor,', 'Sociodemographic, Institutional, and Neighborhood Characteristics. J Clin Oncol . 2018;36:25-33. 38. Newman LA. Parsing the Etiology of Breast Cancer', 'Disparities. J Clin Oncol . 2016;34:1013-1014. 39. Daly B, Olopade OI. A perfect storm: How tumor biology, genomics, and health care delivery', 'patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin .']\n",
            "Texts: Neighborhood Characteristics: Breast, Cervical, Lung, and Colorectal Cancers, Massachusetts, 2001–2015. Am J Epidemiol . 2020;189:1065- 1075. 37. Ellis L, Canchola AJ, Spiegel D,Ladabaum U, Haile R, Gomez SL. Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor,Sociodemographic, Institutional, and Neighborhood Characteristics. J Clin Oncol . 2018;36:25-33. 38. Newman LA. Parsing the Etiology of Breast CancerDisparities. J Clin Oncol . 2016;34:1013-1014. 39. Daly B, Olopade OI. A perfect storm: How tumor biology, genomics, and health care deliverypatterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  192\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  193  doc chunk text: ['2015;65:221-238. 40. Lawson MB, Bissell MCS, Miglioretti DL, et al. Multilevel Factors Associated With Time to Biopsy After Abnormal Screening', 'Mammography Results by Race and Ethnicity. JAMA Oncol . 2022;8(8):1115-1126.', 'doi:10.1001/jamaoncol.2022.1990. 41. Star J, Bandi P, A KM, Jemal A, S AF. A first look at breast cancer screening in over 1000', 'community health centers in the United States. Prev Med . 2022;161:107115. 42. Nyante SJ, Abraham L, Aiello Bowles EJ, et al.', 'Diagnostic Mammography Performance across Racial and Ethnic Groups in a National Network of Community-Based Breast Imaging Facilities. Cancer Epidemiol Biomarkers Prev .']\n",
            "Texts: 2015;65:221-238. 40. Lawson MB, Bissell MCS, Miglioretti DL, et al. Multilevel Factors Associated With Time to Biopsy After Abnormal ScreeningMammography Results by Race and Ethnicity. JAMA Oncol . 2022;8(8):1115-1126.doi:10.1001/jamaoncol.2022.1990. 41. Star J, Bandi P, A KM, Jemal A, S AF. A first look at breast cancer screening in over 1000community health centers in the United States. Prev Med . 2022;161:107115. 42. Nyante SJ, Abraham L, Aiello Bowles EJ, et al.Diagnostic Mammography Performance across Racial and Ethnic Groups in a National Network of Community-Based Breast Imaging Facilities. Cancer Epidemiol Biomarkers Prev .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  193\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  194  doc chunk text: ['2022;31:1324-1333. 43. Coughlin SS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat .', '2019;177:537-548. 44. American Cancer Society. Cancer Facts & Figures 2022 . Atlanta: American Cancer Society; 2022. 45. Loo LWM, Williams M,', 'Hernandez BY. The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population. Cancer Epidemiol .', '2019;58:71-76. 46. Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF. The impact of follow-up type and missed deaths on', 'population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr .']\n",
            "Texts: 2022;31:1324-1333. 43. Coughlin SS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat .2019;177:537-548. 44. American Cancer Society. Cancer Facts & Figures 2022 . Atlanta: American Cancer Society; 2022. 45. Loo LWM, Williams M,Hernandez BY. The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population. Cancer Epidemiol .2019;58:71-76. 46. Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF. The impact of follow-up type and missed deaths onpopulation-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  194\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  195  doc chunk text: ['2014;2014:210-217. 47. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Trends in Cancer Survival by Health Insurance Status in', 'California From 1997 to 2014. JAMA Oncol . 2018;4:317-323. 48. Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer', 'Mortality, Incidence, and Survival in the United States, 1950-2014: Over Six Decades of Changing Patterns and Widening', 'Inequalities. J Environ Public Health . 2017;2017:2819372. 49. Shariff-Marco S, DeRouen MC, Yang J, et al. Neighborhood archetypes and breast cancer survival in', 'California. Ann Epidemiol . 2021;57:22-29. 50. Malinowski C, Lei X, Zhao H, Giordano SH,']\n",
            "Texts: 2014;2014:210-217. 47. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Trends in Cancer Survival by Health Insurance Status inCalifornia From 1997 to 2014. JAMA Oncol . 2018;4:317-323. 48. Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in CancerMortality, Incidence, and Survival in the United States, 1950-2014: Over Six Decades of Changing Patterns and WideningInequalities. J Environ Public Health . 2017;2017:2819372. 49. Shariff-Marco S, DeRouen MC, Yang J, et al. Neighborhood archetypes and breast cancer survival inCalifornia. Ann Epidemiol . 2021;57:22-29. 50. Malinowski C, Lei X, Zhao H, Giordano SH,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  195\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  196  doc chunk text: ['Chavez-MacGregor M. Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer. JAMA Oncol .', '2022;8:863-870.Breast Cancer Facts & Figures 2022-2024 3751. SEER*Stat Database: NAACCR Incidence Data - CiNA Analytic File, 1995-2019, for NHIAv2 Origin, Custom File With', 'County, ACS Facts and Figures projection Project (which includes data from CDC’s National Program of Cancer Registries (NPCR), CCCR’s Provincial and', 'Territorial Registries, and the NCI’s Surveillance, Epidemiology and End Results (SEER) Registries), certified by the North American Association of Central Cancer', 'Registries (NAACCR) as meeting high-quality incidence data standards for the specified time periods, submitted December 2021. 52. Anderson WF, Devesa SS. Breast']\n",
            "Texts: Chavez-MacGregor M. Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer. JAMA Oncol .2022;8:863-870.Breast Cancer Facts & Figures 2022-2024 3751. SEER*Stat Database: NAACCR Incidence Data - CiNA Analytic File, 1995-2019, for NHIAv2 Origin, Custom File WithCounty, ACS Facts and Figures projection Project (which includes data from CDC’s National Program of Cancer Registries (NPCR), CCCR’s Provincial andTerritorial Registries, and the NCI’s Surveillance, Epidemiology and End Results (SEER) Registries), certified by the North American Association of Central CancerRegistries (NAACCR) as meeting high-quality incidence data standards for the specified time periods, submitted December 2021. 52. Anderson WF, Devesa SS. Breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  196\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  197  doc chunk text: ['carcinoma in men. Cancer . 2005;103:432-433; author reply 433. 53. Surveillance, Epidemiology, and End Results (SEER) Program', '(www.seer.cancer.gov ) SEER*Stat Database: Mortality – All COD, Aggregated With State, Total U.S. (1990-2020) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS,', 'Surveillance Research Program, released April 2022. Underlying mortality data provided by NCHS ( www.cdc.gov/nchs ). 54. Yadav S, Karam D, Bin Riaz I, et al. Male', 'breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer .', '2020;126(1):26-36. doi:10.1002/cncr.32472. 55. Gucalp A, Traina TA, Eisner JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat .']\n",
            "Texts: carcinoma in men. Cancer . 2005;103:432-433; author reply 433. 53. Surveillance, Epidemiology, and End Results (SEER) Program(www.seer.cancer.gov ) SEER*Stat Database: Mortality – All COD, Aggregated With State, Total U.S. (1990-2020) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS,Surveillance Research Program, released April 2022. Underlying mortality data provided by NCHS ( www.cdc.gov/nchs ). 54. Yadav S, Karam D, Bin Riaz I, et al. Malebreast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer .2020;126(1):26-36. doi:10.1002/cncr.32472. 55. Gucalp A, Traina TA, Eisner JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  197\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  198  doc chunk text: ['2019;173:37-48. 56. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling', 'project results. J Natl Cancer Inst . 2014;106:djt465. 57. Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis,', 'treatment, and survivorship. Ann Oncol . 2013;24:1434-1443. 58. Sung H, DeSantis C, Jemal A.', 'Subtype-Specific Breast Cancer Incidence Rates in Black versus White Men in the United States. JNCI Cancer Spectr . 2019;4. 59. Cook MB, Guenel P,', 'Gapstur SM, et al. Tobacco and alcohol in relation to male breast cancer: An analysis of the male breast cancer pooling project']\n",
            "Texts: 2019;173:37-48. 56. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer poolingproject results. J Natl Cancer Inst . 2014;106:djt465. 57. Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis,treatment, and survivorship. Ann Oncol . 2013;24:1434-1443. 58. Sung H, DeSantis C, Jemal A.Subtype-Specific Breast Cancer Incidence Rates in Black versus White Men in the United States. JNCI Cancer Spectr . 2019;4. 59. Cook MB, Guenel P,Gapstur SM, et al. Tobacco and alcohol in relation to male breast cancer: An analysis of the male breast cancer pooling project\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  198\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  199  doc chunk text: ['consortium. Cancer Epidemiol Biomarkers Prev . 2015;24:520-531. 60. Arem H, Brinton LA, Moore SC, et al. Physical Activity and Risk of Male Breast', 'Cancer. Cancer Epidemiol Biomarkers Prev . 2015;24: 1898-1901. 61. Choi YJ, Myung SK, Lee JH. Light Alcohol Drinking and Risk of Cancer: A', 'Meta-Analysis of Cohort Studies. Cancer Res Treat . 2018;50:474-487. 62. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and', 'deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin .', '2018;68:31-54. 63. Morra A, Jung AY, Behrens S, et al. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast']\n",
            "Texts: consortium. Cancer Epidemiol Biomarkers Prev . 2015;24:520-531. 60. Arem H, Brinton LA, Moore SC, et al. Physical Activity and Risk of Male BreastCancer. Cancer Epidemiol Biomarkers Prev . 2015;24: 1898-1901. 61. Choi YJ, Myung SK, Lee JH. Light Alcohol Drinking and Risk of Cancer: AMeta-Analysis of Cohort Studies. Cancer Res Treat . 2018;50:474-487. 62. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases anddeaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin .2018;68:31-54. 63. Morra A, Jung AY, Behrens S, et al. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  199\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  200  doc chunk text: ['Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev . 2021;30:623-642. 64. Tamimi RM, Spiegelman D, Smith-Warner SA, et al. Population', 'Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer. Am J Epidemiol .', '2016;184:884-893. 65. Dall GV, Britt KL. Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. Front Oncol .', '2017;7:110. 66. Gaudet MM, Gierach GL, Carter BD, et al. Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor', 'Molecular Subtype. Cancer Res . 2018;78:6011-6021.67. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.8.0; Statistical Research and']\n",
            "Texts: Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev . 2021;30:623-642. 64. Tamimi RM, Spiegelman D, Smith-Warner SA, et al. PopulationAttributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer. Am J Epidemiol .2016;184:884-893. 65. Dall GV, Britt KL. Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. Front Oncol .2017;7:110. 66. Gaudet MM, Gierach GL, Carter BD, et al. Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by TumorMolecular Subtype. Cancer Res . 2018;78:6011-6021.67. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.8.0; Statistical Research and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  200\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  201  doc chunk text: ['Applications Branch, National Cancer Institute, April 2022.', 'surveillance.cancer.gov/devcan . 68. Momozawa Y, Sasai R, Usui Y, et al. Expansion of Cancer Risk Profile for BRCA1 and BRCA2', 'Pathogenic Variants. JAMA Oncol . 2022. 69. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the', 'intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA .', '2013;310:1353-1368. 70. Shiyanbola OO, Arao RF, Miglioretti DL, et al. Emerging Trends in Family History of Breast Cancer and Associated Risk. Cancer']\n",
            "Texts: Applications Branch, National Cancer Institute, April 2022.surveillance.cancer.gov/devcan . 68. Momozawa Y, Sasai R, Usui Y, et al. Expansion of Cancer Risk Profile for BRCA1 and BRCA2Pathogenic Variants. JAMA Oncol . 2022. 69. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during theintervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA .2013;310:1353-1368. 70. Shiyanbola OO, Arao RF, Miglioretti DL, et al. Emerging Trends in Family History of Breast Cancer and Associated Risk. Cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  201\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  202  doc chunk text: ['Epidemiol Biomarkers Prev . 2017;26:1753-1760. 71. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect of', 'multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast Cancer Res Treat .', '2014;144:185-192. 72. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52', 'epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet .', '2001;358:1389-1399. 73. Beebe-Dimmer JL, Yee C, Cote ML, et al. Familial clustering of breast and prostate cancer and risk of']\n",
            "Texts: Epidemiol Biomarkers Prev . 2017;26:1753-1760. 71. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect ofmultiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast Cancer Res Treat .2014;144:185-192. 72. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet .2001;358:1389-1399. 73. Beebe-Dimmer JL, Yee C, Cote ML, et al. Familial clustering of breast and prostate cancer and risk of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  202\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  203  doc chunk text: ['postmenopausal breast cancer in the Women’s Health Initiative Study. Cancer .', '2015;121:1265-1272. 74. Tung N, Lin NU, Kidd J, et al. Frequency of Germline Mutations in 25 Cancer', 'Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol .', '2016;34:1460-1468. 75. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet . 2008;9:', '321-345. 76. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S']\n",
            "Texts: postmenopausal breast cancer in the Women’s Health Initiative Study. Cancer .2015;121:1265-1272. 74. Tung N, Lin NU, Kidd J, et al. Frequency of Germline Mutations in 25 CancerSusceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol .2016;34:1460-1468. 75. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet . 2008;9:321-345. 76. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  203\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  204  doc chunk text: ['A . 2014;111:14205-14210. 77. Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA mutations in young black women with breast', 'cancer residing in Florida. Cancer . 2015;121:4173-4180. 78. Weitzel JN, Clague J, Martir-Negron A, et al. Prevalence and type of BRCA', 'mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research', 'Network. J Clin Oncol . 2013;31:210-216. 79. Domchek SM, Yao S, Chen F, et al. Comparison of the Prevalence of', 'Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. JAMA Oncol .']\n",
            "Texts: A . 2014;111:14205-14210. 77. Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA mutations in young black women with breastcancer residing in Florida. Cancer . 2015;121:4173-4180. 78. Weitzel JN, Clague J, Martir-Negron A, et al. Prevalence and type of BRCAmutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community ResearchNetwork. J Clin Oncol . 2013;31:210-216. 79. Domchek SM, Yao S, Chen F, et al. Comparison of the Prevalence ofPathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. JAMA Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  204\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  205  doc chunk text: ['2021;7:1045-1050. 80. Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med .', '2021;384:440-451. 81. McCarthy AM, Bristol M, Domchek SM, et al. Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With', 'Breast Cancer. J Clin Oncol . 2016;34:2610-2618. 82. Palmer JR, Polley EC, Hu C, et al. Contribution of Germline', 'Predisposition Gene Mutations to Breast Cancer Risk in African American Women. J Natl Cancer Inst .', '2020;112:1213-1221. 83. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2']\n",
            "Texts: 2021;7:1045-1050. 80. Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med .2021;384:440-451. 81. McCarthy AM, Bristol M, Domchek SM, et al. Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women WithBreast Cancer. J Clin Oncol . 2016;34:2610-2618. 82. Palmer JR, Polley EC, Hu C, et al. Contribution of GermlinePredisposition Gene Mutations to Breast Cancer Risk in African American Women. J Natl Cancer Inst .2020;112:1213-1221. 83. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  205\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  206  doc chunk text: ['Mutation Carriers. JAMA . 2017;317:2402-2416.38 Breast Cancer Facts & Figures 2022-202484. Antoniou AC, Casadei S, Heikkinen T, et al.', 'Breast-cancer risk in families with mutations in PALB2. N Engl J Med .', '2014;371:497-506. 85. Yang X, Leslie G, Doroszuk A, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An', 'International Study of 524 Families. J Clin Oncol . 2020;38:674-685. 86. Dorling L, Carvalho S, Allen J, et al. Breast Cancer Risk Genes –', 'Association Analysis in More than 113,000 Women. N Engl J Med . 2021;384:428-439. 87. Ferreira MA, Gamazon ER, Al-Ejeh F, et al.']\n",
            "Texts: Mutation Carriers. JAMA . 2017;317:2402-2416.38 Breast Cancer Facts & Figures 2022-202484. Antoniou AC, Casadei S, Heikkinen T, et al.Breast-cancer risk in families with mutations in PALB2. N Engl J Med .2014;371:497-506. 85. Yang X, Leslie G, Doroszuk A, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: AnInternational Study of 524 Families. J Clin Oncol . 2020;38:674-685. 86. Dorling L, Carvalho S, Allen J, et al. Breast Cancer Risk Genes –Association Analysis in More than 113,000 Women. N Engl J Med . 2021;384:428-439. 87. Ferreira MA, Gamazon ER, Al-Ejeh F, et al.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  206\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  207  doc chunk text: ['Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun .', '2019;10:1741. 88. Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new', 'susceptibility loci for breast cancer. Nat Genet . 2015;47:373-380. 89. Consortium BCA. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer', 'Susceptibility Genes. JAMA Oncol . 2022;8:e216744-e216744. 90. Chen H, Wu J, Zhang Z, et al. Association Between BRCA Status and', 'Triple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol . 2018;9:909. 91. Force UPST. Risk Assessment, Genetic Counseling, and Genetic Testing for']\n",
            "Texts: Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun .2019;10:1741. 88. Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 newsusceptibility loci for breast cancer. Nat Genet . 2015;47:373-380. 89. Consortium BCA. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast CancerSusceptibility Genes. JAMA Oncol . 2022;8:e216744-e216744. 90. Chen H, Wu J, Zhang Z, et al. Association Between BRCA Status andTriple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol . 2018;9:909. 91. Force UPST. Risk Assessment, Genetic Counseling, and Genetic Testing for\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  207\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  208  doc chunk text: ['BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA . 2019;322:652-665. 92. Moyer VA. Risk assessment, genetic counseling, and genetic testing for', 'BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med .', '2014;160:271-281. 93. Sung H, Freedman RA, Siegel RL, et al. Risks of subsequent primary cancers among breast cancer survivors according to hormone', 'receptor status. Cancer . 2021;127:3310-3324. 94. Kramer I, Schaapveld M, Oldenburg HSA, et al. The influence of adjuvant systemic regimens on', 'contralateral breast cancer risk and receptor subtype. J Natl Cancer Inst . 2019;30:30. 95. Watt GP, John EM, Bandera EV, et al. Race,']\n",
            "Texts: BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA . 2019;322:652-665. 92. Moyer VA. Risk assessment, genetic counseling, and genetic testing forBRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med .2014;160:271-281. 93. Sung H, Freedman RA, Siegel RL, et al. Risks of subsequent primary cancers among breast cancer survivors according to hormonereceptor status. Cancer . 2021;127:3310-3324. 94. Kramer I, Schaapveld M, Oldenburg HSA, et al. The influence of adjuvant systemic regimens oncontralateral breast cancer risk and receptor subtype. J Natl Cancer Inst . 2019;30:30. 95. Watt GP, John EM, Bandera EV, et al. Race,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  208\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  209  doc chunk text: ['ethnicity and risk of second primary contralateral breast cancer in the United States. Int J Cancer .', '2021;148:2748-2758. 96. Nichols HB, Berrington de Gonzalez A, Lacey JV, Jr., Rosenberg PS, Anderson WF. Declining incidence of', 'contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol .', '2011;29:1564-1569. 97. Gierach GL, Curtis RE, Pfeiffer RM, et al. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With', 'Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol .']\n",
            "Texts: ethnicity and risk of second primary contralateral breast cancer in the United States. Int J Cancer .2021;148:2748-2758. 96. Nichols HB, Berrington de Gonzalez A, Lacey JV, Jr., Rosenberg PS, Anderson WF. Declining incidence ofcontralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol .2011;29:1564-1569. 97. Gierach GL, Curtis RE, Pfeiffer RM, et al. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy WithContralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  209\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  210  doc chunk text: ['2017;3:186-193. 98. Ramin C, Withrow DR, Davis Lynn BC, Gierach GL, Berrington de González A. Risk of', 'contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016. Breast Cancer Res .', '2021;23:24. 99. Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol .', '2015;12:227-238. 100. Stout NK, Cronin AM, Uno H, et al. Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res Treat .', '2018;171:777-781. 101. Wong SM, King T, Boileau JF, Barry WT, Golshan M. Population- Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women']\n",
            "Texts: 2017;3:186-193. 98. Ramin C, Withrow DR, Davis Lynn BC, Gierach GL, Berrington de González A. Risk ofcontralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016. Breast Cancer Res .2021;23:24. 99. Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol .2015;12:227-238. 100. Stout NK, Cronin AM, Uno H, et al. Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res Treat .2018;171:777-781. 101. Wong SM, King T, Boileau JF, Barry WT, Golshan M. Population- Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  210\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  211  doc chunk text: ['Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol .', '2017;24:2509-2517.102. Dania V, Liu Y, Ademuyiwa F, Weber JD, Colditz GA. Associations of race and ethnicity with risk of developing invasive breast cancer after', 'lobular carcinoma in situ. Breast Cancer Res . 2019;21:120. 103. Liu Y, West R, Weber JD, Colditz GA. Race and risk of', 'subsequent aggressive breast cancer following ductal carcinoma in situ. Cancer .', '2019;125:3225-3233. 104. Masannat YA, Husain E, Roylance R, et al. Pleomorphic LCIS what do we know? A UK multicenter audit of']\n",
            "Texts: Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol .2017;24:2509-2517.102. Dania V, Liu Y, Ademuyiwa F, Weber JD, Colditz GA. Associations of race and ethnicity with risk of developing invasive breast cancer afterlobular carcinoma in situ. Breast Cancer Res . 2019;21:120. 103. Liu Y, West R, Weber JD, Colditz GA. Race and risk ofsubsequent aggressive breast cancer following ductal carcinoma in situ. Cancer .2019;125:3225-3233. 104. Masannat YA, Husain E, Roylance R, et al. Pleomorphic LCIS what do we know? A UK multicenter audit of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  211\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  212  doc chunk text: ['pleomorphic lobular carcinoma in situ. Breast . 2018;38:120-124. 105. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk', 'associated with benign breast disease: systematic review and meta- analysis. Breast Cancer Res Treat .', '2015;149:569-575. 106. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med .', '2015;372:78-89. 107. Mazzola E, Coopey SB, Griffin M, et al. Reassessing risk models for atypical hyperplasia: age may not matter. Breast Cancer Res Treat .', '2017;165:285-291. 108. Gaudet MM, Deubler E, Diver WR, et al. Breast cancer risk factors by mode of detection among screened women in the Cancer']\n",
            "Texts: pleomorphic lobular carcinoma in situ. Breast . 2018;38:120-124. 105. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer riskassociated with benign breast disease: systematic review and meta- analysis. Breast Cancer Res Treat .2015;149:569-575. 106. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med .2015;372:78-89. 107. Mazzola E, Coopey SB, Griffin M, et al. Reassessing risk models for atypical hyperplasia: age may not matter. Breast Cancer Res Treat .2017;165:285-291. 108. Gaudet MM, Deubler E, Diver WR, et al. Breast cancer risk factors by mode of detection among screened women in the Cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  212\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  213  doc chunk text: ['Prevention Study-II. Breast Cancer Res Treat . 2021;186:791-805. 109. Newman LA, Stark A, Chitale D, et al. Association Between Benign Breast Disease in', 'African American and White American Women and Subsequent Triple-Negative Breast Cancer. JAMA Oncol .', '2017;3:1102-1106. 110. Bertrand KA, Tamimi RM, Scott CG, et al. Mammographic density and risk of breast cancer by age and tumor', 'characteristics. Breast Cancer Res . 2013;15:R104. 111. Byrne C, Ursin G, Martin CF, et al. Mammographic Density Change With Estrogen and', 'Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst . 2017;109. 112. Boyd NF, Guo H, Martin LJ, et al.']\n",
            "Texts: Prevention Study-II. Breast Cancer Res Treat . 2021;186:791-805. 109. Newman LA, Stark A, Chitale D, et al. Association Between Benign Breast Disease inAfrican American and White American Women and Subsequent Triple-Negative Breast Cancer. JAMA Oncol .2017;3:1102-1106. 110. Bertrand KA, Tamimi RM, Scott CG, et al. Mammographic density and risk of breast cancer by age and tumorcharacteristics. Breast Cancer Res . 2013;15:R104. 111. Byrne C, Ursin G, Martin CF, et al. Mammographic Density Change With Estrogen andProgestin Therapy and Breast Cancer Risk. J Natl Cancer Inst . 2017;109. 112. Boyd NF, Guo H, Martin LJ, et al.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  213\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  214  doc chunk text: ['Mammographic density and the risk and detection of breast cancer. N Engl J Med .', '2007;356:227-236. 113. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst .', '2014;106. 114. Huo CW, Chew GL, Britt KL, et al. Mammographic density-a review on the current understanding of its', 'association with breast cancer. Breast Cancer Res Treat . 2014;144:479-502. 115. Hoeven J. Agriculture, Rural Development, Food and Drug', 'Administration and Related Agencies Appropriations Bill of 2019. 2 ed; 2018. 116. Bakker MF, de Lange SV, Pijnappel RM, et al.']\n",
            "Texts: Mammographic density and the risk and detection of breast cancer. N Engl J Med .2007;356:227-236. 113. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst .2014;106. 114. Huo CW, Chew GL, Britt KL, et al. Mammographic density-a review on the current understanding of itsassociation with breast cancer. Breast Cancer Res Treat . 2014;144:479-502. 115. Hoeven J. Agriculture, Rural Development, Food and DrugAdministration and Related Agencies Appropriations Bill of 2019. 2 ed; 2018. 116. Bakker MF, de Lange SV, Pijnappel RM, et al.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  214\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  215  doc chunk text: ['Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med .', '2019;381:2091-2102. 117. Weinstein SP, Slanetz PJ, Lewin AA, et al. ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density. J Am Coll', 'Radiol . 2021;18:S456-s473. 118. Keating NL, Pace LE. New Federal Requirements to Inform Patients About Breast Density: Will They Help Patients? JAMA .', '2019;9:9. 119. Rafferty EA, Durand MA, Conant EF, et al. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense', 'Breasts. JAMA . 2016;315:1784-1786. 120. Lowry KP, Coley RY, Miglioretti DL, et al. Screening Performance of Digital Breast']\n",
            "Texts: Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med .2019;381:2091-2102. 117. Weinstein SP, Slanetz PJ, Lewin AA, et al. ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density. J Am CollRadiol . 2021;18:S456-s473. 118. Keating NL, Pace LE. New Federal Requirements to Inform Patients About Breast Density: Will They Help Patients? JAMA .2019;9:9. 119. Rafferty EA, Durand MA, Conant EF, et al. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and NondenseBreasts. JAMA . 2016;315:1784-1786. 120. Lowry KP, Coley RY, Miglioretti DL, et al. Screening Performance of Digital Breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  215\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  216  doc chunk text: ['Tomosynthesis vs Digital Mammography in Community Practice by Patient Age, Screening Round, and Breast Density. JAMA Netw Open .', '2020;3:e2011792-e2011792.Breast Cancer Facts & Figures 2022-2024 39121. Elands RJJ, Offermans NSM, Simons C, et al. Associations of', 'adult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status. Int J Cancer .', '2019;144:1844-1857. 122. Zhang B, Shu XO, Delahanty RJ, et al. Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian', 'Randomization. J Natl Cancer Inst . 2015;107:11. 123. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer']\n",
            "Texts: Tomosynthesis vs Digital Mammography in Community Practice by Patient Age, Screening Round, and Breast Density. JAMA Netw Open .2020;3:e2011792-e2011792.Breast Cancer Facts & Figures 2022-2024 39121. Elands RJJ, Offermans NSM, Simons C, et al. Associations ofadult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status. Int J Cancer .2019;144:1844-1857. 122. Zhang B, Shu XO, Delahanty RJ, et al. Height and Breast Cancer Risk: Evidence From Prospective Studies and MendelianRandomization. J Natl Cancer Inst . 2015;107:11. 123. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  216\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  217  doc chunk text: ['incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol .', '2011;12:785-794. 124. Goldberg M, D’Aloisio AA, O’Brien KM, Zhao S, Sandler DP. Pubertal timing and breast cancer risk in the Sister Study cohort. Breast', 'Cancer Res . 2020;22:112. 125. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual', 'participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol .', '2012;13:1141-1151. 126. Qu X, Zhang X, Qin A, et al. Bone mineral density and risk of breast cancer in']\n",
            "Texts: incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol .2011;12:785-794. 124. Goldberg M, D’Aloisio AA, O’Brien KM, Zhao S, Sandler DP. Pubertal timing and breast cancer risk in the Sister Study cohort. BreastCancer Res . 2020;22:112. 125. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individualparticipant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol .2012;13:1141-1151. 126. Qu X, Zhang X, Qin A, et al. Bone mineral density and risk of breast cancer in\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  217\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  218  doc chunk text: ['postmenopausal women. Breast Cancer Res Treat . 2013;138:261-271. 127. Grenier D, Cooke AL, Lix L, Metge C, Lu H, Leslie WD. Bone mineral', 'density and risk of postmenopausal breast cancer. Breast Cancer Res Treat . 2011;126:679-686. 128. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E,', 'Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst .', '2005;97:368-374. 129. Zhang Y, Mao X, Yu X, Huang X, He W, Yang H. Bone mineral density and risk of breast cancer: A cohort study and', 'Mendelian randomization analysis. Cancer . 2022. 130. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin .']\n",
            "Texts: postmenopausal women. Breast Cancer Res Treat . 2013;138:261-271. 127. Grenier D, Cooke AL, Lix L, Metge C, Lu H, Leslie WD. Bone mineraldensity and risk of postmenopausal breast cancer. Breast Cancer Res Treat . 2011;126:679-686. 128. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E,Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst .2005;97:368-374. 129. Zhang Y, Mao X, Yu X, Huang X, He W, Yang H. Bone mineral density and risk of breast cancer: A cohort study andMendelian randomization analysis. Cancer . 2022. 130. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  218\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  219  doc chunk text: ['2010;60:207-221. 131. Hu Y, Zhang X, Ma Y, et al. Incident Type 2 Diabetes Duration and Cancer Risk: A', 'Prospective Study in Two US Cohorts. J Natl Cancer Inst . 2021;113:381-389. 132. Cejuela M,', 'Martin-Castillo B, Menendez JA, Pernas S. Metformin and Breast Cancer: Where Are We Now? Int J Mol Sci .', '2022;23:2705. 133. Sampson JN, Falk RT, Schairer C, et al. Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts of', 'Postmenopausal Women. Cancer Res . 2017;77:918-925. 134. Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast,']\n",
            "Texts: 2010;60:207-221. 131. Hu Y, Zhang X, Ma Y, et al. Incident Type 2 Diabetes Duration and Cancer Risk: AProspective Study in Two US Cohorts. J Natl Cancer Inst . 2021;113:381-389. 132. Cejuela M,Martin-Castillo B, Menendez JA, Pernas S. Metformin and Breast Cancer: Where Are We Now? Int J Mol Sci .2022;23:2705. 133. Sampson JN, Falk RT, Schairer C, et al. Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts ofPostmenopausal Women. Cancer Res . 2017;77:918-925. 134. Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  219\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  220  doc chunk text: ['endometrial, and ovarian cancers. Steroids . 2015;99:8-10. 135. Tin Tin S, Reeves GK, Key TJ. Endogenous hormones and risk of invasive breast cancer in pre- and', 'post-menopausal women: findings from the UK Biobank. Br J Cancer . 2021;125:126-134. 136. Key T, Appleby P, Barnes I, Reeves G.', 'Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst .', '2002;94:606-616. 137. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk:', 'individual participant meta-analysis of the worldwide epidemiological evidence. Lancet . 2019;394:1159-1168. 138. Key TJ, Appleby PN, Reeves GK, al. e. Sex hormones and risk of']\n",
            "Texts: endometrial, and ovarian cancers. Steroids . 2015;99:8-10. 135. Tin Tin S, Reeves GK, Key TJ. Endogenous hormones and risk of invasive breast cancer in pre- andpost-menopausal women: findings from the UK Biobank. Br J Cancer . 2021;125:126-134. 136. Key T, Appleby P, Barnes I, Reeves G.Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst .2002;94:606-616. 137. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk:individual participant meta-analysis of the worldwide epidemiological evidence. Lancet . 2019;394:1159-1168. 138. Key TJ, Appleby PN, Reeves GK, al. e. Sex hormones and risk of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  220\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  221  doc chunk text: ['breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol .', '2013;14:1009-1010.139. Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE. Premenopausal endogenous steroid hormones and breast cancer risk: results from the', 'Nurses’ Health Study II. Breast Cancer Res . 2013;15:R19. 140. Li K, Anderson G, Viallon V, et al. Risk prediction for estrogen', 'receptor-specific breast cancers in two large prospective cohorts. Breast Cancer Res . 2018;20:147. 141. Chlebowski RT, Manson JE, Anderson GL, et al.', 'Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst .']\n",
            "Texts: breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol .2013;14:1009-1010.139. Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE. Premenopausal endogenous steroid hormones and breast cancer risk: results from theNurses’ Health Study II. Breast Cancer Res . 2013;15:R19. 140. Li K, Anderson G, Viallon V, et al. Risk prediction for estrogenreceptor-specific breast cancers in two large prospective cohorts. Breast Cancer Res . 2018;20:147. 141. Chlebowski RT, Manson JE, Anderson GL, et al.Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  221\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  222  doc chunk text: ['2013;105:526-535. 142. Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer mortality. Lancet .', '2019;394:1139. 143. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During', 'Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA . 2020;324:369-380. 144. Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of', 'Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials. JAMA Oncol .', '2015;1:296-305. 145. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment:']\n",
            "Texts: 2013;105:526-535. 142. Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer mortality. Lancet .2019;394:1139. 143. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality DuringLong-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA . 2020;324:369-380. 144. Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use ofEstrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials. JAMA Oncol .2015;1:296-305. 145. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment:\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  222\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  223  doc chunk text: ['nationwide cohort study in the Netherlands. BMJ . 2019;365:l1652. 146. Nichols HB, Schoemaker MJ, Cai J, et al. Breast Cancer Risk After Recent', 'Childbirth: A Pooled Analysis of 15 Prospective Studies. Ann Intern Med . 2018;11:11. 147. Fortner RT, Sisti J, Chai B, et al. Parity,', 'breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses’ Health Studies. Breast Cancer Res .', '2019;21:40. 148. Brinton LA. Fertility Status and Cancer. Semin Reprod Med . 2017;35:291-297. 149. Beebeejaun Y, Athithan A, Copeland TP, Kamath MS, Sarris I,', 'Sunkara SK. Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta- analysis. Fertil Steril .']\n",
            "Texts: nationwide cohort study in the Netherlands. BMJ . 2019;365:l1652. 146. Nichols HB, Schoemaker MJ, Cai J, et al. Breast Cancer Risk After RecentChildbirth: A Pooled Analysis of 15 Prospective Studies. Ann Intern Med . 2018;11:11. 147. Fortner RT, Sisti J, Chai B, et al. Parity,breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses’ Health Studies. Breast Cancer Res .2019;21:40. 148. Brinton LA. Fertility Status and Cancer. Semin Reprod Med . 2017;35:291-297. 149. Beebeejaun Y, Athithan A, Copeland TP, Kamath MS, Sarris I,Sunkara SK. Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta- analysis. Fertil Steril .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  223\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  224  doc chunk text: ['2021;116:198-207. 150. van den Belt-Dusebout AW, Spaan M, Lambalk CB, et al. Ovarian Stimulation for In Vitro', 'Fertilization and Long-term Risk of Breast Cancer. JAMA . 2016;316:300-312. 151. Gennari A, Costa M, Puntoni M, et al. Breast cancer', 'incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. Breast Cancer Res Treat .', '2015;150:405-413. 152. Williams CL, Jones ME, Swerdlow AJ, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with', 'assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ .']\n",
            "Texts: 2021;116:198-207. 150. van den Belt-Dusebout AW, Spaan M, Lambalk CB, et al. Ovarian Stimulation for In VitroFertilization and Long-term Risk of Breast Cancer. JAMA . 2016;316:300-312. 151. Gennari A, Costa M, Puntoni M, et al. Breast cancerincidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. Breast Cancer Res Treat .2015;150:405-413. 152. Williams CL, Jones ME, Swerdlow AJ, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated withassisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  224\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  225  doc chunk text: ['2018;362:k2644. 153. Brinton LA, Scoccia B, Moghissi KS, et al. Long-term relationship of', 'ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev . 2014;23:584-593. 154. Reigstad MM, Storeng R, Myklebust T, et al. Cancer Risk in Women', 'Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study. Cancer Epidemiol Biomarkers Prev .', '2017;26:953-962.40 Breast Cancer Facts & Figures 2022-2024155. Guleria S, Kjær SK, Albieri V, Frederiksen K, Jensen A. A Cohort Study of Breast Cancer Risk after 20', 'Years of Follow-Up of Women Treated with Fertility Drugs. Cancer Epidemiol Biomarkers Prev .']\n",
            "Texts: 2018;362:k2644. 153. Brinton LA, Scoccia B, Moghissi KS, et al. Long-term relationship ofovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev . 2014;23:584-593. 154. Reigstad MM, Storeng R, Myklebust T, et al. Cancer Risk in WomenTreated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study. Cancer Epidemiol Biomarkers Prev .2017;26:953-962.40 Breast Cancer Facts & Figures 2022-2024155. Guleria S, Kjær SK, Albieri V, Frederiksen K, Jensen A. A Cohort Study of Breast Cancer Risk after 20Years of Follow-Up of Women Treated with Fertility Drugs. Cancer Epidemiol Biomarkers Prev .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  225\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  226  doc chunk text: ['2019;28:1986-1992. 156. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47', 'epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet .', '2002;360:187-195. 157. Ma H, Ursin G, Xu X, et al. Reproductive factors and the risk of', 'triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res . 2017;19:6. 158. Islami F, Liu Y, Jemal A, et al.', 'Breastfeeding and breast cancer risk by receptor status – a systematic review and meta-analysis. Ann Oncol .']\n",
            "Texts: 2019;28:1986-1992. 156. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet .2002;360:187-195. 157. Ma H, Ursin G, Xu X, et al. Reproductive factors and the risk oftriple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res . 2017;19:6. 158. Islami F, Liu Y, Jemal A, et al.Breastfeeding and breast cancer risk by receptor status – a systematic review and meta-analysis. Ann Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  226\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  227  doc chunk text: ['2015;26:2398-2407. 159. Sanderson M, Pal T, Beeghly-Fadiel A, et al. A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the', 'Southeastern United States. Cancer Epidemiol Biomarkers Prev . 2021;30:1416-1423. 160. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O.', 'Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med .', '2017;377:2228-2239. 161. Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of', 'cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol . 2015;25:193-200. 162. Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral']\n",
            "Texts: 2015;26:2398-2407. 159. Sanderson M, Pal T, Beeghly-Fadiel A, et al. A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in theSoutheastern United States. Cancer Epidemiol Biomarkers Prev . 2021;30:1416-1423. 160. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O.Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med .2017;377:2228-2239. 161. Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks ofcardiovascular disease, cancer, and other health outcomes. Ann Epidemiol . 2015;25:193-200. 162. Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  227\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  228  doc chunk text: ['contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet . 2020;301: 875-884. 163.', 'Westhoff CL, Pike MC. Hormonal contraception and breast cancer. Am J Obstet Gynecol .', '2018;219:169.e161-169.e164. 164. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes – results from a large', 'nested case-control study in a national screening program. Breast Cancer Res . 2017;19:10. 165. Soini T, Hurskainen R, Grenman S, Maenpaa J,', 'Paavonen J, Pukkala E. Cancer risk in women using the']\n",
            "Texts: contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet . 2020;301: 875-884. 163.Westhoff CL, Pike MC. Hormonal contraception and breast cancer. Am J Obstet Gynecol .2018;219:169.e161-169.e164. 164. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes – results from a largenested case-control study in a national screening program. Breast Cancer Res . 2017;19:10. 165. Soini T, Hurskainen R, Grenman S, Maenpaa J,Paavonen J, Pukkala E. Cancer risk in women using the\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  228\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  229  doc chunk text: ['levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol . 2014;124:292-299. 166. Dinger J, Bardenheuer K, Minh TD.', 'Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception . 2011;83:211-217. 167. Conz L, Mota BS, Bahamondes L, et al.', 'Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis. Acta Obstet Gynecol Scand .', '2020;99:970-982. 168. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Effect of', 'depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res .']\n",
            "Texts: levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol . 2014;124:292-299. 166. Dinger J, Bardenheuer K, Minh TD.Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception . 2011;83:211-217. 167. Conz L, Mota BS, Bahamondes L, et al.Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis. Acta Obstet Gynecol Scand .2020;99:970-982. 168. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Effect ofdepo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  229\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  230  doc chunk text: ['2012;72:2028-2035. 169. Jiralerspong S, Goodwin PJ. Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. J Clin Oncol .', '2016;34:4203-4216. 170. Iyengar NM, Arthur R, Manson JE, et al. Association of Body Fat and Risk of Breast Cancer in', 'Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. JAMA Oncol .', '2018;6:6.171. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome:', 'Mechanistic insights and strategies for intervention. CA Cancer J Clin . 2017;67:378-397. 172. Teras LR, Patel AV, Wang M, et al.']\n",
            "Texts: 2012;72:2028-2035. 169. Jiralerspong S, Goodwin PJ. Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. J Clin Oncol .2016;34:4203-4216. 170. Iyengar NM, Arthur R, Manson JE, et al. Association of Body Fat and Risk of Breast Cancer inPostmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. JAMA Oncol .2018;6:6.171. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome:Mechanistic insights and strategies for intervention. CA Cancer J Clin . 2017;67:378-397. 172. Teras LR, Patel AV, Wang M, et al.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  230\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  231  doc chunk text: ['Sustained Weight Loss and Risk of Breast Cancer in Women 50 Years and Older: A Pooled Analysis of Prospective Data. J Natl Cancer Inst .', '2020;112:929-937. 173. Rosner B, Eliassen AH, Toriola AT, et al. Weight and weight changes in early adulthood and later breast cancer risk. Int J', 'Cancer . 2017;140:2003-2014. 174. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and', 'adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst . 2015;107. 175. Schoemaker MJ, Nichols HB, Wright LB, et al.', 'Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. JAMA Oncol .']\n",
            "Texts: Sustained Weight Loss and Risk of Breast Cancer in Women 50 Years and Older: A Pooled Analysis of Prospective Data. J Natl Cancer Inst .2020;112:929-937. 173. Rosner B, Eliassen AH, Toriola AT, et al. Weight and weight changes in early adulthood and later breast cancer risk. Int JCancer . 2017;140:2003-2014. 174. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain andadiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst . 2015;107. 175. Schoemaker MJ, Nichols HB, Wright LB, et al.Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. JAMA Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  231\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  232  doc chunk text: ['2018;4:e181771. 176. García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Moreno- Bueno G. Obesity and Breast Cancer: A', 'Paradoxical and Controversial Relationship Influenced by Menopausal Status. Front Oncol .', '2021;11:705911-705911. 177. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta .', '2015;1856:73-85. 178. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med Sci Sports Exerc .', '2019;51:1252-1261. 179. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol .']\n",
            "Texts: 2018;4:e181771. 176. García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Moreno- Bueno G. Obesity and Breast Cancer: AParadoxical and Controversial Relationship Influenced by Menopausal Status. Front Oncol .2021;11:705911-705911. 177. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta .2015;1856:73-85. 178. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med Sci Sports Exerc .2019;51:1252-1261. 179. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  232\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  233  doc chunk text: ['2017;18:e457-e471. 180. Moore SC, Lee IM, Weiderpass E, et al. Association of Leisure- Time Physical Activity With Risk of 26 Types of Cancer in 1.44', 'Million Adults. JAMA Intern Med . 2016;176:816-825. 181. Pizot C, Boniol M, Mullie P, et al. Physical activity, hormone', 'replacement therapy and breast cancer risk: A meta-analysis of prospective studies. Eur J Cancer .', '2016;52:138-154. 182. Guo W, Fensom GK, Reeves GK, Key TJ. Physical activity and breast cancer risk: results from the UK Biobank', 'prospective cohort. Br J Cancer . 2020;122:726-732. 183. Neilson HK, Friedenreich CM, Brockton NT, Millikan RC. Physical activity and']\n",
            "Texts: 2017;18:e457-e471. 180. Moore SC, Lee IM, Weiderpass E, et al. Association of Leisure- Time Physical Activity With Risk of 26 Types of Cancer in 1.44Million Adults. JAMA Intern Med . 2016;176:816-825. 181. Pizot C, Boniol M, Mullie P, et al. Physical activity, hormonereplacement therapy and breast cancer risk: A meta-analysis of prospective studies. Eur J Cancer .2016;52:138-154. 182. Guo W, Fensom GK, Reeves GK, Key TJ. Physical activity and breast cancer risk: results from the UK Biobankprospective cohort. Br J Cancer . 2020;122:726-732. 183. Neilson HK, Friedenreich CM, Brockton NT, Millikan RC. Physical activity and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  233\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  234  doc chunk text: ['postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol Biomarkers Prev .', '2009;18:11-27. 184. Cao Y, Hou L, Wang W. Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: A', 'meta-analysis of prospective cohort studies. Int J Cancer . 2016;138:1894-1904. 185. Guo F, Wang M, Guo X, et al. The', 'association between fatty acid intake and breast cancer based on the NHANES and Mendelian randomization study. Cancer Epidemiol .', '2021;73:101966. 186. Matta M, Huybrechts I, Biessy C, et al. Dietary intake of trans fatty acids and breast cancer risk in 9']\n",
            "Texts: postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol Biomarkers Prev .2009;18:11-27. 184. Cao Y, Hou L, Wang W. Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: Ameta-analysis of prospective cohort studies. Int J Cancer . 2016;138:1894-1904. 185. Guo F, Wang M, Guo X, et al. Theassociation between fatty acid intake and breast cancer based on the NHANES and Mendelian randomization study. Cancer Epidemiol .2021;73:101966. 186. Matta M, Huybrechts I, Biessy C, et al. Dietary intake of trans fatty acids and breast cancer risk in 9\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  234\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  235  doc chunk text: ['European countries. BMC Med . 2021;19:81. 187. Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. Intake of fish and marine n-3', 'polyunsaturated fatty acids and risk of breast cancer: meta- analysis of data from 21 independent prospective cohort studies. BMJ .', '2013;346:f3706. 188. Chen M, Rao Y, Zheng Y, et al. Association between soy isoflavone intake and breast cancer risk for pre- and', 'post-menopausal women: A meta-analysis of epidemiological studies. PloS One .', '2014;9:e89288.Breast Cancer Facts & Figures 2022-2024 41189. Fraser GE, Jaceldo-Siegl K, Orlich M, Mashchak A, Sirirat R, Knutsen S. Dairy, soy, and risk of']\n",
            "Texts: European countries. BMC Med . 2021;19:81. 187. Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. Intake of fish and marine n-3polyunsaturated fatty acids and risk of breast cancer: meta- analysis of data from 21 independent prospective cohort studies. BMJ .2013;346:f3706. 188. Chen M, Rao Y, Zheng Y, et al. Association between soy isoflavone intake and breast cancer risk for pre- andpost-menopausal women: A meta-analysis of epidemiological studies. PloS One .2014;9:e89288.Breast Cancer Facts & Figures 2022-2024 41189. Fraser GE, Jaceldo-Siegl K, Orlich M, Mashchak A, Sirirat R, Knutsen S. Dairy, soy, and risk of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  235\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  236  doc chunk text: ['breast cancer: those confounded milks. Int J Epidemiol . 2020;49:1526-1537. 190. Farvid MS, Chen WY, Rosner BA, Tamimi RM, Willett WC, Eliassen AH. Fruit and', 'vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up. Int J Cancer .', '2019;144:1496-1510. 191. World Cancer Research Fund and American Institute for Cancer Research. Continuous Update Project Report Expert Report 2018. Diet,', 'nutrition, physical activity, and breast cancer. Available at:', 'dietandcancerreport.org . 192. Jung S, Spiegelman D, Baglietto L, et al. Fruit and vegetable intake and risk of breast cancer by hormone']\n",
            "Texts: breast cancer: those confounded milks. Int J Epidemiol . 2020;49:1526-1537. 190. Farvid MS, Chen WY, Rosner BA, Tamimi RM, Willett WC, Eliassen AH. Fruit andvegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up. Int J Cancer .2019;144:1496-1510. 191. World Cancer Research Fund and American Institute for Cancer Research. Continuous Update Project Report Expert Report 2018. Diet,nutrition, physical activity, and breast cancer. Available at:dietandcancerreport.org . 192. Jung S, Spiegelman D, Baglietto L, et al. Fruit and vegetable intake and risk of breast cancer by hormone\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  236\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  237  doc chunk text: ['receptor status. J Natl Cancer Inst . 2013;105:219-236. 193. Bakker MF, Peeters PH, Klaasen VM, et al. Plasma', 'carotenoids, vitamin C, tocopherols, and retinol and the risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr .', '2016;103:454-464. 194. Wang Y, Gapstur SM, Gaudet MM, Furtado JD, Campos H, McCullough ML. Plasma carotenoids and breast cancer risk in the Cancer', 'Prevention Study II Nutrition Cohort. Cancer Causes Control . 2015. 195. Eliassen AH, Hendrickson SJ, Brinton LA, et al.', 'Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst .']\n",
            "Texts: receptor status. J Natl Cancer Inst . 2013;105:219-236. 193. Bakker MF, Peeters PH, Klaasen VM, et al. Plasmacarotenoids, vitamin C, tocopherols, and retinol and the risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr .2016;103:454-464. 194. Wang Y, Gapstur SM, Gaudet MM, Furtado JD, Campos H, McCullough ML. Plasma carotenoids and breast cancer risk in the CancerPrevention Study II Nutrition Cohort. Cancer Causes Control . 2015. 195. Eliassen AH, Hendrickson SJ, Brinton LA, et al.Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  237\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  238  doc chunk text: ['2012;104:1905-1916. 196. Kim JA, Jang J-H, Lee S-Y. An Updated Comprehensive Review on Vitamin A and Carotenoids in Breast Cancer:', 'Mechanisms, Genetics, Assessment, Current Evidence, and Future Clinical Implications. Nutrients . 2021;13:3162. 197. Wu Y, Huang R, Wang M, et al. Dairy foods,', 'calcium, and risk of breast cancer overall and for subtypes defined by estrogen receptor status: a pooled analysis of 21 cohort studies. Am J Clin Nutr .', '2021;114:450-461. 198. Liu Y, Nguyen N, Colditz GA. Links between alcohol consumption and breast cancer: A look at the evidence. Womens Health (Lond).', '2015;11:65-77. 199. Jayasekara H, MacInnis RJ, Hodge AM, et al. Is breast cancer risk associated with alcohol intake before first full-term']\n",
            "Texts: 2012;104:1905-1916. 196. Kim JA, Jang J-H, Lee S-Y. An Updated Comprehensive Review on Vitamin A and Carotenoids in Breast Cancer:Mechanisms, Genetics, Assessment, Current Evidence, and Future Clinical Implications. Nutrients . 2021;13:3162. 197. Wu Y, Huang R, Wang M, et al. Dairy foods,calcium, and risk of breast cancer overall and for subtypes defined by estrogen receptor status: a pooled analysis of 21 cohort studies. Am J Clin Nutr .2021;114:450-461. 198. Liu Y, Nguyen N, Colditz GA. Links between alcohol consumption and breast cancer: A look at the evidence. Womens Health (Lond).2015;11:65-77. 199. Jayasekara H, MacInnis RJ, Hodge AM, et al. Is breast cancer risk associated with alcohol intake before first full-term\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  238\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  239  doc chunk text: ['pregnancy? Cancer Causes Control . 2016;27:1167-1174. 200. Assi N, Rinaldi S, Viallon V, et al. Mediation analysis of the', 'alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC cohort. Int J Cancer . 2019;10:10. 201. Rustagi AS, Scott CG, Winham SJ, et al.', 'Association of Daily Alcohol Intake, Volumetric Breast Density, and Breast Cancer Risk. JNCI Cancer Spectr .', '2021;5:pkaa124. 202. Jung S, Wang M, Anderson K, et al. Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled', 'analysis of 20 studies. Int J Epidemiol . 2016;45:916-928. 203. Gram IT, Park SY, Maskarinec G, Wilkens LR, Haiman CA, Le Marchand L.']\n",
            "Texts: pregnancy? Cancer Causes Control . 2016;27:1167-1174. 200. Assi N, Rinaldi S, Viallon V, et al. Mediation analysis of thealcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC cohort. Int J Cancer . 2019;10:10. 201. Rustagi AS, Scott CG, Winham SJ, et al.Association of Daily Alcohol Intake, Volumetric Breast Density, and Breast Cancer Risk. JNCI Cancer Spectr .2021;5:pkaa124. 202. Jung S, Wang M, Anderson K, et al. Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooledanalysis of 20 studies. Int J Epidemiol . 2016;45:916-928. 203. Gram IT, Park SY, Maskarinec G, Wilkens LR, Haiman CA, Le Marchand L.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  239\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  240  doc chunk text: ['Smoking and breast cancer risk by race/ethnicity and oestrogen and progesterone receptor status: the Multiethnic Cohort (MEC) study. Int J Epidemiol .', '2019;18:18. 204. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and', 'meta-analysis. J Natl Cancer Inst . 2013;105:515-525. 205. Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ. Smoking and risk of breast cancer in the', 'Generations Study cohort. Breast Cancer Res . 2017;19:118-118.206. White AJ, D’Aloisio AA, Nichols HB, DeRoo LA, Sandler DP. Breast cancer and exposure to', 'tobacco smoke during potential windows of susceptibility. Cancer Causes Control . 2017;28:667-675. 207. Macacu A, Autier P, Boniol M, Boyle P. Active and']\n",
            "Texts: Smoking and breast cancer risk by race/ethnicity and oestrogen and progesterone receptor status: the Multiethnic Cohort (MEC) study. Int J Epidemiol .2019;18:18. 204. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data andmeta-analysis. J Natl Cancer Inst . 2013;105:515-525. 205. Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ. Smoking and risk of breast cancer in theGenerations Study cohort. Breast Cancer Res . 2017;19:118-118.206. White AJ, D’Aloisio AA, Nichols HB, DeRoo LA, Sandler DP. Breast cancer and exposure totobacco smoke during potential windows of susceptibility. Cancer Causes Control . 2017;28:667-675. 207. Macacu A, Autier P, Boniol M, Boyle P. Active and\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  240\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  241  doc chunk text: ['passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat .', '2015;154:213-224. 208. Gram IT, Wiik AB, Lund E, Licaj I, Braaten T. Never-smokers and the fraction of breast cancer', 'attributable to second-hand smoke from parents during childhood: the Norwegian Women and Cancer Study 1991–2018. Int J Epidemiol .', '2021;50:1927-1935. 209. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for', 'Hodgkin’s Lymphoma. N Engl J Med . 2015;373:2499-2511. 210. Ehrhardt MJ, Howell CR, Hale K, et al. Subsequent Breast Cancer in Female']\n",
            "Texts: passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat .2015;154:213-224. 208. Gram IT, Wiik AB, Lund E, Licaj I, Braaten T. Never-smokers and the fraction of breast cancerattributable to second-hand smoke from parents during childhood: the Norwegian Women and Cancer Study 1991–2018. Int J Epidemiol .2021;50:1927-1935. 209. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment forHodgkin’s Lymphoma. N Engl J Med . 2015;373:2499-2511. 210. Ehrhardt MJ, Howell CR, Hale K, et al. Subsequent Breast Cancer in Female\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  241\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  242  doc chunk text: ['Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE). J Clin Oncol . 2019;10. 211. Mulder RL, Hudson MM, Bhatia S, et al.', 'Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the', 'International Guideline Harmonization Group. J Clin Oncol . 2020;38:4194-4207. 212. International Agency for Research on Cancer. IARC monographs on the', 'evaluation of carcinogenic risks to humans. Volume 100A-16, Pharmaceuticals. Diethylstilbestrol. A review of human carcinogens. Lyon: International Agency for Research on Cancer; 2012. 213.', 'Hilakivi-Clarke L. Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters. Breast Cancer Res .']\n",
            "Texts: Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE). J Clin Oncol . 2019;10. 211. Mulder RL, Hudson MM, Bhatia S, et al.Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From theInternational Guideline Harmonization Group. J Clin Oncol . 2020;38:4194-4207. 212. International Agency for Research on Cancer. IARC monographs on theevaluation of carcinogenic risks to humans. Volume 100A-16, Pharmaceuticals. Diethylstilbestrol. A review of human carcinogens. Lyon: International Agency for Research on Cancer; 2012. 213.Hilakivi-Clarke L. Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters. Breast Cancer Res .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  242\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  243  doc chunk text: ['2014;16:208. 214. Reed CE, Fenton SE. Exposure to diethylstilbestrol during sensitive life stages: a legacy of heritable health effects. Birth Defects Res C Embryo Today .', '2013;99:134-146. 215. Troisi R, Hatch EE, Titus L, et al. Prenatal diethylstilbestrol exposure and cancer risk in women. Environ Mol Mutagen .', '2019;60:395-403. 216. Loomis D, Guyton K, Grosse Y, et al. Carcinogenicity of lindane, DDT, and', '2,4-dichlorophenoxyacetic acid. Lancet Oncol . 2015;16: 891-892. 217. Cohn BA, La Merrill M, Krigbaum NY, et al. DDT Exposure in Utero and Breast', 'Cancer. J Clin Endocrinol Metab . 2015;100:2865-2872. 218. Cohn BA, Cirillo PM, Terry MB. DDT and Breast Cancer: Prospective Study of']\n",
            "Texts: 2014;16:208. 214. Reed CE, Fenton SE. Exposure to diethylstilbestrol during sensitive life stages: a legacy of heritable health effects. Birth Defects Res C Embryo Today .2013;99:134-146. 215. Troisi R, Hatch EE, Titus L, et al. Prenatal diethylstilbestrol exposure and cancer risk in women. Environ Mol Mutagen .2019;60:395-403. 216. Loomis D, Guyton K, Grosse Y, et al. Carcinogenicity of lindane, DDT, and2,4-dichlorophenoxyacetic acid. Lancet Oncol . 2015;16: 891-892. 217. Cohn BA, La Merrill M, Krigbaum NY, et al. DDT Exposure in Utero and BreastCancer. J Clin Endocrinol Metab . 2015;100:2865-2872. 218. Cohn BA, Cirillo PM, Terry MB. DDT and Breast Cancer: Prospective Study of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  243\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  244  doc chunk text: ['Induction Time and Susceptibility Windows. J Natl Cancer Inst . 2019;111:803-810. 219. Rodgers KM, Udesky JO, Rudel RA, Brody JG.', 'Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. Environ Res .', '2018;160:152-182. 220. Ahern TP, Broe A, Lash TL, et al. Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study. J Clin Oncol .', '2019;17. 221. Gaudet MM, Deubler EL, Kelly RS, et al. Blood levels of cadmium and lead in relation to breast cancer risk in three', 'prospective cohorts. Int J Cancer . 2019;144:1010-1016. 222. Zeinomar N, Oskar S, Kehm RD, Sahebzeda S, Terry MB.']\n",
            "Texts: Induction Time and Susceptibility Windows. J Natl Cancer Inst . 2019;111:803-810. 219. Rodgers KM, Udesky JO, Rudel RA, Brody JG.Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. Environ Res .2018;160:152-182. 220. Ahern TP, Broe A, Lash TL, et al. Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study. J Clin Oncol .2019;17. 221. Gaudet MM, Deubler EL, Kelly RS, et al. Blood levels of cadmium and lead in relation to breast cancer risk in threeprospective cohorts. Int J Cancer . 2019;144:1010-1016. 222. Zeinomar N, Oskar S, Kehm RD, Sahebzeda S, Terry MB.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  244\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  245  doc chunk text: ['Environmental exposures and breast cancer risk in the context of underlying susceptibility: A systematic review of the', 'epidemiological literature. Environ Res .', '2020;187:109346-109346.42 Breast Cancer Facts & Figures 2022-2024223. White AJ, Keller JP, Zhao S, Carroll R, Kaufman JD, Sandler DP. Air', 'Pollution, Clustering of Particulate Matter Components, and Breast Cancer in the Sister Study: A U.S.-Wide Cohort. Environ Health Perspect .', '2019;127:107002. 224. Coogan PF, Rosenberg L, Palmer JR, Cozier YC, Lenzy YM, Bertrand KA. Hair product use and breast cancer incidence in the Black']\n",
            "Texts: Environmental exposures and breast cancer risk in the context of underlying susceptibility: A systematic review of theepidemiological literature. Environ Res .2020;187:109346-109346.42 Breast Cancer Facts & Figures 2022-2024223. White AJ, Keller JP, Zhao S, Carroll R, Kaufman JD, Sandler DP. AirPollution, Clustering of Particulate Matter Components, and Breast Cancer in the Sister Study: A U.S.-Wide Cohort. Environ Health Perspect .2019;127:107002. 224. Coogan PF, Rosenberg L, Palmer JR, Cozier YC, Lenzy YM, Bertrand KA. Hair product use and breast cancer incidence in the Black\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  245\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  246  doc chunk text: ['Women’s Health Study. Carcinogenesis . 2021;42:924-930. 225. Rao R, McDonald JA, Barrett ES, et al. Associations of hair dye and relaxer use with breast tumor', 'clinicopathologic features: Findings from the Women’s circle of Health Study. Environ Res . 2022;203:111863. 226. Xu S, Wang H, Liu Y, et al. Hair', 'chemicals may increase breast cancer risk: A meta-analysis of 210319 subjects from 14 studies. PLoS One .', '2021;16:e0243792. 227. Manouchehri E, Taghipour A, Ghavami V, Ebadi A, Homaei F, Latifnejad Roudsari R. Night-shift work duration and breast cancer risk: an', 'updated systematic review and meta-analysis. BMC Womens Health . 2021;21:89. 228. Wegrzyn LR, Tamimi RM, Rosner BA, et al. Rotating']\n",
            "Texts: Women’s Health Study. Carcinogenesis . 2021;42:924-930. 225. Rao R, McDonald JA, Barrett ES, et al. Associations of hair dye and relaxer use with breast tumorclinicopathologic features: Findings from the Women’s circle of Health Study. Environ Res . 2022;203:111863. 226. Xu S, Wang H, Liu Y, et al. Hairchemicals may increase breast cancer risk: A meta-analysis of 210319 subjects from 14 studies. PLoS One .2021;16:e0243792. 227. Manouchehri E, Taghipour A, Ghavami V, Ebadi A, Homaei F, Latifnejad Roudsari R. Night-shift work duration and breast cancer risk: anupdated systematic review and meta-analysis. BMC Womens Health . 2021;21:89. 228. Wegrzyn LR, Tamimi RM, Rosner BA, et al. Rotating\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  246\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  247  doc chunk text: ['Night-Shift Work and the Risk of Breast Cancer in the Nurses’ Health Studies. Am J Epidemiol .', '2017;186:532-540. 229. Cordina-Duverger E, Menegaux F, Popa A, et al. Night shift work and breast cancer: a pooled analysis of', 'population-based case-control studies with complete work history. Eur J Epidemiol . 2018;33:369-379. 230. Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast', 'cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin .', '2014;64:207-218. 231. group. IMV. Carcinogenicity of night shift work. Lancet Oncol .']\n",
            "Texts: Night-Shift Work and the Risk of Breast Cancer in the Nurses’ Health Studies. Am J Epidemiol .2017;186:532-540. 229. Cordina-Duverger E, Menegaux F, Popa A, et al. Night shift work and breast cancer: a pooled analysis ofpopulation-based case-control studies with complete work history. Eur J Epidemiol . 2018;33:369-379. 230. Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breastcancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin .2014;64:207-218. 231. group. IMV. Carcinogenicity of night shift work. Lancet Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  247\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  248  doc chunk text: ['2019;20:1058-1059. 232. ACOG Committee Opinion No. 434: induced abortion and breast cancer risk. Obstet Gynecol .', '2009;113:1417-1418. 233. Rookus MA, van Leeuwen FE. Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch', 'case-control study. J Natl Cancer Inst . 1996;88:1759-1764. 234. Couzin J. Cancer risk. Review rules out', 'abortion-cancer link. Science . 2003;299:1498. 235. Chen L, Malone KE, Li CI. Bra wearing not associated with breast cancer risk: a', 'population-based case-control study. Cancer Epidemiol Biomarkers Prev . 2014;23:2181-2185. 236. Leberfinger AN, Behar BJ, Williams NC, et al. Breast Implant-']\n",
            "Texts: 2019;20:1058-1059. 232. ACOG Committee Opinion No. 434: induced abortion and breast cancer risk. Obstet Gynecol .2009;113:1417-1418. 233. Rookus MA, van Leeuwen FE. Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutchcase-control study. J Natl Cancer Inst . 1996;88:1759-1764. 234. Couzin J. Cancer risk. Review rules outabortion-cancer link. Science . 2003;299:1498. 235. Chen L, Malone KE, Li CI. Bra wearing not associated with breast cancer risk: apopulation-based case-control study. Cancer Epidemiol Biomarkers Prev . 2014;23:2181-2185. 236. Leberfinger AN, Behar BJ, Williams NC, et al. Breast Implant-\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  248\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  249  doc chunk text: ['Associated Anaplastic Large Cell Lymphoma: A Systematic Review. JAMA Surg .', '2017;152:1161-1168. 237. Cordeiro PG, Ghione P, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546', 'women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg .', '2020;73:841-846. 238. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated', 'meta-analysis of individual participant data. Lancet . 2013;381:1827-1834. 239. Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Medication Use for the Risk']\n",
            "Texts: Associated Anaplastic Large Cell Lymphoma: A Systematic Review. JAMA Surg .2017;152:1161-1168. 237. Cordeiro PG, Ghione P, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg .2020;73:841-846. 238. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updatedmeta-analysis of individual participant data. Lancet . 2013;381:1827-1834. 239. Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Medication Use for the Risk\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  249\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  250  doc chunk text: ['Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA .', '2019;322:868-886. 240. Force UPST. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force', 'Recommendation Statement. JAMA . 2019;322:857-867.241. Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of', 'prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg .', '2016;212:660-669. 242. Kotsopoulos J, Lubinski J, Gronwald J, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation']\n",
            "Texts: Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA .2019;322:868-886. 240. Force UPST. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task ForceRecommendation Statement. JAMA . 2019;322:857-867.241. Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit ofprophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg .2016;212:660-669. 242. Kotsopoulos J, Lubinski J, Gronwald J, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  250\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  251  doc chunk text: ['Carriers: a Reappraisal. Cancer Epidemiol Biomarkers Prev . 2022. 243. Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral', 'risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat .', '2019;177:723-733. 244. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the', 'American Cancer Society. JAMA . 2015;314:1599-1614. 245. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast', 'screening with MRI as an adjunct to mammography. CA Cancer J Clin . 2007;57:75-89. 246. Souza FH, Wendland EM, Rosa MI,']\n",
            "Texts: Carriers: a Reappraisal. Cancer Epidemiol Biomarkers Prev . 2022. 243. Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateralrisk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat .2019;177:723-733. 244. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From theAmerican Cancer Society. JAMA . 2015;314:1599-1614. 245. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breastscreening with MRI as an adjunct to mammography. CA Cancer J Clin . 2007;57:75-89. 246. Souza FH, Wendland EM, Rosa MI,\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  251\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  252  doc chunk text: ['Polanczyk CA. Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta- analysis. Breast . 2013. 247.', 'Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an', 'independent review. Br J Cancer . 2013;108:2205-2240. 248. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study of', 'mammography screening and mortality from breast cancer. J Natl Cancer Inst . 2014;106. 249. Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW.', 'European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomarkers Prev .']\n",
            "Texts: Polanczyk CA. Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta- analysis. Breast . 2013. 247.Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: anindependent review. Br J Cancer . 2013;108:2205-2240. 248. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study ofmammography screening and mortality from breast cancer. J Natl Cancer Inst . 2014;106. 249. Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW.European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomarkers Prev .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  252\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  253  doc chunk text: ['2014;23:1159-1163. 250. Tabar L, Dean PB, Chen TH, et al. The incidence of fatal breast cancer measures the increased', 'effectiveness of therapy in women participating in mammography screening. Cancer . 2019;125:515-523. 251. Duffy SW, Tabár L, Yen AMF, et al.', 'Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer .', '2020;126:2971-2979. 252. Ryser MD, Lange J, Inoue LYT, et al. Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. Ann Intern Med .', '2022;175:471-478. 253. Lehman CD, Arao RF, Sprague BL, et al. National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer']\n",
            "Texts: 2014;23:1159-1163. 250. Tabar L, Dean PB, Chen TH, et al. The incidence of fatal breast cancer measures the increasedeffectiveness of therapy in women participating in mammography screening. Cancer . 2019;125:515-523. 251. Duffy SW, Tabár L, Yen AMF, et al.Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer .2020;126:2971-2979. 252. Ryser MD, Lange J, Inoue LYT, et al. Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. Ann Intern Med .2022;175:471-478. 253. Lehman CD, Arao RF, Sprague BL, et al. National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  253\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  254  doc chunk text: ['Surveillance Consortium. Radiology . 2017;283:49-58. 254. Miglioretti DL, Lange J, van den Broek JJ, et al. Radiation- Induced Breast Cancer Incidence and', 'Mortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med . 2016;164:205-214. 255. Yaffe MJ, Mainprize JG. Risk of', 'radiation-induced breast cancer from mammographic screening. Radiology . 2011;258:98-105. 256. Freeman K, Geppert J, Stinton C, et al. Use of', 'artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy. BMJ .', '2021;374:n1872. 257. Bahl M, Mercaldo S, McCarthy AM, Lehman CD. Imaging Surveillance of Breast Cancer Survivors with Digital Mammography versus Digital Breast']\n",
            "Texts: Surveillance Consortium. Radiology . 2017;283:49-58. 254. Miglioretti DL, Lange J, van den Broek JJ, et al. Radiation- Induced Breast Cancer Incidence andMortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med . 2016;164:205-214. 255. Yaffe MJ, Mainprize JG. Risk ofradiation-induced breast cancer from mammographic screening. Radiology . 2011;258:98-105. 256. Freeman K, Geppert J, Stinton C, et al. Use ofartificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy. BMJ .2021;374:n1872. 257. Bahl M, Mercaldo S, McCarthy AM, Lehman CD. Imaging Surveillance of Breast Cancer Survivors with Digital Mammography versus Digital Breast\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  254\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  255  doc chunk text: ['Tomosynthesis. Radiology . 2021;298:308-316. 258. Kerlikowske K, Su Y-R, Sprague BL, et al. Association of Screening With Digital Breast', 'Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer. JAMA .', '2022;327:2220-2230.Breast Cancer Facts & Figures 2022-2024 43259. 2022 Scorecard Statistics. Available at:', 'https://www.fda.gov/radiation-', 'emitting-products/mqsa-insights/2022-scorecard-statistics#jun . Accessed July 7, 2022. 260. Allgood KL, Rauscher GH, Whitman S, Vasquez-Jones G, Shah AM. Validating']\n",
            "Texts: Tomosynthesis. Radiology . 2021;298:308-316. 258. Kerlikowske K, Su Y-R, Sprague BL, et al. Association of Screening With Digital BreastTomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer. JAMA .2022;327:2220-2230.Breast Cancer Facts & Figures 2022-2024 43259. 2022 Scorecard Statistics. Available at:https://www.fda.gov/radiation-emitting-products/mqsa-insights/2022-scorecard-statistics#jun . Accessed July 7, 2022. 260. Allgood KL, Rauscher GH, Whitman S, Vasquez-Jones G, Shah AM. Validating\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  255\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  256  doc chunk text: ['self-reported mammography use in vulnerable communities: findings and recommendations. Cancer Epidemiol Biomarkers Prev .', '2014;23:1649-1658. 261. Cronin KA, Miglioretti DL, Krapcho M, et al. Bias associated with self-report of prior screening mammography. Cancer Epidemiol', 'Biomarkers Prev . 2009;18:1699-1705. 262. Rauscher GH, Johnson TP, Cho YI, Walk JA. Accuracy of self- reported', 'cancer-screening histories: A meta-analysis. Cancer Epidemiol Biomarkers Prev . 2008;17:748-757. 263. Fedewa SA, Star J, Bandi P, et al. Changes in Cancer', 'Screening in the US During the COVID-19 Pandemic. JAMA Netw Open . 2022;5:e2215490. 264. Comstock CE, Gatsonis C, Newstead GM, et al.']\n",
            "Texts: self-reported mammography use in vulnerable communities: findings and recommendations. Cancer Epidemiol Biomarkers Prev .2014;23:1649-1658. 261. Cronin KA, Miglioretti DL, Krapcho M, et al. Bias associated with self-report of prior screening mammography. Cancer EpidemiolBiomarkers Prev . 2009;18:1699-1705. 262. Rauscher GH, Johnson TP, Cho YI, Walk JA. Accuracy of self- reportedcancer-screening histories: A meta-analysis. Cancer Epidemiol Biomarkers Prev . 2008;17:748-757. 263. Fedewa SA, Star J, Bandi P, et al. Changes in CancerScreening in the US During the COVID-19 Pandemic. JAMA Netw Open . 2022;5:e2215490. 264. Comstock CE, Gatsonis C, Newstead GM, et al.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  256\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  257  doc chunk text: ['Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. JAMA .', '2020;323:746-756. 265. Miles R, Wan F, Onega TL, et al. Underutilization of Supplemental Magnetic Resonance Imaging Screening Among Patients at High Breast Cancer Risk. J', 'Womens Health (Larchmt). 2018;27:748-754. 266. Haas JS, Hill DA, Wellman RD, et al. Disparities in the use of screening magnetic resonance imaging of the', 'breast in community practice by race, ethnicity, and socioeconomic status. Cancer . 2016;122:611-617. 267. Yang L, Wang S, Zhang L, et al.', 'Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis. BMC Cancer . 2020;20:499. 268. Shen Y, Shamout FE, Oliver JR, et al.']\n",
            "Texts: Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. JAMA .2020;323:746-756. 265. Miles R, Wan F, Onega TL, et al. Underutilization of Supplemental Magnetic Resonance Imaging Screening Among Patients at High Breast Cancer Risk. JWomens Health (Larchmt). 2018;27:748-754. 266. Haas JS, Hill DA, Wellman RD, et al. Disparities in the use of screening magnetic resonance imaging of thebreast in community practice by race, ethnicity, and socioeconomic status. Cancer . 2016;122:611-617. 267. Yang L, Wang S, Zhang L, et al.Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis. BMC Cancer . 2020;20:499. 268. Shen Y, Shamout FE, Oliver JR, et al.\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  257\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  258  doc chunk text: ['Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound exams. Nat Commun . 2021;12:5645. 269. Kanbayashi C, Thompson AM, Hwang ES, et al. The', 'international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). J Clin Oncol .', '2019;37:TPS603. 270. Fan B, Pardo JA, Alapati A, Hopewood P, Mohammad Virk Z, James TA. Analysis of active', 'surveillance as a treatment modality in ductal carcinoma in situ. Breast J .', '2020;26:1221-1226. 271. Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of']\n",
            "Texts: Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound exams. Nat Commun . 2021;12:5645. 269. Kanbayashi C, Thompson AM, Hwang ES, et al. Theinternational collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). J Clin Oncol .2019;37:TPS603. 270. Fan B, Pardo JA, Alapati A, Hopewood P, Mohammad Virk Z, James TA. Analysis of activesurveillance as a treatment modality in ductal carcinoma in situ. Breast J .2020;26:1221-1226. 271. Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  258\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  259  doc chunk text: ['Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Ann Surg .', '2017;265:581-589. 272. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg .', '2015;150:9-16. 273. Albornoz CR, Matros E, Lee CN, et al. Bilateral Mastectomy versus', 'Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction. Plast Reconstr Surg .', '2015;135:1518-1526. 274. Montagna G, Morrow M. Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients. Expert Rev Anticancer Ther .']\n",
            "Texts: Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Ann Surg .2017;265:581-589. 272. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg .2015;150:9-16. 273. Albornoz CR, Matros E, Lee CN, et al. Bilateral Mastectomy versusBreast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction. Plast Reconstr Surg .2015;135:1518-1526. 274. Montagna G, Morrow M. Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients. Expert Rev Anticancer Ther .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  259\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  260  doc chunk text: ['2020;20:159-166. 275. Lautner M, Lin H, Shen Y, et al. Disparities in the Use of Breast- Conserving Therapy Among Patients With', 'Early-Stage Breast Cancer. JAMA Surg . 2015;150:778-786. 276. Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL. Receipt of', 'locoregional therapy among young women with breast cancer. Breast Cancer Res Treat .', '2012;135:893-906.277. Wang T, Baskin AS, Dossett LA. Deimplementation of the Choosing Wisely Recommendations for Low-Value Breast Cancer Surgery: A Systematic Review. JAMA Surg .', '2020;155:759-770. 278. Nash R, Goodman M, Lin CC, et al. State Variation in the Receipt of a']\n",
            "Texts: 2020;20:159-166. 275. Lautner M, Lin H, Shen Y, et al. Disparities in the Use of Breast- Conserving Therapy Among Patients WithEarly-Stage Breast Cancer. JAMA Surg . 2015;150:778-786. 276. Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL. Receipt oflocoregional therapy among young women with breast cancer. Breast Cancer Res Treat .2012;135:893-906.277. Wang T, Baskin AS, Dossett LA. Deimplementation of the Choosing Wisely Recommendations for Low-Value Breast Cancer Surgery: A Systematic Review. JAMA Surg .2020;155:759-770. 278. Nash R, Goodman M, Lin CC, et al. State Variation in the Receipt of a\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  260\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  261  doc chunk text: ['Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012. JAMA Surg .', '2017;152:648-657. 279. Baskin AS, Wang T, Bredbeck BC, Sinco BR, Berlin NL, Dossett LA. Trends in Contralateral Prophylactic Mastectomy', 'Utilization for Small Unilateral Breast Cancer. J Surg Res . 2021;262:71-84. 280. Basu NN, Hodson J, Chatterjee S, et al. The Angelina Jolie', 'effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. Sci Rep . 2021;11:2847. 281. Guth U, Myrick ME, Viehl CT, Weber WP,', 'Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy – a trend made in USA? Eur J Surg Oncol .']\n",
            "Texts: Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012. JAMA Surg .2017;152:648-657. 279. Baskin AS, Wang T, Bredbeck BC, Sinco BR, Berlin NL, Dossett LA. Trends in Contralateral Prophylactic MastectomyUtilization for Small Unilateral Breast Cancer. J Surg Res . 2021;262:71-84. 280. Basu NN, Hodson J, Chatterjee S, et al. The Angelina Jolieeffect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. Sci Rep . 2021;11:2847. 281. Guth U, Myrick ME, Viehl CT, Weber WP,Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy – a trend made in USA? Eur J Surg Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  261\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  262  doc chunk text: ['2012;38:296-301. 282. Gail MH, Jatoi I. Tools for Contralateral Prophylactic Mastectomy Decision Making. J Clin Oncol .', '2022:Jco2102782. 283. McLaughlin SA, Brunelle CL, Taghian A. Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of', 'Locoregional Treatment. J Clin Oncol . 2020;38:2341-2350. 284. Montagna G, Zhang J, Sevilimedu V, et al. Risk Factors and Racial and Ethnic', 'Disparities in Patients With Breast Cancer-Related Lymphedema. JAMA Oncol . 2022. 285. DiSipio T, Rye S, Newman B, Hayes S. Incidence of', 'unilateral arm lymphoedema after breast cancer: a systematic review and meta- analysis. Lancet Oncol .']\n",
            "Texts: 2012;38:296-301. 282. Gail MH, Jatoi I. Tools for Contralateral Prophylactic Mastectomy Decision Making. J Clin Oncol .2022:Jco2102782. 283. McLaughlin SA, Brunelle CL, Taghian A. Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact ofLocoregional Treatment. J Clin Oncol . 2020;38:2341-2350. 284. Montagna G, Zhang J, Sevilimedu V, et al. Risk Factors and Racial and EthnicDisparities in Patients With Breast Cancer-Related Lymphedema. JAMA Oncol . 2022. 285. DiSipio T, Rye S, Newman B, Hayes S. Incidence ofunilateral arm lymphoedema after breast cancer: a systematic review and meta- analysis. Lancet Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  262\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  263  doc chunk text: ['2013;14:500-515. 286. Rafn BS, Christensen J, Larsen A, Bloomquist K. Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and', 'Meta-Analysis. J Clin Oncol . 2022;40:1009-1026. 287. Paramanandam VS, Dylke E, Clark GM, et al. Prophylactic Use of Compression Sleeves Reduces the', 'Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial. J Clin Oncol .', '2022;40:2004-2012. 288. Early Breast Cancer Trialists’ Collaborative Group, Darby S, McGale P, et al. Effect of radiotherapy after', 'breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17']\n",
            "Texts: 2013;14:500-515. 286. Rafn BS, Christensen J, Larsen A, Bloomquist K. Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review andMeta-Analysis. J Clin Oncol . 2022;40:1009-1026. 287. Paramanandam VS, Dylke E, Clark GM, et al. Prophylactic Use of Compression Sleeves Reduces theIncidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial. J Clin Oncol .2022;40:2004-2012. 288. Early Breast Cancer Trialists’ Collaborative Group, Darby S, McGale P, et al. Effect of radiotherapy afterbreast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  263\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  264  doc chunk text: ['randomised trials. Lancet . 2011;378:1707-1716. 289. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice', 'Guidelines in Oncology. J Natl Compr Canc Netw . 2018;16:310-320. 290. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM,', 'investigators PI. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a', 'randomised controlled trial. Lancet Oncol . 2015;16:266-273. 291. Mutter RW, Choi JI, Jimenez RB, et al. Proton Therapy for Breast Cancer: A', 'Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee. Int J Radiat Oncol Biol Phys .']\n",
            "Texts: randomised trials. Lancet . 2011;378:1707-1716. 289. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer, Version 4.2017, NCCN Clinical PracticeGuidelines in Oncology. J Natl Compr Canc Netw . 2018;16:310-320. 290. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM,investigators PI. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): arandomised controlled trial. Lancet Oncol . 2015;16:266-273. 291. Mutter RW, Choi JI, Jimenez RB, et al. Proton Therapy for Breast Cancer: AConsensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee. Int J Radiat Oncol Biol Phys .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  264\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  265  doc chunk text: ['2021;111:337-359. 292. Alterio D, La Rocca E, Volpe S, et al. Hypofractionated proton therapy in breast cancer: where are we? A critical review of the', 'literature. Breast Cancer Res Treat . 2022;192:249-263. 293. Murray Brunt A, Haviland JS, Wheatley DA, et al.', 'Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a', 'multicentre, non-inferiority, randomised, phase 3 trial. Lancet . 2020;395:1613-1626.44 Breast Cancer Facts & Figures 2022-2024294. Hickey BE, James ML, Lehman M, et al.', 'Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev .']\n",
            "Texts: 2021;111:337-359. 292. Alterio D, La Rocca E, Volpe S, et al. Hypofractionated proton therapy in breast cancer: where are we? A critical review of theliterature. Breast Cancer Res Treat . 2022;192:249-263. 293. Murray Brunt A, Haviland JS, Wheatley DA, et al.Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from amulticentre, non-inferiority, randomised, phase 3 trial. Lancet . 2020;395:1613-1626.44 Breast Cancer Facts & Figures 2022-2024294. Hickey BE, James ML, Lehman M, et al.Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  265\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  266  doc chunk text: ['2016;7:CD003860. 295. Early Breast Cancer Trialists’ Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer:', 'meta-analysis of individual patient data from ten randomised trials. Lancet Oncol . 2018;19:27-39. 296. Letourneau JM, Wald K, Sinha N, et al.', 'Fertility preservation before breast cancer treatment appears unlikely to affect disease- free survival at a median follow-up of 43 months after', 'fertility- preservation consultation. Cancer . 2020;126:487-495. 297. Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety of', 'fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Res Treat .']\n",
            "Texts: 2016;7:CD003860. 295. Early Breast Cancer Trialists’ Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer:meta-analysis of individual patient data from ten randomised trials. Lancet Oncol . 2018;19:27-39. 296. Letourneau JM, Wald K, Sinha N, et al.Fertility preservation before breast cancer treatment appears unlikely to affect disease- free survival at a median follow-up of 43 months afterfertility- preservation consultation. Cancer . 2020;126:487-495. 297. Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety offertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Res Treat .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  266\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  267  doc chunk text: ['2018;167:761-769. 298. Greer AC, Lanes A, Poorvu PD, et al. The impact of fertility preservation on the timing of breast cancer', 'treatment, recurrence, and survival. Cancer . 2021;127:3872-3880. 299. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in', 'breast cancer: the CTNeoBC pooled analysis. Lancet . 2014;384:164-172. 300. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant', 'Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med .', '2018;379:111-121. 301. Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in']\n",
            "Texts: 2018;167:761-769. 298. Greer AC, Lanes A, Poorvu PD, et al. The impact of fertility preservation on the timing of breast cancertreatment, recurrence, and survival. Cancer . 2021;127:3872-3880. 299. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit inbreast cancer: the CTNeoBC pooled analysis. Lancet . 2014;384:164-172. 300. Sparano JA, Gray RJ, Makower DF, et al. AdjuvantChemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med .2018;379:111-121. 301. Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  267\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  268  doc chunk text: ['Excellent Responders: Triple-Negative and HER2+ Subtypes. Ann Surg Oncol . 2018;25:2241-2248. 302. Korde LA, Somerfield MR, Carey LA, et al.', 'Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol .', '2021;39:1485-1505. 303. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med .', '2019;380:617-628. 304. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative', 'Chemotherapy. N Engl J Med . 2017;376:2147-2159. 305. American College of Surgeons, Commission on Cancer. National Cancer Database. 2019 Data']\n",
            "Texts: Excellent Responders: Triple-Negative and HER2+ Subtypes. Ann Surg Oncol . 2018;25:2241-2248. 302. Korde LA, Somerfield MR, Carey LA, et al.Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol .2021;39:1485-1505. 303. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med .2019;380:617-628. 304. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after PreoperativeChemotherapy. N Engl J Med . 2017;376:2147-2159. 305. American College of Surgeons, Commission on Cancer. National Cancer Database. 2019 Data\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  268\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  269  doc chunk text: ['Submission. American College of Surgeons.; 2021. 306. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant Endocrine Therapy for Women With Hormone', 'Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol . 2019;37:423-438. 307. Reeder-Hayes KE, Troester MA, Wheeler SB.', 'Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer. Oncologist . 2021;26:910-915. 308. Wheeler SB, Spencer J, Pinheiro LC, et al.', 'Endocrine Therapy Nonadherence and Discontinuation in Black and White Women. J Natl Cancer Inst .', '2019;111:498-508.309. Farias AJ, Du XL. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. J Clin Oncol .']\n",
            "Texts: Submission. American College of Surgeons.; 2021. 306. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant Endocrine Therapy for Women With HormoneReceptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol . 2019;37:423-438. 307. Reeder-Hayes KE, Troester MA, Wheeler SB.Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer. Oncologist . 2021;26:910-915. 308. Wheeler SB, Spencer J, Pinheiro LC, et al.Endocrine Therapy Nonadherence and Discontinuation in Black and White Women. J Natl Cancer Inst .2019;111:498-508.309. Farias AJ, Du XL. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. J Clin Oncol .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  269\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  270  doc chunk text: ['2017;35:86-95. 310. Miles D, Ciruelos E, Schneeweiss A, et al. Final results from the PERUSE study of first-line pertuzumab plus', 'trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide', 'prognostication. Ann Oncol . 2021;32:1245-1255. 311. Cortes J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med .', '2022;386:1143-1154. 312. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med . 2022. 313.', 'Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer. N Engl J Med .']\n",
            "Texts: 2017;35:86-95. 310. Miles D, Ciruelos E, Schneeweiss A, et al. Final results from the PERUSE study of first-line pertuzumab plustrastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guideprognostication. Ann Oncol . 2021;32:1245-1255. 311. Cortes J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med .2022;386:1143-1154. 312. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med . 2022. 313.Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer. N Engl J Med .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  270\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  271  doc chunk text: ['2021;384:2394-2405. 314. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA', 'Mutation. N Engl J Med . 2018;379:753-763. 315. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic', 'Triple-Negative Breast Cancer. N Engl J Med . 2021;384: 1529-1541. 316. Emens LA, Adams S, Barrios CH, et al. First-line', 'atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol .', '2021;32:983-993. 317. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med .']\n",
            "Texts: 2021;384:2394-2405. 314. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCAMutation. N Engl J Med . 2018;379:753-763. 315. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in MetastaticTriple-Negative Breast Cancer. N Engl J Med . 2021;384: 1529-1541. 316. Emens LA, Adams S, Barrios CH, et al. First-lineatezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol .2021;32:983-993. 317. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med .\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  271\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  272  doc chunk text: ['2020;382:810-821. 318. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential', 'nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer', '(IMpassion031): a randomised, double-blind, phase 3 trial. Lancet . 2020;396:1090-1100. 319. Hall PE, Schmid P. Emerging drugs for the treatment of triple-', 'negative breast cancer: a focus on phase II immunotherapy trials. Expert Opin Emerg Drugs .', '2021;26:131-147. 320. Hall PE, Schmid P. Emerging strategies for TNBC with early clinical data: new']\n",
            "Texts: 2020;382:810-821. 318. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequentialnab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer(IMpassion031): a randomised, double-blind, phase 3 trial. Lancet . 2020;396:1090-1100. 319. Hall PE, Schmid P. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. Expert Opin Emerg Drugs .2021;26:131-147. 320. Hall PE, Schmid P. Emerging strategies for TNBC with early clinical data: new\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  272\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  273  doc chunk text: ['chemoimmunotherapy strategies. Breast Cancer Res Treat . 2022;193:21-35. 321. Runowicz CD, Leach CR, Henry NL, et al. American Cancer', 'Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol .', '2016;34:611-635. 322. Arias E, Xu J, Curtin S, Bastian B, Tejada-Vera B. Mortality Profile of the Non-Hispanic American Indian or Alaska Native', 'Population, 2019. Natl Vital Stat Rep .', '2021;70(12):1-27.Acknowledgments We gratefully acknowledge all cancer registries and their staff for their hard work and diligence in collecting cancer']\n",
            "Texts: chemoimmunotherapy strategies. Breast Cancer Res Treat . 2022;193:21-35. 321. Runowicz CD, Leach CR, Henry NL, et al. American CancerSociety/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol .2016;34:611-635. 322. Arias E, Xu J, Curtin S, Bastian B, Tejada-Vera B. Mortality Profile of the Non-Hispanic American Indian or Alaska NativePopulation, 2019. Natl Vital Stat Rep .2021;70(12):1-27.Acknowledgments We gratefully acknowledge all cancer registries and their staff for their hard work and diligence in collecting cancer\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  273\n",
            "================================================================================\n",
            "--------------------------------------------------------------------------------\n",
            "The  274  doc chunk text: ['information, without which this report would not exist. We also would like to acknowledge the following individuals for their valuable', 'contributions: Rick Alteri; Priti Bandi; Rachel Cannady; Joseph Cotter; Ellie Daniels; Lynn Elmore; Ted Gansler; Mamta Kalidas; Joan Kramer; Katie McMahon; Kimberly Miller; Adair', 'Minihan; Lisa A Newman; Ampy Rougeau; Scott Simpson; Robert Smith; Hyuna Sung; Lauren Teras; Lynn Urquhart; Dana Wagner; and Kathy Zamora. Breast Cancer Facts &', 'Figures is a publication of the American Cancer Society, Atlanta, Georgia. For more information, contact: Rebecca Siegel; Angela Giaquinto; or Ahmedin Jemal', 'Surveillance and Health Equity Science Department©2022, American Cancer Society, Inc. No. 861022 Models used for illustrative purposes only. cancer.org |']\n",
            "Texts: information, without which this report would not exist. We also would like to acknowledge the following individuals for their valuablecontributions: Rick Alteri; Priti Bandi; Rachel Cannady; Joseph Cotter; Ellie Daniels; Lynn Elmore; Ted Gansler; Mamta Kalidas; Joan Kramer; Katie McMahon; Kimberly Miller; AdairMinihan; Lisa A Newman; Ampy Rougeau; Scott Simpson; Robert Smith; Hyuna Sung; Lauren Teras; Lynn Urquhart; Dana Wagner; and Kathy Zamora. Breast Cancer Facts &Figures is a publication of the American Cancer Society, Atlanta, Georgia. For more information, contact: Rebecca Siegel; Angela Giaquinto; or Ahmedin JemalSurveillance and Health Equity Science Department©2022, American Cancer Society, Inc. No. 861022 Models used for illustrative purposes only. cancer.org |\n",
            "Embeds length: 1536\n",
            "Upserted vector count is:  274\n",
            "================================================================================\n"
          ]
        }
      ],
      "source": [
        "nlp_upsert(filename2, index_name, \"breastcancer\",\"nlp\", 5, 2, 0, page_len)\n",
        "#signature of nlp_upsert(filename, index_name, name_space, nlp_id, chunk_size, stride, page_begin, page_end)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "acd5980d",
      "metadata": {
        "id": "acd5980d"
      },
      "source": [
        "**Check if the building is successful**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 184,
      "id": "9304e4ea",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "9304e4ea",
        "outputId": "ef90c81a-d57f-41cf-b803-7963cc4728a7"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'dimension': 1536,\n",
              " 'index_fullness': 0.0,\n",
              " 'namespaces': {'breastcancer': {'vector_count': 274}},\n",
              " 'total_vector_count': 274}"
            ]
          },
          "metadata": {},
          "execution_count": 184
        }
      ],
      "source": [
        "index.describe_index_stats()"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "170862c5",
      "metadata": {
        "id": "170862c5"
      },
      "source": [
        "### Create chat memory"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 185,
      "id": "a47ec1cd",
      "metadata": {
        "id": "a47ec1cd"
      },
      "outputs": [],
      "source": [
        "# The following cell is needed for production environement"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 186,
      "id": "c5c8ca35",
      "metadata": {
        "id": "c5c8ca35"
      },
      "outputs": [],
      "source": [
        "delimiter = \"####\"\n",
        "chatContext = [\n",
        "    {'role':'system', 'content': f\"\"\"\\\n",
        "You are an advanced and compassionate healthcare virtual assistant, specifically designed to assist with queries related to breast cancer.\n",
        "\n",
        "As a dedicated healthcare assistant, your role is to provide accurate and helpful responses based on medical guidelines and information \\\n",
        "contained within the specified context, marked by {delimiter}. Your responses should adhere strictly to the context provided, \\\n",
        "which has been drawn from verified breast cancer knowledge resources.\n",
        "\n",
        "In cases where the information is unavailable in the current knowledge base, respond with: \"I'm not certain, as the knowledge base \\\n",
        "doesn't contain the necessary information.\" In such instances, kindly recommend that the user consult a healthcare professional for personalized advice.\n",
        "\n",
        "Your primary goal is to offer reliable, contextually relevant healthcare guidance, supporting users by providing clear and helpful information related to breast cancer symptoms, risk factors, treatments, and preventive measures.\n",
        "\"\"\"\n",
        "}\n",
        "]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 187,
      "id": "ded89b1e",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ded89b1e",
        "outputId": "5b7dbb70-5af7-4330-f3df-b913b2e73012"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'role': 'system',\n",
              "  'content': 'You are an advanced and compassionate healthcare virtual assistant, specifically designed to assist with queries related to breast cancer.\\n\\nAs a dedicated healthcare assistant, your role is to provide accurate and helpful responses based on medical guidelines and information contained within the specified context, marked by ####. Your responses should adhere strictly to the context provided, which has been drawn from verified breast cancer knowledge resources.\\n\\nIn cases where the information is unavailable in the current knowledge base, respond with: \"I\\'m not certain, as the knowledge base doesn\\'t contain the necessary information.\" In such instances, kindly recommend that the user consult a healthcare professional for personalized advice.\\n\\nYour primary goal is to offer reliable, contextually relevant healthcare guidance, supporting users by providing clear and helpful information related to breast cancer symptoms, risk factors, treatments, and preventive measures.\\n'}]"
            ]
          },
          "metadata": {},
          "execution_count": 187
        }
      ],
      "source": [
        "chatContext"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "be90f999",
      "metadata": {
        "id": "be90f999"
      },
      "source": [
        "## <span style=\"color:#00FF00\">Question Put Here</span>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 188,
      "id": "5b675b03",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5b675b03",
        "outputId": "7d31b6fa-764e-4b78-b9e2-20fe89574664"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "User Input: what are the most common breast cancer symptom ?\n"
          ]
        }
      ],
      "source": [
        "query = input(\"User Input: \")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 189,
      "id": "275fbab8",
      "metadata": {
        "id": "275fbab8"
      },
      "outputs": [],
      "source": [
        "query = query + \" \""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 190,
      "id": "b9af84f8",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "b9af84f8",
        "outputId": "5f2e249a-9954-4f79-80e5-af62764d7fb4"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "query: what are the most common breast cancer symptom ? \n",
            "query message: {'role': 'user', 'content': '\\nwhat are the most common breast cancer symptom ? \\n'}\n"
          ]
        }
      ],
      "source": [
        "query_message = {\"role\": \"user\", \"content\": f\"\"\"\n",
        "{query}\n",
        "\"\"\"\n",
        "}\n",
        "print(\"query:\", query)\n",
        "print(\"query message:\", query_message)\n",
        "chatContext.append(query_message)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 195,
      "id": "cb1dc3d4",
      "metadata": {
        "id": "cb1dc3d4"
      },
      "outputs": [],
      "source": [
        "res = client.embeddings.create(\n",
        "    input=[query],\n",
        "    model=embed_model\n",
        ")\n",
        "\n",
        "# retrieve from Pinecone\n",
        "xq = res.data[0].embedding\n",
        "\n",
        "# get relevant contexts\n",
        "res = index.query(vector=xq,\n",
        "                  top_k=3,\n",
        "                  include_metadata=True,\n",
        "                  namespace='breastcancer')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 196,
      "id": "5f3a4843",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5f3a4843",
        "outputId": "b8d528cd-596b-4e34-9e12-1f6ff536335d"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'matches': [{'id': 'nlp_5',\n",
              "              'metadata': {'text': 'cancer typically has no symptoms when the '\n",
              "                                   'tumor is small and most easily treated, '\n",
              "                                   'which is why breast cancer screening '\n",
              "                                   'isimportant for early detection. The most '\n",
              "                                   'common physical sign is a painless lump. '\n",
              "                                   'Sometimes breast cancer can spread to '\n",
              "                                   'underarm lymph nodes and cause a lump '\n",
              "                                   'orswelling even before the original breast '\n",
              "                                   'tumor is large enough to be felt. Less '\n",
              "                                   'common signs and symptoms include breast '\n",
              "                                   'pain orheaviness; dimpling, swelling, '\n",
              "                                   'thickening, or redness of the breast skin; '\n",
              "                                   'and nipple changes, such as spontaneous '\n",
              "                                   'discharge (especially if '\n",
              "                                   'bloody),scaliness, or retraction. Any '\n",
              "                                   'persistent change in the breast should be '\n",
              "                                   'evaluated by a physician. How is breast '\n",
              "                                   'cancer diagnosed? Breast cancer is'},\n",
              "              'score': 0.657812297,\n",
              "              'values': []},\n",
              "             {'id': 'nlp_6',\n",
              "              'metadata': {'text': 'typically detected during mammography '\n",
              "                                   'screening, before symptoms have developed '\n",
              "                                   '(asymptomatic), or after a woman notices a '\n",
              "                                   'lump or change in the breast(symptomatic). '\n",
              "                                   'Detection after symptoms develop is more '\n",
              "                                   'common among younger women who have not '\n",
              "                                   'started breast cancer screening, older '\n",
              "                                   'women who are no longerrecommended for '\n",
              "                                   'screening, and those who lack access to '\n",
              "                                   'preventive screening. Most screen-detected '\n",
              "                                   'masses turn out to be benign '\n",
              "                                   '(notcancerous). When cancer is suspected, '\n",
              "                                   'a biopsy is needed to establish the '\n",
              "                                   'diagnosis through microscopic analysis. A '\n",
              "                                   'needle biopsy(fine-needle or larger '\n",
              "                                   'core-needle) is most common, but sometimes '\n",
              "                                   'a surgical biopsy is performed. Selection '\n",
              "                                   'of the type of biopsy is based on'},\n",
              "              'score': 0.545081317,\n",
              "              'values': []},\n",
              "             {'id': 'nlp_4',\n",
              "              'metadata': {'text': 'permissionsrequests@cancer.org.This '\n",
              "                                   'publication attempts to summarize current '\n",
              "                                   'scientific information about breast '\n",
              "                                   'cancer. Except when specified, it does not '\n",
              "                                   'represent the official policy of '\n",
              "                                   'theAmerican Cancer Society. Suggested '\n",
              "                                   'citation: American Cancer Society. Breast '\n",
              "                                   'Cancer Facts & Figures 2022-2024 . '\n",
              "                                   'Atlanta: American Cancer Society, '\n",
              "                                   'Inc.2022.Breast Cancer Facts & Figures '\n",
              "                                   '2022-2024 1Breast Cancer Basic Facts What '\n",
              "                                   'is breast cancer? Breast cancer is a group '\n",
              "                                   'of diseases in which cells in aperson’s '\n",
              "                                   'breast tissue change and divide '\n",
              "                                   'uncontrolled, typically resulting in a '\n",
              "                                   'lump or mass. Most breast cancers begin in '\n",
              "                                   'the milk glands(lobules) or in the tubes '\n",
              "                                   '(ducts) that connect the milk glands to '\n",
              "                                   'the nipple. What are the signs and '\n",
              "                                   'symptoms of breast cancer? Breast'},\n",
              "              'score': 0.47110641,\n",
              "              'values': []}],\n",
              " 'namespace': 'breastcancer',\n",
              " 'usage': {'read_units': 6}}"
            ]
          },
          "metadata": {},
          "execution_count": 196
        }
      ],
      "source": [
        "res"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 197,
      "id": "f6d3757e-481e-48be-a053-0b226fa1c61f",
      "metadata": {
        "id": "f6d3757e-481e-48be-a053-0b226fa1c61f"
      },
      "outputs": [],
      "source": [
        "contexts = [\n",
        "        x[\"metadata\"][\"text\"] for x in res[\"matches\"]\n",
        "    ]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 198,
      "id": "f5d6135e-6310-4c29-966d-fb5e8a081fdf",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "f5d6135e-6310-4c29-966d-fb5e8a081fdf",
        "outputId": "cde66111-432d-47b9-dfe9-cce6eb3898cb"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['cancer typically has no symptoms when the tumor is small and most easily treated, which is why breast cancer screening isimportant for early detection. The most common physical sign is a painless lump. Sometimes breast cancer can spread to underarm lymph nodes and cause a lump orswelling even before the original breast tumor is large enough to be felt. Less common signs and symptoms include breast pain orheaviness; dimpling, swelling, thickening, or redness of the breast skin; and nipple changes, such as spontaneous discharge (especially if bloody),scaliness, or retraction. Any persistent change in the breast should be evaluated by a physician. How is breast cancer diagnosed? Breast cancer is',\n",
              " 'typically detected during mammography screening, before symptoms have developed (asymptomatic), or after a woman notices a lump or change in the breast(symptomatic). Detection after symptoms develop is more common among younger women who have not started breast cancer screening, older women who are no longerrecommended for screening, and those who lack access to preventive screening. Most screen-detected masses turn out to be benign (notcancerous). When cancer is suspected, a biopsy is needed to establish the diagnosis through microscopic analysis. A needle biopsy(fine-needle or larger core-needle) is most common, but sometimes a surgical biopsy is performed. Selection of the type of biopsy is based on',\n",
              " 'permissionsrequests@cancer.org.This publication attempts to summarize current scientific information about breast cancer. Except when specified, it does not represent the official policy of theAmerican Cancer Society. Suggested citation: American Cancer Society. Breast Cancer Facts & Figures 2022-2024 . Atlanta: American Cancer Society, Inc.2022.Breast Cancer Facts & Figures 2022-2024 1Breast Cancer Basic Facts What is breast cancer? Breast cancer is a group of diseases in which cells in aperson’s breast tissue change and divide uncontrolled, typically resulting in a lump or mass. Most breast cancers begin in the milk glands(lobules) or in the tubes (ducts) that connect the milk glands to the nipple. What are the signs and symptoms of breast cancer? Breast']"
            ]
          },
          "metadata": {},
          "execution_count": 198
        }
      ],
      "source": [
        "contexts"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "959bcd50",
      "metadata": {
        "id": "959bcd50"
      },
      "source": [
        "### The following cell is needed for formal running"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 203,
      "id": "52455086",
      "metadata": {
        "id": "52455086"
      },
      "outputs": [],
      "source": [
        "limit = 8000  #set the limit of knowledge base words, leave some space for chat history and query.\n",
        "\n",
        "def retrieve(query, name_space):\n",
        "    res = client.embeddings.create(\n",
        "        input=[query],\n",
        "        model=embed_model\n",
        "    )\n",
        "\n",
        "    # retrieve from Pinecone knowledge base\n",
        "    xq = res.data[0].embedding\n",
        "\n",
        "    index = pc.Index(index_name)\n",
        "\n",
        "\n",
        "    # get relevant contexts\n",
        "    res = index.query(vector=xq,\n",
        "                      top_k=5,\n",
        "                      include_metadata=True,\n",
        "                      namespace=name_space)\n",
        "    contexts = [\n",
        "        x[\"metadata\"][\"text\"] for x in res[\"matches\"]\n",
        "        ]\n",
        "\n",
        "    #print(\"Length of contexts: \", len(contexts))\n",
        "    #print(contexts)\n",
        "\n",
        "    # build our prompt with the retrieved contexts included\n",
        "    prompt = \" \"\n",
        "\n",
        "    # append contexts until hitting limit\n",
        "    count = 0\n",
        "    proceed = True\n",
        "    while proceed and count < len(contexts):\n",
        "        if len(prompt) + len(contexts[count]) >= limit:\n",
        "            proceed = False\n",
        "        else:\n",
        "            prompt += contexts[count]\n",
        "\n",
        "        count += 1\n",
        "    # End of while loop\n",
        "\n",
        "    prompt = delimiter + prompt + delimiter\n",
        "\n",
        "    return prompt"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 204,
      "id": "c028da4e",
      "metadata": {
        "id": "c028da4e"
      },
      "outputs": [],
      "source": [
        "# first we retrieve relevant items from Pinecone\n",
        "retrieved_knowledge = retrieve(query,\"Breastcancer\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 205,
      "id": "ee53c40c",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "ee53c40c",
        "outputId": "2c501c74-ef31-43ce-acf3-54a0af163e8e"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'#### ####'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 205
        }
      ],
      "source": [
        "retrieved_knowledge"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 206,
      "id": "44918074",
      "metadata": {
        "id": "44918074"
      },
      "outputs": [],
      "source": [
        "# Infuse the knowledge into the final messages\n",
        "knowledge_message = {\"role\": \"system\", \"content\": f\"\"\"\n",
        "{retrieved_knowledge}\n",
        "\"\"\"\n",
        "}"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 207,
      "id": "162d424b",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "162d424b",
        "outputId": "8744a990-c71d-46ca-c35c-a027924f1904"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "context_query_knowledge:  [{'role': 'system', 'content': 'You are an advanced and compassionate healthcare virtual assistant, specifically designed to assist with queries related to breast cancer.\\n\\nAs a dedicated healthcare assistant, your role is to provide accurate and helpful responses based on medical guidelines and information contained within the specified context, marked by ####. Your responses should adhere strictly to the context provided, which has been drawn from verified breast cancer knowledge resources.\\n\\nIn cases where the information is unavailable in the current knowledge base, respond with: \"I\\'m not certain, as the knowledge base doesn\\'t contain the necessary information.\" In such instances, kindly recommend that the user consult a healthcare professional for personalized advice.\\n\\nYour primary goal is to offer reliable, contextually relevant healthcare guidance, supporting users by providing clear and helpful information related to breast cancer symptoms, risk factors, treatments, and preventive measures.\\n'}, {'role': 'user', 'content': '\\nwhat are the most common breast cancer symptom ? \\n'}, {'role': 'system', 'content': '\\n#### ####\\n'}, {'role': 'user', 'content': '\\nwhat are the most common breast cancer symptom ? \\n'}]\n"
          ]
        }
      ],
      "source": [
        "# Come out a temp list to hold knowledge\n",
        "context_query_knowledge = chatContext + [knowledge_message, query_message]\n",
        "print(\"context_query_knowledge: \", context_query_knowledge)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "ee37d967",
      "metadata": {
        "id": "ee37d967"
      },
      "source": [
        "## <span style=\"color:#FF00FF\">ChatBot Response Here</span>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 208,
      "id": "18e0ae9c-3281-45bd-938d-14a004d788b1",
      "metadata": {
        "id": "18e0ae9c-3281-45bd-938d-14a004d788b1"
      },
      "outputs": [],
      "source": [
        "response = chat_complete_messages(context_query_knowledge, temperature=0)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 209,
      "id": "d3360359",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "id": "d3360359",
        "outputId": "99722412-f784-4394-f3a8-b1d5122f4fdd"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "\"I'm not certain, as the knowledge base doesn't contain the necessary information. I recommend consulting a healthcare professional for personalized advice.\""
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 209
        }
      ],
      "source": [
        "response"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 210,
      "id": "39caa59b",
      "metadata": {
        "id": "39caa59b"
      },
      "outputs": [],
      "source": [
        "response_message = {\"role\": \"assistant\", \"content\":f\"{response}\"}\n",
        "\n",
        "chatContext.append(response_message)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 211,
      "id": "cccd406a",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cccd406a",
        "outputId": "d2cefcd4-9806-403c-c401-3812fcb54c6c"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'role': 'system',\n",
              "  'content': 'You are an advanced and compassionate healthcare virtual assistant, specifically designed to assist with queries related to breast cancer.\\n\\nAs a dedicated healthcare assistant, your role is to provide accurate and helpful responses based on medical guidelines and information contained within the specified context, marked by ####. Your responses should adhere strictly to the context provided, which has been drawn from verified breast cancer knowledge resources.\\n\\nIn cases where the information is unavailable in the current knowledge base, respond with: \"I\\'m not certain, as the knowledge base doesn\\'t contain the necessary information.\" In such instances, kindly recommend that the user consult a healthcare professional for personalized advice.\\n\\nYour primary goal is to offer reliable, contextually relevant healthcare guidance, supporting users by providing clear and helpful information related to breast cancer symptoms, risk factors, treatments, and preventive measures.\\n'},\n",
              " {'role': 'user',\n",
              "  'content': '\\nwhat are the most common breast cancer symptom ? \\n'},\n",
              " {'role': 'assistant',\n",
              "  'content': \"I'm not certain, as the knowledge base doesn't contain the necessary information. I recommend consulting a healthcare professional for personalized advice.\"}]"
            ]
          },
          "metadata": {},
          "execution_count": 211
        }
      ],
      "source": [
        "chatContext"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "526dd4c1",
      "metadata": {
        "id": "526dd4c1"
      },
      "source": [
        "### Return to the cell located below <span style=\"color:#00FF00\">Question Put Here</span>. From the notebook menu, select \"Run -> Run Selected Cell and All Below.\" You provide user input, then, scroll down to the section labeled <span style=\"color:#FF00FF\">ChatBot Response Here</span> to observe the outcomes following the incorporation of knowledge from the Vector DB. This process can be reiterated multiple times, essentially creating a while loop."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 212,
      "id": "da9c5aa1",
      "metadata": {
        "id": "da9c5aa1",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "ecf82e5c-d980-478f-ac1b-3c72d9d3a103"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Enter your question (or type 'exit' to quit): hello what is the breast cancer?\n",
            "query: hello what is the breast cancer? \n",
            "ChatBot Response: Breast cancer is a group of diseases where cells in a person's breast tissue change and divide uncontrollably, typically resulting in a lump or mass. Most breast cancers begin in the milk glands (lobules) or in the tubes (ducts) that connect the milk glands to the nipple.\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): what are the symptoms ?\n",
            "query: what are the symptoms ? \n",
            "ChatBot Response: The most common symptom of breast cancer is a painless lump in the breast. Other signs and symptoms can include:\n",
            "\n",
            "- A lump or swelling in the underarm lymph nodes, even before the original breast tumor is large enough to be felt.\n",
            "- Breast pain or heaviness.\n",
            "- Dimpling, swelling, thickening, or redness of the breast skin.\n",
            "- Nipple changes, such as spontaneous discharge (especially if bloody), scaliness, or retraction.\n",
            "\n",
            "Any persistent change in the breast should be evaluated by a physician.\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): when I need to be concern if I have the breast cancer or not\n",
            "query: when I need to be concern if I have the breast cancer or not \n",
            "ChatBot Response: You should be concerned and consider consulting a doctor if you notice any persistent changes in your breast, such as:\n",
            "\n",
            "- A new lump or mass in the breast or underarm area.\n",
            "- Changes in the size, shape, or appearance of the breast.\n",
            "- Dimpling, swelling, thickening, or redness of the breast skin.\n",
            "- Nipple changes, such as discharge (especially if bloody), scaliness, or retraction.\n",
            "\n",
            "Even if you have had a recent normal mammogram, it's important to report any new symptoms to your doctor promptly. Regular breast cancer screening, such as mammography, is crucial for early detection, especially since breast cancer can often have no symptoms when the tumor is small and most easily treated.\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): can you tell me how often I need to go for check up?\n",
            "query: can you tell me how often I need to go for check up? \n",
            "ChatBot Response: For women at average risk of breast cancer, the American Cancer Society recommends the following screening schedule:\n",
            "\n",
            "- Women aged 40 to 44 have the option to begin annual mammography screening.\n",
            "- Women aged 45 to 54 should have a mammogram every year.\n",
            "- Women aged 55 and older can switch to mammograms every two years or continue yearly screening, depending on their preferences.\n",
            "\n",
            "Screening should continue as long as a woman is in good health and has a life expectancy of 10 years or more. It's important to discuss with your healthcare provider to determine the best screening plan for you, considering your personal health and risk factors.\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): what are the stages?\n",
            "query: what are the stages? \n",
            "ChatBot Response: Breast cancer staging is determined by the extent of cancer and its spread at the time of diagnosis, as well as the tumor's microscopic characteristics. The two main staging systems are the American Joint Committee on Cancer (AJCC) staging system and the SEER summary staging system.\n",
            "\n",
            "The AJCC staging system uses the TNM classification:\n",
            "\n",
            "- **T (Tumor size):** Size of the tumor.\n",
            "- **N (Node involvement):** Whether cancer cells have spread to regional lymph nodes.\n",
            "- **M (Metastasis):** Whether cancer has metastasized to distant lymph nodes and/or organs.\n",
            "\n",
            "The SEER summary stage system includes:\n",
            "\n",
            "- **In situ:** Abnormal cells are confined to the layer of cells where they originated.\n",
            "- **Local stage:** Invasive cancer confined to the breast.\n",
            "- **Regional stage:** Cancer has spread to surrounding tissue and/or lymph nodes.\n",
            "- **Distant stage:** Cancer has spread to distant organs and/or lymph nodes, including nodes above the collarbone.\n",
            "\n",
            "These stages help predict prognosis and guide treatment options.\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): can I check it at home?\n",
            "query: can I check it at home? \n",
            "ChatBot Response: While regular breast self-exams are no longer specifically recommended as a routine screening tool, it's important for all women to be familiar with the normal look and feel of their breasts. This is known as breast self-awareness. If you notice any changes, such as lumps, swelling, or other unusual signs, you should contact a healthcare professional promptly.\n",
            "\n",
            "However, breast cancer screening through mammography is the most effective method for early detection and should be done according to the recommended guidelines for your age and risk level. Always consult with your healthcare provider to determine the best screening plan for you.\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): can you provide me a good specialist?\n",
            "query: can you provide me a good specialist? \n",
            "ChatBot Response: I'm not certain, as the knowledge base doesn't contain the necessary information. I recommend consulting a healthcare professional or using resources like the American Cancer Society's website to find a specialist in your area. They can provide guidance on finding a qualified breast cancer specialist.\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): thanks. exit\n",
            "query: thanks. exit \n",
            "ChatBot Response: You're welcome! If you have any more questions in the future, feel free to ask. Take care!\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): quit\n",
            "query: quit \n",
            "ChatBot Response: Goodbye! If you have any more questions in the future, feel free to reach out. Take care!\n",
            "\n",
            "-------------------\n",
            "\n",
            "Enter your question (or type 'exit' to quit): exit\n",
            "Exiting the chat.\n"
          ]
        }
      ],
      "source": [
        "# loop for querying\n",
        "while True:\n",
        "    query = input(\"Enter your question (or type 'exit' to quit): \")\n",
        "    if query.lower() == 'exit':\n",
        "        print(\"Exiting the chat.\")\n",
        "        break\n",
        "\n",
        "    query += \" \"  # Ensures input format consistency\n",
        "\n",
        "    # Prepare query message for chat context\n",
        "    query_message = {\"role\": \"user\", \"content\": f\"\"\"\\n{query}\\n\"\"\"}\n",
        "    print(f\"query: {query}\")\n",
        "    chatContext.append(query_message)\n",
        "\n",
        "    # Retrieve relevant items from Pinecone\n",
        "    res = client.embeddings.create(input=[query], model=embed_model)\n",
        "    xq = res.data[0].embedding\n",
        "\n",
        "    # Perform query in Pinecone to retrieve relevant contexts\n",
        "    res = index.query(vector=xq, top_k=5, include_metadata=True, namespace=\"breastcancer\")\n",
        "    contexts = [x[\"metadata\"][\"text\"] for x in res[\"matches\"]]\n",
        "\n",
        "    # Build the response prompt with retrieved contexts\n",
        "    prompt = \"####\" + \"\\n\".join(contexts) + \"####\"\n",
        "    knowledge_message = {\"role\": \"system\", \"content\": f\"\"\"{prompt}\"\"\"}\n",
        "    chatContext.append(knowledge_message)\n",
        "\n",
        "    # Generate response\n",
        "    response = chat_complete_messages(chatContext, temperature=0)\n",
        "    print(f\"ChatBot Response: {response}\")\n",
        "\n",
        "    # Append response\n",
        "    response_message = {\"role\": \"assistant\", \"content\": f\"{response}\"}\n",
        "    chatContext.append(response_message)\n",
        "\n",
        "    print(\"\\n-------------------\\n\")\n"
      ]
    }
  ],
  "metadata": {
    "kernelspec": {
      "display_name": "Python 3 (ipykernel)",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.10.9"
    },
    "colab": {
      "provenance": []
    }
  },
  "nbformat": 4,
  "nbformat_minor": 5
}